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Abstract 
 
 This thesis describes the development of methodologies for lithiation-trapping and 
lithiation-arylation of -Boc heterocycles in the position α to nitrogen as well as in situ 
infra-red spectroscopic monitoring of lithiation reactions and the application of lithiation-
arylation in total synthesis. 
 Chapter 2 details the use of in situ infra-red spectroscopy to monitor the lithiation of -
Boc pyrrolidine, -Boc piperidine, -Boc homopiperidine, an -Boc acetal piperidine, 
-Boc-ʹ-benzyl piperazine, -Boc-ʹ-i-Pr imidazolidine and an O-alkyl carbamate in 
diethyl ether using s-BuLi and the diamines TMEDA, (–)-sparteine, or the (+)-sparteine 
surrogate. 
 Chapter 3 describes the expansion of a previously reported two-ligand catalytic 
lithiation-trapping procedure for -Boc pyrrolidine, discussing the optimisation of 
catalytic lithiation conditions, the use of new bispidine-derived diamine ligands and 
examples of two-ligand catalytic lithiation-arylation of -Boc pyrrolidine.  
 The application of stoichiometric and catalytic lithiation-arylation of -Boc pyrrolidine 
in total synthesis is presented in chapter 4. Lithiation-arylation is used to complete the 
shortest and most efficient synthesis of (S)-nicotine to date, as well as the shortest 
synthesis of SIB1508Y and to attempt the first asymmetric synthesis of (R)-
dihydroshihunine. Additionally, a protocol for the lithiation-vinylation of -Boc 
pyrrolidine is developed and used to carry out the first asymmetric synthesis of (R)-
maackiamine. 
 Chapter 5 details the development of a new diamine-free racemic lithiation procedure 
for the lithiation-trapping and lithiation-arylation of -Boc pyrrolidine, -Boc-ʹ-i-Pr 
imidazolidine and -Boc-ʹ-benzyl piperazine. Additionally, diamine-free lithiations are 
monitored using in situ infra-red spectroscopy. 
 In chapter 6, benzylic lithiation-trapping of -Boc-2-phenyl pyrrolidine is described. 
Lithiation-trapping of rac--Boc-2-phenyl pyrrolidine is first discussed, followed by 
lithiation-trapping of enantioenriched (R)--Boc-2-phenyl pyrrolidine, giving access to 
products bearing enantioenriched quaternary stereocentres. The use of in situ infra-red 
spectroscopic monitoring was integral to the development of this methodology. 
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Chapter One: Introduction 
 
1.1 Organolithium Reagents in Modern Organic Synthesis 
 It is an understatement to say that organolithiums are of great importance to modern 
organic chemistry. It is a rare total synthesis that proceeds without their use. For example, 
Suzuki’s recently reported synthesis of seragakinone A begins with a n-BuLi-mediated 
bromine-lithium exchange.1 We confidently expect an undergraduate chemist to be 
familiar with the structures and reactivity of the common reagents. While most chemists 
will primarily associate organolithium reagents with deprotonation chemistry, their 
reactivity is broader then this, encompassing a wealth of transformations fundamental to 
organic synthesis. The vast range of organolithium chemistry and the ubiquity of their use 
in total syntheses of natural products and drug molecules remains a cornerstone of 
modern chemistry. The central importance of organolithium reagents drives the discovery 
of new methodologies and reagents. This thesis focuses on the development of new 
methodologies using the common reagents s-BuLi and n-BuLi in their familiar role as 
strong bases. 
 
1.1.1 Structure and Reactivity of Common Organolithium Reagents 
 While it is tempting to think of alkyllithium reagents in purely ionic terms, a closer 
inspection reveals that the C–Li bond which, while ionic in nature, exhibits significant 
covalent character. This makes organolithium reagents very reactive nucleophiles and 
bases, with pKas >35. Although the presence of a highly ionic bond would suggest 
otherwise, organolithium reagents are surprisingly soluble in a range of organic solvents. 
The most common reagents, the BuLi’s, are commercially available in a variety of 
hydrocarbon solvents (commonly cyclohexane/mixed hexanes) and at a range of 
concentrations. Such solutions can be kept for many months in the absence of water and 
air at low (~5 °C) temperatures.2 Two other common organolithium reagents, MeLi and 
PhLi, are less soluble in purely hydrocarbon solutions, and are solubilised by the addition 
of ethereal cosolvents.2 s-BuLi (which contains a stereogenic centre) is widely used in 
place of the stereochemically simpler i-PrLi since i-PrLi is pyrophoric. 
 A single alkyl group does not provide adequate stabilisation to the electron deficient Li 
atom of organolithium compounds. Thus, while alkyllithiums are commonly thought of 
as monomers in terms of synthetic design, in reality they exist in hydrocarbon solution as 
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one of a range of aggregates. Primary alkyllithiums such as EtLi and n-BuLi exist in 
solution as hexamers, with an octahedral arrangement of Li atoms bridged by the alkyl 
groups.2 The more sterically demanding alkyllithiums i-PrLi, s-BuLi and t-BuLi are 
tetramers, with a tetrahedron of Li atoms bridged by the alkyl groups. Dimeric aggregates 
occur with the very sterically hindered alkyl groups benzyllithium and menthyllithium.2 
The propensity of alkyllithium reagents to form aggregates in solution allows chemists to 
carefully modulate their reactivity by addition of cosolvents. By providing an alternative 
source of electron density for the Li atom, we can favour the formation of lower 
aggregates. While it is commonly thought that forming lower aggregates increases the 
reactivity of the alkyllithium, in reality the nature of the ligand plays an equally important 
role in modulating organolithium reactivity. 
  
1.1.2 Ligands for Organolithium Reagents: Modifying Reactivity 
 Frequently, organolithium reagents are used in conjunction with a ligand additive to 
modulate their reactivity. Most commonly, reactions are carried out in diethyl ether or 
THF. Donation of electron density from oxygen favours the formation of smaller 
aggregates than those which occur in hydrocarbon solvents. Thus, in diethyl ether and 
THF, MeLi, EtLi and n-BuLi form tetramers, whereas i-PrLi, s-BuLi, t-BuLi and PhLi 
form dimers.2, 3 Monomers are formed for benzyllithium, t-BuLi and PhLi in THF at 
temperatures below –100 °C.  
 Deaggregation of alkyllithium reagents can also be achieved by the addition of diamine 
or polyamine ligands. These are typically used in proportion to the organolithium reagent 
rather than as solvents. The most important examples are HMPA 1, PMDTA 2, (–)-
sparteine 3, DMPU 4 and TMEDA 5 (figure 1.1).2 
 
Figure 1.1 
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 Other important diamine ligands used in the research described in this thesis include the 
(+)-sparteine surrogate 64 developed in our group, di-i-Pr bispidine 7,5 and the 
cyclohexane diamine (R,R)-86 first developed by Alexakis (figure 1.2).  
 
Figure 1.2 
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 It is important to note that although the reactivity of an organolithium reagent generally 
increases with the deaggregating power of the ligand present, this does not completely 
explain the differences between different organolithium-ligand complexes in solution. 
Care must be taken to avoid confusion between the deaggregating power of the ligand 
and the ability of the organolithium-ligand complex to effect the desired reaction. 
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1.2 Directed Lithiation of Substrates Using Organolithium Reagents 
 Substrate-directed deprotonation reactions provide a method for selective lithiation of 
starting materials. The first example of such a method was reported in 1946 by Roberts.7 
It was shown that lithiation of trifluoromethylbenzene 9 with n-BuLi gave solely ortho- 
and meta-lithiation. Furthermore, a competition experiment treating 1 equivalent of each 
of 9 and anisole 10 with 1 equivalent of n-BuLi followed by trapping with CO2 gave only 
ortho-anisic acid 11 (scheme 1.1). It was concluded that regioselectivity was achieved 
through precomplexation of the alkyllithium to either CF3 or OMe and that OMe was a 
better coordinating group than CF3. Competition experiments allowed the determination 
of the relative coordinating abilities of a small range of aromatic substituents.7  
 
Scheme 1.1 
OMeCF3
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9
1 eq.
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CO2H
1. 1 eq. n-BuLi
Et2O, reflux
2. CO2
3. H+
11
40%  
 
 Directed lithiation has been co-opted for the installation of electrophile-derived 
substituents in synthesis. Typically, such a strategy involves installation of a directing 
group C=Y onto an unprotected heteroatom (e.g. nitrogen) to give 12 which enables 
lithiation at the position α to the heteroatom substituent. Electrophilic trapping then gives 
13 (scheme 1.2). Subsequent removal of the directing group would release the newly 
modified substrate. 
 
Scheme 1.2 
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 This mechanism, wherein the Lewis basic directing group C=Y of substrate 12 
facilitates formation of complex 14 prior to lithiation was termed the “complex induced 
proximity effect” (CIPE) by Beak and Meyers in 1986.8  In 1984,9 Beak reviewed 
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directed lithiations of amines, and further progress via the CIPE facilitated lithiations on a 
range of substrates was reviewed in 199610 and 2004.11 Complex 14 was termed the 
“prelithiation complex.”  Reactivity towards deprotonation is increased by the 
prelithiation complex holding the alkyllithium reagent in close proximity to the reactive 
α-proton. Additionally, lithiated intermediate 15 is stabilised by an adjacent positive 
charge on the heteroatom – a so-called dipole stabilised carbanion. Examples of the 
prelithiation complex and the dipole stabilised carbanion for an amide directing group are 
shown in scheme 1.3.12 
 
Scheme 1.3 
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 The groups of Beak, Seebach and Meyers were instrumental in the development of 
CIPE lithiation methodologies, reporting a number of different directing groups. 
Extensively investigated examples include amides used by Beak,9, 13-20 formamidines 
used by Meyers,9, 21-24 and the more exotic nitroso group used by Seebach (scheme 1.4).25, 
26 
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 Amides, formamidines and the nitroso group are not the only directing groups that have 
been used. The requirements for CIPE directing groups are Lewis basicity to allow 
complexation of the organometallic reagent and a low reactivity towards nucleophilic 
attack to allow deprotonation to occur. Typically, α-deprotonation is favoured by 
installation of a sterically hindered directing group. A recent example of lithiation 
mediated by a different directing group is the lithiation of urea 16, reported by 
Metallinos. In this case, lithiation cis to the directing group occurred to give 17 in 63% 
yield (scheme 1.5).27 Another recent example is Hodgson’s thioamide-mediated lithiation 
of azetidine 18 to give methylated azetidine 19 in 93% yield (scheme 1.5).28 This thesis 
will focus on lithiation of -Boc secondary amines, first reported by Beak, and use of the 
-Boc group is covered in detail in section 1.3.29 
 
Scheme 1.5 
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 Given the requirement for a directing group to be resistant to nucleophilic attack by the 
base used for deprotonation, it is perhaps surprising that esters can be used to effect 
directed lithiation. Beak used a very hindered ester 20 to achieve substitution of methanol 
(scheme 1.6).30 Beak also reported using a similarly hindered system to carry out 
lithiation-trapping of thioester 21 (scheme 1.6).13 
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Scheme 1.6 
Ar O
O
Me
Ar O
O1. s-BuLi, TMEDA
THF, _75 oC, 2 h
2. MeI
20
Ar = 2,4,6-tri-i-Pr-C6H2
Ar S
O
Me
Ar S
O1. n-BuLi, THF,
_75 oC, 2 h
2. MeI
21
Ar = 2,4,6-tri-Et-C6H2
84%
86%
 
 
 As well as facilitating lithiation α to heteroatoms, the CIPE also affects the 
regiochemistry of lithiation to favor kinetic products. For example, lithiation of -
benzylamide 22 gave exclusively benzylic lithiation as opposed to the thermodynamically 
favoured enolate lithiation product (scheme 1.7).8, 31 
 
Scheme 1.7 
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 While the CIPE can explain observed products from lithiation reactions, some debate in 
the literature has taken place over the precise mechanistic details. For example, it was 
initially unclear whether the prelithiation complex existed in solution as a discrete species 
(the CIPE model), or whether deprotonation takes place as soon as the alkyllithium 
reagent becomes associated with the directing group (the “kinetically enhanced 
metallation” model).32 Beak attempted to probe the formation of the prelithiation 
complex using deuterated ureas. Lithiation of α-monodeuterated urea 23 with s-
BuLi/TMEDA resulted in a 20:1 preference for the removal of the proton over deuterium. 
This was expected based on the kinetic isotope effect. However, lithiation using s-
BuLi/TMEDA of a 50:50 mixture of undeuterated urea 24 and α,α-dideuterated urea 25 
resulted in a 50:50 mixture of lithiated products. No preference for the removal of a 
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proton over deuterium was observed. This suggested that the first step in the lithiation is 
the irreversible formation of a prelithiation complex (scheme 1.8).33 In contrast, it can be 
imagined that if lithiation proceeded via the kinetically enhanced metallation model, a 
20:1 kinetic isotope effect would be observed. In situ infra-red spectroscopic studies have 
also been used to verify the CIPE model and these will be presented in chapter 2. 
 
Scheme 1.8 
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1.3 Lithiation-Trapping of Carbamates 
 Seebach reported the first use of carbamates as a directing group for lithiation.34 Using 
sterically bulky carbamate 26, s-BuLi/TMEDA-mediated lithiation was carried out to 
give substituted dimethylamines such as 27 (scheme 1.9). 
 
Scheme 1.9 
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1.3.1 Lithiation α to Oxygen in O-Alkyl Carbamates 
 Complexes of alkyllithiums and chiral diamine ligands can be used to effect 
enantioselective lithiation of carbamate substrates. The most commonly used chiral 
diamine ligand is (–)-sparteine 3. Early work on s-BuLi/(–)-sparteine 3-mediated 
lithiations of carbamates was carried out by Hoppe. Lithiation α to oxygen in O-alkyl 
carbamates using s-BuLi/TMEDA was investigated in the 1980s.35-37 For example, 
lithiation of O-alkyl carbamate 28 with s-BuLi/TMEDA and then trapping with carbon 
dioxide gave a 65% yield of acid rac-29 (scheme 1.10) Subsequently, Hoppe reported 
enantioselective lithiation of O-alkyl carbamates using the s-BuLi/(–)-sparteine 3 
complex. Thus, treatment of carbamate 28 with s-BuLi/(–)-sparteine 3 and then trapping 
with carbon dioxide gave acid (R)-29 in 78% yield and >97.5:2.5 er (scheme 1.10).38, 39 
 
Scheme 1.10 
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 Enantioselective lithiation of O-alkyl carbamates was extensively studied by the Hoppe 
group throughout the 1990s and 2000s. In 2005, Würthwein and Hoppe published DFT 
calculation evidence which confirmed the experimental observations of the preferential 
removal of the pro-S proton by the s-BuLi/(–)-sparteine 3 complex.40 Hoppe’s 
methodology has found some synthetic use as a convenient synthesis of enantioenriched 
2-substituted alcohols. Examples of its use in total syntheses include Hoppe’s syntheses 
of (R)-pantolactone41 and (S)-1-methyldodecylacetate,42 a fruit fly pheromone, Taylor’s 
synthesis of (R)-japonilure43 and Brückner’s synthesis of an algae nonaether.44  
 A further development of Hoppe’s methodology involves trapping a lithiated carbamate 
with an organoboron electrophile and subsequent rearrangement of the trapped product. 
Kocienski and Hoppe both showed that such a trapped product underwent a 1,2-
rearrangement to give a new organoboronate product with loss of the carbamoyl motif.45-
47 The full utility of this methodology was ultimately revealed by Aggarwal and co-
workers, who further optimised the method and applied it to new substrates.48 Thus, O-
alkyl carbamate 30 was lithiated and trapped with a boronate ester to give boronate (S)-
31, which underwent rearrangement in the presence of magnesium bromide to give a new 
boronate ester (R)-32. Cleavage of the C–B bond with H2O2 then reinstalled a hydroxyl 
group. In effect, carbamate 30 has been substituted and deprotected to reveal the parent 
alcohol (R)-33 in one pot (scheme 1.11).  
 
Scheme 1.11 
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1.3.2 Lithiation-Trapping of -Boc Pyrrolidine  
 Carbamate-directed lithiations provide a convenient route for the installation of a 
substituent in the 2-position of pyrrolidines. 2-Substituted pyrrolidines are a common 
motif in natural products and biologically active molecules. Examples include the drug 
molecules Altace 34 (King Pharmaceuticals, heart disease) and Relpax 35 (Pfizer, 
migrane) and the natural products (–)-indolizidine 167B 36 and (–)-aphanorphine 37 
(figure 1.3).49, 50 
 
Figure 1.3 
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 Beak reported in 1989 that treatment of -Boc pyrrolidine 38 with s-BuLi/TMEDA 
followed by electrophilic trapping provided high yields of racemic 2-substituted 
pyrrolidines. It was found that the -Boc carbamate group both facilitated α-lithiation 
and was sufficiently sterically hindered to prevent nucleophilic attack by the s-BuLi at 
the carbamate carbonyl group.29 For example, lithiation of -Boc pyrrolidine 38 with s-
BuLi/TMEDA and then trapping with trimethylsilyl chloride provided racemic silyl 
pyrrolidine rac-39 in 81% yield (scheme 1.12). The well-known chemistry of the -Boc 
protecting group, with ease of installation and removal, was an additional advantage.  
 
Scheme 1.12 
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 In 1991, Beak expanded this methodology to show that lithiation mediated by s-BuLi/ 
(–)-sparteine 3 and then trapping provided high yields of 2-substituted pyrrolidines with 
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high enantioselectivity. For example, upon trapping with trimethylsilyl chloride (S)-39 
was formed in 76% yield and 98:2 er (scheme 1.13).51, 52 
 
Scheme 1.13 
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 A limitation of this methodology is that sparteine 3 has, up until recently, only been 
commercially available as the (–)-enantiomer. Currently, even (–)-sparteine 3 is not 
commercially available. Our group has attempted to address the lack of availability of 
(+)-sparteine by the development of (+)-sparteine surrogate 6.4, 53-56 It is worth noting that 
the synthesis of (+)-sparteine surrogate 6 starts from the natural product (–)-cytisine 40 
which is also only available in one enantiomeric form (scheme 1.14). 
 
Scheme 1.14 
NN N N
Me
(_)-Sparteine 3 (+)-Sparteine Surrogate 6
N N
H
O
(_)-Cytisine 40  
 
 It was shown that (+)-sparteine surrogate 6 displays similar yields and 
enantiocomplementarity to (–)-sparteine 3 in the lithiation-trapping of -Boc pyrrolidine 
38. For example, lithiation of -Boc pyrrolidine 38 with s-BuLi/(+)-sparteine surrogate 6 
gave (R)-39 in 84% yield and 95:5 er after trapping with trimethylsilyl chloride (scheme 
1.15).4, 57 It was also shown to be successful in lithiations of O-alkyl carbamates, 
providing trapped products in high yield and er.58 
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Scheme 1.15 
N
Boc
N
Boc
SiMe3
1. s-BuLi, 6
Et2O,
_78 oC, 5 h
2. Me3SiCl
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 Another alternative chiral diamine ligand for use in the enantioselective lithiation of -
Boc pyrrolidine 38 is the cyclohexane diamine-derived ligand (R,R)-8.59 Lithiation of 38 
by s-BuLi/(R,R)-8 provided substituted pyrrolidines in similar yields and 
enantioselectivity to (–)-sparteine 3 and (+)-sparteine surrogate 6 (scheme 1.16). Thus, 
lithiation-trapping of -Boc pyrrolidine 38 with s-BuLi/(R,R)-8 gave (S)-39 in 72% yield 
and 95:5 er. Conveniently, the synthesis of 8 began with a resolution of the racemic 
parent cyclohexane-1,2-diamine. Thus, either enantiomer of 8 could be prepared.59 
Ligand 8 has recently become commercially available (€164.30/1 g for each enantiomer, 
TCI 2011). 
 
Scheme 1.16 
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 Mechanistically, Beak showed that the enantioenrichment arises in the deprotonation 
step – the chiral diamine/alkyllithium complex removes one prochiral proton faster than 
the other, i.e. enantioselectivity is controlled by the kinetics of deprotonation.52 Another 
method of obtaining enantioenriched products from lithiation-trapping experiments is the 
dynamic-thermodynamic resolution (DTR) lithiation protocol developed by Beak.10 In 
this case, enantioenrichment arises from equilibration of the diastereomeric complex of 
lithiated pyrrolidine and chiral ligand to the most thermodynamically favourable 
diastereomer. Alternatively, one diastereomer can react with the electrophile faster to 
promote dynamic kinetic resolution (DKR). For example, tin-lithium exchange of 
racemic stannane rac-41 with n-BuLi generated racemic lithiopyrrolidine 42. Trapping 
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with trimethylsilyl chloride allowed DKR to give substituted pyrrolidines in good yield 
and high er.Silyl pyrrolidine (S)-39 was obtained in 54% and 96:4 er (scheme 1.17).60  
 
Scheme 1.17 
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 DKR via deprotonation of -Boc pyrrolidine 38 in the presence of s-BuLi/43 was also 
reported, with silyl pyrrolidine (S)-39 isolated in 57% yield and 95:5 er (scheme 1.18).60 
DTR of -alkyl 2-lithiated pyrrolidines has also been reported.61-63 
 
Scheme 1.18 
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1.3.3 Lithiation-Trapping of -Boc Piperidine  
 Given the ease of lithiation of -Boc pyrrolidine 38 using s-BuLi/(–)-sparteine 3, it is 
perhaps surprising that the analogous -Boc piperidine 44 is far more difficult to lithiate. 
The very reactive s-BuLi/TMEDA complex can effect lithiation of -Boc piperidine 44, 
but less favourable results were obtained with (–)-sparteine 3.29, 64 Beak reported the 
results of a computational study which indicated that the α-protons of -Boc piperidine 
44 are less acidic than those of -Boc pyrrolidine 38.64 It was also shown that for -Boc 
piperidine 44, there was less energetic difference between removal of a pro-R and a pro-S 
proton by s-BuLi/(–)-sparteine 3 than for -Boc pyrrolidine 38. Experimentally, lithiation 
of 38 with s-BuLi/(–)-sparteine 3 and then trapping provided a 71% yield of adduct (S)-
 15 
39 after 4-6 h (scheme 1.13), but only 8% of -Boc piperidine product (S)-45. 
Additionally, a 43% yield of enamine 46 was obtained, indicating that attack of s-BuLi at 
the Boc group was competitive with deprotonation (scheme 1.19).64, 65 
 
Scheme 1.19 
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 The next development in -Boc piperidine 44 lithiation methodology came in 2007 
when it was shown that lithiation of -Boc piperidine 44 with s-BuLi/cyclohexane 
diamine (R,R)-8 gave a slightly improved result compared to (–)-sparteine 3: 13%, 90:10 
er of product (S)-45 after 6 h vs. 8%, 87:13 er after 16 h (scheme 1.20).65 Other diamines 
were also investigated, but gave far lower enantioselectivities.  
 
Scheme 1.20 
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 It has also been shown that piperidines with 4-substituents are easier to lithiate than the 
parent -Boc piperidine 44. For example, lithiation of 4-phenyl piperidine 47 with s-
BuLi/(R,R)-8 and then trapping with trimethylsilyl chloride gave adduct 48 in 48% yield 
and 87:13 er. Acetal piperidine 49 was also found to be easier to lithiate than -Boc 
piperidine 44. Thus, lithiation with s-BuLi/(R,R)-8 and then electrophilic trapping gave a 
53% yield of silyl piperidine (S)-50 in 53:47 er (scheme 1.21).65 
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Scheme 1.21 
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 Using competition experiments, it was shown that s-BuLi/(+)-sparteine surrogate 6 is a 
faster lithiator than s-BuLi/(–)-sparteine 3.66 Thus, our group hypothesised that it would 
be of use in lithiating -Boc piperidine 44. Indeed, lithiation of -Boc piperidine 44 with 
s-BuLi/6 gave high yields and ers of substituted piperidines (scheme 1.22).67 
Simultaneously, the configurational stability of the lithiated piperidine was probed. Much 
like -Boc pyrrolidine 38, configurational instability of lithiated -Boc piperidine 44 
becomes a significant factor at temperatures above –40 °C.67 
 
Scheme 1.22 
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 Given that lithiation of -Boc piperidine 44 can easily be effected with s-
BuLi/TMEDA, DTR lithiation is also an attractive way of generating lithiated 
piperidines. Coldham showed that, using ligand 51, trapped piperidines could be obtained 
in acceptable yields and enantioselectivities. Thus, lithiation of -Boc piperidine 44 
using s-BuLi/TMEDA, addition of ligand 51 and warming to –40 °C before electrophilic 
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trapping gave 2-substituted piperidines in 38-67% yield and enantioselectivites between 
74:26 and 87:13 er (scheme 1.23).68 
 
Scheme 1.23 
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 A recent development of this DTR route to substituted piperidines is the catalytic 
dynamic resolution (CDR) lithiation protocol developed by Gawley. Lithiation of -Boc 
piperidine 44 was carried out using s-BuLi and a stoichiometric amount of TMEDA. 
Addition of a substoichiometric amount of chiral ligand syn-52, with warming to –45 °C 
then followed by electrophilic trapping gives access to substituted piperidines in high 
yields and enantioselectivity. For example, trapping with CO2 gives acid (R)-54 in 78% 
yield and 98:2 er. A satisfactory explaination for the enantioselectivity of this protocol 
has yet to be proposed. Nevertheless, products were obtained in 98:2 er – a higher 
enantioselectivity than was obtained using DTR, or enantioselective lithiation. 
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1.3.4 Lithiation-Trapping of Other -Boc Amines 
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 In comparison to pyrrolidine and piperidine, the 7-membered analogue -Boc 
homopiperidine 56 has received relatively little attention. Beak reported racemic 
lithiation-trapping using s-BuLi/TMEDA and Dieter and co-workers carried out another 
isolated example.29, 69 Coldham reported the only example of a lithiation-trapping route to 
enantioenriched 2-substituted homopiperidines. Using a DTR lithiation strategy, trapped 
products 57 were obtained in modest yields (18-33%), and enantioselectivity comparable 
to those obtained in other DTR lithiations (87:13-92:8 er) (scheme 1.25).68 
 
Scheme 1.25 
N
Boc
N
Boc
E
1. s-BuLi, TMEDA
_78 oC, 3 h
2. 58, _30 oC, 1 h
3. E+, _78 oC
56 57
18 - 33%
87:13 - 92:8 er
N
N
LiO58
 
 
 The lithiation-trapping of -Boc piperazines 59 and 60 has also been investigated. In 
2005, Van Maarseveen reported the s-BuLi/TMEDA-mediated racemic lithiation of -
Boc-ʹ-benzyl piperazine 59 and -Boc-ʹ-methyl piperazine 60, obtaining good yields 
(scheme 1.26).70 Martin subsequently used this protocol in a synthesis of the natural 
product (–)-alstonerine.71 
 
Scheme 1.26 
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2. Bu3SnCl N
N
Boc
Bn
N
N
Boc
Me
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 The first example of an enantioselective lithiation of -Boc piperazine was reported by 
McDermott in 2008. In this case, -Boc-ʹ-t-butylpiperazine was lithiated with s-BuLi/(–
)-sparteine 3. However, only one electrophile (CO2) was reported, and the conditions 
were not optimised.72 In contrast, Coldham applied DTR lithiation conditions to -Boc-
ʹ-t-butylpiperazine 63, trapping with a range of electrophiles in modest yields and ers 
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(scheme 1.27). Selected examples of -Boc-ʹ-methyl and -Boc-ʹ-benzyl piperazines 
60 and 59 were also reported.73 
 
Scheme 1.27 
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 In 2001, the enantioselective lithiation of -Boc imidazolidines was reported by 
Coldham. For example, treatment of -Boc-ʹ-isopropylimidazolidine 64 with s-BuLi/(–
)-sparteine and then electrophilic trapping gave products in high er, but with ≤50% 
yield.74, 75 It was hypothesised that at –78 °C, the -Boc rotamers do not interconvert. As 
lithiation depends on the Boc directing group orientating the alkyllithium reagent towards 
the acidic proton, the maximum theoretical yield was defined by the ratio of the Boc 
rotamers in solution (scheme 1.28).74 
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 Lithiation of fused ring systems has also been investigated. Our group reported the 
racemic lithiation of -Boc-ʹ-methylbispidine 65 using s-BuLi/TMEDA and trapped 
products were obtained in modest yields (scheme 1.29).76 Lithiation-trapping of the 
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analogous -Boc-ʹ-benzylbispidine 67 was later used to complete a total synthesis of 
the natural product (±)-cytisine 40 (scheme 1.29).77 
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 Other examples of racemic lithiations of fused ring amines include the s-
BuLi/TMEDA-mediated deprotonation of 69, reported by Jordis et al.,78 and of 70, 
reported by Krow et al. (figure 1.4).79  
 
Figure 1.4 
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1.4 Beyond Simple Electrophiles: Lithiation-Arylations 
 Although lithiation-trapping gives access to a range of 2-substituted pyrrolidines in 
potentially high yield and enantioselectivity, 2-aryl and 2-vinyl pyrrolidines are not 
obtainable using this method. A convenient route to such systems is potentially useful as 
a wide range of synthetic targets bear this motif, for example the natural products 
brevicoline 7180 and crispine A 7281, the C2-symmetric chiral auxiliary 73
82 developed by 
Rawal, and the drug molecules 7483 and 7584 (figure 1.5). 
Figure 1.5 
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 A number of different synthetic routes to the 2-aryl pyrrolidine motif have been 
explored. Ring closing to form the pyrrolidine with an aryl group in place has been 
investigated by a number of different groups, as has transition metal-catalysed installation 
of an aryl group onto a pre-existing ring. Several different lithiation-arylation and 
lithiation-vinylation protocols have also been reported. 
 
1.4.1 Previous Lithiation-Arylation and Lithiation-Vinylation of -Boc Pyrrolidine 
38 
 Arylation and vinylation of pyrrolidine have been reported by Dieter. In 1995, it was 
shown that lithiation of -Boc pyrrolidine 38 using s-BuLi/TMEDA to form 
lithiopyrrolidine 76 followed by coupling of electron rich aryl iodides in the presence of 5 
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mol% Pd and 10 mol% copper(I) cyanide provided 2-aryl pyrrolidines in modest yields. 
In this case, rac-77 was obtained in 54% yield (scheme 1.30).85 It was found that 
coupling did not proceed with electron-poor aryl iodides. Arylation of piperidines was 
also successful.85 
 
Scheme 1.30 
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 Dieter subsequently found that higher yields could be obtained with softer palladium 
ligands such as AsPh3 and PbPh3. Vinylations via coupling of vinyl iodides were also 
carried out. However, only racemic lithiation-couplings were reported, and the group 
were still unable to effect coupling with electro-poor aryl iodides.86 
 Enantioselective lithiation of -Boc pyrrolidine 38 using s-BuLi/(–)-sparteine 3 
followed by transmetallation with copper(I) cyanide to organocuprate 78 and then 
trapping with vinyl iodides gave 2-alkenyl pyrrolidines in high yields. For example, vinyl 
pyrrolidine (R)-79 was obtained in 98% yield and 93:7 er (scheme 1.31). It was found 
that enantioselectivities varied greatly depending on the electrophile used.87, 88 Arylations 
were not, however, reported.87, 88 
 
Scheme 1.31 
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1.4.2 Lithiation-7egishi coupling of -Boc Pyrrolidine  
 In 2006, Campos presented a new paradigm in pyrrolidine lithiation chemistry.89 
Lithiation of -Boc pyrrolidine 38 using s-BuLi/(–)-sparteine 3 and then transmetallation 
with zinc chloride gave organozinc species 80. A palladium-catalysed Negishi coupling 
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was then used to install aryl substituents in high yields and ers (scheme 1.32).89 For 
example, reaction with bromobenzene gave (R)-77 in 82% yield and 96:4 er. 
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 During optimisation of the arylation protocol, it was shown that the highest yields were 
achieved with palladium(II) acetate and t-Bu3PHBF4, developed by Fu.
89, 90 Interestingly, 
it was shown that PdCl2(dppf), regarded as the optimal catalyst for effecting Negishi 
couplings gave <5% yield.89, 91 Aryl bromides were the coupling agents of choice – 
reduced yields were obtained when using chlorobenzene or pseudohalides. A wide range 
of aryl bromides were successfully used including unprotected amines to give (R)-81 
(78%) and (R)-82 (77%). Couplings were performed at rt, with the exception of 3-
bromopyridine, which required coupling to be performed at 60 °C and gave (R)-84 in 
60% yield. Two recent reviews have summarised lithiation-arylations of carbamates and 
synthetic methods for the installation of substituents including aryl groups in the α-
position of -heterocycles, including Campos’ new protocol.47, 92 
 With the new methodology in hand, Campos was then able to carry out the synthesis of 
glucokinase activator 74 on a large scale, via coupling to give (R)-85.83 As a measure of 
the utility of the Negishi coupling strategy, the new protocol was used to provide (R)-85 
of 96:4 er in 2.13 kg from two lithiation-arylation batches, each on a 6.0 mol scale 
(scheme 1.33).83 
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 Other groups have made use of this convenient route to 2-aryl pyrrolidines. In the first 
reported example, Jacobsen used Campos’ methodology as a route to a range of thiourea 
organocatalysts of the general structure 86 (scheme 1.34).93 The products were 
investigated as catalysts for the addition of 1-chloroisochromans to ketene acetals.93 
Jacobsen also used this method for the synthesis of 2-aryl pyrrolidine thiourea 
organocatalysts for addition of indoles to -acyliminiums and catalytic 
polycyclisations.94, 95 
 
Scheme 1.34 
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 A feature of the lithiation-transmetallation-coupling sequence is that while lithiated 
pyrrolidine 42 is subject to epimerisation at high temperatures (≥–40 °C in diethyl ether), 
organozinc 80 remains chemically and configurationally stable up to 60 °C.52, 96, 97 Sutton 
and co-workers took advantage of this fact during a parallel synthesis of a range of Hsp90 
inhibitors. A large batch of organozinc 80 was synthesised and then aliquots were 
separated out for coupling with different aryl bromides.98 Campos had also taken 
advantage of this feature when optimising the reaction conditions.89 
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1.4.3 Lithiation-7egishi Coupling of Other -Boc Heterocycles 
 The lithiation-Negishi coupling methodology has been applied to the arylation of -
Boc piperidine 44. Coldham reported a racemic arylation procedure via s-BuLi/TMEDA 
mediated lithiation in 2008.99 Coupling of a range of aryl bromides was reported and, as a 
representative example, phenyl piperidine rac-87 was obtained in 75% yield (scheme 
1.35).99 
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 Our group recently reported an isolated example of enantioselective synthesis of an aryl 
piperidine via lithiation of -Boc piperidine 44 with s-BuLi/(+)-sparteine surrogate 6.67 
Yield and enantioselectivity were modest: aryl piperidine (S)-88 of 82:18 er was obtained 
in 33% yield (scheme 1.36).67 
 
Scheme 1.36 
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 Coldham attempted to apply the DTR lithiation procedure to form 2-arylpiperidines, 
but was unable to effect coupling.68 It was shown that transmetallation to the organozinc 
proceeded, and it was thus hypothesised that residual DTR ligand prevented palladium-
catalysed coupling. Instead, tin-lithium exchange of enantioenriched piperidinyl stannane 
(S)-89 was used to access lithiated piperidine, and coupling was achieved in high yields, 
although modest ers. Phenyl piperidine (R)-87 was obtained in 71% yield and 82:18 er, 
while (R)-90 was obtained in 56% yield and the same er (scheme 1.37).68 
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Scheme 1.37 
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 As an alternative, Gawley has recently shown that lithiation of -Boc piperidine 44 by 
catalytic dynamic resolution allows coupling to give 2-aryl piperidines in high yields and 
enantioselectivities. Vinylations were also reported (scheme 1.38).100 Presumably, either 
the CDR ligand does not interfere with coupling in the same manner as Coldham’s DTR 
ligand, or the lower amount of lithium ligand present allows coupling of 
uncomplexed/TMEDA complexed organozinc species. Thus, for example, aryl piperidine 
(R)-88 was obtained in 75% yield and 97:3 er and vinyl piperidine (R)-91 of 92:8 er was 
formed in 63% yield. 
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 Racemic arylation of -Boc piperidine 44 can be accomplished using a s-
BuLi/TMEDA-mediated lithiation as reported by Coldham. Access to enantioenriched 2-
aryl piperidines, which has proved problematic using kinetically-controlled lithiation or 
DTR lithiation conditions, can now be effected using the CTR lithiation-arylation 
procedure demonstrated by Gawley. 
 Recently, Knochel reported the use of lithiation-arylations on substituted -Boc 
piperidines. Thus, disubstituted piperidines were formed in high yields and 
enantioselectivities.101  
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1.5 Alternative Routes to 2-Aryl Pyrrolidines 
 Several different routes have been investigated as alternatives to lithiation-arylation of 
-Boc pyrrolidine 38 for the synthesis of 2-aryl pyrrolidines. In 1992, Meyers reported a 
ring closing protocol for the formation of 2-substituted pyrrolidines, including 2-
phenylpyrrolidine.102 Savoia presented an alternative route to (S)-2-phenylpyrrolidine 
beginning from (S)-valine two years later.103 Higashiyama104 and Ellman105 have also 
reported ring closing syntheses of 2-aryl pyrrolidines. Cyclisation of sulfinyl imines has 
perhaps shown the most promise as a protocol for the formation of aryl pyrrolidines. 
Beak presented a lithiation protocol on an acyclic -Boc amine, using an internal 
electrophile to effect cyclisation to a pyrrolidine ring.106 Transition metal-catalysed 
processes have been presented as an alternative to cyclisation routes to 2-aryl 
pyrrolidines. Buchwald reported a titanium-catalysed reduction of 2-phenyl-1-
pyrroline.107 Sames used a ruthenium catalyst to effect arylation of pyrrolidine via C–H 
activation to give 2,5-diaryl pyrrolidines.108 The same catalyst was used in a 
decarboxylative coupling of a methyl proline ester, affording racemic 2-aryl pyrrolidines 
in moderate yields.109 
 Of these approaches, two are discussed in detail. De Kimpe reported the reductive ring 
closing of γ-chloro--sulfinyl ketimine 92 using LiBEt3H.
110 Simultaneously, however, 
Reddy reported the reduction of 92 with LiBEt3H with greater yield (94%) and improved 
diastereoselectivity (99:1 dr). Furthermore, it was found that reductive cyclisation using 
DIBAL-H then LiHMDS gave comparable (92%) yield of the opposite diastereomer with 
the same degree of selectivity (scheme 1.39).111 Reddy also demonstrated the 
methodology with a wide range of different aryl groups, as well as an extended sulfinyl 
ketimine to access 2-phenylpiperidine.111 
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 The methodology reported by Reddy and De Kimpe requires the synthesis of 
sulfinylketimine 92 with the required aryl group already in place. As an alternative, 
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Reddy developed a slightly different protocol, wherein a stock starting material 94 was 
treated with any one of a range of organomagnesium chlorides to effect installation of the 
required group and cyclisation to a pyrrolidine ring in one pot (scheme 1.40).112 A variety 
of aryl, vinyl and alkyl organometallic reagents were investigated, giving high yields and 
drs (91%, 97:3 dr for phenyl). While this method is more convenient for the synthesis of 
a series of 2-arylpyrrolidine, both stereochemical series of product are not accessible 
from the same enantiomer of starting material. 
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 A final ring closing strategy to 2-arylpyrrolidines relies on s-BuLi/(–)-sparteine 3-
mediated lithiation of an -Boc amine 95 followed by intramolecular trapping with an 
alkyl halide. A range of different aryl groups were used to access a range of 2-aryl 
pyrrolidines in modest yields (21 – 75%) but acceptable enantioselectivities (92:8 – 98:2 
er).106 It is notable that this lithiation-trapping route results in a product of the opposite 
enantiomeric series to that obtained from (–)-sparteine/s-BuLi mediated lithiation-
arylation of -Boc pyrrolidine (scheme 1.41).106 
 
Scheme 1.41 
 
 
 
 
 Beak’s work was carried out before our group reported the use of (+)-sparteine 
surrogate 6 in lithiations. Thus, it was only possible to access the (S)-enantiomeric series 
of 2-aryl pyrrolidines. This route also constitutes an example of lithiation-trapping using 
an internal electrophile. Lithiation of the benzylic position takes place preferentially to 
nucleophilic attack of s-BuLi at the alkyl halide.  
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1.6 Project Outline 
 This thesis will focus on a number of different areas of research concerning the 
lithiation-trapping of -Boc heterocycles. Using a newly acquired ReactIR system, we 
hoped to use in situ infra-red spectroscopy to observe formation of prelithiation 
complexes, and also to follow the progress of α-lithiation by observing changes in the 
carbamate νC=O stretch (scheme 1.42). The intention was to directly compare different 
carbamate substrates and diamine ligands in lithiation reactions (chapter 2).  
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 Our group has previously reported a two-ligand catalytic lithiation of -Boc pyrrolidine 
38, allowing the use of substoichiometric amounts of chiral diamines to obtain high 
yields of trapped products in high enantioselectivities. We wished to further investigate 
this protocol, assaying a number of new “secondary” ligands, and also applying this 
methodology to two-ligand catalytic lithiation-arylations (chapter 3). It was also hoped to 
use Campos’ lithiation-arylation methodology in the total syntheses of the natural 
products (R)-dihydroshihunine (R)-96 and (S)-nicotine (S)-97 and the drug molecule 
SIB1508Y (S)-98. Additionally, we hoped to modify Campos’ procedure to allow for 
lithiation-vinylations, and complete a total synthesis of the natural product (R)-
maackiamine (R)-99 (figure 1.6). The results are presented in chapter 4. 
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 As detailed in chapter 5, we then decided to investigate a new racemic lithiation 
protocol. We hoped that this methodology, carried out at high (–30 °C) temperature and 
without the use of a diamine, would prove useful to chemists operating on a large-scale. 
Finally, we wished to take the products of a lithiation-arylation reaction and resubject 
 30 
them to lithiation-trapping, forming a new quaternary stereocentre α to nitrogen (scheme 
4.3) (chapter 6). 
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Chapter 2: In Situ ReactIR Spectroscopic Monitoring of 
Carbamate Lithiations 
 
 This chapter is concerned with following s-BuLi/diamine-mediated lithiations in diethyl 
ether using in situ infra-red spectroscopy via a ReactIR system. The seven carbamates 
shown in figure 2.1 were selected for our studies. To directly compare different ring sizes 
of nitrogen heterocycles, lithiations of -Boc pyrrolidine 38, -Boc piperidine 44 and -
Boc homopiperidine 56 were investigated. Lithiations of -Boc acetal piperidine 49 and 
-Boc piperazine 59 were also studied, in order to compare their rate of lithiation with 
that of -Boc piperidine 44. -Boc imidazolidine 64 was chosen as we were interested in 
exploring the issue of regiochemistry and the affect of -Boc group rotamers on the 
lithiation. Finally, lithiation α to oxygen of O-alkyl carbamate 100 would provide a 
comparison to the -Boc nitrogen heterocycles. 
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2.1 Previous In Situ Infra-Red Spectroscopic Monitoring of Lithiations 
 Substrate-directed lithiations at sp3 carbon centres have previously been followed by in 
situ infra-red spectroscopy. An early example was reported by Beak in 1983.16, 18 Using a 
stopped-flow infra-red apparatus, direct observation of a prelithiation complex was 
achieved.16 Studying the reaction of aryl amide 101 (νC=O 1650 cm
–1) with s-BuLi in 
toluene, rapid formation of prelithiation complex 102 (νC=O 1625 cm
–1) was observed 
followed by the slower conversion of 102 to lithiated intermediate 103 (νC=O 1588 cm
–1) 
(scheme 2.1).16 
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 Beak then expanded this work with an investigation into the kinetics of lithiation of aryl 
amide 101 by s-BuLi in toluene, both by free alkyllithium and in the presence of 
TMEDA.18 Interestingly, it was concluded that prelithiation complex 102 was formed 
between aryl amide 101 and alkyllithium aggregates, rather than monomeric s-BuLi.18 
 In 1984, Smith reported following the reaction of s-BuLi or n-BuLi with ketone 104 via 
prelithiation complex 105 to give lithium enolate 106  in cyclohexane (scheme 2.2).113 As 
with Beak’s work, it was found that in cyclohexane, both formation of prelithiation 
complex 105 and lithiation to give 106 involved the action of complex alkyllithium 
aggregates.113 In this study, νC=O stretches were broad and exact wavenumbers were not 
reported.  
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 Next, Smith investigated the reaction of alkyllithiums with esters.114 Working in 
cyclohexane, it was shown that substrates formed complexes with alkyllithium 
aggregates. Upon treating aryl ester 107 with s-BuLi, it proved possible to observe both 
ester-s-BuLi complex 108 and intermediate ketone-s-BuLi complex 110 (scheme 2.3). 
The kinetics of the reaction of s-BuLi with ester 107 and a range of aryl-substituted 
analogues were also reported.114 
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 In comparison to Beak and Smith’s work, Collum reported a study of the LDA-
mediated enolisation of esters.115 The reactive LDA-THF complex was determined to be 
a dimeric complex LDA2THF2. When ester 112 (νC=O 1727 cm
–1) was treated with LDA 
in Et2O, prelithiation complex 113 (νC=O 1703 cm
–1) was observed before deprotonation 
to give enolate 114 (νC=C 1646-1664 cm
–1) (scheme 2.4).115 Subsequently, Collum studied 
a range of lithiation conditions/solvents and used kinetic data to place different LDA-
solvent complexes in order of lithiation activity.116 
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 Although the carbonyl group presents itself as an ideal spectroscopic “handle” for 
following reactions by infra-red spectroscopy due to a clear νC=O remote from other 
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absorbances, the imine νC=N has also been used. For example, Collum followed the 
lithiation of imine 115 (νC=N 1661 cm
–1) to give enamide 116 with n-BuLi and PhLi 
(scheme 2.5).117 By following the disappearance of νC=N, the kinetics of lithiation with 
different organolithium/diamine complexes was studied. The nucleophilic addition of 
PhLi and n-BuLi to a different imine  has also been investigated.117 
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 Two previous examples of the use of in situ ReactIR spectroscopy to monitor the 
lithiation of -Boc activated substrates have been reported. In 2001, Beak used ReactIR 
to determine the kinetics of lithiation of allylamine 117 (νC=O 1695 cm
–1) to lithiated 
product 119 (νC=O 1640 cm
–1) via prelithiation complex 118 (νC=O 1675 cm
–1) (scheme 
2.6).118 
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 Most recently, in collaboration with Campos at Merck, our group has reported the 
ReactIR spectroscopic monitoring of the lithiation of -Boc piperidine 44 (νC=O 1695  
cm–1) by s-BuLi/TMEDA, s-BuLi/(–)-sparteine 3 or s-BuLi/(+)-sparteine surrogate 6.67 
For example, treatment of -Boc piperidine 44 with s-BuLi in diethyl ether led to the 
formation of prelithiation complex 120 (νC=O 1675 cm
–1). Then, addition of TMEDA 
promoted reaction to give lithiated intermediate 55 (νC=O 1644 cm
–1) (scheme 2.7). It was 
shown that lithiation with s-BuLi/(+)-sparteine surrogate 6 led to rapid formation of 55 
whereas use of s-BuLi/(–)-sparteine 3 gave only a small amount of 55 after 6 h.67 
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2.2 ReactIR Spectroscopic Monitoring of Carbamate Lithiations 
 Several limitations were imposed by the equipment that was available for our use. The 
apparatus was equipped with a silicon-tipped (SiComp) ReactIR probe tip. As we were 
worried about potential degradation of the silicon window, lithiations were run at the 
maximum dilution which still allowed clear observation of the relevant νC=O peak. 
Typically, reactions were carried out with 1.0 mmol of substrate in 14 mL of solvent. 
This is more dilute than standard synthetic experimental conditions which are usually 2.0 
mmol of substrate in 7 mL of solvent.  
 Additionally, the reaction flask was not completely air-tight as the ReactIR probe tip 
was inserted into the flask though a pierced Suba-Seal®. Trial and error testing suggested 
that at reaction times of longer than 90 min, an unacceptable quenching of alkyllithium 
reagent or lithiated substrate took place. We therefore limited the gathering of data to 
within this time period.  
 The ReactIR reactions were run under two different protocols. In one method, we 
hoped to form a prelithiation complex by reacting the substrate with s-BuLi alone. Then, 
some time later, diamine would be added to effect lithiation. In the second method, we 
wished to investigate conditions used in synthetic experiments. In this case, substrate and 
diamine would be premixed, and then s-BuLi added to effect the lithiation depending on 
the substrate and diamine. 
 
2.2.1 -Boc Piperidine 
 To begin our investigations, we verified the previously reported observations for the 
lithiation of -Boc piperidine 44 carried out by Campos.67 The intention was to form a 
prelithiation complex between -Boc piperidine 44 and s-BuLi in diethyl ether at –78 °C 
and then TMEDA would be added to initiate the lithiation. The ReactIR results are 
presented in two forms in scheme 2.8. The three-dimensional plot (A) allows the 
appearance and disappearance of new signals to be clearly seen as a reaction progresses. 
Alternatively, the absorbance of a specific wavelength can be plotted as a function of 
time (B). In graph B, units of time are expressed as days:hours:minutes. 
 
 
 
 37 
 In this case, when s-BuLi was added, a decrease in absorbance of the 1698 cm–1 peak 
(νC=O of -Boc piperidine 44) was observed, with an increase in the 1674 cm
–1 peak (νC=O 
of prelithiation complex 120). After addition of TMEDA, an immediate increase in the 
1698 cm–1 peak and a corresponding decrease in the 1674 cm–1 peak was noted. Then, a 
slow increase in absorbance at 1647 cm–1 (νC=O of lithiated intermediate 55) was 
observed. Lithiation was found to be complete after 90 min. 
 
Scheme 2.8 
N
Ot -BuO
N
Ot -BuO
N
Ot -BuO
Li
N
N
Li
44
ν C=O 1698 cm
-1
120
ν C=O 1674 cm
-1
55
ν C=O 1647 cm
-1
s-BuLi TMEDA
 
 
44
ν C=O 1698 cm
-1
120
ν C=O 1674 cm
-1
55
ν C=O 1647 cm
-1
+44
+s-BuLi
+TMEDA
 
           A                   B 
 
 Since the lithiation of -Boc piperidine 44 by s-BuLi/TMEDA is complete in 90 min  
the 3.5 h lithiation time used by Beak in typical synthetic experiments is clearly 
unnecessary.29  Interestingly, after TMEDA addition, some of prelithiation complex 120 
(νC=O 1674 cm
–1) reverted back to uncomplexed -Boc piperidine 44 (νC=O 1698 cm
–1). 
This observation indicates that the position of the substrate-prelithiation complex 
equilibrium is affected by the presence of diamine ligands. 
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 Next, the reaction of -Boc piperidine 44 with s-BuLi and (–)-sparteine 3 under 
experimental conditions was investigated. It was likely that we would not observe 
lithiated piperidine 121, as Beak had previously shown only 8% lithiation after 16 h 
under these conditions.64 Thus, -Boc piperidine 44 (νC=O 1695 cm
–1) and (–)-sparteine 3 
were premixed in diethyl ether at –78 °C. Then, s-BuLi was added. A new peak emerged 
at 1676 cm–1, which was assigned to νC=O in prelithiation complex 122 (scheme 2.9). 
 In the time period (40 min), no peak corresponding to νC=O in lithiated piperidine 121 
(expected in the range 1640-1650 cm–1) was observed. After addition of s-BuLi, only 
partial formation of prelithiation complex 122 observed. This confirms the observation 
(scheme 2.8) that the presence of a diamine ligand affects the position of the substrate-
prelithiation complex equilibrium. 
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2.2.2 -Boc Pyrrolidine 
 For comparison,  the lithiation of -Boc pyrrolidine 38 using s-BuLi/TMEDA was then 
investigated.29 We planned to form the prelithiation complex between s-BuLi and -Boc 
pyrrolidine 38 and then effect lithiation by addition of TMEDA. Thus, -Boc pyrrolidine 
38 (νC=O 1699 cm
–1) was stirred in diethyl ether at –78 °C and s-BuLi was added. A new 
peak appeared, which was assigned to prelithiation complex 123 (νC=O 1681 cm
–1). 
Finally, TMEDA was added, and another peak appeared, assigned to lithiated pyrrolidine 
76 (νC=O 1646 cm
–1) (scheme 2.10).  
  
Scheme 2.10 
N
Ot -BuO
N
Ot -BuO
N
Ot -BuO
Li
N
N
Li
38
ν C=O 1699 cm
-1
123
ν C=O 1681 cm
-1
76
ν C=O 1646 cm
-1
s-BuLi TMEDA
 
 
38
ν C=O 1699 cm
-1 123
ν C=O 1681 cm
-1
76
ν C=O 1646 cm
-1
+38
+s-BuLi
+TMEDA
 
 
 Unlike -Boc piperidine 44, after the addition of TMEDA no dissociation of s-BuLi 
from complex 123 was observed. Lithiation was very fast and complete formation of 
lithiated pyrrolidine 76 was observed within 3 min of addition of TMEDA. The 3.5 h 
lithiation time reported by Beak is unnecessary.29 It is also worth noting that in the 
absence of diamine, no lithiation was observed. We conclude that diethyl ether is not a 
sufficiently activating ligand to effect this lithiation at –78 °C. 
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 Then, the lithiation of -Boc pyrrolidine 38 under typical experimental conditions 
using s-BuLi and (–)-sparteine 3 was investigated.52 Thus, -Boc pyrrolidine 38 (νC=O 
1702 cm–1) and (–)-sparteine 3 were premixed at –78 °C in diethyl ether. Then, s-BuLi 
was added, and a new peak emerged (νC=O 1680 cm
–1) which was assigned to prelithiation 
complex 124. The formation of lithiated pyrrolidine 125 (νC=O 1646 cm
–1) also began 
with the addition of s-BuLi (scheme 2.11). 
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 Formation of prelithiation complex 124 was very fast, happening within 2 min. 
Lithiation to give 125 was also fast and was complete within 15 min. As with the 
TMEDA example, this lithiation proceeds more quickly than suggested by previous 
literature: Beak reported lithiating -Boc pyrrolidine 38 with s-BuLi/(–)-sparteine for 4 
h.51 
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2.2.3 -Boc Homopiperidine 
 Following in situ infra-red spectroscopic monitoring of the lithiation of -Boc 
pyrrolidine 38 and -Boc piperidine 44, the investigation of different ring sizes of -Boc 
nitrogen heterocycles was completed by monitoring the lithiation of -Boc 
homopiperidine 56. Beak has previously reported the s-BuLi/TMEDA-mediated 
lithiation-trapping of -Boc homopiperidine 56: after trapping, an adduct was obtained in 
72% yield.119 The slower rate of lithiation of -Boc homopiperidine 56 compared to -
Boc pyrrolidine 38 has been noted.68 First, formation of the prelithiation complex was 
studied. Thus, -Boc homopiperidine 56 (νC=O 1695 cm
–1) was stirred in diethyl ether at 
–78 °C and s-BuLi was added. A new peak appeared, which was assigned to prelithiation 
complex 126 (νC=O 1673 cm
–1). Then, TMEDA was added and the slow evolution of a 
new peak at 1631 cm–1 was observed. This peak was assigned to νC=O in the lithiated 
product 127 (scheme 2.12). 
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 After addition of TMEDA, some of prelithiation complex 126 reverted to uncomplexed 
-Boc homopiperidine 56 and s-BuLi – a 50:50 mixture of 56 and 126 was observed. 
Then, lithiation took place slowly and only a small amount of lithiated product 127 was 
observed after a reaction time of 40 min. 
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 Next, the lithiation of -Boc homopiperidine 56 by s-BuLi/TMEDA under typical 
experimental conditions was investigated. -Boc homopiperidine 56 (νC=O 1695 cm
–1) 
and TMEDA were stirred in diethyl ether at –78 °C and then s-BuLi was added. A peak 
at 1679 cm–1 appeared (νC=O in prelithiation complex 128), followed by the slow 
emergence of a peak at 1646 cm–1 (νC=O in lithiated homopiperidine 127) (scheme 2.13). 
 
Scheme 2.13 
N N N
Ot -BuO Ot -BuO Ot -BuO
LiLi
N
N
s-BuLi
TMEDA
slow
56
ν C=O 1695 cm
-1
128
ν C=O 1679 cm
-1
127
ν C=O 1646 cm
-1
N
N
 
56
νC=O 1695 cm
-1
128
νC=O 1679 cm
-1
127
νC=O 1646 cm
-1
+56, TMEDA
+s-BuLi
 
 
 Incomplete formation of prelithiation complex 128 was observed after addition of s-
BuLi. Then, lithiation to give lithiated substrate 127 was slow. Only partial lithiation was 
observed after 40 min reaction time. We note that in this experiment, lithiated product 
127 shows an absorbace at νC=O 1646 cm
–1, compared with νC=O 1631 cm
–1 from the 
previous experiment (scheme 2.12). As the two solutions contained the same species at 
identical concentrations and temperature, this discrepancy is presumably due to software 
issues. 
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 Since only slow lithiation of -Boc homopiperidine 56 had been observed using s-BuLi 
and TMEDA, we expected that lithiation using s-BuLi/(–)-sparteine 3 would not proceed. 
To verify this, -Boc homopiperidine 56 (νC=O 1694 cm
–1) and (–)-sparteine 3 were 
mixed in diethyl ether at –78 °C and then s-BuLi was added. The appearance of a new 
peak at 1679 cm–1 was observed and assigned to νC=O in the prelithiation complex 129 
(scheme 2.14). 
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 In common with the lithiation of -Boc homopiperidine 56 using s-BuLi/TMEDA, 
only partial formation of prelithiation complex 129 was observed. In this case, no peak 
corresponding to lithiated product 130 was seen. 
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 The complex of s-BuLi/(+)-sparteine surrogate 6 has been shown to be a more effective 
lithiator than s-BuLi/(–)-sparteine 3.66 We therefore decided to investigate the use of (+)-
sparteine surrogate 6 in the lithiation of -Boc homopiperidine 56. Thus, -Boc 
homopiperidine 56 (νC=O 1694 cm
–1) and (+)-sparteine surrogate 6 were stirred in diethyl 
ether at –78 °C and then s-BuLi was added. After addition of s-BuLi, a new peak 
corresponding to prelithiation complex 131 (νC=O 1679 cm
–1) appeared. Then, another 
peak corresponding to lithiated product 132 (νC=O 1638 cm
–1) slowly emerged (scheme 
2.15). 
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 After addition of s-BuLi, only partial formation of prelithiation complex 131 was 
observed, as observed with treatment of 56 with s-BuLi/TMEDA and s-BuLi/(+)-
sparteine surrogate 6. Partial lithiation of -Boc homopiperidine 56 by s-BuLi/(+)-
sparteine surrogate 6 was noted after 30 min reaction time. Possible future work may 
involve synthetic experiments utilising s-BuLi/(+)-sparteine surrogate 6-mediated 
asymmetric lithiation of 56, although a long lithiation time of 3-6 h is likely to be needed. 
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2.2.4 -Boc Acetal Piperidine 
 Beak reported the s-BuLi/TMEDA-mediated lithiation-trapping of -Boc acetal 
piperidine 49 in 1989.29 It was shown in 2007 that the α- position of -Boc acetal 
piperidine 49 was easier to lithiate than that of parent -Boc piperidine 44. For example, 
lithiation mediated by s-BuLi/cyclohexane diamine (R,R)-8 and trapping with 
trimethylsilyl chloride gave a 53% yield of silyl adduct, compared with 13% yield from 
lithiation-trapping of -Boc piperidine 44 under the same conditions.65 We therefore 
decided to investigate the lithiation of 49 using in situ infra-red spectroscopy. First, the 
lithiation of 49 via formation of prelithiation complex 133 was studied. -Boc acetal 
piperidine 49 (νC=O 1702 cm
–1) was stirred in diethyl ether at –78 °C and s-BuLi was 
added. A new peak corresponding to prelithiation complex 133 (νC=O 1676 cm
–1) 
appeared. Then, TMEDA was added and a new peak at νC=O 1646 cm
–1 was observed and 
assigned to νC=O in the lithiated product 134 (scheme 2.16). 
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 After TMEDA addition, a small amount of prelithiation complex 133 dissociated to free 
-Boc acetal piperidine 49 and s-BuLi. Then, lithiation took place. Complete lithiation 
was observed after 40 min reaction time.  
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 Lithiation of -Boc acetal piperidine 49 by s-BuLi/TMEDA was then repeated under 
typical experimental condtions. Thus, 49 (νC=O 1702 cm
–1) and TMEDA were mixed in 
diethyl ether at –78 °C and then s-BuLi was added. A new peak appeared at 1680 cm–1, 
assigned to νC=O in the prelithiation complex 135. Then, lithiation to give organolithium 
species 134 (νC=O 1646 cm
–1) took place (scheme 2.17). 
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 After addition of s-BuLi, lithiation of -Boc acetal piperidine 49 to give 135 was 
relatively fast – complete lithiation was observed within 25 min, indicating that extended 
lithiation times are unnecessary.29 This is a shorter lithiation time than the 90 min 
reaction time required for complete lithiation of -Boc piperidine 44 (see scheme 2.8). 
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 Next, lithiation of 49 using s-BuLi/(–)-sparteine 3 was studied. -Boc acetal piperidine 
49 (νC=O 1702 cm
–1) and (–)-sparteine 3 were stirred in diethyl ether at –78 °C and s-BuLi 
was added. Formation of prelithiation complex 136 (νC=O 1680 cm
–1) and then slow 
lithiation to give product 137 (νC=O 1639 cm
–1) was observed (scheme 2.18). 
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 Although it has previously been reported that attempted lithiation-trapping of -Boc 
acetal piperidine 49 mediated by s-BuLi and (–)-sparteine 3 gave no products,65 we were 
able to observe a small amount of lithiation after a reaction time of 15 min. It is possible 
that repeated synthetic experiments under these conditions allowing longer lithiation 
times may be successful in producing 2-substituted analogues of 49.  
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 Finally, the s-BuLi/(+)-sparteine surrogate 6-mediated lithiation of -Boc acetal 
piperidine 49 was investigated. Thus, 49 and (+)-sparteine surrogate 6 (νC=O 1702 cm
–1) 
were stirred in diethyl ether at –78 °C and then s-BuLi was added. Peaks corresponding 
to prelithiation complex 138 (νC=O 1672 cm
–1) and lithiated product 139 (νC=O 1639 cm
–1) 
were observed (scheme 2.19). 
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 After s-BuLi addition, fast but incomplete lithiation to give 139 was observed. Previous 
lithiations of -Boc acetal piperidine 49 (using other diamines) have used a 6 h lithiation 
time.65 When using (+)-sparteine surrogate 6, it appears that such a long reaction time 
would not be needed. The reason for incomplete lithiation in this case is not known. 
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2.2.5 -Boc-ʹ-Benzylpiperazine 
  The next substrate selected for monitoring by in situ infra-red spectroscopy was -Boc-
ʹ-benzylpiperazine 59. First, lithiation via formation of prelithiation complex 140 was 
investigated. Thus, piperazine 59 (νC=O 1702 cm
–1) was stirred in diethyl ether at –78 °C 
and s-BuLi was added. A new peak at 1679 cm–1 emerged and was assigned to νC=O in 
prelithiation complex 140. Then, TMEDA was added to effect lithiation, and a peak at 
1646 cm–1 was observed (scheme 2.20). 
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 After addition of s-BuLi, complete formation of prelithiation complex 140 was 
observed. Then, after TMEDA addition, lithiation to give lithiated product 141 (νC=O 
1646 cm–1) was fast. Lithiation was complete within 5 min. No dissociation of 
prelithiation complex 140 to free piperazine 59 and s-BuLi was observed after addition of 
TMEDA. 
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 Next, the lithiation of -Boc-ʹ-benzyl piperazine 59 under experimental conditions 
was investigated. Piperazine 59 (νC=O 1702 cm
–1) and TMEDA were stirred in diethyl 
ether at –78 °C and s-BuLi was added. A small peak corresponding to prelithiation 
complex 142 (νC=O 1682 cm
–1) appeared, as did a peak at 1646 cm–1, assigned to νC=O in 
lithiated product 141 (scheme 2.21). 
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 After addition of s-BuLi, lithiation to give lithiated product 141 was very fast. 
Complete formation of 141 was observed within 5 min. Consequently, it was hard to 
observe prelithiation complex 142, which appeared only as a small peak presumably due 
to its transience. 
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 Then, lithiation of piperazine 59 using s-BuLi/(–)-sparteine 3 was investigated. Thus, 
59 (νC=O 1699 cm
–1) and (–)-sparteine 3 were premixed in diethyl ether at –78 °C and 
then s-BuLi was added. After addition of s-BuLi, formation of prelithiation complex 143 
(νC=O 1680 cm
–1) took place, followed by lithiation to give lithiated piperazine 144 (νC=O 
1644 cm–1) (scheme 2.22). Upon addition of s-BuLi, formation of prelithiation complex 
143 was instant, and then lithiation to give lithiated product 144 was found to be 
complete after 75 min.  
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 For comparison to the use of (–)-sparteine 3, we next investigated the lithiation of -
Boc-ʹ-benzyl piperazine 59 by s-BuLi/(+)-sparteine surrogate 6.  Thus, 59 (νC=O 1698 
cm–1) and 6 were stirred in diethyl ether at –78 °C and then s-BuLi was added. After 
addition of s-BuLi, peaks corresponding to prelithiation complex 145 (νC=O 1680 cm
–1)  
and lithiated piperazine 146 (νC=O 1646 cm
–1) were observed (scheme 2.23). 
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 After addition of s-BuLi, lithiation of -Boc-ʹ-benzyl piperazine 59 to give 146 was 
complete within 5 min. This lithiation time is the same as that observed using TMEDA. 
Due to the fast lithiation, prelithiation complex only appeared briefly as a small peak.We 
note that -Boc-ʹ-benzyl piperazine 59 and -Boc pyrrolidine 38 are similarly easy to 
lithiate, although the results of lithiation using s-BuLi/(–)-sparteine 3 indicate that -Boc 
pyrrolidine 3 is easier to lithiate (see schemes 2.11 and 2.22). 
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2.2.6 -Boc-ʹ-isopropylimidazolidine 
 Coldham has previously reported both the racemic and enantioselective lithiation of -
Boc-ʹ-isopropylimidazolidine 64 at –78 °C, obtaining maximum yields of 50%.74, 75 It 
was proposed that modest yields were obtained due to a lack of -Boc rotamer 
interconversion at –78 °C (see scheme 1.28). We wished to study this phenomenon using 
in situ infra-red spectroscopic monitoring. Thus, -Boc imidazolidine 64 (νC=O 1709 cm
–
1) was stirred in diethyl ether at –78 °C and then s-BuLi was added. A new peak was 
observed at 1683 cm–1 and assigned to νC=O in prelithiation complex 147. Then, TMEDA 
was added and a peak corresponding to lithiated product 148 νC=O 1661 cm
–1 emerged 
(scheme 2.24). 
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 After addition of s-BuLi, formation of prelithiation complex 147 by the majority of 
imidazolidine 64 present was observed, as well as partial lithiation. After addition of 
TMEDA, the rate of lithiation increased.  
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 For comparison to the lithiation of -Boc-ʹ-isopropylimidazolidine 64 at –78 °C, we 
decided to investigate lithiation at a higher temperature where the -Boc rotamers could 
interconvert. Thus, imidazolidine 64 (νC=O 1709 cm
–1) was stirred in diethyl ether at –30 
°C and then s-BuLi was added. New peaks were observed at 1680 cm–1 (νC=O in 
prelithiation complex 147) and 1663 cm–1 (νC=O in lithiated product 148). Then, TMEDA 
was added (scheme 2.25). 
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 We note that upon addition of s-BuLi, formation of both prelithiation complex 147 and 
lithiated product 148 took place. Lithiation of imidazolidine 64 took place in diethyl ether 
at –30 °C in the absence of diamine. Lithiation mediated by s-BuLi only also took place 
at –78 °C, to a lesser degree (scheme 2.24). After 10 min of reaction time, both -Boc-
ʹ-i-Pr imidazolidine 64 and prelithiation complex 147 had been consumed, indicating 
that at –30 °C the -Boc rotamers interconvert and complete lithiation of 64 may be 
carried out. 
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2.2.7 O-Alkyl Carbamate 
 Thus far, only lithiations of -Boc heterocycles had been studied using in situ infra-red 
spectroscopy. Wishing to expand the range of our study, we turned our attention to the 
lithiation of O-alkyl carbamate 100. The first reaction conditions to be studied were 
formation of the prelithiation complex then addition of TMEDA. Thus, O-alkyl 
carbamate 100 (νC=O 1697 cm
–1) was stirred in diethyl ether at –78 °C and s-BuLi was 
added. A new peak appeared at 1672 cm–1 and was assigned to νC=O in prelithiation 
complex 149. Then, TMEDA was added and a peak corresponding to lithiated carbamate 
150 (νC=O 1613 cm
–1) emerged (scheme 2.26). 
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 After addition of TMEDA, lithiation proceeded quickly and complete formation of 
lithiated product 150 was observed after 20 min. The peak corresponding to νC=O of 
lithiated product 150 was broader than those of lithiated -Boc heterocyles 38, 44, 49, 56 
59 and 64, which may be due to a greater conformational flexibility in this acyclic 
compound.  
 
 
 
 
 56 
 Next, s-BuLi/TMEDA-mediated lithiation of carbamate 100 was investigated under 
typical experimental conditions. Thus, O-alkyl carbamate 100 (νC=O 1695 cm
–1) and 
TMEDA were mixed in diethyl ether at –78 °C and then s-BuLi was added. New peaks 
corresponding to prelithiation complex 151 (νC=O 1680 cm
–1) and lithiated product 150 
(νC=O 1610 cm
–1) emerged (scheme 2.27). 
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 After addition of s-BuLi, lithiation proceeded quickly and formation of lithiated 
product 151 was found to be complete within 15 min. We note, however, that lithiation of 
O-alkyl carbamate 100 by s-BuLi/TMEDA is slower than the corresponding lithiation of 
-Boc pyrrolidine 38 (3 min lithiation time, see scheme 2.10). 
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 Then, the lithiation of 100 using s-BuLi/(–)-sparteine 3 was monitored using in situ 
infra-red spectroscopy. Thus, O-alkyl carbamate 100 (νC=O 1696 cm
–1) and (–)-sparteine 3 
were stirred in diethyl ether at –78 °C and then s-BuLi was added. Peaks assigned to 
prelithiation complex 152 (νC=O 1680 cm
–1) and lithiated carbamate 153 (νC=O 1609 cm
–1) 
were observed (scheme 2.28). 
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 After addition of s-BuLi, complete lithiation to give product 153 was observed in 45 
min. As with TMEDA, it was found that lithiation of O-alkyl carbamate 100 using s-
BuLi/(–)-sparteine 3 was slower than the corresponding lithiation of -Boc pyrrolidine 
38.  
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 For a final comparison, lithiation of 100 using s-BuLi/(+)-sparteine surrogate 6 was 
investigated. Thus, O-alkyl carbamate 100 (νC=O 1694 cm
–1) and (+)-sparteine surrogate 6 
were stirred in diethyl ether at –78 °C and then s-BuLi was added. Peaks at 1665 cm–1 
(νC=O in prelithiation complex 154) and 1609 cm
–1 (νC=O in lithiated carbamate 155) were 
observed (scheme 2.29). 
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 We note that after addition of s-BuLi, lithiation to give 155 was faster than the 
lithiation using s-BuLi/TMEDA (scheme 2.27), with complete formation of lithiated 
product 155 observed in 3 min. Due to the fast reaction, prelithiation complex 154 was 
only observable as a small peak. 
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2.3 Conclusions and Future Work 
 Using in situ infra-red spectroscopic monitoring of carbamate lithiations, we are able to 
place the carbamates examined in order of reactivity to deprotonation using s-
BuLi/diamines, as shown in figure 2.2. 
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 As the only substrate to undergo some lithiation in the presence of s-BuLi/Et2O, -Boc-
ʹ-isopropylimidazolidine 64 is the most easily deprotonated compound (schemes 2.24 
and 2.25). Then, comparing s-BuLi/(–)-sparteine 3-mediated lithiations, lithiation of -
Boc pyrrolidine 38 was fastest (20 min, scheme 2.11), followed by O-alkyl carbamate 
100 (45 min, scheme 2.28) and then -Boc-ʹ-benzyl piperazine 59 (75 min, scheme 
2.22). -Boc heterocycles 44, 49 and 56 did not undergo complete lithiation by s-BuLi/(–
)-sparteine 3 (schemes 2.9, 2.14 and 2.18). Instead, considering the results from forming 
a prelithiation complex then adding TMEDA, -Boc acetal piperidine 49 was lithiated in 
35 min (scheme 2.16), -Boc piperidine 44 was lithiated in 90 min (scheme 2.8) and -
Boc homopiperidine 56 underwent incomplete lithiation in 45 min (scheme 2.12), but 
was visibly slower than -Boc piperidine 44 under the same conditions. 
 We have observed that -Boc-ʹ-isopropylimidazolidine 64 and -Boc-ʹ-benzyl 
piperazine 59 are both easier to lithiate than their respective analogues -Boc pyrrolidine 
38 and -Boc piperidine 44, which lack a second nitrogen. A possible explanation for 
this is that the reactive C–H bond α to nitrogen is weakened by feeding electron density 
into the antiperiplanar σ* C-N anti-bonding orbital, as shown in scheme 2.3. 
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Figure 2.3 
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 It is clear that ReactIR is a powerful tool for the chemist interested in carbonyl-directed 
lithiations. Even without gathering kinetic data, it is possible to ascertain the time taken 
for a particular reaction without the need for multiple synthetic experiments with 
different reaction times. Information on the mechanism of reaction can be determined by 
observing the formation of intermediates and products. Finally, in the investigation of the 
lithiation of a new substrate, the facility of reaction can be determined without worrying 
about inefficient trapping – formation of the lithated product is observed directly rather 
than via a potentially uncooperative electrophile. Our work represents a preliminary 
set of results in the ReactIR observation of -Boc heterocycle lithiations. Several further 
avenues of inquiry are immediately apparent. Imidazolidine 64 displays low yielding 
lithiation at low temperatures due to a lack of interconversion of an unreactive -Boc 
rotamer. At higher temperatures, interconversion, and so higher degrees of lithiation take 
place. It is obvious that a further investigation of this system with chiral ligands, and of 
other non-symmetric -Boc heterocycles would be of interest. 
  -Boc piperidine 44 and -Boc homopiperidine 56 display incomplete formation of 
prelithiation complexes under experimental conditions. Furthermore, when deliberately 
forming a prelithiation complex, addition of diamine ligand causes dissociation back to 
uncomplexed substrate. It may be that investigation of lithiation of these heterocycles 
with different alkyllithium aggregates of alkyllithium/diamine complexes may give rise 
to conditions which favour greater formation of prelithiation complex, and thus more 
facile lithiation. 
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Chapter 3: Two-Ligand Catalytic Asymmetric 
Lithiation of -Boc Pyrrolidine 
 
 This chapter is concerned with the development of two-ligand catalytic asymmetric 
lithiation of -Boc pyrrolidine 38 using a substoichiometric amount of a chiral diamine 
in the presence of a stoichiometric amount of a secondary achiral diamine. For 
comparison to previously reported achiral diamine 7, new ligands 156-159 were 
synthesised and evaluated in catalytic lithiations (figure 3.1). 
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 In addition, two-ligand catalytic lithiation-arylation of -Boc pyrrolidine is described. 
Finally, lithiation of -Boc pyrrolidine 38 using s-BuLi and diamines 160 and 7 was 
followed using in situ infra-red spectroscopic monitoring in order to gain insight into 
lithiation mediated by such hindered ligands (figure 3.2). 
 
Figure 3.2   
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3.1 Two-Ligand Catalytic Asymmetric Lithiation of Carbamates 
 Enantioselective lithiation-trapping is a facile route to α-substituted carbamates in high 
yields and enantioselectivity. However, this methodology is hindered by the lack of an 
ideal chiral ligand. (–)-Sparteine 3 can be obtained by extraction from papilionaceous 
plants such as C. scoparius.120 It is thus suitable for use on a small scale but is rather 
expensive for industrial use (£181.50/100 g, Aldrich, 2009). Unreliable supply is also a 
problem, as (–)-sparteine has been commercially unavailable throughout 2010/early 
2011. (+)-Sparteine surrogate 6 is accessed through a three-step synthesis, starting from 
the natural product (–)-cytisine 40 (US$ 920.00/50 g, Chemdel, 2011). (–)-Cytisine 40 
may also be extracted in the laboratory from the seeds of L. anagyroides cytisus.121 (+)-
Sparteine surrogate 6 has recently become commercially available but is expensive even 
for use on a small scale in the research laboratory (£140.50/100 mg, Aldrich 2011). In 
2008, our group reported the use of trans-cyclohexane diamine (R,R)-8 in lithiations of 
-Boc pyrrolidine 38.59 Originally introduced by Alexakis, (R,R)- and (S,S)-8 have since 
become commercially available, but remain expensive (€164.30/1 g for either 
enantiomer, TCI, 2011).6 
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 Due to the lack of a readily accessible or cheap chiral diamine, our group decided to 
investigate lithiation using a substoichiometric amount of chiral diamine. Simply 
reducing the amount of chiral diamine in the lithiation reaction did not facilitate catalytic 
turnover. For example, lithiation of O-alkyl carbamate 100 with 1.4 equivalents of s-BuLi 
and 0.2 equivalents of  (–)-sparteine 3 followed by trapping with n-Bu3SnCl gave 
stannane (S)-161 in only 17% yield and 85:15 er, compared to the 73% yield and 99:1 er 
obtained with stoichiometric (–)-sparteine 3 (scheme 3.1).5 
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Scheme 3.1  
Ph O
1. 1.4 eq. s-BuLi
1.4 eq. (_)-sparteine 3
Et2O,
_78 oC
2. Bu3SnCl
Ph O
Bu3Sn
73%
99:1 er
Ph O
1. 1.4 eq. s-BuLi
0.2 eq. (_)-sparteine 3
Et2O,
_78 oC
2. Bu3SnCl
Ph O
Bu3Sn
17%
85:15 er
100
100
(S)-161
(S)-161
Ni-Pr2
O
Ni-Pr2
O
Ni-Pr2
O
Ni-Pr2
O
 
 
 Similarly, lithiation of -Boc pyrrolidine 38 with 1.3 equivalents of s-BuLi and 0.2 
equivalents of (–)-sparteine 3 followed by trapping with trimethylsilyl chloride gave silyl 
pyrrolidine (S)-39 in 34% yield and 75:25 er compared with 87% yield and 95:5 er for 
lithiation using a stoichiometric amount of chiral diamine (scheme 3.2).5 
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 In the case of both -Boc pyrrolidine 38 and O-alkyl carbamate 100, low 
enantioselectivities are obtained due to competing racemic lithiation from a s-BuLi/Et2O 
complex. Low yields are obtained as the most active lithiating species, the s-BuLi/(–)-
sparteine complex, is only present in low amounts. After lithiation, the chiral diamine 
remains coordinated to the lithiated carbamate intermediate until electrophile is added. 
 In 2005, Chong reported an asymmetric alkynyl boration of enones such as 162.122 In 
this study, boration was achieved using a substoichiometric amount of chiral binaphthol 
(S)-163. Following the boration of one molecule of substrate, cheap achiral boronate 164 
was used to displace the chiral ligand back into solution, where further enantioselective 
boration could then take place (scheme 3.3).122 
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 A range of enones were boronated using this methodology, giving >78% yields of 
products and better than 91:9 er. Chong’s work demonstrated a synthetic example 
wherein a substoichiometric amount of a chiral ligand can be used to effect an 
enantioselective reaction by releasing the chiral ligand from the reaction intermediate 
using a second achiral ligand. It was hypothesised in our group that this approach could 
allow use of a substoichiometric amount of chiral diamine in asymmetric lithiations. Such 
a protocol is termed “two-ligand catalysis” or “ligand exchange catalysis.” 
 Chong’s work suggested a plausible experimental set-up under which catalytic turnover 
of a chiral ligand in asymmetric lithiations might be achieved. However, a suitable 
achiral secondary ligand needed to be identified. Our group decided that such a ligand 
must either be cheap or accessible from cheap starting materials in one or two synthetic 
steps, must promote catalytic turnover of the chiral ligand, and must not cause competing 
racemic lithiation via its own s-BuLi complex.  
 During research into the development of a (+)-sparteine surrogate 6, i-Pr analogue 160 
was synthesised. It was found that s-BuLi/160 did not give rise to lithiation of -Boc 
pyrrolidine 38, despite DFT calculations suggesting that if a prelithiation complex 
formed, lithiation would indeed take place.123 It was thus suggested that the simpler 
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diamine di-i-Pr bispidine 7 would be a suitable achiral ligand to investigate in ligand 
exchange catalytic lithiation (figure 3.2). 
 
Figure 3.4 
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 Fortunately, di-i-Pr bispidine 7 did indeed effect catalytic turnover of both (–)-sparteine 
3 and (+)-sparteine surrogate 6. Thus, lithiation of -Boc pyrrolidine 38 in the presence 
of 1.3 equivalents of s-BuLi, 0.2 equivalents of chiral diamine and 1.2 equivalents of 
bispidine 7 in Et2O at –78 °C for 5 h followed by trapping with trimethylsilyl chloride 
gave silyl pyrrolidine (S)-39 in 76% yield and 90:10 er with (–)-sparteine 3 and (R)-39 in 
66% yield and 94:6 er with (+)-sparteine surrogate 6 (scheme 3.4).5 
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 Better enantioselectivity was observed when using (+)-sparteine surrogate 6 compared 
with (–)-sparteine 3. This is explained by the observation that the s-BuLi complex of 6 is 
a faster lithiater than s-BuLi/(–)-sparteine 3 as shown by a competition experiment. Thus, 
lithiation of -Boc pyrrolidine 38 with 2.6 equivalents of s-BuLi in the presence of 1.3 
equivalents each of (–)-sparteine 3 and (+)-sparteine surrogate 6 followed by trapping 
with trimethylsilyl chloride gave silyl pyrrolidine (R)-39 in 62% yield and 90:10 er 
(scheme 3.5).  
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Scheme 3.5 
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 It was shown that two-ligand catalytic lithiations could also be carried out on O-alkyl 
carbamate 100. Here, lithiation by 1.3 equivalents of s-BuLi in the presence of 0.2 
equivalents of (–)-sparteine 3 and 1.2 equivalents of di-i-Pr bispidine 7 in Et2O at –78 °C 
followed by trapping with n-Bu3SnCl gave stannane (S)-161 in 77% yield and 92:8 er. 
Similarly, lithiation by 1.3 equivalents of s-BuLi in the presence of 0.2 equivalents of 
(+)-sparteine surrogate 6 and 1.2 equivalents of di-i-Pr bispidine 7 and trapping gave 
stannane (R)-161 in 72% yield and 94:6 er (scheme 3.6).5 
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 Finally, it was also shown that two-ligand catalytic lithiation could be carried out with 
phosphine borane 166. Thus, lithiation of 166 with 1.3 equivalents of s-BuLi, 0.2 
equivalents of (–)-sparteine 3 and 1.2 equivalents of di-i-Pr bispidine 7 followed by 
trapping with Ph2CO gave alcohol (S)-167 in 67% yield and 83:17 er.
5 It should be noted, 
however, that it was later found that unlike the carbamates 38 and 100, catalytic turnover 
of chiral diamine was successful with phosphine borane 166 without the need for a 
secondary ligand. In this case, lithiation of 166 with 1.1 equivalents of s-BuLi and 0.2 
equivalents of (–)-sparteine 3 followed by trapping with O2 gave alcohol (R)-168 in 57% 
yield and 77:23 er (scheme 3.7).124 
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 Enantioselective lithiations using a substoichiometric amount of chiral diamine ligand 
without a secondary achiral ligand have also been reported on a number of other 
substrates. Examples include cyclooctene-derived epoxides,125 phosphine sulfides,126 
ferrocene amides127 and paracyclophanes.128 
 Having demonstrated two-ligand catalytic lithiation using di-i-Pr bispidine 7, our group 
subsequently investigated other secondary achiral ligands for use with this methodology. 
A range of different diamines were investigated, roughly divided into three “families”: 
TMEDA analogues, TMPDA analogues, and a hybrid of the two, 1,4-homopiperazine 
analogues (figure 3.3). 
 
Figure 3.5 
N N NN
N NR R'
RR
R'R'
R'
R
R'
R
TMEDA
analogues
TMPDA
analogues
Homopiperazine
analogues  
 
The results of the best ligands are shown in scheme 3.8.129 Using di-i-Pr bispidine 7, two-
ligand catalytic lithiation of -Boc pyrrolidine 38 (using 0.3 equivalents of (–)-sparteine 
3) followed by trapping with trimethylsilyl chloride gave silyl pyrrolidine (S)-39 in 70% 
yield and 95:5 er. The TMEDA analogue 169 gave (S)-39 in 64% yield and 89:11 er. An 
alternative TMEDA analogue, rac-170, gave (S)-39 in 61% yield and 90:10 er. Finally, 
homopiperazine analogue 171 gave (S)-39 in 64% yield and 86:14 er.129 Ultimately, it 
was found that in two-ligand catalytic lithiations the best yields and enantioselectivities 
were obtained through the use of original bispidine 7.  
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 A further investigation into other secondary ligands found that high yield and 
enantioselectivity could be obtained using lithium dimethylamino ethoxide (LiDMAE) 
172: silyl pyrrolidine (S)-39 was obtained in 66% yield and 88:12 er after trapping with 
trimethylsilyl chloride. Interestingly, it was found that both the dimethylamino motif and 
the lithium alkoxide motif were necessary for high yield and enantioselectivity. Use of 
lithium ethoxide gave (S)-39 in low yield (33%) and high er (90:10), while ,-dimethyl-
2-methoxyethylamine 174 gave rac-39 in 74% yield (scheme 3.9).130 
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 Two-ligand catalytic lithiation-trapping of -Boc pyrrolidine 38 using LiDMAE 172 
was then used to complete a formal total synthesis of the neurokinin-1 substance P 
receptor agonist (+)-L-733,060.130 The use of LiDMAE 172 differs from diamine 
secondary ligands as extra equivalent of alkyllithium must be added to the lithiation 
reaction mixture in order to deprotonate dimethylamino-ethanol. Crucially, however, it 
was shown that the chiral diamine could be recovered from the reaction mixture after 
work-up by extraction of ,-dimethylamino ethanol into NaOH(aq).
130 Such a separation 
of chiral diamine from achiral ligands had not previously been demonstrated.   
 Investigation of the use of a range of secondary achiral ligands in two-ligand catalytic 
lithiation of -Boc pyrrolidine 38 had failed to discover a ligand superior to di-i-Pr 
bispidine 7. We therefore wished to investigate the use of a small range of analogous 
bispidine achiral diamines. As part of this study, we would also attempt to optimise the 
two-ligand catalytic lithiation conditions. Furthermore, we hoped to use an optimised 
procedure to effect two-ligand catalytic lithiation-arylations which were previously 
unreported. 
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3.2 Synthesis of Achiral Bispidines 
 Two-ligand catalytic lithiation was shown to give optimal yields and enantioselectivity 
with di-i-Pr bispidine 7. We were therefore interested in investigating other achiral 
ligands based on the bispidine motif. A second motivation for pursuing this line of 
inquiry was the somewhat modest yields obtained in the synthesis of 7 previously 
reported in our group. A double Mannich reaction of -i-Pr-piperid-4-one 175 with 
paraformaldehyde and i-PrNH2 gave bispidone 176 in 69% yield and then a Huang-
Minlon modified Wolff-Kishner reduction gave bispidine 7 in 38% yield (scheme 
3.10).131 Both 176 and 7 also required extensive purification by successive distillations. 
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 It was hoped that any new bispidine-derived diamine ligands would be accessible in 
higher yields and more easily than 7. To start with, we found that bispidone 176 could be 
accessed cleanly and in acceptable (67%) yields using the same method previously 
described by employing a careful distillation of starting material, -i-Pr piperid-4-one 
175, and then fractional distillation of the crude product. This reaction was reproducible 
and has been carried out on a 20 g scale.  
 We therefore decided to derive our new ligands from 176. For example, it was 
envisioned that the alkyllithium sensitive carbonyl group could be “removed” using a 
Wittig reaction to give alkene 156. Further hydrogenation of the alkene would give 
methyl bispidine 157. Alternatively, treatment of bispidone 176 with ethane dithiol would 
give dithiane 177. Finally, reduction of bispidone 176 would give bispidol 158. In this 
case, extra alkyllithium would be added to lithiation mixtures in order to first deprotonate 
the alcohol, as with dimethylamino ethanol. We also wished to prepare ,’-di-n-Pr 
bispidine 159 to investigate whether use of a less hindered bispidine ligand would lead to 
poor enantioselectivities in two-ligand catalytic lithiations due to increased competing 
racemic lithiation (figure 3.4). 
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 To start with, the formation of alkene 156 using a Wittig reaction on bispidone 176 
with triphenylmethyl phosphonium bromide was investigated. Use of n-BuLi to form the 
phosphonium ylide did not give rise to alkene 156 at either room temperature or reflux in 
THF, with reaction times of up to 16 h. It was hypothesised that this was due to 
coordination of the alkyllithium to bispidone 176. When KHMDS was used to generate 
the ylide, alkene 156 was obtained in 65% yield after removal of triphenylphosphine 
oxide by acid/base washing and purification by Kügelrohr short-path distillation. A 
reaction time of 16 h at reflux in THF gave the best yield. It was then found that methyl 
bispidine 157 could be obtained via transfer hydrogenation with ammonium formate and 
Pearlman’s catalyst, giving the product in 65% yield (scheme 3.11). 
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 Dithiane bispidine 177 was first described by Garrison and co-workers.132 
Unfortunately, due to difficulty in purification we were unable to prepare dithiane 177 in 
high enough yields to investigate its use in lithiation reactions. In contrast, reduction of 
bispidone 176 with sodium borohydride gave bispidol 158 in 69% yield. The crude 
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product was considered pure enough for use in lithiation reactions without further 
purification (scheme 3.12). 
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 With 156, 157 and 158 in hand, it was decided to reinvestigate the reduction of 
bispidone 176 to di-i-Pr bispidine 7. After reaction of bispidone 176 under the original 
reduction conditions (N2H4, KOH, diethylene glycol, 180 °C, 4 h), careful analysis of the 
1H NMR spectrum of the crude product revealed a broad singlet at δ 4.91 ppm. We 
hypothesised that this peak could belong to the NH2 protons of reaction intermediate 178 
(figure 3.5). 
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 Thus, we proposed that the reason for low yields of di-i-Pr bispidine 7 was an 
incomplete reaction rather than any lack of reactivity or competing side reactions. 
Gratifyingly, reduction of bispidone 176 with N2H4.H2O and KOH in diethylene glycol at 
reflux for 16 h gave di-i-Pr bispidine 7 in 88% yield (scheme 3.13). Notably, after work-
up, di-i-Pr bispidine 7 was free of impurities although, as with all diamines, it was 
distilled over calcium hydride before use in lithiation reactions. 
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 Finally, di-n-Pr bispidine 159 was synthesised using the same route as bispidine 7. 
Double Mannich reaction of n-Pr-piperid-4-one 179 with n-PrNH2 and paraformaldehyde 
gave bispidone 180 in 44% yield. Then, reduction gave di-n-Pr bispidine 159 in 84% 
yield (scheme 3.14). As with 7, reduction proceeded without the need for further 
purification. Thus, multi-gram quantities of a range of new bispidines were readily 
prepared.  
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3.3 Two-Ligand Catalytic Lithiation-Trapping of -Boc Pyrrolidine 
 With our new bispidines in hand, it was decided to first identify the optimal two-ligand 
catalytic lithiation conditions using the original di-i-Pr bispidine 7. Three different sets of 
catalytic conditions have previously been used in our group (scheme 3.15). The originally 
reported two-ligand catalytic lithiation conditions, using 0.2 equivalents of (–)-sparteine 3 
in the presence of 1.3 equivalents of s-BuLi and 1.2 equivalents of di-i-Pr bispidine 7 and 
trapping with trimethylsilyl chloride gave silyl pyrrolidine (S)-39 in 76% yield and 90:10 
er.5 More recently, work from our group has shown that catalytic lithiation with 0.3 
equivalents of (–)-sparteine 3 in the presence of 1.6 equivalents of s-BuLi and 1.3 
equivalents of di-i-Pr bispidine 7 and trapping with trimethylsilyl chloride gave (S)-39 in 
70% yield and 95:5 er.130 A final set of conditions previously used in the group showed 
that catalytic lithiation with 0.25 equivalents of (+)-sparteine surrogate 6 in the presence 
of 1.0 equivalent of s-BuLi and 1.0 equivalent of di-i-Pr bispidine 7 and trapping via 
arylation (Negishi coupling) gave arylated pyrrolidine (S)-181 in 87% yield and 96:4 er 
(scheme 3.15).133 
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 The er of silyl pyrrolidine 39 cannot be determined using the HPLC set-up available in 
our group. It was therefore decided that our optimisation of two-ligand catalytic 
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lithiations would be carried out using benzaldehyde as an electrophile. To compare with 
catalytic lithiations, lithiation of -Boc pyrrolidine 38 with s-BuLi and stoichiometric (–
)-sparteine 3 was carried out. After trapping with benzaldehyde, alcohol syn-182 was 
obtained in 62% yield and 97:3 er and alcohol anti-182 was obtained in 18% yield and 
97:3 er (scheme 3.16). This is the benchmark for comparing all of our catalytic 
asymmetric lithiation reactions. The relative stereochemistry of syn-182 and anti-182 was 
assigened by comparison with a previously reported X-ray crystal structure of anti-
182.130 
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 A small range of different catalytic conditions using substoichiometric (–)-sparteine 3 
and di-i-Pr bispidine 7 was then investigated (Table 3.1). Thus, lithiation with 1.2 
equivalents of s-BuLi, 0.2 equivalents of (–)-sparteine 3 and 1.0 equivalent of di-i-Pr 
bispidine 7 gave alcohols syn-182 in 55% yield and 85:15 er and anti-182 in 29% yield 
and 85:15 er (entry 1). Keeping the amounts of s-BuLi and 3 the same but increasing the 
amount of di-i-Pr bispidine 7 to 1.2 equivalents made little difference, giving syn-182 in 
54% yield and 84:16 er, and anti-182 in 31% yield and 82:18 er (entry 2). The use of 1.3 
equivalents of s-BuLi with 0.2 equivalents of (–)-sparteine 3 and 1.2 equivalents of di-i-
Pr bispidine 7 gave syn-182 in 57% yield and 82:18 er and anti-182 in 33% yield and 
82:18 er (entry 3). Increasing the loading of (–)-sparteine 3 to 0.25 equivalents, with 1.0 
equivalent of s-BuLi and 1.0 equivalent of di-i-Pr bispidine 7 gave syn-172 in 58% yield 
and 88:12 er and anti-182 in 29% yield and 88:12 er (entry 4). Finally, a further increase 
in the (–)-sparteine 3 loading to 0.3 equivalents, along with the use of 1.6 equivalents of 
s-BuLi and 1.3 equivalents of di-i-Pr bispidine 7 gave syn-182 in 62% yield and 91:9 er 
and anti-182 in 33% and 91:9 er (entry 5).  
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Table 3.1 
N
Boc
N
Boc
Ph
N
Boc
Ph
H H
OH OH
1. s-BuLi
3, 7
Et2O,
_78 oC, 4 h
2. PhCHO
3. H+
+
38 syn-182 ant i-182  
 
Entry Eq. s-BuLi   Eq. 3         Eq. 7     %Yield syn-182 (er)a    %Yield anti-182 (er)a 
   1      1.2  0.2    1.0  55 (85:15)  29 (85:15) 
   2      1.2  0.2    1.2  54 (84:16)  31 (82:18) 
   3      1.3  0.2    1.2  57 (82:18)  33 (82:18) 
   4      1.0  0.25    1.0  58 (88:12)  29 (88:12) 
   5      1.6  0.3    1.3  62 (91:9)  33 (91:9)iiiiiiiiiii 
a 
% Yield after chromatography, er determined by CSP-HPLC. 
 
 Under all conditions, a high (84-95%) combined yield of diastereomeric products was 
obtained. The optimum conditions involved the use of 1.6 equivalents of s-BuLi with 0.3 
equivalents of (–)-sparteine and 1.3 equivalents of di-i-Pr bispidine 7, which gave a 
combined 95% yield of syn-182 and anti-182 (both in 91:9 er). It was therefore decided 
that these would be the conditions under which the new bispidine ligands were 
investigated. First, however, the use of (+)-sparteine surrogate 6 and cyclohexane 
diamine (R,R)-8 under the optimal catalytic conditions was investigated (table 3.2). 
 (+)-Sparteine surrogate 6 had previously been used in catalytic lithiation-arylation 
using the conditions described in entry 1 (see scheme 3.15). When trapping with 
benzaldehyde, 1.0 equivalent of s-BuLi, 0.25 equivalents of 6 and 1.0 equivalent of di-i-
Pr bispidine 7 gave syn-182 in 56% yield and 93:7 er and anti-182 in 25% yield and 93:7 
er. Under our new optimal conditions, 1.6 equivalents of s-BuLi with 0.3 equivalents of 6 
and 1.3 equivalents of 7 gave slightly improved yield and enantioselectivity, with syn-182 
being obtained in 65% yield and 94:6 er and anti-182 in 29% yield and 94:6 er (entry 2). 
As expected based on previous findings in the literature (see scheme 3.4), (+)-sparteine 
surrogate 6 gave higher enantioselectivities than (–)-sparteine 3 under the same 
conditions. Cyclohexane diamine (R,R)-8 proved to be less suitable for use in catalytic 
lithiations, with the optimised conditions giving syn-182 in 63% yield and 84:16 er and 
anti-182 in 27% yield and 85:15 er (entry 3). 
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Table 3.2 
N N
Me
6
N
N
Me
Me
t -Bu
t -Bu
(R,R)-8
N
Boc
N
Boc
Ph
N
Boc
PhH H
OH OH
1. s-BuLi
chiral ligand, 7
Et2O,
_78 oC, 4 h
2. PhCHO
3. H+
+
38 syn-182 ant i-182
 
 
Entry Eq. s-BuLi Chiral Ligand (eq.) Eq. 7  %Yield syn-182 (er)a %Yield anti-182 (er)a 
   1      1.0         6 (0.25)             1.0        56 (93:7)         25 (93:7) 
   2      1.6         6 (0.3)             1.3        65 (94:6)         29 (94:6) 
   3      1.6      (R,R)-8 (0.3) 1.3        63 (16:84)        27 (15:85)iiii 
a 
% Yield after chromatography, er determined by CSP-HPLC. 
 
 Having optimised our catalytic lithiation conditions, and investigated three different 
chiral diamines using these conditions, we assayed the new bispidine ligands (table 3.3). 
Due to ease of use, (–)-sparteine 3 was the chiral diamine used in this investigation. 
Under these conditions, lithiation of -Boc pyrrolidine 38 with alkene bispidine 156 gave 
alcohol syn-182 in 61% yield and 92:8 er and alcohol anti-182 in 30% yield and 88:12 er 
(entry 1). Methyl bispidine 157 gave poorer enantioselectivity, affording syn-182 in 60% 
yield and 79:21 er and anti-182 in 32% yield and 78:22 er (entry 2). Use of bispidol 158 
required the addition of extra s-BuLi. Enantioselectivity was poor, giving syn-182 in 54% 
yield and 83:17 er and anti-182 in 31% yield and 77:23 er (entry 3).Unfortunately, di-n-
Pr-bispidine 159 gave almost racemic product, with syn-182 being obtained in 61% yield 
and 55:45 er and anti-182 in 34% yield and 55:45 er (entry 4). 
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Table 3.3 
N N
i-Pr
156
i-Pr
N N
i-Pr
157
i-Pr
N N
i-Pr
158
i-Pr
N N
n-Pr
159
n-Pr
CH2
Me OHH H
N
Boc
N
Boc
Ph
N
Boc
PhH H
OH OH
Et2O,
_78 oC, 4 h
2. PhCHO
3. H+
+
38 syn-182 ant i-182
1. s-BuLi
(_)-sparteine 3
bispidine
 
 
Entry  Bispidine %Yield syn-182 (er)a  %Yield anti-182 (er)a 
   1     156         61 (92:8)         30 (88:12) 
   2     157         60 (79:21)        32 (78:22) 
   3     158b         54 (83:17)        31 (77:23) 
   4     159         61 (55:45)        34 (55:45)iiiiiiiii 
a % Yield after chromatography, er determined by CSP-HPLC 
b 2.9 equivalents of s-BuLi used 
 
 None of the new achiral bispidine ligands gave higher enantioselectivities than the 
original bispidine 7. Alkene bispidine 156 gave the highest er of the new ligands (92:8 er 
for syn-182 and 88:12 er for anti-182). Use of di-n-Pr bispidine 159 gave nearly racemic 
products (55:45 er for both syn- and anti-182). This confirms our hypothesis that a 
sterically demanding ligand such as 7 is required to access products in high er. 
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3.4 Two-Ligand Catalytic Lithiation-Arylation of -Boc Pyrrolidine 
 Previous work in our group and at Merck had demonstrated two-ligand catalytic 
lithiation-arylation with (+)-sparteine surrogate 6.133, 134 We wished to carry out a further 
example, coupling with o-bromobenzotrifluoride. Thus, lithiation with 1.0 equivalent of 
s-BuLi, 0.25 equivalents of (+)-sparteine surrogate 6 and 1.0 equivalent of di-i-Pr 
bispidine 7 followed by transmetallation with zinc chloride and palladium-catalysed 
arylation gave aryl pyrrolidine (S)-183 in 75% yield and 91:9 er (scheme 3.17). 
 
Scheme 3.17 
 
 
 
 
 
 For comparison with (+)-sparteine surrogate 6-mediated catalytic lithiation arylations, 
we decided to carry out (–)-sparteine two-ligand catalytic lithiations under the same 
conditions, and couple with three different aryl bromides (table 3.4).  
  
Table 3.4 
N
Boc
1. 1.0 eq. s-BuLi
0.25 eq. 3
1.0 eq. 7
Et2O,
_78 oC, 4 h
2. ZnCl2
3. Pd(OAc)2
t -Bu3PHBF4
ArBr
N
Boc
CF3
N
Boc
OMe
N
Boc
CO2Me
38
or or
(R)-181 (R)-183 (R)-184
 
 
     Entry    Aryl Bromide   Product %Yielda  era 
      1             o-bromoanisole  (R)-181       50           80:20 
      2     o-bromobenzotrifluoride  (R)-183       76           80:20 
      3     methyl 2-bromobenzoate  (R)-184       50           81:19 
          a % Yield after chromatography, er determined by CSP-HPLC 
 
 Thus, lithiation of -Boc pyrrolidine 38 with 1.0 equivalent of s-BuLi, 0.25 equivalents 
of (–)-sparteine 3 and 1.0 equivalent of di-i-Pr bispidine 7 followed by tranmetallation 
N
Boc
1. 1.0 eq. s-BuLi
0.25 eq. 6
1.0 eq. 7
Et2O,
_78 oC, 4 h
2. ZnCl2
3. Pd(OAc)2
t-Bu3PHBF4
ArBr
N
Boc
CF3
38 (S)-183
75%
91:9 er
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and coupling with o-bromoanisole gave aryl pyrrolidine (R)-181 in 50% yield and 80:20 
er (entry 1). Lithiation and transmetallation under the same conditions, followed by 
coupling with o-bromobenzotrifluoride gave (R)-183 in 76% yield and 80:20 er (entry 2). 
Finally, coupling with methyl 2-bromobenzoate gave ester (R)-184 in 50% yield and 
81:19 er (entry 3). 
 As expected, use of these lithiation conditions did not yield aryl pyrrolidines (R)-181, 
(R)-183 and (R)-184 in as high enantioselectivity as using (+)-sparteine surrogate 6. It 
was therefore decided to repeat the (–)-sparteine 3-mediated catalytic lithiation-arylations 
using our optimised two-ligand catalysis conditions (table 3.5). Lithiation of -Boc 
pyrrolidine 38 with 1.6 equivalents of s-BuLi, 0.3 equivalents of (–)-sparteine 3 and 1.3 
equivalents of di-i-Pr bispidine 7 followed by transmetallation and palladium-catalysed 
coupling with o-bromoanisole gave (R)-181 in 92% yield and 89:11 er (entry 1). 
Coupling with o-bromobenzotrifluoride gave aryl pyrrolidine (R)-183 in 88% yield and 
80:20 er (entry 2). In this case, the enantioselectivity of the reaction did not improve with 
our optimal lithiation conditions, despite repeated attempts. The reason for this is 
unknown. Finally, lithiation-transmetallation-coupling with methyl 2-bromobenzoate 
gave ester (R)-184 in 71% yield and 89:11 er (entry 3). Thus, two-ligand catalytic 
lithiation-arylation using both (–)-sparteine 3 and (+)-sparteine surrogate 6 has now been 
demonstrated. 
 
Table 3.5 
N
Boc
1. 1.6 eq. s-BuLi
0.3 eq. 3
1.3 eq. 7
Et2O,
_78 oC, 4 h
2. ZnCl2
3. Pd(OAc)2
t -Bu3PHBF4
ArBr
N
Boc
CF3
N
Boc
OMe
N
Boc
CO2Me
38
or or
(R)-181 (R)-183 (R)-184
 
 
    Entry   Aryl Bromide   Product %Yielda eraiii 
      1             o-bromoanisole  (R)-181       92           89:11 
      2     o-bromobenzotrifluoride  (R)-183       88           80:20 
      3     methyl 2-bromobenzoate  (R)-184       71           89:11 
                       a % Yield after chromatography, er determined by CSP-HPLC 
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3.5 In Situ Infra-Red Spectroscopic Insights into Lithiation in the 
Presence of Hindered Ligands  
 It was believed in the group that high enantioselectivity in catalytic two-ligand 
lithiations was facilitated due to a lack of lithiation of -Boc pyrrolidine 38 by the s-
BuLi/di-i-Pr bispidine 7 complex. Previously, in collaboration with Wiberg and Bailey 
DFT calculations were used to show that i-PrLi/-i-Pr ligand 160 would lithiate -Boc 
pyrrolidine 38 if a prelithiation complex was formed. In fact, attempted lithiation with s-
BuLi/160 gave no product.123 Similarly, attempted lithiation of -Boc pyrrolidine 38 with 
s-BuLi/bispidine 7 gave trapped product 39 in only 5% yield (scheme 3.18).5 
 
Scheme 3.18 
N N
i-Pr
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N N
i-Pr
7
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N
Boc
N
Boc
SiMe3
1. 1.3 eq. s-BuLi
1.3 eq. 7
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2. Me3SiCl
N
Boc
1. 1.3 eq. s-BuLi
1.3 eq. 160
Et2O,
_78 oC, 5 h
2. Me3SiCl
No Reaction
38
38 39
5%  
 
 We planned to use in situ infra-red spectroscopic monitoring to show that the 
complexes s-BuLi/160 and s-BuLi/7 would not form a prelithiation complex in attempted 
lithiations of -Boc pyrrolidine 38. We also wondered whether formation of a 
prelithiation complex between s-BuLi and -Boc pyrrolidine 38 followed by addition of 
160 or 7 would lead to lithiation.  
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 First, the use of -i-Pr surrogate 160 for the s-BuLi-mediated lithiation of -Boc 
pyrrolidine 38 was investigated, via formation of a prelithiation complex. Thus, -Boc 
pyrrolidine 38 (νC=O 1702 cm
–1) was stirred in diethyl ether at –78 °C and then s-BuLi 
was added. A new peak appeared, which was assigned to prelithiation complex 123 (νC=O 
1679 cm–1). Then, -i-Pr surrogate 160 was added and another peak appeared, assigned 
to lithiated product 185 (νC=O 1646 cm
–1) (scheme 3.19). 
 
Scheme 3.19 
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 To our surprise, after addition of -i-Pr surrogate 160, a significant amount of lithiation 
of -Boc pyrrolidine 38 took place. We note that after addition of the hindered diamine 
160, some of the prelithiation complex dissociated to free -Boc pyrrolidine 38 and s-
BuLi. The lithiation was slow and, after 40 min reaction time, incomplete lithiation was 
observed. In contrast, lithiation with s-BuLi/(–)-sparteine 3 has been shown to be 
complete in 20 min (see scheme 2.11). 
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 Next, the lithiation of -Boc pyrrolidine 38 by s-BuLi/-i-Pr surrogate 160 was studied 
under typical experimental conditions. Thus, -i-Pr surrogate 160 and s-BuLi were 
stirred in diethyl ether at –78 °C and -Boc pyrrolidine 38 was added. Peaks 
corresponding to -Boc pyrrolidine 38 (νC=O 1702 cm
–1) and prelithiation complex 186 
(νC=O 1680 cm
–1) were immediately observed. Then, slow evolution of a new peak (νC=O 
1645 cm–1) was noted. This peak was assigned to lithiated product 185 (scheme 3.20). 
 
Scheme 3.20 
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 In contrast to the previously published results from our group,123 lithiation of -Boc 
pyrrolidine 38 by s-BuLi/-i-Pr surrogate 160 does proceed. The rate of lithiation is 
slow, with incomplete lithiation observed after 50 min reaction time. 
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 Based on this unexpected ReactIR result, two synthetic experiments were investigated 
with -i-Pr surrogate 160. It was found that lithiation of -Boc pyrrolidine 38 with 1.3 
equivalents of s-BuLi and 1.3 equivalents of -i-Pr surrogate 160 at –78 °C in Et2O for 3 
h followed by trapping with benzaldehyde gave alcohol syn-182 in 50% yield and 90:10 
er and alcohol anti-182 in 25% and 89:11 er. Similarly, lithiation under the same 
conditions and trapping with trimethylsilyl chloride led to silyl pyrrolidine (R)-39 in 81% 
yield and 91:9 er (scheme 3.21). These results are fully consistent with the ReactIR 
experiments. 
 
Scheme 3.21 
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 Having shown that the complex of s-BuLi/-i-Pr surrogate 160 does effect lithiation of 
-Boc pyrrolidine 38 we next investigated that use of di-i-Pr bispidine 7, by first forming 
a prelithiation complex. Thus, -Boc pyrrolidine 38 (1702 cm-1) was stirred in diethyl 
ether at –78 °C and then s-BuLi was added. A new peak emerged, which was assigned to 
prelithiation complex 123 (1679 cm–1). Then, di-i-Pr bispidine 7 was added and a new 
peak appeared, assigned to lithiated product 187 (1645 cm–1) (scheme 3.22) 
 
Scheme 3.22 
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 After addition of di-i-Pr bispidine 7, some of prelithiation complex 123 dissociated to 
free -Boc pyrrolidine 38 and s-BuLi. Then, lithiation proceeded slowly, but in this case 
complete formation of lithiated product 187 was observed after 45 min.  
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 Finally, we investigated the lithiation of -Boc pyrrolidine 38 by s-BuLi/bispidine 7 
under experimental conditions. Thus, s-BuLi and di-i-Pr bispidine 7 were stirred in 
diethyl ether at –78 °C. Then -Boc pyrrolidine 38 was added, and peaks corresponding 
to -Boc pyrrolidine 38 (1701 cm–1) and prelithiation complex 188 (1682 cm–1) were 
observed. A new peak then slowly emerged and was assigned to lithiated product 187 
(1648 cm–1) (scheme 3.23). 
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 Thus, the s-BuLi/di-i-Pr bispidine 7 complex does indeed effect the lithiation of -Boc 
pyrrolidine 38 and complete lithiation was observed after 1 h. The previously published 
result that s-BuLi/di-i-Pr bispidine 7-mediated lithiation only proceeds very slowly is in 
error. This was confirmed by two synthetic experiments.  
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 Lithiation of -Boc pyrrolidine 38 with 1.3 equivalents of s-BuLi and 1.3 equivalents 
of di-i-Pr bispidine 7 at –78 °C in Et2O for 3 h followed by trapping with benzaldehyde 
gave  alcohol syn-182 in 61% yield and alcohol anti-182 in 31% yield. Lithiation under 
the same conditions and trapping with trimethylsilyl chloride gave silyl pyrrolidine rac-
39 in 86% yield (scheme 3. 24). 
 
Scheme 3.24 
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 The success of two-ligand catalysis with di-i-Pr bispidine 7 must be due to different 
rates of lithiation. Lower enantioselectivities compared with lithiations using a 
stoichiometric amount of chiral diamine are observed due to competing lithiation 
mediated by the s-BuLi/7 complex. This observation highlights the usefulness of in situ 
infra-red spectroscopic monitoring of lithiations in determining reaction pathways. 
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3.6 Conclusions and Future Work 
 Conditions for two-ligand catalytic lithiation of -Boc pyrrolidine 38 using s-BuLi, (–)-
sparteine 3 and di-i-Pr bispidine 7 have been optimised, and a small range of new 
bispidine ligands 156-159 were investigated in this reaction. It was found that none of the 
new ligands showed improved yields or enantioselectivity over the use of 7. It was also 
shown that two-ligand lithiation with (+)-sparteine surrogate 6 gave higher 
enantioselectivity than (–)-sparteine 3, while cyclohexane diamine (R,R)-8 gave poorer 
enantioselectivity. 
 (–)-Sparteine 3-mediated two-ligand catalytic lithiation-arylation of -Boc pyrrolidine 
38 has also been demonstrated under two different catalytic lithiation conditions. The 
best yields and enantioselectivities were obtained using the optimised lithiation 
conditions. An example of two-ligand lithiation-arylation with (+)-sparteine surrogate 6 
was also carried out. 
 Finally, using ReactIR experiments, it was shown that the s-BuLi complexes of both di-
i-Pr bispidine 7 and -i-Pr surrogate 160 do in fact promote the lithiation of -Boc 
pyrrolidine 38, in contrast to previously published results from our group. It is possible 
that a more sterically hindered ligand such as -i-Pr-ʹ-t-Bu bispidine 189 would 
promote lithiation of -Boc pyrrolidine 38 to a lesser degree than 7 (figure 3.8). If this is 
the case, it is possible that the use of 189 in two-ligand catalytic lithiations would allow 
us to access products in higher er, or allow for the use of lower loadings of chiral 
diamine. This could form the basis of a future study. 
 
Figure 3.8 
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Chapter 4: Application of Lithiation-7egishi Coupling 
to the Total Synthesis of 7atural Products and Drug 
Molecules 
 
 This chapter details the use of Campos’ lithiation-arylation of -Boc pyrrolidine 38 in 
total synthesis. A wide range of 2-aryl and 2-vinyl pyrrolidine natural products and drug 
molecules have previously been reported. 2-Aryl pyrrolidine natural products include (S)-
nicotine (S)-97,135 (R)-dihydroshihunine (R)-96,136 (R)-harmicine (R)-190137 and (R)-
crispine A (R)-72.81 2-Vinyl pyrrolidine natural products have also been isolated; (R)-
Maackiamine (R)-99138 and (R)-tenuamine (R)-191139, 140 are two such compounds (figure 
4.1). 
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 The biological activity of natural products frequently inspires the development of 
analogous drug molecules. For example, the activity of (S)-nicotine (S)-97 has led to the 
investigation of ABT418 (S)-192141-144 and SIB1508Y (S)-98145 for the treatment of a 
range of CNS diseases (figure 4.2). 
 
Figure 4.2 
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 The primary aim of the results presented in this chapter was to exemplify the lithiation-
arylation of -Boc pyrrolidine 38 by completing a number of total syntheses. The natural 
products (S)-nicotine (S)-97 and (R)-dihydroshihunine (R)-96 were selected as targets, as 
was the drug molecule SIB1508Y (S)-98. Additionally, it was hypothesised that the 
reported lithiation-arylation procedure could be modified to effect vinylation of -Boc 
pyrrolidine 38 and complete a total synthesis of (R)-maackiamine (R)-99. Our efforts on 
the synthesis of these four target molecules are presented in this chapter. 
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4.1 Dihydroshihunine 
 (S)-Dihydroshihunine (S)-96 is an amino acid natural product first reported in 1982 by 
Kawanishi, and isolated from the Ayahuasca vine,  B. cappi (figure 4.3).146 Isolation of 
(S)-96 has also been reported from B. tenuiflora.147 (R)-dihydroshihunine has also been 
reported from R. chiliantha in 2001 by Kouno.136  
 
Figure 4.3 
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4.1.1 Previous Total Synthesis of Dihydroshihunine  
 A total synthesis of rac-dihydroshihunine rac-96 carried out by Leete and co-workers is 
the only previous synthesis of which we are aware (scheme 4.1).148 It is worth noting that 
this work was carried out en route to another natural product, shihunine, and was 
completed before dihydroshihunine had been reported from natural sources. 
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Starting from -methylpyrrolidone 193, treatment with sodium hydride and aryl ester 294 
gave pyrrolidone ketone 195 in 71% yield. Then, refluxing 195 with HBr led to a 
decarboxylative rearrangement, affording pyrrolinium salt 196. Subsequent reduction 
with sodium borohydride in one pot gave aryl pyrrolidine 197 in 59% yield. Finally, 
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lithium-bromine exchange with n-BuLi, followed by trapping with CO2 gave rac-
dihydroshihunine rac-96 in 67% yield (scheme 4.1).148  
 
4.1.2 Attempted Synthesis of (R)-Dihydroshihunine via Lithiation-Arylation of -
Boc Pyrrolidine 
 As there are no asymmetric syntheses of dihydroshihunine, we selected it as a suitable 
target molecule. It was proposed that the first step towards (R)-dihydroshihunine (R)-96 
would be a lithiation-arylation of -Boc pyrrolidine 38. Thus, 38 was treated with s-BuLi 
and a stoichiometric amount of (–)-sparteine 3. Transmetallation was then effected using 
zinc chloride, and coupling of methyl 2-bromobenzoate was carried out using 
palladium(II) acetate and t-Bu3PHBF4. Aryl pyrrolidine (R)-184 was obtained in 53% 
yield and 95:5 er (scheme 4.2). 
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 With aryl pyrrolidine (R)-184 in hand, two different routes to the natural product were 
proposed. In the first route, global deprotection would provide amino acid (R)-198, which 
would then be methylated to give (R)-dihydroshihunine (R)-96. Alternatively, global 
hydride reduction would give -methyl amino alcohol (R)-199, and then reoxidation 
would allow access to (R)-dihydroshihunine (R)-96 (scheme 4.3). 
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Scheme 4.3 
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 Removal of the Boc protecting group of (R)-184 using TFA was successful but also led 
to cyclisation and formation of lactam 200. To prove this reactivity, we optimised the 
synthesis of lactam 200, using TFA-mediated Boc deprotection followed by treatment 
with K2CO3 to induce cyclisation. This gave lactam 200 in 68% yield (scheme 4.4).  
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 In order to prevent cyclisation following Boc deprotection, ester (R)-184 was 
hydrolysed in 76% yield using sodium hydroxide to give acid (R)-201 without the need 
for purification after work-up (scheme 4.5). Unfortunately, following treatment of (R)-
201 with TFA, it was not possible to isolate product (R)-198 or starting material (R)-201. 
One pot deprotection-methylation to give dihydroshihunine (R)-96 also met with failure. 
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 Hence, the other route to dihydroshihunine was investigated, namely global reduction 
then re-oxidation. Treatment of Negishi product (R)-184 with LiAlH4 gave amino alcohol 
(R)-199 in 72% yield (scheme 4.6). However, we were then unable to effect oxidation to 
either the corresponding aldehyde 202 or acid 96 under any conditions. Oxidation was 
attempted using manganese dioxide in dichloromethane at room temperature and in 1,4-
dioxane at reflux, pyridinium chlorochromate in dichloromethane at room temperature, 
pyridinium dichromate in dimethylformamide at room temperature and Swern oxidation 
conditions. In each case, neither the desired product nor starting material was 
recoverable. 
 
Scheme 4.6 
N
Boc
CO2Me
(R)-184
LiAlH4
THF N
Me
OH
[O]
N
Me
H
N
Me
OH
202 96
O O
or
(R)-199
72%  
 
 Unfortunately, neither of the proposed synthetic routes to (R)-dihydroshihunine (R)-96 
was successful in completing the synthesis. A possible alternative route that could have 
been investigated is shown in scheme 4.7. This would proceed via lithiation-arylation of 
-Boc pyrrolidine 38 with 1,2-dibromobenzene to give aryl pyrrolidine (R)-203. Boc 
deprotection and then methylation would give (R)-197 which is an intermediate in 
Leete’s synthesis of rac-dihydroshihunine rac-96. This would then constitute a formal 
synthesis of (R)-dihydroshihunine (R)-96 (scheme 4.7). 
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4.2 7icotine 
 (S)-Nicotine (S)-97 is a natural product primarily associated with the tobacco plants . 
rustica and . tabacum (figure 4.4). The alkaloid can also be found in vegetables of the 
nightshade family Solanaceae, including tomato, potato, aubergine and bell peppers.149  
 
Figure 4.4 
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 Interest in nicotine 97 by chemists stretches back over 150 years. The pure alkaloid was 
first isolated from tobacco in 1828, and the correct structure was proposed in 1893 by 
Pinner.135, 150 Pictet reported the first racemic synthesis in 1904151 and the first 
asymmetric synthesis was published by Chavdarian in 1982.152 Initial chemical interest in 
nicotine 97 was driven by continuing widespread recreational use of tobacco products. 
However, nicotine 97 has also historically been used as an insecticide – as much as 2800 
tons were used per year as crop protectant.135 In recent years, further interest in nicotine 
97 and its analogues has been created by the revelation that nicotine 97 is potentially 
active in the treatment of a wide range of CNS diseases.135 The synthesis of nicotine 97 
and the more common natural product and drug molecule analogues has been recently 
reviewed.135 
 
4.2.1 Selected Previous Syntheses of (S)-7icotine  
 A common theme running through previous syntheses of nicotine 97, and indeed many 
2-aryl pyrrolidines, is the need to start a synthesis with one ring system intact, and build 
up the other ring through two or more synthetic steps. An example is the first asymmetric 
synthesis of (S)-nicotine (S)-97 reported by Chavdarian, wherein the synthesis started 
from L-proline and the pyridine ring was then built up (scheme 4.8).152, 153 
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 Starting from L-proline 204, installation of the -methyl group and the pyridine ring 
atoms was achieved in 9% yield over 5 steps to give 205. As the two new stereocentres in 
205 would be lost in subsequent steps, the mixture of product diastereomers was used as 
obtained. Cyclisation was then accomplished using a route pioneered by Bryson, treating 
205 with HBr in acetic acid to give (S)-bromonicotine (S)-206 in 46% yield.154 Finally, 
high pressure hydrogenation using a palladium(II) chloride catalyst removed the bromine 
to give (S)-nicotine (S)-97 in 55% yield and 62:38 er (4% overall yield from L-proline). It 
was believed that the loss of er came during the cyclisation step, although epimerisation 
could also have occurred when forming 205.152 
 In contrast to Chavdarian’s synthesis is the approach reported in 2005 by Helmchen.155 
Beginning with a pyridine starting material 207, stereochemistry was installed in the first 
step using an allylic amination. Using ligand 208, first developed by Alexakis, Helmchen 
reported optimising this amination using an iridium/208 catalyst which afforded product 
(R)-209 in high yields and >99:1 er (scheme 4.9).155, 156  
 
Scheme 4.9 
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 Following amination, (S)-nicotine (S)-97 was formed in 60% yield over 4 steps. Thus, 
(S)-nicotine (S)-97 was synthesised in >99:1 er in 5 steps with an overall yield of 42%. 
 
4.2.2 Synthesis of (S)-7icotine via Two-Ligand Catalytic Lithiation-Arylation of -
Boc Pyrrolidine 
 It was proposed that lithiation-arylation of -Boc pyrrolidine 38 with 3-bromopyridine 
would provide a convenient starting point for our new synthesis of (S)-nicotine (S)-97. 
Due to ease of use and availability, the synthetic route was first optimised using (–)-
sparteine 3, which would eventually lead to unnatural (R)-97. Thus, using the conditions 
reported by Campos,89 (R)-pyridyl pyrrolidine (R)-84 was obtained in 40% yield (scheme 
4.10). Determination of the er of (R)-84 by CSP-HPLC did not prove possible, but we 
were later able to determine the er of (R)-nicotine (R)-97 by 1H NMR spectroscopy in the 
presence of a chiral shift reagent. 
 
Scheme 4.10 
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 We had hoped that LiAlH4 reduction of (R)-84 would convert the -Boc group to a -
Me group and thus complete the synthesis of (R)-nicotine (R)-97. Unfortunately, using 
this approach traces of an inseparable impurity remained in the resulting sample of (R)-
nicotine (R)-97. It was then found that TFA-mediated Boc deprotection to give (R)-
nornicotine (R)-210 and then Eschweiler-Clarke methylation to give (R)-nicotine (R)-97 
both proceeded in high yields (76% and 91% respectively) (scheme 4.11). Furthermore, 
purification was not required after either step. The er of the sample of (R)-nicotine (R)-97 
was then determined using chiral shift 1H NMR spectroscopy in the presence of Pirkle’s 
alcohol. The er found (96:4) is that expected from the lithiation-arylation protocol, 
indicating that no epimerisation took place during the deprotection-methylation steps. 
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Scheme 4.11 
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 With a facile synthesis of (R)-nicotine (R)-97 in hand, we were able to turn our 
attention to the naturally occurring enantiomer, (S)-nicotine (S)-97. Thus, two-ligand 
catalytic lithiation of -Boc pyrrolidine 38 mediated by s-BuLi, 0.25 equivalents of (+)-
sparteine surrogate 6 and 1.0 equivalent of di-i-Pr bispidine 7, followed by 
transmetallation with zinc chloride and finally Negishi coupling with 3-bromopyridine 
gave (S)-pyridyl pyrrolidine (S)-84 in 46% yield. Deprotection-methylation then gave 
(S)-nicotine (S)-97 in 96% yield and 92:8 er (scheme 4.12). In this case, we did not 
isolate (S)-nornicotine (S)-210 after Boc deprotection. The er was determined by chiral 
shift 1H NMR spectroscopy in the presence of Pirkle’s alcohol. 
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 To the best of our knowledge this is the shortest and most efficient synthesis of (S)-
nicotine (S)-97 to date. It is also the first synthesis in which both rings and the 
stereochemistry are installed in a single synthetic step. Finally, our synthesis represents a 
synthetic protocol in which the two rings are joined directly, rather than requiring a ring 
closing step. 
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4.3 SIB1508Y 
 SIB1508Y (S)-98 (Altinicline) is a nicotine analogue first reported by a group at SIBIA 
led by Cosford (figure 4.5).145 Like (S)-nicotine (S)-97, it acts as a nicotinic acetylcholine 
receptor (NAChR) agonist, but displays a greater selectivity between receptor 
subtypes.145 
 
Figure 4.5 
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4.4.1 Selected Previous Syntheses of SIB1508Y 
 The first asymmetric synthesis of SIB1508Y (S)-98 was reported by Lebreton in 2001 
(scheme 4.13).157 Ketone 211 was first formed in 61% over 3 steps from bromonicotinic 
acid. Then, reduction to alcohol (R)-212 in 79% yield and 97:3 er using (+)-Ipc2BCl 
installed the stereocentre. Quantitative mesylation then allowed nucleophilic 
displacement by sodium azide to give azide (S)-213 in 83% yield, setting the system up 
for cyclisation. 
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 Formation of the pyrrolidine ring was achieved by a dicyclohexyl borane-mediated 
hydroboration-cyclisation to give bromo nornicotine (S)-214 in 62% yield. Then, 
methylation and installation of the alkyne motif was accomplished in 78% over two steps 
to give (S)-215. Deprotection using sodium hydride provided SIB1508Y (S)-98 in 92% 
yield and 97:3 er (10 steps and 18% overall yield).157 
 In contrast to Lebreton’s synthesis of SIB1508Y (S)-98, Comins has published two total 
syntheses of the drug molecule starting from (S)-nicotine (S)-97.158, 159 The optimal 
synthesis afforded enantiopure SIB1508Y (S)-98 in 5 steps and 32% overall yield.159 
Dihalo nicotine analogue (S)-216 has previously been prepared from natural (S)-nicotine 
(S)-97 in two steps.160 Sonogashira coupling with tri-i-Pr-silyl acetylene installed the 
alkyne motif, giving (S)-217 in almost quantitative (99%) yield. Removal of chlorine 
using zinc metal in acetic acid, and silyl deprotection using TBAF was achieved in 51% 
yield (scheme 4.14).159  
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4.3.2 Synthesis of SIB1508Y via Lithiation-Arylation of -Boc Pyrrolidine 
 With a synthesis of (S)-nicotine (S)-97 in hand, we decided to attempt a synthesis of the 
nicotine analogue SIB1508Y (S)-98. In this case, the relevant bromopyridine 218 was not 
commercially available and so it was synthesised in 72% yield via a Sonogashira 
coupling of 3,5-dibromopyridine 219 and trimethylsilyl acetylene, as reported by Fujita 
(scheme 4.15).161 
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 A stoichiometric lithiation of -Boc pyrrolidine 38 mediated by s-BuLi/(+)-sparteine 
surrogate 6 was used to complete the synthesis. Thus, lithiation-arylation of -Boc 
pyrrolidine 38 with alkynyl bromopyridine 218 gave (S)-aryl pyrrolidine (S)-220 in 44% 
yield (scheme 4.16). Determination of the er of (S)-220 by CSP-HPLC did not prove 
possible, but we were later able to determine the er of SIB1508Y (S)-98 using 1H NMR 
spectroscopy in the presence of the chiral shift reagent Pirkle’s alcohol. 
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 It was found that reduction of the Boc group with LiAlH4 led to degradation of the 
alkyne bond – neither the expected product nor starting material were recovered. 
Fortunately, Boc deprotection with TFA and then removal of the trimethylsilyl group 
with caesium fluoride could be accomplished in one pot, giving deprotected product (S)-
221 in 76% yield. Eschweiler-Clarke methylation then installed the -methyl group, 
completing the synthesis in 68% yield (scheme 4.17). 
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 The er of the final sample of SIB1508Y (S)-98 was determined as 92:8 by 1H NMR 
spectroscopy in the presence of Pirkle’s alcohol. This is the shortest (4 steps) synthesis of 
SIB1508Y (S)-98 to date.159 
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4.4 Maackiamine 
 Maackiamine 99 is an alkaloid natural product isolated from the flower of the Amur 
Maackia tree, M. amurensis.138 Although the deciduous Amur Maackia is occasionally 
used in central Asian folk medicine, maackiamine (R)-99 has not to our knowledge been 
tested for biological activity – presumably due to unavailability. We are unaware of any 
previous asymmetric synthesis of maackiamine (R)-99. Djerassi reported a racemic 
procedure for the synthesis of maackiamine (R)-99 (referred to as ‘norammodendrine’), 
while carrying out mass spectrometry studies on ammodendrine (R)-222, before 
maackiamine (R)-99 had been isolated from natural sources (figure 4.6).162   
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4.4.1 Previous Synthesis of rac-Maackiamine 
 Djerassi’s synthesis began with a palladium-catalysed hydrogenation of nicotinoyl 
pyrrolidone 223 to give tetrahydropyridine 224 in quantitative yield. An acid-catalysed 
rearrangement then installed the two ring systems in the correct positions in 89% yield. 
Finally, acetylation-reduction of imine salt 225 was carried out in one pot to give rac-
maackiamine rac-99 in 52% yield (scheme 4.18).162 
 
Scheme 4.18 
N
O
NH
O
N
H
O
NH
O
N
N
H
N
H
N
Ac
H2, 10% Pd/C
1. HCl(aq) 1. Ac2O, NaOAc
2. NaBH4, EtOH2. K2CO3, EtOH
MeOH
224
100%
225
89%
rac-99
52%
223
 
 
 
 103 
4.4.2 Synthesis of (R)-Maackiamine via Lithiation-Vinylation of -Boc Pyrrolidine  
 Our retrosynthetic analysis of (R)-maackiamine (R)-99 is shown in scheme 4.19. (R)-
Maackiamine (R)-99 would be derived, by Boc deprotection, from (R)-226, itself formed 
from the lithiation-vinylation of -Boc pyrrolidine 38. We proposed that the relevant 
vinyl bromide 227 could be formed via bromination of enamide 228. Enamide 228 could 
be formed by acetylation of the known trimer 229, obtained from piperidine 230. At the 
time this work was carried out, lithiation-vinylation of -Boc pyrrolidine 38 via Negishi 
coupling had not been reported. Since then, Gawley has reported the lithiation-vinylation 
of -Boc piperidine 44.100 
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 Starting from piperidine 230, -chlorination using -chloro succinimide followed by 
base-mediated elimination using sodium methoxide gave imine 231, which spontaneously 
trimerised to give 229 in 56% yield. The synthesis of trimer 229 had previously been 
reported by Poupon,163 and also by de Kimpe164 (-chlorination using ClOt-Bu) (scheme 
4.20).  
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 Trimer 229 was then acetylated in 65% yield by heating in acetic anhydride to give 
enamide 228. Next, enamide 228 was brominated in 91% yield using a bromination 
procedure developed by Shipman for an analogous enamide (scheme 4.21).165 During 
bromination, care had to be taken to achieve optimal yields – when adding bromine 
dropwise, a colour change from pale yellow to dark orange was observed. Addition of 
further bromine after this colour change resulted in a reduced yield of vinyl bromide 227. 
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 Initial results for the lithiation-vinylation of -Boc pyrrolidine 38 indicated that a more 
detailed optimisation was required. Therefore, we decided to investigate a small range of 
different lithiation-transmetallation-coupling conditions. The palladium source used 
(palladium(II) acetate vs. Pd2dba3) was altered, as was the solvent (diethyl ether vs. t-
butyl methyl ether). The time allowed for coupling, and the coupling temperature were 
also optimised (table 4.1). 
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Table 4.1 
N
Boc
N
Boc N
Ac
1. s-BuLi, (_)-sparteine 3
solvent, _78 oC, 1 h
2. ZnCl2, Et2O, solvent
_78 oC 30 min, rt 30 min
3. 0.7 equiv. vinyl bromide 227
5 mol% Pd
6 mol% t-Bu3PHBF4
solvent, Et2O
38 (R)-226
 
 Entry Solvent    Pd Source Coupling Time    Coupling Temp    % Yielda (er)a 
    1  Et2O     Pd(OAc)2         16 h      rt  29 (94:6) 
    2 TBME     Pd(OAc)2         16 h      rt           37 (80:20) 
    3 TBME     Pd(OAc)2             16 h  reflux  43 (93:7) 
    4 TBME      Pd2dba3             16 h      rt  40 (92:8) 
    5 TBME      Pd2dba3         72 h      rt  56 (95:5)iiii 
 a % Yield after chromatography, er determined by CSP-HPLC 
 
 Using Campos’ conditions, lithiation of -Boc pyrrolidine 38 with s-BuLi/(–)-sparteine 
3 in diethyl ether, followed by transmetallation with zinc chloride and then coupling of 
vinyl bromide 227 with palladium(II) acetate at rt for 16 h gave (R)--Boc maackiamine 
(R)-226 in 29% yield and 94:6 er (entry 1). Using the same conditions but exchanging 
diethyl ether for t-butyl methyl ether led to an increase in yield to 37%, but a reduction in 
er (80:20 vs. 94:6) (entry 2). Lithiation-vinylation of -Boc pyrrolidine 38 in t-butyl 
methyl ether and then coupling vinyl bromide 227 with palladium(II) acetate at reflux for 
16 h gave (R)--Boc maackiamine (R)-226  in 43% yield and 93:7 er (entry 3). We then 
investigated the use of Pd2dba3 as the palladium source. Thus, lithiation of -Boc 
pyrrolidine 38 in t-butyl methyl ether, transmetallation with zinc chloride and then 
coupling of vinyl bromide 227 with Pd2dba3 at rt for 16 h gave (R)-226 in 40% yield and 
92:8 er (entry 4). Using identical conditions, but extending the coupling time to 72 h gave 
(R)--Boc maackiamine (R)-226 in 56% yield and 95:5 er (entry 5). It was decided that 
these conditions were adequate for the completion of the synthesis. 
 To complete the synthesis of the natural product, removal the -Boc group to give the 
free secondary amine was necessary. Unfortunately, it was found that treatment of (R)--
Boc maackiamine (R)-226 with TFA gave a 96% yield of racemic maackiamine rac-99 
(scheme 4.22). 
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 We propose that the mechanism for this racemisation is that shown in scheme 4.23. 
Protonation of the new secondary amine and then ring opening would occur to give 
planar iminium 232. Recyclisation on work-up will then lead to rac-maackiamine rac-99. 
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 An attempted deprotection using the Lewis acid BF3·OEt2 also led to racemisation and 
rac-maackiamine rac-99 was obtained in 53% yield. Qu recently published a non-acidic 
Boc deprotection method using refluxing neutral H2O.
166 Several examples of the 
deprotection of -Boc secondary amines were described. We attempted to access (R)-
maackiamine (R)-99 under these conditions, but were unable to isolate maackiamine 99 
or recover -Boc maackiamine 226. 
 Ohfune has previously reported a two-step acid-free silylation-desilylation Boc 
deprotection methodology.167, 168 One example presented by Ohfune was the deprotection 
of an -Boc proline methyl ester. Thus, we hypothesised that this method might be of use 
in the deprotection of (R)--Boc maackiamine (R)-99. The first step of Ohfune’s protocol 
involves treatment of an -Boc amine 233 with 2,6-lutidine and a trialkylsilyl triflate. 
The resulting silylcarbamate 234 is then treated with TBAF. Fluoride abstraction of the 
trialkylsilyl group followed by loss of CO2 leaves the deprotected amine 235 (scheme 
4.24). 
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 In our hands, Ohfune’s methodology provided a sample of maackiamine contaminated 
with several difficult-to-remove impurities: residual lutidine, TBAF and silyl-containing 
compounds. We were able to avoid some of these contaminants by slightly modifying the 
reaction conditions. Thus, 2,6-lutidine was replaced with pyridine, which could be 
removed after reaction by evaporation under high vacuum. Similarly, TBAF was replaced 
with caesium fluoride which could be removed by a basic aqueous wash. The residual 
silyl-containing compounds proved difficult to remove, but were eventually separated 
from the product using preperative TLC. Thus, (R)-maackiamine (R)-99 was obtained in 
54% yield (scheme 4.25). 
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 The sample of (R)-maackiamine (R)-99 was shown to be 95:5 er by chiral shift 1H 
NMR in the presence of Pirkle’s alcohol. The modest (54%) yield does not reflect a lack 
of reactivity to deprotection on the part of -Boc maackiamine 226, but rather the 
difficulty of purification of the final product. To conclude, we have completed the first 
asymmetric synthesis of (R)-maackiamine (R)-99, accessing (R)-99 of 95:5 er in 10% 
yield over 5 steps from piperidine 230. 
 It is worth noting that although our sample was shown to be 95:5 er by 1H NMR 
spectroscopy in the presence of a chiral shift reagent, the optical rotation ([α]D +12.8 (c 
1.0 in EtOH)) is almost an order of magnitude lower than that reported for the natural 
product ([α]D +110 (c 0.01 in EtOH)). 
138 The reason for this discrepancy is unknown. 
 
 108 
To conclude, lithiation-arylation of -Boc pyrrolidine has been used to complete total 
syntheses of (S)-nicotine (S)-97 and SIB1508Y (S)-98. Unfortunately, we were unable to 
complete the synthesis of (R)-dihydroshihunine (R)-96. Finally, Campos’ lithiation-
arylation procedure was modified to allow lithiation-vinylation, and the first asymmetric 
synthesis of the natural product (R)-maackiamine (R)-99 was completed. 
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Chapter 5: Diamine-Free Lithiation of 7itrogen 
Heterocycles 
 
 This chapter details the development of a new diamine-free protocol for racemic α-
lithiation of -Boc nitrogen heterocycles. Following optimisation of the new lithiation 
conditions, both lithiation-trapping and lithiation-arylation of -Boc pyrrolidine 38 are 
reported. Then, expansion of the new methodology to effect diamine-free racemic α-
lithiations of other -Boc heterocycles is explored, notably on -Boc-ʹ-benzyl 
piperazine 59 and -Boc-ʹ-i-Pr imidazolidine 64 (figure 5.1).  
 
Figure 5.1 
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 In addition to synthetic experiments, in situ infra-red spectroscopic monitoring of 
diamine-free lithiations of a range of carbamates was carried out. Issues of solvent 
stability to s-BuLi at different temperatures are also addressed.  
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5.1 Previous Racemic Lithiations of Carbamates 
 Historically, racemic lithiation-trapping of -Boc nitrogen heterocycles has been 
carried out as reported by Beak in 1989.29 Treatment with s-BuLi and TMEDA in diethyl 
ether at –78 °C for 3.5 h followed by electrophilic quench afforded racemic 2-substituted 
heterocycles in high yields. For example, lithiation of -Boc pyrrolidine 38 using this 
protocol followed by trapping with trimethylsilyl chloride gave silyl pyrrolidine rac-39 in 
81% yield, while -Boc piperidine 44 gave silyl piperidine rac-45 in 94% yield under the 
same conditions (scheme 5.1).29 
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 These conditions have been adopted for a range of applications in recent years.70, 119, 169-
173 Examples include Feringa’s 2008 synthesis of (+)-myrtine169 and Stoltz’s synthesis of 
the alkaloid (–)-lobeline.170 Indeed, TMEDA has become widely used by organometallic 
chemists to increase the reactivity of organolithium reagents.2 However, the efficiency of 
TMEDA as a ligand for lithium was questioned as early as 1992 by Collum.174 For 
example, addition of THF to a solution of the LDA/TMEDA complex caused complete 
dissociation of TMEDA from the organolithium.175 Additionally, THF outcompetes 
TMEDA for complexation to LiHMDS.176 
 
5.1.1 Displacement of Diamines from Alkyllithiums by THF 
 While sufficient for the research chemist, the low reaction temperature and use of 
TMEDA make Beak’s methodology inconvenient for use on a large scale. A re-
evaluation of previous literature led us to propose that a simpler racemic lithiation 
protocol could be developed. Specifically, it was noticed that s-BuLi/(–)-sparteine-
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mediated asymmetric lithiations gave high enantioselectivity when carried out in non-
coordinating solvents, but near racemic products when attempted in THF.106, 177-182 This 
effect was first noted by Hoppe.177 For example, Beak showed that lithiation of -Boc 
benzylamine 95 using s-BuLi/(–)-sparteine 3 in toluene followed by internal electrophilic 
trapping to effect cyclisation gave 2-phenyl pyrrolidine (S)-77 in 72% yield and 98:2 er. 
In contrast, lithiation using s-BuLi/(–)-sparteine gave (S)-77 in 58% yield and 48:52 er 
when carried out in THF (scheme 5.2).106 
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 Our group presented another example of poor enantioselectivity when using s-BuLi/(–)-
sparteine 3 in THF. Thus, treatment of aziridine 236 with s-BuLi and (–)-sparteine 3 in 
diethyl ether gave alkynyl sulfonamide (R)-237 in 48% yield and 78:22 er. Alternatively, 
the same conditions in THF gave (R)-237 in 63% yield and 53:47 er (scheme 5.3).182 
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 It is known that the coordinating solvent THF can displace (–)-sparteine 3 from 
alkyllithiums in solution.183, 184 Thus, we propose that when attempting a s-BuLi/(–)-
sparteine-mediated lithiation in THF, the active lithiating species is in fact a s-BuLi/THF 
complex such as dimer 238 or tetramer 239. In the less strongly coordinating solvent 
diethyl ether, the diamine remains associated with alkyllithium. The active species in this 
case is presumably analogous to known dimers 240 and 241 (figure 5.2).117, 185 
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Figure 5.2 
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 We therefore reasoned that a s-BuLi/THF complex was a sufficiently active lithiating 
agent for effecting diamine-free racemic lithiations. It was hoped that not only could such 
a diamine-free lithiation protocol be developed, but that the procedure could be optimised 
for use at temperatures more amenable for large-scale synthetic experiments.  
 Industrial chemists must expend their efforts not only in making large-scale syntheses 
economical, but also in reducing their environmental impact. Such concerns drive recent 
interest in “green” solvents. We hoped that a THF-mediated lithiation protocol could also 
be carried out using 2-Me THF. This alternative solvent is considered to be preferable to 
THF as it is not water-miscible, reducing contamination of the waste stream.186 
Additionally, 2-Me THF is ultimately derived from a renewable resource (2-furaldehyde 
from agricultural waste).186 The use of 2-Me THF in organometallic reactions has 
recently been reviewed.186 
 
5.1.2 Previous THF-Mediated Diamine-Free Racemic Lithiations 
 There have been several isolated reports of diamine-free lithiations of carbamates 
carried out in THF.74, 75, 187, 188 For example, Orito reported lithiation of -Boc 
pyrrolidine 38 using LDA in THF,188 although it should be noted that we were unable to 
reproduce this result, despite several attempts. Coldham reported racemic lithiation of -
Boc-ʹ-isopropylimidazolidine 64 using s-BuLi in THF, obtaining substituted 
imidazolidines in modest yields (scheme 5.4).74, 75 
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Scheme 5.4 
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 Lithiation of the analogous substrate 243 was also reported under the same conditions. 
It was found, however, that racemic lithiation of pyrimidine 244 required s-BuLi in THF 
with TMEDA as a co-solvent for optimal yields (figure 5.3).75 
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5.2 Diamine-Free Racemic Lithiation of -Boc Pyrrolidine 
 First, we confirmed that s-BuLi/(–)-sparteine 3-mediated lithiation of -Boc 
pyrrolidine 38 in THF would give racemic products. Thus, 38 was  lithiated using (–)-
sparteine 3 and s-BuLi in THF at –78 °C and then benzaldehyde was added. Alcohol syn-
182 was obtained in 62% yield and 50:50 er, together with anti-182 in 35% yield and 
50:50 er (scheme 5.5). Hence, the s-BuLi/THF complex is presumably more reactive than 
any s-BuLi/(–)-sparteine 3 present in the solution. In collaboration with Hilmerson, our 
group has recently reported 6Li NMR spectroscopic evidence that in THF, (–)-sparteine 3 
does not coordinate to i-PrLi, when using 3 equivalents of diamine.183 
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5.2.1 Diamine-Free Lithiation of -Boc Pyrrolidine 
To optimise the new diamine-free racemic lithiation conditions, -Boc pyrrolidine 38 
was treated with s-BuLi in THF, 2-Me THF or diethyl ether at a range of temperatures 
and reaction times. Due to ease of availability and efficient trapping, we selected 
benzaldehyde as the electrophile in these lithiations. In all cases, a roughly 75:25 mixture 
of syn:anti diastereomers of alcohols syn-182 and anti-182 were obtained. For clarity, the 
total combined yield of syn-182 and anti-182 is also shown (table 5.1). 
  Lithiation in diethyl ether at –78 °C for 60 min gave a low 8% yield of trapped 
products (entry 1) as the s-BuLi/Et2O complex is not reactive enough to effect complete 
lithiation. In contrast, the same conditions in THF and 2-Me THF gave 89% yield and 
92% yield respectively (entries 2 and 3). 
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Table 5.1 
N
Boc
N
Boc
PhH
N
Boc
PhH
OH OH
+
38 syn-182 anti-182
1. s-BuLi, solvent
Temp, time
2. PhCHO
3. H+
 
 
       Reaction    %Yield       %Yield       %Yield 
Entry  Solvent   Temp (°C)   Time (min)    syn-182a      anti-182a      Totala iiiii 
   1   Et2O          –78       60          6        2            8 
   2   THF          –78       60         57      32           89 
   3       2-Me THF       –78       60         55      37           92 
   4   Et2O          –40       60         18       8           26 
   5   THF           –40         60         43      21           64 
   6       2-Me THF       –40        60         57      37           94 
   7   Et2O          –30       60          0       0            0 
   8   THF          –30       60         25     12           37 
   9       2-Me THF       –30       60          0        0            0 
  10   THF          –30       10         58      31           89 
  11   THF          –30         5         56       28           84 
  12      2-Me THF       –30         5         49       24           73 
  13   THF          –20       30          7        3           10 
  14   THF          –20         5         44      22           66 
  15   THF          –20         2         37       20           57 
  16   THF          –10         5         19       10           29 
  17   THF          –10         1          0         0            0 
  18   THF             0       30          0         0            0iiiiiiiii 
  a %Yield of syn-182 and anti-182 after chromatography 
 
 Next, lithiations at higher temperatures were investigated. Lithiation at –40 °C for 60 
min gave 26% yield of trapped product when carried out in diethyl ether (entry 4), 64% 
yield in THF (entry 5) and 94% yield in 2-Me THF (entry 6). Then, the reaction 
temperature was further raised to –30 °C. Lithiation for 60 min gave no product in diethyl 
ether (entry 7) or 2-Me THF (entry 9) and only 37% yield in THF (entry 8). Disappointed 
by these low yielding lithiations, we next decided to investigate shorter lithiation times. 
Lithiation for 10 min in THF at –30 °C gave 89% combined yield of alcohols syn-182 
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and anti-182 (entry 10), while a 5 min lithiation time in THF gave a total yield of 84% 
(entry 11). Use of 2-Me THF gave a slightly poorer result – 73% yield was obtained after 
5 min (entry 12).  
 Lithiations at temperatures higher than –30 °C in THF gave at best modest yields. 
Treatment of -Boc pyrrolidine 38 with s-BuLi in THF at –20 °C and then trapping with 
benzaldehyde gave 10% combined yield after a lithiation time of 30 min (entry 13), 66% 
yield after 5 min (entry 14) and 57% yield after 2 min (entry 15). Yields reduced even 
further with higher temperatures. Thus, lithiation at –10 °C for 5 min gave 29% yield of 
trapped products (entry 16), while no products were isolated after a 1 min reaction time at 
–10 °C (entry 17). As might be expected from these results, lithiation at 0 °C for 30 min 
also gave no products (entry 18). The conditions selected as our new optimised diamine-
free racemic lithiation protocol were those shown in entry 11: treatment with s-BuLi in 
THF at –30 °C for 5 min and then electrophilic trapping. 
 We note that at temperatures higher than –30 °C, optimal yields could not be obtained 
from s-BuLi/THF-mediated lithiations (table 5.1, entries 13-18). It was likely that at these 
temperatures, low yields were obtained due to preferential lithiation of THF rather than 
substrate. The stability of s-BuLi in THF has not, to our knowledge, been reported. 
However, the breakdown of THF by other alkyllithiums has been studied by a number of 
groups, and has been shown to proceed by one of two routes. The most common is shown 
in scheme 5.6.2 
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 Lithiation of THF in the 2-position gives lithiated species 245. This can then undergo a 
reverse [3+2]-cycloaddition to give lithium enolate 246 which can be trapped out with 
electrophiles.189, 190 Cycloreversion also leads to the formation of ethene which upon 
carbolithiation with another equivalent of alkyllithium gives rise to homologated 
alkyllithiums such as 248.191-193 Following this solvent decomposition pathway one 
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molecule of solvent therefore consumes two equivalents of alkyllithium. An alternative 
pathway can lead to the formation of but-3-en-1-oxide via α-elimination from 245 or 3-
lithiation of THF, but this has only been observed when using a very basic organolithium 
solution (e.g. t-BuLi/HMPA in THF).194 
 It was decided to attempt to confirm the breakdown of THF at high temperatures and 
thus explain the low yield we had obtained from diamine-free lithiations at > –30 °C. 
First, we attempted to trap s-BuLi with benzaldehyde under conditions which would not 
lead to solvent breakdown as a control reaction: s-BuLi was stirred in diethyl ether at –78 
°C for 1 h and then the electrophile was added. Alcohol 249 was isolated in 66% yield 
(Scheme 5.7). 
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Li
Li
1. Et2O,
_78 oC, 1 h
2. PhCHO
Ph
OH
1. THF, 0 oC, 30 min
2. PhCHO
Ph
OH
249
66%
250
29%  
 
 Then, s-BuLi was stirred in THF at 0 °C for 30 min and one equivalent of 
benzaldehyde was added to trap the organolithium species present. This yielded a 29% 
yield of alcohol 250, derived from ethene-homologated s-BuLi (scheme 5.7). As two 
equivalents of s-BuLi are required to form the primary alkyllithium, at least 58% of the s-
BuLi present has been consumed. It is possible that some gaseous ethene escaped the 
reaction solution, explaining the modest yield of 250. We did not observe any evidence of 
trapped enolate 246 or trapped s-BuLi. We have thus determined that the cause of poor 
yields in diamine-free racemic lithiations at tempertures > –30 °C is breakdown of THF 
by s-BuLi. 
 We wondered whether diamine-free racemic lithiations of -Boc pyrrolidine 38 in THF 
could be carried out using the bases n-BuLi or LDA instead of s-BuLi. Advantages of this 
would be that these bases are more stable in THF than s-BuLi, and are considered safer to 
use. A range of attempted reaction conditions is shown in table 5.2. In each case, no 
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product was formed – inspection of the 1H NMR spectrum of the crude product revealed 
only unreacted starting material 38 and electrophile. 
 
Table 5.2 
N
Boc
N
Boc
E
1. Base, THF
Temp, time
2. E+
 
 
  Entry        Base          Temp (°C)      Time (min)  Electrophile 
     1      n-BuLi        0        60      PhCHO 
     2      n-BuLi        rt        60      PhCHO 
     3       LDA      –78        60      PhCHO 
     4       LDA      –40        30      PhCHO 
     5       LDA      –20        30      PhCHO 
     6       LDA         0        60      PhCHO 
     7       LDA        0      180      PhCHO 
     8       LDA       rt        30      PhCHO 
     9       LDA        0        30        BnBr 
    10       LDA       rt        30        BnBriiiii 
 
 First, lithiation using n-BuLi was attempted. Treatment of -Boc pyrrolidine 38 with n-
BuLi in THF for 60 min at either 0 °C or rt followed by attempted trapping with 
benzaldehyde gave no products (entries 1 and 2). Ortio has previously reported the 
lithiation of -Boc pyrrolidine 38 using LDA in THF followed by trapping with benzyl 
bromide, but did not report the conditions used. In our hands, lithiation of 38 using LDA 
at –78 °C for 60 min, –40 °C for 30 min, –20 °C for 30 min, 0 °C for 60 min or 180 min 
or rt for 30 min followed by addition of PhCHO gave only recovered starting material 
and electrophile (entries 3-8). Attempted LDA-mediated lithiation of -Boc pyrrolidine 
38 for 30 min at either 0 °C or rt and then trapping with benzyl bromide also met with 
failure (entries 9 and 10). 
 With a set of optimised reaction conditions for diamine-free racemic lithiation of -Boc 
pyrrolidine 38 in hand, a range of different electrophiles was assayed, giving 2-
substituted pyrrolidines 39 and 251-256 (scheme 5.8). 
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 Trapping with dimethyl sulfate gave methyl pyrrolidine 251 in 70% yield. When 
trapping with allyl bromide, the lithiated pyrrolidine intermediate was first 
transmetallated to an organocuprate species using a CuCN/2LiCl complex, as it has 
previously been shown that this procedure gives higher yields of trapped -heterocycles 
than a direct trap.67 A lithium-zinc-copper double transmetallation procedure has since 
been shown to give even higher yields.195 Allyl pyrrolidine 252 was obtained in 65% 
yield. Use of carbon dioxide as electrophile gave -Boc proline 253 in 49% yield, while 
methyl chloroformate gave -Boc methyl prolinate 254 in 51% yield. Silyl pyrrolidine 39 
was accessed in 71% yield when trapping with trimethylsilyl chloride. Finally, two 
dimethyl amide electrophiles were used. DMF gave 255 in 67% yield, while dimethyl 
benzamide gave ketone 256 in 77% yield (scheme 5.8) 
 When trapping with methyl chloroformate, product 254 was obtained in only 51% 
yield. The disubstituted pyrrolidine 257 was also obtained (18% yield). This indicated 
that after trapping once, residual s-BuLi would preferentially deprotonate 254 to give the 
enolate which would then trap to give disubstituted product 257, rather than undergoing 
nucleophilic attack on excess electrophile. Thus, we were able to optimise the synthesis 
of product 257. Treatment of -Boc pyrrolidine 38 with 2 equivalents of s-BuLi in THF 
at –78 °C for 1 h and then adding 3 equivalents of methyl chloroformate gave 
disubstituted pyrrolidine 257 in 76% yield (scheme 5.9). We note that Coldham had 
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observed a similar disubstitution when trapping lithiated imidazolidine 64 with ethyl 
chloroformate.74, 75 
Scheme 5.9 
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 Although Campos had reported the s-BuLi/(–)-sparteine 3-mediated enantioselective 
lithiation-arylation of -Boc pyrrolidine 38, racemic lithiation-arylation has not 
previously been reported. It was hoped that our new racemic lithiation procedure could be 
used to access such products. Gratifyingly, lithiation of -Boc pyrrolidine 38 using our 
optimised conditions followed by transmetallation using zinc chloride and then 
palladium-catalysed Negishi coupling with 2-bromobenzotrifluoride gave aryl pyrrolidine 
183 in 73% yield (scheme 5.10). 
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 Next, racemic lithiation-arylation was demonstrated with a range of different aryl 
bromides. For convenience, lithiation of -Boc pyrrolidine 38 and then transmetallation 
to the organozinc species was carried out on a large scale. Then, aliquots of this stock 
solution were taken and used to carry out seven parallel Negishi couplings (scheme 5.11). 
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 Coupling with bromobenzene gave 2-phenyl pyrrolidine 77 in 79% yield. 2-
Bromoanisole gave product 181 in 80% yield while methyl 2-bromobenzoate gave 184 in 
69% yield. Aryl pyrrolidines 258 and 259 were obtained in 74% yield and 85% yield, 
respectively, while coupling methyl 4-bromobenzoate gave 260 in 57% yield. Campos 
has previously shown that the lithiation-Negishi coupling strategy is compatible with aryl 
bromides containing unprotected amine; 4-bromoaniline was coupled to give 81 in 64% 
yield. 
 We have thus developed a new protocol for the lithiation-trapping and lithiation-
arylation of -Boc pyrrolidine 38. Compared to the existing procedure (s-BuLi, TMEDA, 
3.5 h in Et2O at –78 °C), our new lithiation conditions (s-BuLi in THF at –30 °C for 5 
min) are simpler, less time consuming and more suitable for use on a large scale. We 
have demonstrated both lithiation followed by trapping with a range of electrophiles, and 
the previously unreported racemic lithiation-arylation of -Boc pyrrolidine 38. 
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5.3 Diamine-Free Lithiation of Other -Boc Heterocycles 
 Having demonstrated diamine-free lithiation-trapping and lithiation-arylation of -Boc 
pyrrolidine 38, we turned our attention to other -Boc heterocycles. Unfortunately, we 
were unable to effect diamine-free lithiation-trapping of -Boc piperidine 44 (attempted 
lithiation-trapping conditions shown in table 5.3). In each case, the 1H NMR spectrum of 
the crude product showed only unreacted starting material and electrophile. 
 
Table 5.3 
N
Boc
N
Boc
E
1. s-BuLi, THF
Temp, time
2. E+  
 
 Entry  Reaction Temp (°C)  Reaction Time Electrophileii 
    1   –78            3 h   MeOCOCl 
    2   –78           6 h   MeOCOCl 
    3   –40           3 h       DMF 
    4   –40           1 h       DMF 
    5   –40           1 h   MeOCOCl 
    6   –40        30 min       DMF 
    7   –30          5 min       DMF  
    8   –30          5 min   MeOCOCliii 
 
 We first attempted to effect lithiation in THF at –78 °C. Disappointingly, after lithiating 
for 3 or 6 h followed by addition of methyl chloroformate, no trapped product could be 
isolated (entries 1 and 2). Then, lithiation under our optimised conditions and then 
trapping with methyl chloroformate and DMF was attempted (entries 7 and 8). Finally, 
lithiation at –40 °C was attempted. Treatment of -Boc piperidine 44 with s-BuLi in THF 
for 3 h and 1 h followed by addition of DMF gave only recovered starting material 
(entries 3 and 4). Lithiation for 1 h then addition of methyl chloroformate gave no 
product (entry 5), as did lithiation for 30 min then addition of DMF (entry 6). 
 Next, we attempted diamine-free lithiation-trapping of -Boc homopiperidine 56. 
Unfortunately, we were unable to isolate trapped products under any of the conditions 
which were attempted (table 5.4). 
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Table 5.4 
1. s-BuLi, THF
Temp, time
2. E+
N
Boc
N
Boc
E
 
 
 Entry  Reaction Temp (°C)  Reaction Time Electrophileii 
    1   –78            6 h   MeOCOCl 
    2   –78           6 h       DMF 
    3   –40           3 h   MeOCOCl 
    4   –40           3 h       DMF 
    5   –40           1 h   MeOCOCl 
    6   –40           1 h       DMF 
    7   –40        30 min       DMF  
    8   –30          5 min   MeOCOCl 
    9   –30          5 min       DMFiiiiiii 
 
 Attempted lithiation of -Boc homopiperidine 56 in THF at –78 °C for 6 h using s-
BuLi followed by addition of methyl chloroformate or DMF gave no products (entries 1 
and 2). Lithiation-trapping under our optimised diamine-free lithiation conditions, then 
trapping with methyl chloroformate or DMF also gave only recovered starting material 
(entries 8 and 9). We also attempted to carry out lithiation of -Boc homopiperidine 56 at 
–40 °C. After lithiation for 3 h or 1 h, then addition of methyl chloroformate or DMF we 
were unable to isolate any trapped products (entries 3-6). Lithiation also did not take 
place after treatment of -Boc homopiperidine 56 with s-BuLi in THF at –40 °C for 30 
min, then trapping with DMF (entry 7). 
 Instead, the diamine-free lithiation of -Boc pyrroline 261 was investigated. It was 
proposed that in this substrate, substitution could be effected in the 2- and 5-positions 
using lithiation-trapping, and then the alkene motif could act a synthetic “handle” for 
installation of substituents in the 3- and 4-positions. In 1977, Pandit reported the LDA-
mediated trapping of -CO2Me pyrroline 262 (scheme 5.12).
187 In this case, the activated 
allylic α-protons can be removed by LDA, a weaker base than BuLi. Use of the less 
nucleophilic LDA in turn allowed the use of the less sterically demanding methoxy 
carbonyl directing group rather than the Boc group which is required to prevent 
nucleophilic attack when using s-BuLi or n-BuLi. 
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 Unfortunately, lithiation of -Boc pyrroline 261 in THF at –30 °C for 5 min followed 
by trapping with DMF gave aldehyde 264 in only 20% yield (scheme 5.13). Attempted 
lithiation-trapping with trimethylsilyl chloride and methyl chloroformate did not give rise 
to the desired products. 
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 As discussed in chapter 2, -Boc acetal piperidine 49 has been shown to be easier to 
lithiate than -Boc piperidine 44.65 We therefore hoped that racemic lithiation of 49 
could be effected using the optimised diamine-free lithiation conditions. Unlike -Boc 
piperidine 44, lithiation of -Boc acetal piperidine 49 did take place using s-BuLi in THF 
at –30 °C followed by trapping with methyl chloroformate, but unfortunately product 265 
was obtained in only 28% yield. Alternatively, lithiation under the same conditions and 
then trapping with trimethylsilyl chloride gave silyl piperidine 50 in 14% yield (scheme 
5.14) 
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 Better results were achieved from diamine-free lithiations of -Boc-ʹ-benzyl 
piperazine 59 (scheme 5.15). Thus, lithiation using the optimised conditions followed by 
trapping with DMF gave aldehyde 266 in 71% yield. Trapping with methyl 
chloroformate and trimethylsilyl chloride gave products 267 and 268 in 83% yield and 
78% yield, respectively. Lithiation-trapping using benzophenone as the electrophile led to 
cyclisation of the resultant alkoxide onto the Boc group and oxazolidinone 269 was 
obtained in 79% yield. The comparative ease of lithiation of -Boc-ʹ-benzyl piperazine 
59 compared to -Boc piperidine 44 has been discussed in chapter 2. 
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 Next, we carried out the first example of lithiation-arylation of -Boc-ʹ-benzyl 
piperazine 59. After lithiation-transmetallation and then palladium-catalysed Negishi 
coupling with bromobenzene, phenyl piperazine 270 was obtained in 55% yield (scheme 
5.16). In this case, palladium-catalysed Negishi coupling was carried out under reflux for 
16 h since attempted arylation at rt for 16 h did not result in the formation of phenyl 
piperazine 270. 
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 Additionally, we attempted to carry out a 2,2-disubstitution of -Boc-ʹ-benzyl 
piperazine 59 under the same conditions as -Boc pyrrolidine 38 – treatment with 2.6 
equivalents of s-BuLi in THF at –78 °C and then addition of 3 equivalents of methyl 
chloroformate. Under these conditions, ring opening of the piperazine occurred together 
with vinyl lithiation-trapping, and alkene 271 was isolated in 45% yield (scheme 5.17). 
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 Having demonstrated diamine-free lithiation-trapping of -Boc-ʹ-benzyl piperazine 
59, we investigated lithiation of -Boc-ʹ-benzyl homopiperazine 272. Unfortunately, 
lithiation under our optimised conditions followed by trapping with DMF gave aldehyde 
273 in only 41% yield, and we were subsequently unable to repeat this reaction (scheme 
5.18). The regioselectivity of this lithiation has not been established unequivocally. 
Attempted lithiation-trapping with methyl chloroformate, trimethylsilyl chloride or 
benzophenone as electrophile gave 0% yields. 
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 For comparison to piperazine 59, we also investigated the lithiation-trapping of -Boc 
morpholine 274. Lithiation using the optimised conditions followed by trapping using 
benzaldehyde gave an inseparable mixture of products. Instead, lithiation using 2 
equivalents of s-BuLi in THF at –30 °C for 5 min followed by trapping with 
benzophenone gave oxazolidinone 275 in 64% yield (scheme 5.17). In this case, lithiation 
gave organolithium species 276, which underwent ring opening to give alkene 277. Then, 
a second lithiation at the vinyl position followed by trapping gave alkoxide 278. 
Cyclisation then gave product 275. Lautens has previously reported a similar lithiation-
induced ring opening of an analogous bicyclic system.196 
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 For comparison, we also wished to verify whether ring opening of -Boc morpholine 
would occur after a s-BuLi/(–)-sparteine 3-mediated lithiation. -Boc morpholine 274 
was treated with s-BuLi and (–)-sparteine in diethyl ether at –78 °C for 1 h, and then 
trimethylsilyl chloride was added. Silyl ether 279 (76% yield) and amino alcohol 280 
(7% yield) were isolated (scheme 5.20). Presumably, the enamine part of the molecule is 
hydrolysed during the work up to account for the loss of the C2 unit. 
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 For our final example, we investigated the diamine-free lithiation of -Boc-ʹ-
isopropylimidazolidine 64. Lithiation under our optimised conditions and then trapping 
with trimethylsilyl chloride gave silyl imidazolidine 281 in 63% yield (scheme 5.21). 
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 The 63% yield of silyl imidazolidine 281 obtained suggested that interconversion of the 
-Boc rotamers was taking place at –30 °C, overcoming the maximum of 50% yield 
obtained by Coldham (see scheme 1.28).74, 75 We hypothesised that a longer lithiation 
time would allow for more rotamer interconversion and so furnish us with substituted 
imidazolidines in higher yields. Indeed, lithiation with s-BuLi in THF at –30 °C for 10 
min followed by trapping with trimethylsilyl chloride gave silyl imidazolidine 281 in 
73% yield (scheme 5.22). 
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 Imidazolidine 64 was then lithiated using these conditions and trapped with a range of 
electrophiles (scheme 5.22). Direct trapping with allyl bromide gave 282 in 50% yield 
without transmetallation to an organocuprate species. Trapping with phenyl isocyanate 
gave amide 283 in 74% yield. Finally, trapping with dimethyl sulfate gave 284 in 66% 
yield, and tri-n-butyltin chloride gave stannane 285 in 57% yield. 
 The first example of lithiation-arylation of imidazolidine 64 was also demonstrated. 
Lithiation using s-BuLi in THF at –30 °C for 10 min followed by transmetallation with 
zinc chloride and then palladium-catalysed Negishi coupling with bromobenzene gave 
phenyl imidazolidine 286 in 43% yield (scheme 5.23). Heating at reflux during the 
coupling step was required for optimal yields; when coupling was carried out at rt, phenyl 
imidazolidine 286 was isolated in only 21% yield. 
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5.4 In Situ Infra-Red Spectroscopic Monitoring of Diamine-Free 
Lithiations 
 To complete our study of diamine-free lithiations of carbamates, we wished to follow 
such lithiations using in situ infra-red spectroscopic monitoring. Six substrates were 
chosen to be investigated (figure 5.5). 
 
Figure 5.5 
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 We studied the lithiations of -Boc pyrrolidine 38 and -Boc-ʹ-benzyl piperazine 59 
at –30 °C and at –78 °C. It has been found that s-BuLi-mediated lithiation of -Boc 
piperidine 44 does not proceed in THF, even in the presence of TMEDA or (+)-sparteine 
surrogate 6.197 We wished to confirm this lack of reactivity. Interested in the 
interconversion of -Boc rotamers at different temperatures, -Boc-ʹ-i-Pr imidazolidine 
64 and -Boc-ʹ-benzyl homopiperazine 272 were also chosen to be monitored using in 
situ infra-red spectroscopy. Finally for comparison to the -Boc heterocycles, lithiation 
of O-alkyl carbamate 100 was also investigated. 
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5.4.1 -Boc Pyrrolidine 
 First, diamine-free lithiation of -Boc pyrrolidine 38 under the optimised conditions 
was observed. Thus, -Boc pyrrolidine 38 (νC=O 1698 cm
–1) was stirred in THF at –30 °C 
and then s-BuLi was added. A new peak emerged, corresponding to lithiated product 287 
(νC=O 1646 cm
–1) (scheme 5.24). 
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 Confirming our optimal yields after 5 min at –30 °C in THF, lithiation of -Boc 
pyrrolidine 38 was fast: complete lithiation was observed after 3 min. No peak 
corresponding to a prelithiation complex was observed. 
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 For comparison, we next investigated the diamine-free lithiation of -Boc pyrrolidine 
38 in THF at –78 °C. Thus, -Boc pyrrolidine 38 (νC=O 1698 cm
–1) was stirred in THF at 
–78 °C and then s-BuLi was added. A new peak emerged at 1660 cm–1 which was 
assigned to νC=O of lithiated product 287 (scheme 5.25). 
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 As expected, lithiation of -Boc pyrrolidine 38 by s-BuLi/THF at –78 °C was slower 
than at –30 °C. After 45 min, lithiation of -Boc pyrrolidine 38 was still incomplete. No 
peak corresponding to a prelithiation complex was observed, despite the slow lithiation. 
Two possible hypotheses can be proposed to explain the lack of prelithiation complex in 
this case. Only a small amount of prelithiation complex could form in solution due to 
preferential coordination of the THF to the s-BuLi. Subsequent lithiation then takes place 
quickly to give product 287, preventing direct observation of the prelithiation complex. 
Alternatively, the s-BuLi/THF complex may directly abstract an α-proton without any 
pre-complexation. 
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5.4.2 -Boc-ʹ-Benzyl Piperazine 
 Next, s-BuLi/THF-mediated lithiation of -Boc-ʹ-benzyl piperazine 59 under the 
optimised diamine-free lithiation conditons was monitored. Thus, piperazine 59 (νC=O 
1698 cm–1) was stirred in THF at –30 °C and s-BuLi was added. Lithiated piperazine 288 
formed, indicated by a peak at 1646 cm–1 (scheme 5.26). 
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 In common with the lithiation of -Boc pyrrolidine 38 under these conditions, lithiation 
proceeded quickly and complete formation of product 288 was observed within 3 min. 
No peak corresponding to a prelithiation complex could be observed. 
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 For comparison, s-BuLi-mediated lithiation of -Boc-ʹ-benzyl piperazine 59 in THF 
at –78 °C was next investigated. Thus, 59 (νC=O 1696 cm
–1) was stirred in THF at –78 °C 
and then s-BuLi was added. Lithiated product 288 (νC=O 1646 cm
–1) formed more slowly 
(scheme 5.27). 
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 Complete conversion to give 288 was observed in 45 min. Despite the slow lithiation, 
no prelithiation complex could be detected. 
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5.4.3 -Boc Piperidine  
  It had been found that attempted lithiation-trapping of -Boc piperidine 44 under the 
optimised diamine-free lithiation conditions gave no yield of substituted products. To 
verify this result, the lithiation was observed using in situ infra-red spectroscopic 
monitoring. Thus, -Boc piperidine 44 (νC=O 1694 cm
–1) was stirred in THF at –30 °C 
and then s-BuLi was added. As expected, no new peaks emerged – neither prelithiation 
complex nor lithiated product was formed over 20 min. 
 Additionally, we had found that attempted lithiation-trapping of -Boc piperidine 44 
using s-BuLi and TMEDA or (+)-sparteine surrogate 6 in THF at –78 °C gave no 
products; treatment of -Boc piperidine 44 with s-BuLi and TMEDA in diethyl ether at –
78 °C for 6 h followed by addition of methyl chloroformate gave only recovered 44. 
Additionally, treatment of -Boc piperidine 44 with s-BuLi and (+)-sparteine surrogate 6 
in diethyl ether at –78 °C for 6 h and then trapping with methyl chloroformate gave 
trapped product (S)-289 in only 4% yield and 82:18 er (scheme 5.28).197 For comparison, 
lithiation of -Boc piperidine 44 with s-BuLi and (+)-sparteine surrogate 6 in diethyl 
ether followed by electrophilic trapping gives substituted piperidines in up to 92% yield 
and 88:12 er (electrophile = CO2).
67 
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 This result was also confirmed using the ReactIR set-up. -Boc piperidine 44 (νC=O 
1695 cm–1) and TMEDA or (+)-sparteine surrogate were stirred in THF at –78 °C and 
then s-BuLi was added. Neither prelithiation complex nor lithiated products were formed 
over 20 min. 
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5.4.4 Unsymmetrical -Boc Heterocycles 
 Using s-BuLi/THF-mediated lithiation-trapping of -Boc-ʹ-isopropylimidazolidine 64 
at –30 °C, access to trapped products in yields > 50% is possible (scheme 5.22). In 
contrast, Coldham had shown that at –78 °C, maximum yields were deteremined by the 
ratio of -Boc rotamers in solution.74, 75 We wished to observe this phenomenon using in 
situ infra-red spectroscopic monitoring. First, 64 (νC=O 1705 cm
–1) was stirred in THF at –
78 °C and then s-BuLi was added. The lithiated product 290 peak appeared at 1663 cm–1 
(scheme 5.29). 
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 After addition of s-BuLi, partial lithiation of -Boc-ʹ-isopropylimidazolidine 64 took 
place within 3 min, after which no further lithiation took place. This is a faster lithiation 
than that of -Boc pyrrolidine 38 at –78 °C. This would be consistent with a fast 
lithiation of one rotamer and then no further lithiation as the unreactive rotamer could not 
convert into the reactive rotamer. No IR stretch for a prelithiation complex was observed. 
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 Then, the lithiation of -Boc-ʹ-isopropylimidazolidine 64 was repeated under our 
optimised conditions. Thus, 64 (νC=O 1705 cm
–1) was stirred in THF at –30 °C and then s-
BuLi was added. A new peak emerged, corresponding to lithiated product 290 (νC=O 1662 
cm–1) (scheme 5.30). 
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 At –30 °C, it was found that the -Boc rotamers did interconvert, allowing >50% 
lithiation of -Boc-ʹ-isopropylimidazolidine 64 to take place. Complete conversion of 
64 to lithiated product 290 was observed in 10 min. No IR stretch for a prelithiation 
complex was observed. 
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 Another non-symmetrical -Boc heterocycle is -Boc-ʹ-benzyl homopiperazine 272. 
We wondered whether diamine-free lithiation could be affected on this substrate, and if 
-Boc rotamers would influence the outcome of lithiation. First, lithiation at –78 °C was 
investigated. Thus, -Boc-ʹ-benzyl homopiperazine 272 (νC=O 1694 cm
–1) was stirred in 
THF and s-BuLi was added. A new peak, corresponding to lithiated product 291 (νC=O 
1645 cm–1) emerged (scheme 5.31). 
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 Lithiation of substrate 272 was slow: only partial conversion to lithiated product 291 
was observed after 60 min. No prelithiation complex was observed. Due to the slow 
lithiation, it is hard to determine whether the -Boc rotamers are interconverting. Note 
that lithiation of susbtrate 272 under these conditions followed by electrophilic trapping 
with DMF gives rise to a 44% yield of substituted product (Scheme 5.18). 
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 Lithiation of -Boc-ʹ-benzyl homopiperidine 272 at –30 °C gave a clearer insight into 
the conversion of -Boc rotamers. 272 (νC=O 1695 cm
–1) was stirred in THF at –30 °C 
and then s-BuLi was added. The lithiated product peak at νC=O 1646 cm
–1 then emerged 
(Scheme 5.32). 
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 After addition of s-BuLi, fast but incomplete lithiation to give product 291 took place 
within 20 min. After a further 40 min of incubation, no further lithiation was observed. 
We thus conclude that in the case of -Boc-ʹ-benzyl homopiperazine 272, the -Boc 
rotamers do not interconvert at –30 °C. 
 
 
 
 
 
 
 
 
 
 
5.4.5 O-Alkyl Carbamate 
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 For comparison to the -Boc heterocycles that had previously been studied, we wished 
to monitor the diamine-free lithiation of O-alkyl carbamate 100 using in situ infra-red 
spectroscopy. Additionally, we wondered whether a prelithiation complex could be 
observed during this lithiation as such a complex had not been seen during s-BuLi/THF-
mediated lithiations of -Boc heterocycles. Thus, O-alkyl carbamate 100 (νC=O 1694 cm
–
1) was stirred in THF at –78 °C and then s-BuLi was added. A peak at 1630 cm–1 
emerged and was assigned to νC=O of lithiated product 292 (scheme 5.33). 
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 In common with the diamine-free lithiation of -Boc heterocycles, no prelithiation 
complex was observed in the s-BuLi/THF-mediated lithiation of O-alkyl carbamate 100. 
Lithiation was slow at –78 °C, and only partial lithiation was observed after 1 h. 
 
 
 
 
 
 
 
 
 
5.5 Conclusions and Future Work 
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 A new diamine-free racemic lithiation procedure has been developed for -Boc 
pyrrolidine 38, -Boc-ʹ-benzyl piperazine 59 and -Boc-ʹ-i-Pr imidazolidine 64. 
Substituted products of lithiation-trapping and lithiation-arylations were obtained in high 
yields. In the case of 64, products were obtained in yields greater than the 50% yield limit 
previously reported. The new racemic lithiation conditions which have been developed 
are both simpler, as no diamine is required, and more suitable for use on a large scale, as 
cooling to –78 °C is not necessary; –30 °C is sufficient. Additionally, our new conditions 
can also be carried out using the “green” solvent 2-Me THF as opposed to diethyl ether, 
which had previously been used. 
 Unfortunately, lithiation-trapping of other -Boc heterocycles under the same 
conditions gave low yields of products, or no products at all. Future work may include 
testing lithiation of a wider range of substrates under the new conditions. Additionally, s-
BuLi/THF-mediated lithiation of O-alkyl carbamates may be investigated. 
 Diamine-free lithiations of carbamates have been monitored using in situ infra-red 
spectroscopy. The results obtained confirmed the synthetic results already obtained on 
different substrates. In addition, it was shown that O-alkyl carbamate 100 underwent s-
BuLi/THF-mediated lithiation.  
 We were unable to observe any peak corresponding to a prelithiation complex using 
ReactIR spectroscopic monitoring. A further investigation of these reactions with a view 
to determining whether complexation of alkyllithium to the carbonyl group takes place 
prior to lithiation could be carried out.  
 
 
 
 
 
 
 
 
 
 
 
Chapter Six: Benzylic Lithiation-Trapping of 
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 -Boc-2-Phenyl Pyrrolidine 
 
 This chapter concerns the development of a new synthetic route to 2,2-disubstituted 
pyrrolidines via lithiation-trapping of -Boc-2-phenyl pyrrolidine (R)-77 (scheme 6.1). 
The aim was to identify suitable conditions for lithiation at the more acidic benzylic 
position. There are several issues to consider including rotamer interconversion and 
maintaining the er through the lithiation-trapping process. 
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 The development of an efficient lithiation-trapping protocol on rac-77 is described, and 
the optimised conditions are illustrated with a range of electrophiles. Then, lithiation-
trapping of enantioenriched (R)-77 is described. The use of in situ infa-red spectroscopic 
monitoring would be used to gain insight into the progress of the lithiation reaction, and 
to observe the interconversion of the -Boc rotamers at different temperatures. 
 
 
 
 
 
 
 
 
 
 
 
 
6.1 Synthesis of 2,2-Disubstituted 7itrogen Heterocycles 
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 As discussed so far in this thesis, 2-substituted nitrogen heterocycles are an important 
substructure in drug molecules and natural products. Of the examples reported in the 
chemical literature, several are 2,2-disubstituted heterocycles. Examples include MK-801 
(dizocilpine) 293, a ligand for the PCP receptor198 which possesses both anti-
convulsant199 and neuroprotective200, 201 properties, and NK1 antagonists 294
202 and 
295
203 (figure 6.1). 
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 Several synthetic approaches to 2,2-disubstituted nitrogen heterocycles in which one 
substituent is an aryl group using metal-catalysed processes have been  reported. An early 
example is the lanthanide-catalysed intramolecular hydroamination reported by Molander 
in 1998. A range of different 2,2-disubstituted heterocyclic skeletons was formed from 
secondary alkenes. For example, 2-phenyl-2-methyl pyrrolidine 296 was obtained in 90% 
yield from alkene 297 (scheme 6.2).204 
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 Another example of intramolecular hydroamination has recently been reported by 
Liu.205 Using a palladium-based catalyst, an isolated example of formation of a 2,2-
disubstituted pyrrolidine in modest yield was reported. Szymoniak used an unusual 
zirconium-catalysed reaction of imines to access 2,2-disubstituted pyrrolidines and 
azetidines. The reaction proceeded via complexation of Cp2ZrCl2 with ethyl magnesium 
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chloride to give a zirconocene-ethylene species. Then, the C2 unit was inserted into the 
imine C=N bond. Displacement of zirconium with two more equivalents of the Grignard 
reagent then released dimagnesium species 299. Addition of a double electrophile such as 
diiodomethane then allowed trapping and cyclisation to give spirocyclic products such as 
300 (scheme 6.3).206 
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 An alternative metal-catalysed route to 2,2-disubstituted pyrrolidines involves the gold-
catalysed ring opening of a methylene cyclopropane reported by Shi. For example, 
treatment of cyclopropane-alkene 301 with p-toluene sulfonamide and an in situ prepared 
Au(PPh3)OTf catalyst gave disubstituted pyrrolidine 302 in 72% yield (scheme 6.4).
207 
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 Isolated examples of gold-catalysed ring opening of cyclopropanes to give 2,2-
disubstituted pyrrolidines have also been reported by Togni208 and Chan.209 Limitations 
of the metal-catalysed procedures discussed so far are the unusual catalysts employed, 
and the need for both substituents in the final product to be present in the starting 
material. Thus, a range of different products cannot be accessed from a common starting 
point. Additionally, these methodologies all provide racemic products. 
 Recently, Penso and Tagliabue have reported the rearrangement of -aryl sulfonyl 
proline esters as a route to 2,2-disubstituted pyrrolidines. Building on earlier work on an 
acyclic system, 2,2-disubstituted pyrrolidines such as 303 were accessed in good yields 
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and ers.210 The mechanism of the reaction proceeds via sodium amide-mediated 
enolisation of starting material 304. Deprotonation of the favoured (less sterically 
crowded) conformer of 304 gave enolate 305 which then underwent S-Cα aryl migration 
with loss of SO2 via spiro-Meisenheimer complex 306. Thus, 2-aryl prolines were 
accessed with retention of stereochemistry (scheme 6.5). The methodology suffers from 
the limitation that in order to form complex 306, electron-withdrawing substituents on the 
aryl portion are required; without such groups, only starting material was recovered.211  
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 In 1997, Tourwé reported using a Mitsunobu cyclisation to form 2-phenyl prolines. 
Thus, treatment of -Boc amine (R)-307 of 98:2 er with triphenylphosphine and DEAD 
gave -Boc-2-phenyl ethyl prolinate (R)-308 in 55% yield. Replacement of the Boc 
group with Cbz gave an increase in yield to 63% (scheme 6.6). Unfortunately, formation 
of amine (R)-307 used an enzymatic resolution. Hence, synthesis of the other 
enantiomeric series could not be achieved in high er. Additionally, 2-phenyl ethyl 
prolinates were the only examples reported.212 
 
 
Scheme 6.6 
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 Maruoka recently reported another synthesis of 2-substituted prolines. Using caesium 
hydroxide and phase transfer catalyst (S)-309, alkylation of imine ester 310 with 1-
chloro-3-iodo propane took place with high enantioselectivity. Imine hydrolysis and 
accompanying cyclisation then gave 2-substituted prolines in high yield and er. For 
example, 2-phenyl-t-Bu prolinate (R)-311 was obtained in 88% yield and 77:23 er 
(scheme 6.7). Replacing the phenyl substituent with alkyl groups gave an increase in 
enantioselectivity. For example, 2-methyl-t-Bu prolinate was obtained in 87% yield and 
>99:1 er. Using other dihalo alkanes, examples with larger ring analogues was also 
described.213 
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 In summary, no general strategy to 2,2-disubstituted pyrrolidines with one aryl group 
has been reported. The methods reported here all require both α-substituents in the final 
product to be present in the starting material. 
 
 
6.2 Overview of Benzylic Lithiation Methodology 
 Our proposed approach to 2,2-disubstituted pyrrolidines would rely on lithiation at the 
benzylic position of -Boc-2-phenyl pyrrolidine 77. Benzylic lithiation α to a heteroatom 
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on other systems has been reported by a number of different groups. Early examples 
focused on benzylic lithiation of formamidine-protected -heterocycles. In the first such 
example of which we are aware, Meyers reported lithiation of indole derivative 312 using 
t-BuLi and then electrophilic trapping. For example, trapping with methyl iodide gave 
313 in 84% yield (scheme 6.8).21 
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 Subsequently, Rice used this methodology to prepare a range of analogues of the drug 
molecule MK-801. Thus, for example, treatment of formamidine-protected heterocycle 
314 with s-BuLi in diethyl ether and then trapping with ethyl iodide gave product 315 in 
97% yield (scheme 6.9).214 The formamide group was then removed to give 316 in 56% 
yield. A range of secondary amine analogues were investigated as PCP receptor 
ligands.215 
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 Meyers later reported the benzylic lithiation of a formamidine-protected amine. 
Lithiation of C2 symmetric azepine 317 using s-BuLi in THF and then trapping with 
methyl iodide gave trapped product 318 in 90% yield as a mixture of diastereomers 
(scheme 6.10).216 
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 Benzylic lithiation of -Boc substrates was first investigated by Beak wherein the 
lithiation of -Boc benzylamines was used as a route to 2-aryl nitrogen heterocycles, via 
internal electrophilic trapping.106, 173 For example, s-BuLi/TMEDA-mediated lithiation of 
-Boc amine 95 followed by internal trapping gave -Boc-2-phenyl pyrrolidine rac-77 
in 82% yield (scheme 6.11).173 Subsequently it was found that enantioselective lithiation 
using s-BuLi/(–)-sparteine 3 gave access to enantioenriched 2-aryl pyrrolidines (see 
scheme 1.41).106 
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 Beak then investigated enantioselective benzylic lithiations as a route to α-substituted 
primary amines.178, 217 In this case, the chloroalkyl substituent was replaced with a para-
methoxyphenyl group, which could subsequently be removed using CAN. Thus, for 
example, treatment of -Boc benzylamine 319 with n-BuLi and (–)-sparteine 3 and then 
trapping with methyl triflate gave methyl benzylamine (S)-320 in 87% yield and 97:3 er, 
which was then recrystallised to 99:1 er. Treatment of (S)-320 with n-BuLi/TMEDA 
followed by addition of allyl triflate then installed another benzylic substituent. The para-
methoxy phenyl group was then removed using CAN in one pot to give -Boc 
benzylamine (R)-321 in 52% yield and 98:2 er (scheme 6.12).178  
Scheme 6.12 
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 Interestingly, lithiation-trapping using trimethyltin chloride to give stannane (S)-322 
followed by n-BuLi/(–)-sparteine 3-mediated tin-lithium exchange and then trapping with 
methyl triflate gave product (R)-320 in 81% yield and high er (scheme 6.13). Thus, both 
enantiomers of 320 and 321 could be obtained using (–)-sparteine 3.178 Additionally, 
during the second lithiation, direct lithiation-trapping proceeded with retention of 
configuration (see scheme 6.12), whereas lithiation-trapping with trimethyltin chloride 
and then tin-lithium exchange-electrophilic trapping gave products of the opposite 
enantiomeric series. For example, treatment of (S)-320 with n-BuLi and TMEDA and 
then trapping with trimethyltin chloride gave stannane (S)-323. Then, treatment with n-
BuLi and TMEDA and trapping with MeOD gave deuterated product (R)-324 in 80% 
yield and 99:1 er (scheme 6.13).217 
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 Clayden recently reported the use of Beak’s protocol to provide enantioenriched 
samples of isotopically labelled anilines.218 Concurrent with Beak’s research, Voyer 
reported s-BuLi/(–)-sparteine 3-mediated lithiation of -methyl--Boc benzylamine 325 
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and trapping with carbon dioxide to effect a simple synthesis of -Boc phenyl sarcosine 
(R)-326 (scheme 6.14). However, yields and enantioselectivity were modest (55% yield, 
89:11 er) and only two electrophiles were used: carbon dioxide and trimethylsilyl 
chloride.219  
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(–)-Sparteine-mediated lithiation of -methyl--Boc benzylamine 325 has also been 
studied by Schlosser and co-workers.220 
 Another example of the benzylic lithiation of -Boc amines was reported by Wallace in 
2009.221 Thus, treatment of methyl -Boc azepine 327 with s-BuLi in THF and then 
trapping with methyl iodide gave a 50% yield of trans-328, a 6% yield of cis-328 and a 
28% yield of gem-dimethyl product 329 (scheme 6.15). 
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 Clayden has reported a number of interesting benzylic lithiation-aryl migration 
protocols. In the first such example, benzylic lithiation of ureas was used to gain access 
to compounds containing tertiary and quaternary nitrogen bearing stereocentres. For 
example, treatment of urea (R)-330 with s-BuLi and DMPU in THF followed by 
quenching with water gave product (R)-331 in 82% yield and 97:3 er (scheme 6.16).222 
 
 
Scheme 6.16 
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 The same group also reported similar benzylic lithiation-aryl migration procedures on 
carbamates, giving access to α-arylated benzylic alcohols,223 and thiocarbamates, forming 
the analogous thiols.224 More relevant to our work, it was also found that lithiation-aryl 
migration could be effected on cyclic ureas. For example, treatment of pyrrolidine urea 
rac-332 with LDA and DMPU and then quenching resulted in the isolation of 2,2-biaryl 
pyrrolidine urea rac-333 in 89% yield (scheme 6.17). Lithiation-aryl migration was also 
reported on other cyclic ureas, but not on enantioenriched substrates.225 
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 Xiao and co-workers at Schering-Plough have reported the n-BuLi/TMEDA-mediated 
lithiation of racemic -Boc-2-phenylpyrrolidine rac-77.226 Lithiation of rac-77 using n-
BuLi/TMEDA followed by trapping with methyl iodide or ethyl bromide gave products 
rac-334 and rac-335 in 44% yield and 33% yield respectively (scheme 6.18). No other 
electrophiles or lithiation conditions were investigated. While not discussed by the 
authors, we believe that the modest yields obtained may due to a lack of interconversion 
of the -Boc rotamers under the lithiation conditions used (n-BuLi/TMEDA in THF at    
–78 °C for 1 h and then electrophilic trapping).226 
Scheme 6.18 
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 Using the same conditions, lithiation-trapping of racemic 2-phenylpiperidine was also 
carried out. The results are summarised in table 6.1. 
 
Table 6.1 
N
Boc
Ph N
Boc
Ph
E
1. n-BuLi, TMEDA
THF, _78 oC, 1 h
2. E+
r ac-87  
 
  Entry  Electrophile   Product  %Yield 
     1     MeOD   rac-336          94a 
     2       MeI   rac-337          51 
     3    AllylBr   rac-338          43 
     4      DMF   rac-339          52 
     5   MeCHO   rac-340          59biii 
   a 2 h lithiation time used. 
   b 1:1.4 mixture of diastereomers obtained 
 
 Higher yields of trapped products were obtained from lithiation trapping of -Boc-2-
phenyl piperidine rac-87 than from -Boc-2-phenylpyrrolidine rac-77. For example, 
deuteration via quench with MeOD gave rac-336 in 94% yield (entry 1). Lower yields 
were obtained with other electrophiles. Trapping with methyl iodide gave rac-337 in 51% 
yield (entry 2), while allyl bromide gave rac-338 in 43% yield (entry 3). Carbonyl 
electrophiles were also investigated. Use of DMF gave rac-339 in 52% yield (entry 4), 
while trapping with acetaldehyde gave rac-340 in 59% yield in a 1:1.4 mixture of 
unresolved diastereomers (entry 5). The high yield obtained when trapping with MeOD 
suggests that -Boc rotamer interconversion is not an issue for this substrate. 
 Finally, our group has published an isolated example of a benzylic lithiation-derived 
disubstituted pyrolidine obtained as an unwanted side-product. Thus, s-BuLi/(–)-sparteine 
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3-mediated lithiation of -Boc-2-phenyl pyrrolidine (R)-77 followed by trapping with 
carbon dioxide and then in situ methylation of the resultant acid and TFA-mediated Boc 
deprotection gave desired product trans-341 in 27% yield, and 342 in 18% yield. The er 
of 342 was not determined (scheme 6.19).59 
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 The aim of this part of the project was to build on the results reported by the Schering-
Plough group and attempt to obtain higher yields of trapped products, with a wider range 
of electrophiles. Additionally, it was hoped that lithiation-trapping of enantioenriched 
starting material (prepared by asymmetric lithiation-arylation of -Boc pyrrolidine 38) 
would provide us with products bearing quaternary stereocentres in high ers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Benzylic Lithiation-Trapping of Racemic Phenylpyrrolidine 
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 To begin our investigations, racemic -Boc-2-phenylpyrrolidine rac-77 (prepared using 
the racemic lithiation-arylation procedure developed in chapter 5) was treated with s-
BuLi or n-BuLi in THF or diethyl ether at –78 °C for a range of different lithiation times. 
TMEDA was added as a ligand in some examples. The lithiated phenyl pyrrolidine thus 
obtained was then trapped with methyl chloroformate to give disubstituted product rac-
343. The results of this optimisation study are shown in table 6.2. 
 
Table 6.2 
 
 
 
   Entry  Base     Solvent       Diamine     Time(min)   %Yielda 
       1 s-BuLi       THF  None             30              17 
      2 n-BuLi       THF  None  60        33 
       3 n-BuLi       THF  None            180        39 
       4 n-BuLi       THF         TMEDA 60        31 
       5 n-BuLi       THF         TMEDA          180        33 
       6 n-BuLi       Et2O         TMEDA 60        29 
       7 n-BuLi       Et2O         TMEDA          180        32iiiii 
  a %Yield after chromatography 
 
 Lithiating -Boc-2-phenylpyrrolidine rac-77 with s-BuLi in THF at –78 °C for 30 min 
followed by trapping gave only a 17% yield of 2,2-disubstituted product rac-343 (entry 
1). No starting material was recovered. We believe that the low yield can be accounted 
for by competing lithiation in the 5-position, but it was not possible to adequately purify 
the 2,5-disubstituted products. 
 Changing the base led to an increase in yield. Treating starting material rac-77 with n-
BuLi in THF at –78 °C and then trapping gave 33% yield of rac-343 after a lithiation 
time of 60 min (entry 2) and 39% yield after 180 min (entry 3). Addition of TMEDA did 
not improve the yield. After lithiation with n-BuLi and TMEDA in THF at –78 °C, 
disubstituted product rac-343 was obtained in 31% yield after 60 min (entry 4) and in 
33% yield after 180 min. Next, we investigated changing the solvent. Lithiation-trapping 
with n-BuLi and TMEDA in diethyl ether at –78 °C for 60 min and then addition of 
methyl chloroformate gave a 29% yield of rac-343 (entry 6). Extending the lithiation 
N
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O
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rac-77 r ac-343
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time to 180 min resulted in a 32% yield of disubstituted product rac-343 being obtained 
(entry 7). These results are essentially the same as those in THF alone or in THF with 
TMEDA. 
 We hypothesised that the modest yields observed when lithiating at –78 °C were due to 
a lack of interconversion of -Boc rotamers. Thus, n-BuLi-mediated lithiation of rotamer 
344 was facile, whereas rotamer 345 was unreactive to n-BuLi, as noted by Beak for -
Boc pyrrolidine 38 (scheme 6.20).52  
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 To probe the behaviour of the -Boc rotamers, we decided to monitor the progress of 
the benzylic lithiation using in situ infra-red monitoring. First, n-BuLi/THF-mediated 
lithiation at –78 °C was investigated. -Boc-2-phenyl pyrrolidine 77 (νC=O 1696 cm
–1) 
was stirred in THF at –78 °C and then n-BuLi was added. Lithiation to give lithiated 
product 346 (νC=O 1644 cm
–1) took place (scheme 6.21). 
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 Lithiation of the reactive -Boc rotamer 344 was fast, and complete within 2 min. 
Then, no further formation of lithiated product was observed since, presumably, the 
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unreactive rotamer 345 was not interconverting to the reactive one. The roughly 60:40 
mixture of starting material 77 and lithiated product 346 observed after reaction of one 
rotamer would explain the 33% yield of trapped product 343 obtained from synthetic 
experiments carried out at –78 °C (Table 6.2). 
 Then, lithiation at 0 °C was followed using ReactIR. Thus, -Boc-2-phenylpyrrolidine 
77 (νC=O 1701 cm
–1) was stirred in THF at 0 °C and then n-BuLi was added. A new peak 
appeared at νC=O 1643 cm
–1 and was assigned to lithiated species 346 (scheme 6.22). 
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 After addition of n-BuLi, complete lithiation to give lithiated product 346 was observed 
within 2 min, confirming that the -Boc rotamers were interconverting. We thus 
concluded that lithiation-trapping of -Boc-2-phenylpyrrolidine 77 at 0 °C should allow 
us to isolate 2,2-disubstituted products in high yields. 
 To determine whether high yields of trapped products could be obtained, -Boc-2-
phenyl pyrrolidine rac-77 was lithiated using n-BuLi in THF at 0 °C and rt and then 
trapped with methyl chloroformate to give rac-343. The results are shown in table 6.3. 
 
 
 
Table 6.3 
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  Entry  Temperature(°C) Time(min)  %Yielda 
     1           –78      180       39 
     2           –78       60       33 
     3   0       10       72 
     4   0        5       77 
     5   rt        5       41iiii 
   a %Yield after chromatography 
 
 Thus, -Boc-2-phenylpyrrolidine rac-77 was treated with n-BuLi in THF at 0 °C for 5 
min and then trapped with methyl chloroformate. A 77% yield of product 343 was 
obtained (entry 4). Lithiation under the same conditions for 10 min gave a 72% yield of 
343 (entry 3). These yields compare favourably with the previously discussed lithiations 
at –78 °C (entries 1 and 2). Raising the temperature even further led to reduced yields: a 
41% yield of 343 was obtained after lithiation of starting material 77 with n-BuLi in THF 
at rt for 5 min followed by trapping (entry 5). The conditions shown in entry 4 (lithiation 
with n-BuLi for 5 min in THF) were chosen for our optimal racemic benzylic lithiation 
procedure.  
 
 
 
 
 
 
 
 
 
 
 With an optimised route to racemic 2,2-disubstituted pyrrolidine rac-343 in hand, the 
synthesis of a range of products using different electrophiles was studied (scheme 6.23). 
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 A 98% yield of disubstituted products rac-334 and rac-347 was obtained when trapping 
with dimethyl sulfate and phenyl isocyanate. Use of benzophenone as an electrophile 
gave oxazolidinone rac-348 in 84% yield via cyclisation of the alkoxide onto the Boc 
group. Direct trapping with allyl bromide gave rac-349 in 95% yield. An 84% yield of 
stannane rac-350 was obtained when using tri-n-butyltin chloride. Slightly reduced yield 
was observed when trapping with trimethylsilyl chloride: silyl pyrrolidine rac-351 was 
obtained in 65% yield. 
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 Our racemic benzylic lithiations are an improvement on the results reported by the 
Schering-Plough group. For example, methylation was achieved in 98% yield under our 
conditions (electrophile = Me2SO4) but in only 44% yield as reported by Xiao and Lavey 
(electrophile = MeI).226 The development of a high temperature lithiation protocol to 
overcome the yield limitation imposed by the lack of -Boc rotamer interconversion was 
informed by the lithiation of -Boc-ʹ-i-Pr imidazolidine 64 discussed in chapter 5. 
Using our racemic lithiation-arylation of -Boc pyrrolidine 38 and then our new high 
temperature benzylic lithiation-trapping method, we have developed a 2-step route to 2,2-
disubstituted pyrrolidines in high yields, without the need for carrying out either reaction 
at –78 °C. 
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6.4 Benzylic Lithiation-Trapping of Enantioenriched Phenylpyrrolidine 
 Having successfully developed racemic benzylic lithiation of -Boc-2-
phenylpyrrolidine rac-77, we next investigated lithiation of enantioenriched (R)-77. We 
were concerned that at high temperatures (e.g. 0 °C), racemisation of lithiated -Boc-2-
phenyl pyrrolidine (R)-77 would take place. On the other hand, at low temperatures (e.g. 
–78 °C), low yields would be obtained due to a lack of -Boc rotamer interconversion. 
Thus, we first decided to use in situ infra-red spectroscopy to monitor the progress of 
lithiations at –30 °C, –40 °C, –50 °C and –60 °C to determine the temperature at which 
-Boc rotamer interconversion became too slow for synthetically useful conversions. -
Boc-2-phenyl pyrrolidine 77 (νC=O 1698 cm
–1) was stirred in THF at  –30 °C, –40 °C, –50 
°C or –60 °C and then n-BuLi was added. The peak corresponding to νC=O in the lithiated 
product 346 appeared at 1642 or 1643 cm–1. The results are shown in figure 6.2. 
 
Figure 6.2 
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 At –30 °C and –40 °C, interconversion of the -Boc rotamers was fast, and complete 
lithiation was observed in 3 min. At –50 °C, rotamer interconversion began to slow 
down. Fast lithiation of the reactive rotamer in 1 min was observed, and then 
interconversion and lithiation of the remaining rotamer took another 5 min. Further 
cooling to –60 °C slowed -Boc C-N bond rotation further still. Lithiation of the reactive 
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rotamer was complete in 1 min, but then conversion and lithiation of the remaining 
starting material was still incomplete after 30 min. 
 Next, we carried out a lithiation of enantioenriched starting material under our 
optimised conditions racemic conditions. Thus, -Boc-2-phenylpyrrolidine (R)-77 of 
97:3 er (synthesised using an asymmetric Negishi reaction using (–)-sparteine 3) was 
treated with n-BuLi in THF at 0 °C for 5 min and then methyl chloroformate was added. 
After work-up and purification, product 343 was obtained in 82% yield and 50:50 er: 
complete racemisation had not surprisingly taken place (scheme 6.24). 
 
Scheme 6.24 
 
 
 
 
 Instead, lithiation of (R)-77 of 97:3 er using n-BuLi in THF and then trapping with 
methyl chloroformate was investigated at a range of different temperatures. The results of 
this study are shown in table 6.4. 
  
Table 6.4 
 
 
 
 
  Entry Temperature (°C)    Time (min)  %Yielda Product era 
     1        –78 °C             60             31     97:3 
     2        –50 °C          10             74     90:10 
     3        –50 °C            5              78                94:6 
     4        –40 °C            5              69     85:15 
     5        –30 °C            5              79     65:35iiii 
   a %Yield after chromatography, er determined by CSP-HPLC 
 
 First, we verified that no epimerisation would take place at low temperature. Lithiation 
of (R)-77 of 97:3 er using n-BuLi in THF at –78 °C for 1 h gave a 31% yield of product 
(R)- or (S)-343 in 97:3 er (entry 1). Next, we investigated lithiations at –30 °C, –40 °C 
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and –50 °C. Significant racemisation took place at –30 °C. Lithiation of (R)-77 of 97:3 er 
in THF at –30 °C for 5 min gave product (R)- or (S)-343 in 79% yield but 65:35 er (entry 
5). At –40 °C, lithiation of phenylpyrrolidine (R)-77 of 97:3 er for 5 min in THF gave 
(R)- or (S)-343 in 69% yield and 85:15 er (entry 4). Finally, lithiation at –50 °C was 
investigated. Treatment of -Boc-2-phenylpyrrolidine (R)-77 of 97:3 er in THF at –50 °C 
for 5 min followed by trapping with methyl chloroformate afforded product (R)- or (S)-
343 in 78% yield and 94:6 er (entry 3). These were found to be the optimal conditions. 
Enantiomerisation still took place slowly at –50 °C, as lengthening the lithiation time to 
10 min gave product (R)- or (S)-343 in 74% yield and 90:10 er (entry 2). 
 With an optimal set of conditions for lithiation of -Boc-2-phenylpyrrolidine (R)-77 in 
hand, lithiation-trapping was carried out with a small range of electrophiles using a 
sample of (R)--Boc-2-phenyl pyrrolidine of 97:3 er (scheme 6.25). 
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 Trapping with dimethyl sulfate gave -Boc-2-methyl-2-phenylpyrrolidine (R)- or (S)-
334 in 87% yield and 93:7 er. Use of phenyl isocyanate yielded amide (R)- or (S)-347 in 
83% yield and 95:5 er. Trapping with allyl bromide gave an 84% yield of racemic 
product rac-349. We propose that trapping occurs via a single electron transfer process, 
leading to racemisation. Future work may include attempting to access enantioenriched 
allylated products via lithium-copper exchange. 
 These products have been drawn assuming retention of stereochemistry through 
lithiation-trapping. However, at present, the absolute configuration of 334, 343 or 347 has 
not been unequivocally established. 
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6.5 Conclusions and Future Work 
 A successful procedure for the lithiation-trapping of -Boc-2-phenylpyrrolidine 77 has 
been developed. Lithiation trapping of racemic 77 was optimised, and use of a range of 
electrophiles was demonstrated under the optimal conditions (5 min at 0 °C in THF). It 
was found that lithiation of enantioenriched starting material (97:3 er) under these 
conditions gave racemic product. Instead, lithiation at lower temperatures (5 min in THF 
at –50 °C) gave products of ≥93:7 er in high yields. A small range of different 
electrophiles was then assayed under these conditions. The use of in situ infra-red 
spectroscopic monitoring of lithiations was of crucial importance in developing both 
lithiation procedures. 
 Future work will focus on trapping with different electrophiles to access solid products 
and thus ascertain the product configuration by X-ray crystallography, determining 
whether lithiation-trapping of enantioenriched -Boc-2-phenyl pyrrolidine (R)-77 
proceeds with retention or inversion of stereochemistry.  
 Other potential future work may involve benzylic-lithiation trapping of -Boc-2-phenyl 
piperidine 87, or substituted 2-aryl pyrrolidines such as 181 and 183 (figure 6.3). Another 
potential future development could be the synthesis of spirocyclic compounds (e.g. 352) 
via benzylic lithiation and internal electrophilic trap of aryl pyrrolidines such as 353 
(scheme 6.26). 
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Chapter Seven: Experimental 
7.1 General Methods 
 All non-aqueous reactions were carried out under oxygen free Ar using flame-dried 
glassware. Et2O and THF were dried on a Pure Solv MD-7 solvent purification system or 
distilled from sodium and benzophenone. Alkyllithiums were titrated against -
benzylbenzamide before use.227 All diamines used in lithiations were distilled over CaH2 
before use. Petrol refers to the fraction of petroleum ether boiling in the range 40-60 °C 
and was purchased in Winchester quantities. Brine refers to a saturated solution. Water is 
distilled water. 
 Flash chromatography was carried out using Fluka Chemie GmbH silica (220-440 
mesh). Thin layer chromatography was carried out using commercially available Merck 
F254 aluminium backed silica plates. Preparative thin layer chromatography was carried 
out using Analtech alumina matrix TLC uniplates. Proton (400 MHz) and carbon (100.6 
MHz) NMR spectra were recorded on a Jeol ECX-400 instrument using an internal 
deuterium lock. For samples recorded in CDCl3, chemical shifts are quoted in parts per 
million relative to CHCl3 (δH 7.27) and CDCl3 (δC 77.0, central line of triplet). Carbon 
NMR spectra were recorded with broad band proton decoupling and assigned using 
DEPT experiments. Coupling constants (J) are quoted in Hertz. Melting points were 
carried out on a Gallenkamp melting point apparatus. Boiling points given for 
compounds purified by Kügelrohr distillation correspond to the oven temperature during 
distillation. For compounds purified by fractional distillation, boiling points correspond 
to the vapor temperature at the top of the Vigreaux column. Infra-red spectra were 
recorded on an ATI Mattson Genesis FT-IR spectrometer. Electrospray high and low 
resonance mass spectra were recorded on a Bruker Daltronics microOTOF spectrometer. 
Optical rotations were recored at room temperature on a Jasco DIP-370 polarimeter 
(using sodium D line; 259 nm) and [α]D given in units of 10
–1 deg cm3 g–1. Chiral 
stationary phase HPLC was performed on an Agilent 1200 series chromatograph. Chiral 
stationary phase GC was performed on either an Agilent 6890 gas chromatograph using 
the column indicated for individual compounds, or a Perkin Elmer Autosystem XL gas 
chromatograph. In situ ReactIR infra-red spectroscopic monitoring was performed on a 
Mettler-Toledo ReactIR iC10 spectrometer equipped with a silicon-tipped (SiComp) 
probe. 
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7.2 General Procedures 
General Procedure A: Stoichiometric lithiation-trapping of -Boc pyrrolidine 38 
s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of -
Boc pyrrolidine 38 (342 mg, 350 µL, 2.0 mmol) and diamine (1.3 eq.) in Et2O (7 mL) at 
–78 °C under Ar. The resulting solution was stirred at –78 °C for 1 or 3 h. Then, the 
electrophile (2.0 eq.) was added and the resulting solution was stirred at –78 °C for 10 
min and allowed to warm to rt. Saturated NH4Cl(aq) (10 mL) was added and the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL) and the 
combined organic layers were dried (MgSO4) and evaporated under reduced pressure to 
give the crude product. 
 
General Procedure B: Catalytic two-ligand lithiation-trapping of -Boc pyrrolidine 
38 
s-BuLi (1.3 M solution in hexanes, 1.0-1.6 eq.) was added dropwise to a stirred solution 
of chiral diamine (0.2-0.3 eq.) and achiral diamine (1.0-1.3 eq.) in Et2O (6 mL) at –78 °C 
under Ar. After stirring at –78 °C for 15 min, a solution of -Boc pyrrolidine 38 (161 
mg, 165 µL, 0.94 mmol) in Et2O (1 mL) was added dropwise. The resulting pale yellow 
solution was stirred at –78 °C for 4 h. Then, benzaldehyde (2.0 eq.) was added and the 
resulting solution was allowed to warm to rt over 16 h. Saturated NH4Cl(aq) (10 mL) was 
added and the two layers were separated. The aqueous layer was extracted with Et2O (3 × 
10 mL) and the combined organic layers were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product. 
 
General Procedure C: Catalytic two-ligand lithiation-7egishi trapping of -Boc 
pyrrolidine 38 
s-BuLi (1.3 M solution in hexanes, 1.0-1.6 eq.) was added dropwise to a stirred solution 
of chiral diamine (0.25-0.3 eq.) and achiral diamine (1.0-1.3 eq.) in Et2O (6 mL) at –78 
°C under Ar. After stirring at –78 °C for 15 min, a solution of -Boc pyrrolidine 38 (493 
mg, 493 µL, 2.88 mmol) in Et2O (1 mL) was added dropwise. The resulting pale yellow 
solution was stirred at –78 °C for 4 h. Then, ZnCl2 (1.0 M solution in Et2O, 0.6 eq.) was 
added and the resulting solution was stirred at –78 °C for 30  min. The solution was 
allowed to warm to rt and stirred for 30 min. Then, the aryl bromide (0.7 eq.) was added. 
A mixture of t-Bu3PHBF4 (6.25 mol%) and Pd(OAc)2 (5 mol%) was added in one portion 
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and the resulting mixture was stirred at rt for 16 h. Then, 35% NH4OH(aq) (0.2 mL) was 
added and the resulting mixture was stirred at rt for 1 h. The solids were removed by 
filtration through a pad of Celite® and washed with Et2O (2 × 10 mL). The filtrate was 
washed with 1 M HCl(aq) (20 mL) and H2O (2 × 20 mL), dried (MgSO4) and evaporated 
under reduced pressure to give the crude product. 
 
General Procedure D: Stoichiometric lithiation-arylation of -Boc pyrrolidine 38 
s-BuLi (1.3 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of -
Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and (–)-sparteine (1.3 eq.) in Et2O (7 
mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, ZnCl2 
(1.0 M solution in Et2O, 0.6 eq.) was added and the resulting solution was stirred at –78 
°C for 30 min. The solution was allowed to warm to rt and stirred for 30 min. Then, the 
aryl bromide (0.7 eq.) was added. A mixture of t-Bu3PHBF4 (6.25 mol%) and Pd(OAc)2 
(5 mol%) was added in one portion and the resulting mixture was stirred at rt for 16 h. 
Then, 35% NH4OH(aq) (0.3 mL) was added and the resulting mixture was stirred at rt for 
1 h. The solids were removed by filtration through a pad of Celite®, and washed with 
Et2O (20 mL). The filtrate was washed with H2O (20 mL) and brine (20 mL), dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product. 
 
General Procedure E: Lithiation-vinylation of -Boc pyrrolidine 38 
s-BuLi (1.3 M solution in hexanes, 1.0 eq.) was added dropwise to a stirred solution of -
Boc pyrrolidine 38 (219 mg, 225 µL, 1.28 mmol, 1.0 eq.) and (–)-sparteine (1.3 eq.) in 
Et2O or TBME (7 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C 
for 1 h. Then, ZnCl2 (1.0 M solution in Et2O, 0.6 eq.) was added and the resulting 
solution was stirred at –78 °C for 30 min. The solution was allowed to warm to rt and 
stirred at rt for 30 min. Then, a solution of vinyl bromide 227 (0.7 eq.) in Et2O or TBME 
(1 mL) was added. A mixture of Pd(OAc)2 (5 mol%) or Pd2dba3 (2.5 mol%) and t-
Bu3PHBF4 (6.25 mol%) was added in one portion and the resulting solution was stirred at 
rt for 16 h. Then, 35% NH4OH(aq) (0.5 mL) was added and the resulting mixture was 
stirred at rt for 1 h. The solids were removed by filtration through a pad of Celite®, and 
washed with Et2O (20 mL). The filtrate was washed with 10% NH4Cl(aq), dried (MgSO4) 
and evaporated under reduced pressure to give the crude product. 
 
 
 166 
General Procedure F: TFA-mediated Boc deprotection 
TFA (5-20 eq.) was added dropwise to a stirred solution of -Boc amine (750 mg, 3.02 
mmol) in CH2Cl2 (40 mL) at rt under Ar. The resulting solution was stirred at rt for 4-16 
h. The resulting solution was evaporated under reduced pressure. 5 M NaOH(aq) (20 mL) 
and Et2O (45 mL) were added. The layers were separated and the aqueous layer was 
extracted with Et2O (7 × 45 mL). The combined organic layers were dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. 
 
General Procedure G: Eschweiler-Clarke methylation 
A solution of unprotected pyrrolidine (169 mg, 1.14 mmol), paraformaldehyde (5 eq.) 
and formic acid (5 eq.) in H2O (15 mL) under air was stirred and heated at reflux for 16 
h. Then, the solvent was evaporated under reduced pressure. 5 M NaOH(aq) (10 mL) and 
Et2O (25 mL) were added. The two layers were separated and the aqueous layer was 
extracted with Et2O (8 × 25 mL). The combined organic layers were dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. 
 
General Procedure H: Lithiation-benzaldehyde trapping of -Boc pyrrolidine 38  
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in Et2O, THF or 2-methyl THF (7 mL) at –78 °C, –40 °C, –30 °C, –20 °C, –
10 °C or 0 °C under Ar. The resulting solution was stirred at the specified temperature 
for 1 min, 2 min, 5 min, 10 min, 30 min or 60 min. Then, benzaldehyde (212 mg, 203 
µL, 2.0 mmol, 2.0 eq.) was added and the resulting solution was stirred at the 
specified temperature for 10 min and allowed to warm to rt. Saturated NH4Cl(aq) (10 
mL) was added and the two layers were separated. The aqueous layer was extracted 
with Et2O (3 × 10 mL) and the combined organic layers were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product.  
 
General Procedure I: Attempted lithiation-trapping of -Boc pyrrolidine 38 with 
n-BuLi or LDA 
n-BuLi (520 µL of a 2.5 M solution in hexanes, 1.3 mmol, 1.3 eq.) or LDA (1.0 mL of 
a 1.3 M solution in THF/n-heptane/ethyl benzene, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –78 °C, –40 °C, –20 °C,  0 °C or rt under Ar. The resulting 
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solution was stirred at the specified temperature for 30 min, 60 min or 180 min. Then, 
benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) or benzyl bromide (342 mg, 238 
µL, 2.0 mmol, 2.0 eq.) was added and the resulting solution was stirred at the 
specified temperature for 10 min and allowed to warm to rt. Saturated NH4Cl(aq) (10 
mL) was added and the two layers were separated. The aqueous layer was extracted 
with Et2O (3 × 10 mL) and the combined organic layers were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product.  
 
General Procedure J: Attempted lithiation-trapping of -Boc piperidine 44 and 
-Boc homopiperidine 56 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 
eq.) or -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at –78 
°C, –40 °C or –30 °C under Ar. The resulting solution was stirred at the specified 
temperature for 5 min, 30 min, 60 min, 180 min or 360 min. Then, DMF (146 mg, 
155 µL, 2.0 mmol, 2.0 eq.) or methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 
eq.) was added and the resulting solution was stirred at the specified temperature for 
10 min and allowed to warm to rt. Saturated NH4Cl(aq) (10 mL) was added and the two 
layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL) and 
the combined organic layers were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product.  
 
General Procedure K: Optimised lithiation-trapping of -Boc heterocycles using 
s-BuLi in THF 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc heterocycle (1.0 mmol) in THF (7 mL) at –30 
°C under Ar. The resulting solution was stirred at –30 °C for 5 min. Then, the 
electrophile (2.0 mmol) was added and the resulting solution was stirred at –30 °C for 
10 min and then allowed to warm to rt over 15 min. Saturated NH4Cl(aq) (10 mL) was 
added and the two layers were separated. The aqueous layer was extracted with Et2O 
(3 × 10 mL) and the combined organic layers were dried (MgSO4) and evaporated 
under reduced pressure to give the crude product. 
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General Procedure L: Racemic arylation of -Boc pyrrolidine 38 
s-BuLi (10 mL of a 1.3 M solution in hexanes, 13.0 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (1.71 g, 1.75 mL, 10.0 mmol) 
in THF (70 mL) at –30 °C under Ar. The resulting solution was stirred at –30 °C for 5 
min. Then, ZnCl2 (6.0 mL of a 1.0 M solution in Et2O, 6.0 mmol, 0.6 eq.) was added 
and the resulting solution was stirred at –30 °C for 30 min. The solution was allowed 
to warm to rt and stirred for 30 min.  
 Aryl bromide (0.7 mmol) was added to a stirred 7.0 mL aliquot of arylzinc reagent 
at rt. A mixture of Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%) and t-Bu3PHBF4 (11 mg, 
0.0625 mmol, 6.25 mol%) were added in one portion and the resulting solution was 
stirred at rt for 16 h. Then, 35% NH4OH(aq) was added and the solution was stirred at 
rt for 1 h. The solids were removed by filtration through a pad of Celite®, and washed 
with Et2O (20 mL). The filtrate was washed with a 1 M HCl(aq) (20 mL) and saturated 
brine (20 mL), dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. 
 
General Procedure M: Lithiation-trapping of imidazolidine 64 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol) 
in THF (7 mL) at –30 °C under Ar. The resulting solution was stirred at –30 °C for 5 
or 10 min. Then, the electrophile (2.0 mmol) was added and the resulting solution was 
stirred at –30 °C for 10 min and then allowed to warm to rt over 15 min. Saturated 
NaHCO3(aq) (10 mL) was added and the two layers were separated. The aqueous layer 
was extracted with Et2O (3 × 10 mL) and the combined organic layers were dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product. 
 
General Procedure 7:  Diamine free lithiation-methyl chloroformate trapping of 
phenyl pyrrolidine rac-77 
s-BuLi (1.3 M solution in hexanes, 1.3 eq.) or n-BuLi (2.5 M solution in hexanes, 1.3 eq.) 
was added dropwise to a stirred solution of -Boc-2-phenylpyrrolidine rac-77 (100 mg, 
0.4 mmol) in THF (4 mL) at –78 °C, 0 °C or rt under Ar. The resulting solution was 
stirred at the specified temperature for 5 min, 10 min, 30 min, 60 min or 180 min. Then, 
methyl chloroformate (2.0 eq.) was added dropwise and the resulting solution was stirred 
at the specified temperature for 10 min and allowed to warm to rt. Saturated NH4Cl(aq) (6 
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mL) was added and the two layers were separated. The aqueous layer was extracted with 
Et2O (3 × 10 mL) and the combined organic layers were dried (MgSO4) and evaporated 
under reduced pressure to give the crude product. 
 
General Procedure O: TMEDA-mediated lithiation-methyl chloroformate trapping 
of phenyl pyrrolidine rac-77 
n-BuLi (2.5 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
-Boc-2-phenylpyrrolidine rac-77 (100 mg, 0.4 mmol) and TMEDA (1.3 eq.) in THF (4 
mL) or Et2O (4 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 
60 min or 180 min. Then, methyl chloroformate (2.0 eq.) was added dropwise and the 
resulting solution was stirred at –78 °C for 10 min and allowed to warm to rt. Saturated 
NH4Cl(aq) (6 mL) was added and the two layers were separated. The aqueous layer was 
extracted with Et2O (3 × 10 mL) and the combined organic layers were dried (MgSO4) 
and evaporated under reduced pressure to give the crude product. 
 
General Procedure P: Lithiation-trapping of phenyl pyrrolidine rac-77 
n-BuLi (2.5 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
-Boc-2-phenylpyrrolidine rac-77 (110 mg, 0.44 mmol) in THF (4 mL) at 0 °C under Ar. 
The resulting solution was stirred at 0 °C for 5 min. Then, the electrophile (2.0 eq.) was 
added dropwise and the resulting solution was stirred at 0 °C for 10 min and allowed to 
warm to rt. Saturated NH4Cl(aq) (6 mL) as added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL) and the combined organic layers 
were dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
 
General Procedure Q: Lithiation-methyl chloroformate trapping of phenyl 
pyrrolidine (R)-77 
n-BuLi (2.5 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
-Boc-2-phenylpyrrolidine (R)-77 (70 mg, 0.28 mmol, 97:3 er) in THF (4 mL) at –78 °C, 
–50 °C, –40 °C, –30 °C or 0 °C under Ar. The resulting solution was stirred at the 
specified temperature for 5 min, 10 min or 60 min. Then, the electrophile (2.0 eq.) was 
added dropwise and the resulting solution was stirred at the specified temperature for 10 
min and allowed to warm to rt. Saturated NH4Cl(aq) (6 mL) was added and the two layers 
were separated. The aqueous layer was extracted with Et2O (3 × 10 mL) and the 
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combined organic layers were dried (MgSO4) and evaporated under reduced pressure to 
give the crude product. 
 
General Procedure R: Lithiation-trapping of phenyl pyrrolidine (R)-77 
n-BuLi (2.5 M solution in hexanes, 1.3 eq.) was added dropwise to a stirred solution of 
-Boc-2-phenylpyrrolidine (R)-77 (46 mg, 0.18 mmol, 97:3 er) in THF (4 mL) at –50 °C 
under Ar. The resulting solution was stirred at –50 °C for 5 min. Then, the electrophile 
(2.0 eq.) was added dropwise and the resulting solution was stirred at –50 °C for 10 min 
and allowed to warm to rt. Saturated NH4Cl(aq) (6 mL) was added and the two layers were 
separated. The aqueous layer was extracted with Et2O (3 × 10 mL) and the combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. 
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7.3 Experimental for Chapter 2 
-Boc Piperidine 44
119
      
 
44
N
Boc  
 
Piperidine (11.7 g, 11.7 mL, 137.5 mmol) was added dropwise to a stirred solution of 
di-t-butyl dicarbonate (20.0 g, 91.64 mmol) in THF (100 mL) at 0 °C under Ar. The 
resulting colourless solution was allowed to warm to rt and stirred for 30 min. Then, 
10% NaHCO3(aq) (100 mL) was added and the two layers were separated. The 
aqueous layer was extracted with Et2O (2 × 200 mL). The combined organic layers 
were washed with saturated brine (300 mL), dried (K2CO3) and evaporated under 
reduced pressure to give the crude product. Purification by Kügelrohr short path 
distillation gave -Boc piperidine 44 (14.55 g, 86%) as a colourless oil, bp 100-110 
°C/0.2 mmHg (lit.,119 bp 60-70 °C/1.0 mmHg); 1H NMR (400 MHz, CDCl3) δ 3.46-
3.23 (m, 4H, NCH2), 1.69-1.43 (m, 6H, CH2), 1.43 (s, 9H, CMe3); 
13C NMR (100.6 
MHz, CDCl3) δ 154.6 (C=O), 78.8 (CMe3), 44.2 (br s, NCH2), 28.2 (CMe3), 25.5 
(NCH2CH2), 24.3 (NCH2CH2CH2). Spectroscopic data consistent with those reported 
in the literature.119 
Lab Book Reference GB6/489 
 
1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 49 
 
49
N
O O
Boc  
 
A solution of -Boc-4-piperidone (6.03 g, 30.26 mmol), p-toluenesulfonic acid 
monohydrate (4.22 mg, 2.22 mmol) and diethylene glycol (18.78 g, 16.88 mL, 302.6 
mmol) in toluene (150 mL) was stirred and heated at reflux under Dean-Stark 
conditions for 72 h. After cooling to rt, the solvent was evaporated under reduced 
pressure and CH2Cl2 (60 mL) was added. The organic solution was washed with 
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saturated NaHCO3(aq) (60 mL), dried (MgSO4) and evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica with 
7:3 petrol-EtOAc as eluent gave the acetal piperidine 49 (5.10 g, 69%) as a colourless 
oil, RF (7:3 petrol-EtOAc) 0.6; bp180-190 °C/0.4 mmHg; IR(CHCl3) 3010, 2978, 
2882, 1683 (C=O), 1426, 1366, 1244, 1171, 1114, 757 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 3.95 (s, 4H, OCH2), 3.48 (t, J = 5.5 Hz, 4H, NCH2), 1.63 (t, J = 5.5 Hz, 4H, 
NCH2CH2), 1.44 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 154.0 (C=O), 107.1 
(OCO), 79.5 (CMe3), 64.3 (OCH2), 41.6 (NCH2), 34.8 (NCH2CH2), 28.3 (CMe3); MS 
(ESI) m/z 266 [(M + Na)+, 24], 244 [(M + H)+, 5], 188 (16), 144 (100); HRMS (ESI) 
m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1360 (–2.9 ppm error). 
Lab Book Reference GB6/516 
 
Azepane-1-carboxylic acid tert-butyl ester 56
119
   
 
56
N
Boc  
 
A solution of hexamethylene imine (5.82 g, 6.75 mL, 58.69 mmol) in THF (15 mL) 
was added dropwise to a stirred solution of di-t-butyl dicarbonate (12.2 g, 55.9 mmol) 
at 0 °C under Ar. The resulting colourless solution was allowed to warm to rt and 
stirred for 30 min. Then, the solvent was evaporated under reduced pressure to give 
the crude product. Purification by Kügelrohr short path distillation gave -Boc 
azepine 56  (8.93 g, 80%) as a colourless oil, bp 110-115 °C/1.0 mmHg; 1H NMR 
(400 MHz, CDCl3) (50:50 mixture of rotamers) δ 3.36 (t, J = 6.0 Hz, 1H, NCH2), 3.29 
(t, J = 6.0 Hz, 1H, NCH2), 3.32-3.24 (m, 2H, NCH2), 1.71-1.55 (m, 4H, NCH2CH2), 
1.55-1.47 (m, 4H, NCH2CH2CH2), 1.43 (s, 9H, CMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 155.5 (C=O), 78.6 (CMe3), 46.8 (NCH2), 46.4 (NCH2), 28.3 
(CMe3), 27.3 (CH2), 26.7 (CH2). Spectroscopic data consistent with those reported in 
the literature.119 
Lab Book Reference GB6/490 
 
3-Isopropyl imidazolidine-1-carboxylic acid tert-butyl ester 64
74
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i-Pr
Boc
64
 
 
-i-Pr-ethylene diamine (5.0 g, 6.1 mL, 48.93 mmol) was added dropwise to a stirred 
suspension of paraformaldehyde (1.47 g, 48.93 mmol), K2CO3 (22.8 g, 165.0 mmol) 
and MgSO4 (22.75 g, 189.0 mmol) in CHCl3 (165 mL) at rt. The resulting solution 
was stirred at rt for 16 h. Then, di-t-butyl dicarbonate (10.68 g, 48.93 mmol) was 
added and the resulting solution was stirred at rt for 24 h. The solids were removed by 
filtration through Celite® and washed with CHCl3 (150 mL). The filtrate was 
evaporated under reduced pressure and the residue was partitioned between saturated 
brine (50 mL) and CH2Cl2 (50 mL). The two layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (2 × 50 mL). The combined organic layers were 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by Kügelrohr short path distillation gave -Boc-′-i-Pr imidazolidine 64 
(9.12 g, 87%) as a colourless oil, bp 165-167 °C/12.0 mmHg; 1H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 3.97 (s, 1H, NCH2N), 3.90 (s, 1H, NCH2N), 
3.41 (t, J = 6.5 Hz, 1H, BocNCH2), 3.37 (t, J = 6.5 Hz, 1H, BocNCH2), 2.76 (t, J = 
6.5 Hz, 1H, NCH2), 2.75 (t, J = 6.5 Hz, 1H, NCH2), 2.37 (septet, J = 6.5 Hz, 0.5 H, 
NCH), 2.36 (septet, J = 6.5 Hz, 0.5 H, NCH), 1.39 (s, 9H, CMe3), 1.05 (br d, J = 6.5 
Hz, 6H, NCHMe2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 153.3 (C=O), 153.2 
(C=O), 79.4 (CMe3), 79.3 (CMe3), 66.5 (NCH2N), 66.5 (NCH2N), 53.1 (NCH), 53.0 
(NCH), 50.9 (BocNCH2), 50.1 (BocNCH2), 44.8 (NCH2), 44.3 (NCH2), 28.3 (CMe3), 
28.3 (CMe3), 21.5 (NCHMe2). Spectroscopic data consistent with those reported in the 
literature.75 
Lab Book Reference GB7/597 
 
Piperazine-1-carboxylic acid tert-butyl ester
228
   
 
N
H
N
Boc  
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A solution of di-t-butyl dicarbonate (7.62 g, 34.9 mmol) in CH2Cl2 (95 mL) was 
added dropwise to a stirred solution of piperazine (6.0 g, 69.6 mmol) in CH2Cl2 (190 
mL) at rt. The resulting colourless solution was stirred at rt for 16 h. Then, the solvent 
was evaporated under reduced pressure and the residue was dissolved in H2O (170 
mL). The aqueous solution was extracted with CH2Cl2 (4 × 170 mL). The combined 
organic layers were dried (Na2SO4) and evaporated under reduced pressure to give -
Boc piperazine  (4.34 g, 67%) as a colourless oil, 1H NMR (400 MHz, CDCl3) δ 3.38 
(t, J = 5.0 Hz, 4H, NCH2), 2.80 (t, J = 5.0 Hz, 4H, NCH2), 1.60 (br s, 1H, NH), 1.45 
(s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) δ 154.8 (C=O), 79.5 (CMe3), 45.9 
(NCH2), 44.7 (NCH2), 28.4 (CMe3). Spectroscopic data consistent with those reported 
in the literature.228 
Lab Book Reference GB7/598 
 
4-Benzyl-piperazine-1-carboxylic acid ester 59
229
 
 
N
N
Boc
Bn
59
 
 
-Boc piperazine (4.67 g, 25.07 mmol) and K2CO3 (6.93 g, 50.15 mmol) were added 
portionwise to a stirred solution of benzyl chloride (3.17 g, 2.88 mL, 25.07 mmol) in 
EtOH (70 mL) at rt. The resulting white suspension was stirred and heated at reflux 
for 16 h. After cooling to rt, the solvent was evaporated under reduced pressure and 
the residue was partitioned between H2O (45 mL) and CH2Cl2 (45 mL). The two 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 25 mL). 
The combined organic layers were dried (Na2SO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 95:5 toluene-Et2O as eluent gave -Boc-′-benzyl piperazine 59 (2.14 g, 
31%) as a white solid, mp 72-74 °C (lit.,230 72-75 °C); 1H NMR (400 MHz, CDCl3) δ 
7.38-7.22 (m, 5H, Ar), 3.52 (s, 2H, PhCH2), 3.43 (t, J = 5.0 Hz, 4H, BocNCH2), 2.39 
(t, J = 5.0 Hz, 4H, NCH2), 1.46 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3), δ 
154.7 (C=O), 137.8 (ipso-Ph), 129.0 (Ph), 128.2 (Ph), 127.1 (Ph), 79.5 (CMe3), 63.0 
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(PhCH2), 52.8 (BocNCH2), 44.1 (NCH2), 28.4 (CMe3). Spectroscopic data consistent 
with those reported in the literature.231 
Lab Book Reference GB6/515 
 
ReactIR monitoring of the lithiation of -Boc piperidine 44 by s-BuLi/TMEDA 
(Scheme 2.8) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc piperidine 44 (185 mg, 192 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
min to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 5 min (to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 
1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 90 min. 
 For -Boc piperidine 44, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1674 cm
–1 which was assigned to 
νC=O of prelithiation complex 120. After addition of TMEDA, a new peak appeared at 
1647 cm–1 which was assigned to νC=O of lithiated intermediate 55. After a lithiation time 
of 90 min, complete lithiation of -Boc piperidine 44 to lithiated intermediate 55 was 
observed. 
Lab Book Reference GB8/668 
 
ReactIR monitoring of the lithiation of -Boc piperidine 44 by s-BuLi/(–)-sparteine 
3 
(Scheme 2.9) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc piperidine 44 (185 mg, 192 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 3 
min (to verify the stability of readout on ReactIR). The,n a solution of (–)-sparteine 3 
(305 mg, 299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was 
stirred at –78 °C for 2 min (to verify the stability of readout on ReactIR). Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was 
stirred at –78 °C for 40 min. 
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 For -Boc piperidine 44, a peak at 1695 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1676 cm
–1 which was assigned to 
νC=O of prelithiation complex 122. No other peaks were observed. 
Lab Book Reference GB9/775 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/TMEDA 
(Scheme 2.10) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 10 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 10 min (to verify the stability of readout on ReactIR). Then, TMEDA (116 mg, 151 
µL, 1.3 mmol) was added dropwise. The solutin was stirred at –78 °C for 15 min. 
 For -Boc pyrrolidine 38, a peak at 1699 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1681 cm
–1 which was assigned to 
νC=O of prelithiation complex 123. After addition of TMEDA, a new peak appeared at 
1646 cm–1 which was assigned to νC=O of the lithiated intermediate 76. After a lithiation 
time of 3 min, complete lithiation of -Boc pyrrolidine 38 to lithiated intermediate 76 
was observed. 
Lab Book Reference GB8/666 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/(–)-sparteine 
3 
(Scheme 2.11) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 
min (to verify the stability of readout on ReactIR). Then, a solution of (–)-sparteine 3 
(305 mg, 299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was 
stirred at –78 °C for 10 min (to verify the stability of readout on ReactIR). Then, s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was 
stirred at –78 °C for 20 min. 
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 For -Boc pyrrolidine 38, a peak at 1702 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1680 cm
–1 which was assigned to 
prelithiation complex 124. A new peak also appeared at 1646 cm–1 which was assigned to 
lithiated intermediate 125. After a lithiation time of 20 min, complete lithiation of -Boc 
pyrrolidine 38 to lithiated intermediate 125 was observed. 
Lab Book Reference GB9/774 
 
ReactIR monitoring of the lithiation of homopiperidine 56 by s-BuLi/TMEDA 
(Scheme 2.12) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of homopiperidine 56 (199 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 min (to 
verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in 
hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 5 min (to 
verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 30 min. 
 For homopiperidine 56, a peak at 1695 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1673 cm–1 which was assigned to νC=O 
of prelithiation complex 126. Upon addition of TMEDA, the peak at 1673 cm–1 decreased 
substantially, and the peak at 1695 cm–1 increased. Over the course of 30 min, new peak 
at 1631 cm–1 then emerged, assigned to  νC=O of lithiated intermediate 127. After a 
lithiation time of 30 min, incomplete lithiation of homopiperidine 56 to lithiated 
intermediate 127 was observed. 
Lab Book Reference GB8/757 
 
ReactIR monitoring of the lithiation of homopiperidine 56 by s-BuLi/TMEDA 
(Scheme 2.13) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of homopiperidine 56 (199 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 min (to 
verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 5 min (to verify the stability 
of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 40 min. 
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 For homopiperidine 56, a peak at 1695 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1679 cm–1 which was assigned to νC=O 
of prelithiation complex 128. A new peak also appeared at 1646 cm–1 which was assigned 
to νC=O of lithiated intermediate 127. After a lithiation time of 40 min, incomplete 
lithiation of homopiperidine 56 to lithiated intermediate 127 was observed. 
Lab Book Reference GB8/758 
 
ReactIR monitoring of the lithiation of homopiperidine 56 by s-BuLi/(–)-sparteine 3 
(Scheme 2.14) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of homopiperidine 56 (199 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 min (to 
verify the stability of readout on ReactIR). Then, a solution of (–)-sparteine 3 (305 mg, 
299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 
°C for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 30 min. 
 For homopiperidine 56, a peak at 1694 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a peak appeared at 1679 cm–1 which was assigned to νC=O of 
prelithiation complex 129. No peak corresponding to lithiated intermediate 130 was 
observed. 
Lab Book Reference GB8/759 
 
ReactIR monitoring of the lithiation of homopiperidine 56 by s-BuLi/(+)-sparteine 
surrogate 6 
(Scheme 2.15) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of homopiperidine 56 (199 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 min (to 
verify the stability of readout on ReactIR). Then, a solution of (+)-sparteine surrogate 6 
(258 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 
°C for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 30 min. 
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 For homopiperidine 56, a peak at 1694 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1679 cm–1 which was assigned to νC=O 
of prelithiation complex 131. A new peak also appeared at 1638 cm–1 which was assigned 
to νC=O of lithiated intermediate 132. After a lithiation time of 30 min, incomplete 
lithiation of homopiperidine 56 to lithiated intermediate 132 was observed. 
Lab Book Reference GB8/760 
 
ReactIR monitoring of the lithiation of acetal piperidine 49 by s-BuLi/TMEDA 
(Scheme 2.16) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of acetal piperidine 49 (243 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 min (to 
verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in 
hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 5 min (to 
verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 40 min. 
 For acetal piperidine 49, a peak at 1702 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1676 cm–1 which was assigned to νC=O 
of prelithiation complex 133. After addition of TMEDA, a new peak appeared at 1646 
cm–1 which was assigned to νC=O of lithiated intermediate 134. After a lithiation time of 
30 min, complete lithiation of acetal piperidine 49 to lithiated intermediate 134 was 
observed. 
Lab Book Reference GB8/749 
 
ReactIR monitoring of the lithiation of acetal piperidine 49 by s-BuLi/TMEDA 
(Scheme 2.17) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of acetal piperidine 49 (243 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 3 min to 
verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 2 min (to verify the stability 
of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol) 
was added dropwise. The solution was stirred at –78 °C for 30 min. 
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 For acetal piperidine 49, a peak at 1702 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1680 cm–1 which was assigned to νC=O 
of prelithiation complex 135. A new peak also appeared at 1646 cm–1 which was assigned 
to νC=O of lithiated intermediate 134. After a lithiation time of 20 min, complete lithiation 
of acetal piperidine 49 to lithiated intermediate 134 was observed.  
Lab Book Reference GB9/773 
 
ReactIR monitoring of the lithiation of acetal piperidine 49 by s-BuLi/(–)-sparteine 
3  
(Scheme 2.18) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of acetal piperidine 49 (243 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 min to 
verify the stability of readout on ReactIR). Then, a solution of (–)-sparteine 3 (305 mg, 
299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 
°C for 3 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 30 min. 
 For acetal piperidine 49, a peak at 1702 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1680 cm–1 which was assigned to νC=O 
of prelithiation complex 136. A new peak also appeared at 1639 cm–1 which was assigned 
to νC=O of lithiated intermediate 137. After a lithiation time of 30 min, incomplete 
lithiation of acetal piperidine 49 to lithiated intermediate 137 was observed. 
Lab Book Reference GB9/768 
 
ReactIR monitoring of the lithiation of acetal piperidine 49 by s-BuLi/(+)-sparteine 
surrogate 6 
(Scheme 2.19) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of acetal piperidine 49 (243 mg, 1.0 mmol) 
in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 3 min (to 
verify the stability of readout on ReactIR). Then, a solution of (+)-sparteine surrogate 6 
(258 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 
°C for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
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1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 20 min. 
 For acetal piperidine 49, a peak at 1702 cm–1 was observed which was assigned to νC=O. 
After addition of s-BuLi, a new peak appeared at 1672 cm–1 which was assigned to νC=O 
of prelithiation complex 138. A new peak also appeared at 1639 cm–1 which was assigned 
to νC=O of lithiated intermediate 139. After a lithiation time of 5 min, incomplete 
lithiation of acetal piperidine 49 to lithiated intermediate 139 was observed. No further 
lithiation of acetal piperidine 49 was observed. 
Lab Book Reference GB9/769 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/TMEDA 
(Scheme 2.20) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzylpiperazine 59 (270 mg, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 5 min (to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 
1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 20 min. 
 For -Boc-ʹ-benzylpiperazine 59, a peak at 1702 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1679 cm
–1 which was 
assigned to νC=O of prelithiation complex 140. After addition of TMEDA, a new peak 
appeared at 1646 cm–1 which was assigned to νC=O of lithiated intermediate 141. After a 
lithiation time of 5 min, complete lithiation of -Boc-ʹ-benzylpiperazine 59 to lithiated 
intermediate 141 was observed. 
Lab Book Reference GB8/752 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/TMEDA 
(Scheme 2.21) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzylpiperazine 59 (276 mg, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 
min ( to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 
mmol) was added dropwise. The solution was stirred at –78 °C for 3 min (to verify the 
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stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 10 min. 
 For -Boc-ʹ-benzylpiperazine 59, a peak at 1702 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a small peak appeared at 1682 cm
–1 for a 
single scan which was assigned to νC=O of prelithiation complex 142. A new peak also 
appeared at 1646 cm–1 which was assigned to νC=O of lithiated intermediate 141. After a 
lithiation time of 5 min, complete lithiation of -Boc-ʹ-benzylpiperazine 59 to lithiated 
intermediate 141 was observed. 
Lab Book Reference GB8/753 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/(–)-sparteine 3 
(Scheme 2.22) 
Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzylpiperazine 59 (276 mg, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
min (to verify the stability of readout on ReactIR). Then, a solution of (–)-sparteine 3 
(305 mg, 299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was 
stirred for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 80 min. 
 For -Boc-ʹ-benzylpiperazine 59, a peak at 1699 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1680 cm
–1 which was 
assigned to νC=O of prelithiation complex 143. A new peak also appeared at 1644 cm
–1 
which was assigned to νC=O of lithiated intermediate 144. After a lithiation time of 75 
min, complete lithiation of -Boc-ʹ-benzylpiperazine 59 to lithiated intermediate 144 
was observed. 
Lab Book Reference GB8/754 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/(+)-sparteine 
surrogate 6 
(Scheme 2.23) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzylpiperazine 59 (276 mg, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
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min (to verify the stability of readout on ReactIR). Then, a solution of (+)-sparteine 
surrogate 6 (258 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was 
stirred for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 15 min. 
 For -Boc-ʹ-benzylpiperazine 59, a peak at 1698 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1646 cm
–1 which was 
assigned to νC=O of lithiated intermediate 144. After a lithiation time of 3 min, complete 
lithiation of -Boc-ʹ-benzylpiperazine 59 to lithiated intermediate 144 was observed. 
No peak corresponding to prelithiation complex 143 could be observed. 
Lab Book Reference GB8/755 
 
ReactIR monitoring of the lithiation of imidazolidine 64 by s-BuLi/TMEDA (–78 °C) 
(Scheme 2.24) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-isopropylimidazolidine 64 
(214 mg, 1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 
°C for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 5 min. Then, TMEDA (151 mg, 196 µL, 1.3 mmol) was added dropwise. The 
solution was stirred at –78 °C for 15 min. 
 For -Boc-ʹ-isopropylimidazolidine 64, a peak at 1709 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1683 cm
–1 which was 
assigned to νC=O of prelithiation complex 147 and another peak appeared at 1661 cm
–1 
which was assigned to νC=O of lithiated intermediate 148. After addition of TMEDA, a 
decrease in the peak at 1683 cm–1 was observed with a corresponding further increase in 
the peak at 1661 cm–1. After a lithiation time of 8 min, partial lithiation of -Boc-ʹ-
isopropylimidazolidine 64 to lithiated intermediate 148 was observed. No further 
lithiation of -Boc-ʹ-i-Pr imidazolidine 64 was observed. 
Lab Book Reference GB8/746 
 
ReactIR monitoring of the lithiation of imidazolidine 64 by s-BuLi/TMEDA (–30 °C) 
(Scheme 2.25) 
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 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of -Boc-ʹ-isopropylimidazolidine 64 
(214 mg, 1.0 mmol) in Et2O was added dropwise. The solution was stirred at –30 °C for 
10 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol was added dropwise. The solution was stirred at –30 °C 
for 5 min. Then, TMEDA (151 mg, 196 µL, 1.3 mmol) was added dropwise. The solution 
was stirred at –30 °C for 15 min. 
 For -Boc-ʹ-isopropylimidazolidine 64, a peak at 1709 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1680 cm
–1 which was 
assigned to νC=O of prelithiation complex 147. A new peak also appeared at 1663 cm
–1 
which was assigned to νC=O of lithiated intermediate 148. After a lithiation time of 5 min 
complete lithiation of -Boc-ʹ-isopropylimidazolidine 64 to lithiated intermediate 148 
was observed. 
Lab Book Reference GB8/747 
 
ReactIR monitoring of the lithiation of O-alkyl carbamate 100 by s-BuLi/TMEDA 
(Scheme 2.26) 
 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of O-alkyl carbamate 100 (265 mg, 1.0 
mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 10 min 
(to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution 
in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 10 min 
(to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 
mmol) was added dropwise. The solution was stirred at –78 °C for 20 min. 
 For O-alkyl carbamate 100, a peak at 1697 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1672 cm
–1 which was assigned to 
νC=O of prelithiation complex 149. After addition of TMEDA, a new broad peak appeared 
at 1613 cm–1 which was assigned to νC=O of lithiated intermediate 150. After a lithiation 
time of 20 min, complete lithiation of O-alkyl carbamate 100 to lithiated intermediate 150 
was observed. 
Lab Book Reference GB8/683 
 
ReactIR monitoring of the lithiation of O-alkyl carbamate 100 by s-BuLi/TMEDA 
(Scheme 2.27) 
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 Et2O (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of O-alkyl carbamate 100 (265 mg, 1.0 
mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 min 
(to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 µL, 1.3 
mmol) was added dropwise. The solution was stirred at –78 °C for 2 min (to verify the 
stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 10 min. 
 For O-alkyl carbamate 100, a peak at 1695 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1680 cm
–1 which was assigned to 
νC=O of prelithiation complex 151. A new broad peak also appeared at 1610 cm
–1 which 
was assigned to νC=O of lithiated intermediate 150. After a lithiation time of 10 min, 
complete lithiation of O-alkyl carbamate 100 to lithiated intermediate 150 was observed. 
Lab Book Reference GB9/772 
 
ReactIR monitoring of the lithiation of O-alkyl carbamate 100 by s-BuLi/(–)-
sparteine 3 
(Scheme 2.28) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of O-alkyl carbamate 100 (265 mg, 1.0 
mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 min 
(to verify the stability of readout on ReactIR). Then, a solution of (–)-sparteine 3 (305 
mg, 299 µL, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –
78 °C for 5 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 60 min. 
 For O-alkyl carbamate 100, a peak at 1696 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak appeared at 1680 cm
–1 which was assigned to 
νC=O of prelithiation complex 152. A new broad peak also appeared at 1609 cm
–1 which 
was assigned to νC=O of lithiated intermediate 153. After a lithiation time of 60 min, 
complete lithiation of O-alkyl carbamate 100 to lithiated intermediate 153 was observed. 
Lab Book Reference GB9/766 
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ReactIR monitoring of the lithiation of O-alkyl carbamate 100 by s-BuLi/(+)-
sparteine surrogate 6 
(Scheme 2.29) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of O-alkyl carbamate 100 (265 mg, 1.0 
mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 2 min 
(to verify the stability of readout on ReactIR). Then, a solution of (+)-sparteine surrogate 
6 (258 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –
78 °C for 2 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 5 min. 
 For O-alkyl carbamate 100, a peak at 1694 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new peak briefly appeared at 1665 cm
–1 which was 
assigned to νC=O of prelithiation complex 154. A new broad peak also appeared at 1609 
cm–1 which was assigned to νC=O of lithiated intermediate 155. After a lithiation time of 3 
min, complete lithiation of O-alkyl carbamate 100 to lithiated intermediate 155 was 
observed. 
Lab Book Reference GB9/767 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 187 
7.4 Experimental for Chapter 3 
3,7-Diisopropyl-3,7-diazabicyclo[3.3.1]nonan-9-one 176
131 
 
N N
O
176
 
i-PrNH2 (12.2 mL, 142.0 mmol) was added dropwise to a stirred solution of -i-Pr-4-
piperidone (21.1 mL, 142.0 mmol), paraformaldehyde (12.78 g, 426.0 mmol) and AcOH 
(8.46 mL, 148.0 mmol) in MeOH (200 mL) at rt under Ar. The resulting solution was 
stirred and heated at reflux for 16 h. The solvent was evaporated under reduced pressure. 
Then, 50% KOH(aq) solution (500 mL) and Et2O (500 mL) were added to the residue and 
the layers were separated. The aqueous layer was extracted with Et2O (2 × 500 mL) and 
the combined organic layers were dried (Na2SO4) and evaporated under reduced pressure 
to give the crude product. Purification by fractional distillation gave bispidone 176 (21.39 
g, 67%) as a colourless oil, bp 128-130 ºC/2.0 mmHg (lit.,X bp 110-120 ºC/10-5 mmHg); 
1H NMR (400 MHz, CDCl3) δ 3.01 (dd, J = 10.5, 3.0 Hz, 4H, NCHAHB), 2.86 (dd, J = 
10.5, 7.0 Hz, 4H, NCHAHB), 2.85-2.76 (m, 2H, NCH), 2.61-2.54 (m, 2H, COCH), 0.99 
(d, J = 6.5 Hz, 12H, Me). Spectroscopic data consistent with those reported in the 
literature.132 
Lab Book reference GB2/113 
 
3,7-Diisopropyl-3,7-diazabicyclo[3.3.1]nonane 7 
 
N N
7
 
 
Hydrazine monohydrate (6.22 mL, 127.9 mmol) was added dropwise to a stirred mixture 
of bispidone 176 (5.17 g, 23.0 mmol) and KOH (15.1 g, 269.0 mmol) in diethylene 
glycol (130 mL) at rt under Ar. The resulting mixture was stirred and heated at 180 °C 
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for 16 h. After cooling to 60 °C,1 the mixture was transferred to a separating funnel and 
H2O (155 mL) was added. Then, Et2O (85 mL) was added and the layers were separated. 
The aqueous layer was extracted with Et2O (6 × 85 mL) and the combined organic layers 
were washed with 20% NaOH(aq) (6 × 100 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give di-i-Pr bispidine 7 (4.29 g, 88%) as a colourless oil, 1H NMR 
(400 MHz, CDCl3) δ 2.68-2.57 (m, 2H, NCH), 2.53 (dd, J = 10.5, 5.5 Hz, 4H, NCH2), 
2.46 (br d, J = 10.5 Hz, 4H, NCH2), 1.97-1.92 (m, 2H, NCH2CH), 1.46-1.41 (m, 2H, 
NCH2CHCH2), 0.97 (d, J = 6.5 Hz, 12H, NCHMe2). Spectroscopic data consistent with 
those reported in the literature.131 Di-i-Pr bispidine 7 was purified by Kügelrohr 
distillation (bp 110-120 °C, 0.4 mmHg) immediately before use. 
Lab Book Reference GB2/109 
3,7-Diisopropyl-9-methylene-3,7-diazabicyclo[3.3.1]nonane 156 
 
N N
156
CH2
 
 
KHMDS (65.4 mL of a 0.5 M solution in toluene, 32.7 mmol) was added dropwise to a 
stirred solution of MePh3P
+Br– (11.68 g, 32.7 mmol) in THF (240 mL) at 0 °C under Ar. 
After stirring at 0 °C for 30 min, a solution of bispidone 176 (7.00 g, 31.2 mmol) in THF 
(60 mL) was added dropwise. The resulting solution was stirred at 0 °C for 15 min and 
then stirred and heated at reflux for 16 h. The solvent was evaporated under reduced 
pressure and 5 M HCl(aq) solution (250 mL) was added to the residue. The aqueous 
solution washed with CH2Cl2 (2 × 500 mL) and then basified to pH 14 by addition of 5 M 
NaOH(aq). The aqueous solution was stirred at rt for 1 h and then extracted with Et2O (8 × 
200 mL). The combined organic extracts were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product as a yellow oil. Purification by Kügelrohr 
distillation gave alkene 156 (4.48 g, 65%) as a colourless oil, bp 120-130 °C/1.2 mmHg; 
IR (film) 3069, 2931, 1670 (C=C), 1469, 1386, 1358, 1176, 880 cm-1; 1H NMR (400 
MHz, CDCl3) δ 4.67 (s, 2H, C=CH2), 2.78-2.68 (m, 2H, NCH), 2.68-2.60 (m, 8H, 
                                                 
1 If the diethylene glycol solution is cooled to rt before addition of H2O then the mixture becomes very 
viscous and difficult to work with. 
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NCH2), 2.58-2.40 (m, 2H, NCH2CH), 0.99 (d, J = 6.5 Hz, 12H, Me); 
13C NMR (100.6 
MHz, CDCl3) δ 151.4 (C=CH2), 104.7 (C=CH2), 53.8 (NCH2), 53.4 (NCH), 39.0 
(NCH2CH), 18.1 (Me); MS (ESI) m/z 223 [(M + H)
+, 100], 150 (15), 123 (30); HRMS 
(ESI) m/z calcd for C14H26N2 (M + H)
+ 223.2169, found 223.2169 (–0.26 ppm error). 
Lab Book Reference GB1/77 
 
3,7-Diisopropyl-9-methyl-3,7-diazabicyclo[3.3.1]nonane 157 
 
N N
157
MeH
 
A solution of alkene 156 (4.48 g, 20.1 mmol) and NH4
+HCO2
– (4.16 g, 66.0 mmol) in 
EtOH (130 mL) was stirred and heated at reflux under Ar. Then, 20% Pd(OH)2/C (1.22 g, 
1.4 mmol) was added in one portion. The resulting mixture was stirred and heated at 
reflux for 2 h. After cooling to rt, the resulting mixture was basified to pH 14 by addition 
of 5 M NaOH(aq) solution. The aqueous solution was stirred at rt for 1 h. Then, the solids 
were removed by filtration through a minimum amount of Celite® and washed with 5 M 
NaOH(aq) solution (20 mL). The EtOH was evaporated under reduced pressure and the 
aqueous residue was extracted with Et2O (8 × 200 mL). The combined organic extracts 
were dried (Na2SO4) and evaporated under reduced pressure to give the crude product as 
a yellow oil. Purification by Kügelrohr distillation gave methyl bispidine 157 (2.87 g, 
65%) as a colourless oil, bp 130-140 °C/0.4 mmHg; IR (film) 2963, 2932, 1381, 1179, 
1110 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.79-2.60 (m, 8H, NCH2), 2.40-2.34 (m, 2H, 
NCH), 1.86-1.78 (m, 1H, CHMe), 1.66 (br s, 2H, NCH2CH), 1.05-0.95 (m, 15H, CHMe 
+ CHMe2); 
13C NMR (100.6 MHz, CDCl3) δ 53.9 (NCH), 53.6 (NCH), 53.5 (NCH2), 
47.1 (NCH2), 34.2 (CH), 30.2 (CH), 18.2 (Me), 17.9 (Me), 16.5 (Me); MS (ESI) m/z 225 
[(M + H)+, 100]; HRMS (ESI) m/z calcd for C14H28N2 (M + H)
+ 225.2325, found 
225.2326 (–0.42 ppm error). 
Lab Book Reference GB1/80 
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3,7-Diisopropyl-3,7-diazabicyclo[3.3.1]nonan-9-ol 158 
 
N N
158
OHH
 
 
A solution of NaBH4 (37 mg, 1.0 mmol) in H2O (1.5 mL) was added dropwise to a stirred 
solution of bispidone 176 (200 mg, 0.9 mmol) in EtOH (3.0 mL) at rt under air. The 
resulting solution was stirred at rt for 16 h. The EtOH was evaporated under reduced 
pressure and the residue was basified to pH 14 by addition of 5 M NaOH(aq) solution. The 
solution was stirred at rt for 1 h and then extracted with Et2O (8 × 10 mL). The combined 
organic extracts were dried (Na2SO4) and evaporated under reduced pressure to give 
bispidol 158 (138 mg, 69%) as a colourless oil, bp 170-180 ºC/5 mmHg; IR (film) 3328 
(OH), 2965, 2924, 1469, 1382, 1360, 1221, 1174, 1096, 1069, 1052 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.06 (br s, 1H, OH), 3.31 (br s, 1H, CHOH), 2.99 (br t, J = 10.5 Hz, 2H), 
2.72-2.62 (m, 2H), 2.62-2.42 (m, 4H), 2.28-2.15 (m, 4H), 0.99 (d, J = 6.5 Hz, 6H, Me), 
0.94 (d, J = 6.5 Hz, 6H, Me); 13C NMR (100.6 MHz, CDCl3) δ 73.2 (CHOH), 53.3 
(NCH), 52.9 (NCH), 52.4 (NCH2), 48.5 (NCH2), 34.6 (NCH2CH), 18.2 (Me), 18.1 (Me); 
MS (ESI) m/z 227 [(M + H)+, 100]; HRMS (ESI) m/z calcd for C13H26N2O (M + H)
+ 
227.2118, found 227.2124 (–2.85 ppm error). 
Lab Book Reference GB1/48 
 
3,7-Dipropyl-3,7-diazabicyclo[3.3.1]nonan-9-one 180 
 
N N
180
O
 
 
n-PrNH2 (5.83 mL, 70.81 mmol) was added dropwise to a stirred solution of -n-Pr-4-
piperidone (10.7 mL, 10 g, 70.81 mmol), paraformaldehyde (6.38 g, 212.4 mmol) and 
AcOH (4.22 mL, 73.8 mmol) in MeOH (100 mL) at rt under Ar. The resulting solution 
was stirred and heated at reflux for 16 h. The solvent was evaporated under reduced 
pressure. Then, 50% KOH(aq) solution (250 mL) and Et2O (250 mL) were added to the 
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residue and the layers were separated. The aqueous layer was extracted with Et2O (2 × 
250 mL) and the combined organic layers were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by fractional distillation gave di-
n-Pr bispidone 180 (7.01 g, 44%) as a yellow oil, bp 95-100 °C/0.2 mmHg; IR (film) 
2958, 1739 (C=O), 1469, 1359, 1208, 1137, 1087, 1036, 735 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 2.99 (dd, J = 11.0, 2.0 Hz, 4H, NCHAHB), 2.79 (dd, J = 11.0, 6.5 Hz, 4H, 
NCHAHB), 2.56 (br s, 2H, COCH), 2.31 (t, J = 7.5 Hz, 4H, NCH2CH2), 1.50-1.40 (m, 4H, 
NCH2CH2), 0.89 (t, J = 7.5 Hz, 6H, Me); 
13C NMR (100.6 MHz, CDCl3) δ 215.1 (C=O), 
58.5 (NCH2), 58.4 (NCH2), 46.6 (NCH2CH), 20.3 (CH2Me), 11.8 (Me); MS (ESI) m/z 
257 [(M + MeOH + H)+, 100], 225 [(M + H)+, 1]; HRMS (ESI) m/z calcd for C14H24N2O 
(M + H)+ 225.1961, found 225.1770 (minor peak); m/z calcd for C14H24N2O (M + MeOH 
+ H)+ 257.2224, found 257.2220 (+1.3 ppm error). 
Lab Book Reference GB2/148 
 
3,7-Dipropyl-3,7-diazabicyclo[3.3.1]nonane 159 
 
N N
159
 
 
Hydrazine monohydrate (4.72 mL, 86.5 mmol) was added dropwise to a stirred mixture 
of di-n-Pr bispidone 180 (3.5 g, 15.6 mmol) and KOH (9.11 g, 182.0 mmol) in diethylene 
glycol (90 mL) at rt under Ar. The resulting mixture was stirred and heated at 180 °C for 
16 h. After cooling to 60 °C,2 the mixture was transferred to a separating funnel and H2O 
(80 mL) was added. Then, Et2O (60 mL) was added and the layers separated. The 
aqueous layer was extracted with Et2O (6 × 60 mL) and the combined organic layers 
were washed with 20% NaOH(aq) (6 × 90 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give di-n-Pr bispidine 159 (2.77 g, 84%) as a colourless oil, bp 100-
110 °C/2.0 mmHg; IR (film) 2955, 2932, 1462, 1375, 1290, 1272, 1148, 1106, 1068, 
1001 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.69 (br d, J = 10.5 Hz, 4H, NCHAHB), 2.28 
(dd, J = 10.5, 4.5 Hz, 4H, NCHAHB), 2.19 (t, J = 7.5 Hz, 4H, NCH2CH2), 1.91 (br s, 2H, 
NCH2CH), 1.52-1.41 (m, 6H, NCH2CH2 + CH2CHCH2), 0.87 (t, J = 7.5 Hz, 6H, Me); 
                                                 
2  If the diethylene glycol solution is cooled to rt before addition of H2O then the mixture becomes very 
viscous and difficult to work with. 
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13C NMR (100.6 MHz, CDCl3) δ 61.0 (NCH2), 57.9 (NCH2), 29.9 (bridge CH2), 29.2 
(NCH2CH), 20.1 (NCH2CH2), 11.9 (Me); MS (ESI) m/z 211 [(M + H)
+, 100], 199 (12); 
HRMS (ESI) m/z calcd for C13H26N2 (M + H)
+ 211.2169, found 211.2162 (+2.97 ppm 
error). 
Lab Book Reference GB2/150 
 
2-(Hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (1R,2R)-182 
and (1S,2R)-182 
 
N
Boc
Ph
H
N
Boc
Ph
H
OH OH
(1R,2R)-182 (1S,2R)-182
 
 
Using general procedure A, s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol), 
-Boc pyrrolidine 38 (342 mg, 350 µL, 2.0 mmol) and (–)-sparteine 3 (609 mg, 595 µL, 
2.6 mmol) for 1 h and then benzaldehyde (424 mg, 406 µL, 4.0 mmol) gave the crude 
product which contained a  75:25 mixture of (1R,2R)-182 and (1S,2R)-182 by 1H NMR 
spectroscopy. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (343 mg, 62%, 97:3 er by  CSP-HPLC) as a 
colourless oil, [α]D –3.1 (c 1.0 in CHCl3) (lit.,
130 [α]D –1.9 (c 1.0 in CHCl3) for (1R,2R)-
182 of 97:3 er); RF (98:2 CH2Cl2-acetone) 0.4; 
1H NMR (400 MHz, CDCl3) δ 7.39-7.25 
(m, 5H, Ph), 5.93 (br s, 1H, OH), 4.53 (br d, J = 8.0 Hz, 1H, CHO), 4.10 (td, J = 8.0, 3.5 
Hz, 1H, NCH), 3.51-3.42 (m, 1H, NCH2), 3.41-3.33 (m, 1H, NCH2), 1.79-1.15 (m, 2H, 
CH2), 1.14-1.45 (m, 2H, CH2), 1.53 (s, 9H, CMe3); CSP-HPLC: Chiralcel OD (98:2 
hexane-i-PrOH, 0.5 mLmin-1) (1R,2R)-182 24.12 min, (1S,2S)-182 28.85 min and 
(1S,2R)-182 (100 mg, 18%, 97:3 er by CSP-HPLC) as a colourless oil, [α]D +75.4 (c 1.00 
in CHCl3) (lit.,
130 [α]D +95.3 (c 1.00 in CHCl3) for (1S,2R)-182 of 97:3 er); RF (98:2 
CH2Cl2-acetone) 0.3; 
1H NMR (400 MHz, CDCl3) (75:25 mixture of rotamers) δ 7.41-
7.23 (m, 5H, Ph), 5.52 (br s, 0.75H, OH), 5.15 (br s, 0.25H, OH), 4.87 (br s, 0.75H, 
CHO), 4.31 (br s, 0.75H, NCH), 4.00 (br s, 0.25H, CHO), 3.56 (br s, 0.25H, NCH), 3.30 
(br s, 1H, NCH2), 2.82 (br s, 0.75H, NCH2), 2.51 (br s, 0.25H, NCH2), 2.01-1.86 (m, 1H, 
CH2), 1.85-1.72 (m, 1H, CH2), 1.68 (s, 2.25H, CMe3), 1.66-1.46 (m, 1H, CH2), 1.52 (s, 
6.75H, CMe3), 1.21-1.13 (m, 1H, CH2); CSP-HPLC: Chiralcel OD (98:2 hexane-i-PrOH, 
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0.5 mLmin-1) (1S,2R)-182 19.61 min, (1R,2S)-182 24.00 min. Spectroscopic data 
consistent with those reported in the literature.130 
Lab Book Reference GB1/84 
 
 (Table 3.1, Entry 1) 
Using general procedure B, s-BuLi (0.87 mL of a 1.3 M solution in hexanes, 1.13 mmol, 
1.2 eq.), (–)-sparteine 3 (44 mg, 0.19 mmol, 0.2 eq.), di-i-Pr bispidine 7 (198 mg, 0.94 
mmol, 1.0 eq.) and -Boc pyrrolidine 38 (161 mg, 165 µL, 0.94 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (198 mg, 190 µL, 1.88 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (119 mg, 55%, 85:15 er by CSP-HPLC) as a 
colourless oil, [α]D –2.4 (c 1.0 in CHCl3) and (1S,2R)-182 (73 mg, 29%, 85:15 er by 
CSP-HPLC) as a colourless oil, [α]D +59.4 (c 1.0 in CHCl3). 
Lab Book Reference GB4/309 
 
 (Table 3.2, Entry 2) 
Using general procedure B, s-BuLi (1.15 mL of a 1.3 M solution in hexanes, 1.50 mmol, 
1.2 eq.), (–)-sparteine 3 (58 mg, 0.25 mmol, 0.2 eq.), di-i-Pr bispidine 7 (315 mg, 1.50 
mmol, 1.2 eq.) and -Boc pyrrolidine 38 (215 mg, 220 µL, 1.25 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (261 mg, 250 µL, 2.50 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (180 mg, 54%, 84:16 er by CSP-HPLC) as a 
colourless oil, [α]D –2.6 (c 1.0 in CHCl3) and (1S, 2R)-182 (103 mg, 31%, 82:18 er by 
CSP-HPLC) as a colourless oil, [α]D +56.3 (c 1.0 in CHCl3). 
Lab Book Reference GB4/310 
 
 (Table 3.1, Entry 3) 
Using general procedure B, s-BuLi (1.98 mL of a 1.3 M solution in hexanes, 2.58 mmol, 
1.3 equiv.), (–)-sparteine 3 (93 mg, 0.40 mmol, 0.2 equiv.), di-i-Pr bispidine 7 (500 mg, 
2.38 mmol, 1.2 equiv.) and -Boc pyrrolidine 38 (350 µL, 1.98 mmol, 1.0 equiv.) in Et2O 
(8 mL) and then benzaldehyde (405 µL, 3.97 mmol, 2.0 equiv.) gave the crude product. 
Purification by flash column chromatography on silica with 98:2 CH2Cl2-acetone as 
eluent gave (1R,2R)-182 (298 mg, 57%, 82:18 er by CSP-HPLC) as a colourless oil, [α]D 
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–2.1 (c 1.0 in CHCl3) and (1S,2R)-182 (173 mg mg, 33%, 82:18 er by CSP-HPLC) as a 
colourless oil, [α]D +49.9 (c 1.0 in CHCl3). 
Lab Book Reference GB7/317 
 
 (Table 3.1, Entry 4) 
Using general procedure B, s-BuLi (1.06 mL of a 1.3 M solution in hexanes, 1.38 mmol, 
1.0 eq.), (–)-sparteine 3 (81 mg, 0.34 mmol, 0.25 eq.), di-i-Pr bispidine 7 (290 mg, 1.38 
mmol, 1.0 eq.) and -Boc pyrrolidine 38 (234 mg, 240 µL, 1.38 mmol, 1.0 eq.) in Et2O 
(8 mL) then benzaldehyde (293 mg, 280 µL, 2.76 mmol, 2.0 eq.) gave the crude product. 
Purification by flash column chromatography on silica with 98:2 CH2Cl2-acetone as 
eluent gave (1R,2R)-182 (214 mg, 58%, 88:12 er by CSP-HPLC) as a colourless oil, [α]D 
–2.9 (c 1.0 in CHCl3) and (1S,2R)-182 (106 mg, 29%, 88:12 er by CSP-HPLC) as a 
colourless oil, [α]D +52.4 (c 1.0 in CHCl3). 
Lab Book Reference GB4/333 
 
 (Table 3.1, Entry 5) 
Using general procedure B, s-BuLi (1.65 mL of a 1.3 M solution in hexanes, 2.14 mmol, 
1.6 eq.), (–)-sparteine 3 (94 mg, 0.40 mmol, 0.3 eq.), di-i-Pr bispidine 7 (366 mg, 1.74 
mmol, 1.3 eq.) and -Boc pyrrolidine 38 (230 mg, 235 µL, 1.34 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (282 mg, 270 µL, 2.68 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (221 mg, 62%, 91:9 er by CSP-HPLC) as a 
colourless oil, [α]D –1.24 (c 1.0 in CHCl3), and (1S,2R)-182 (116 mg, 33%, 91:9 er by 
CSP-HPLC) as a colourless oil, [α]D +93.0 (c 1.0 in CHCl3). 
Lab Book Reference GB4/318 
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2-(Hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (1S,2S)-182 
and (1R,2S)-182 
(Table 3.2, Entry 1) 
 
N
Boc
Ph
H
N
Boc
Ph
H
OH OH
(1S,2S)-182 (1R,2S)-182
 
 
Using general procedure B, s-BuLi (1.13 mL of a 1.3 M solution in hexanes, 1.47 mmol, 
1.0 eq.), (+)-sparteine surrogate 6 (64 mg, 0.37 mmol, 0.25 eq.), di-i-Pr bispidine 7 (309 
mg, 1.47 mmol, 1.0 eq.) and -Boc pyrrolidine 38 (254 mg, 260 µL, 1.47 mmol, 1.0 eq.) 
in Et2O (8 mL) and then benzaldehyde (313 mg, 300 µL, 2.94 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1S,2S)-182 (220 mg, 56%, 93:7 er by CSP-HPLC) as a colourless 
oil, [α]D +2.8 (c 1.0 in CHCl3) and (1R,2S)-182 (96 mg, 25%, 93:7 er by CSP-HPLC) as a 
colourless oil, [α]D –87.2 (c 1.0 in CHCl3). 
Lab Book Reference GB4/323 
 
 (Table 3.2, Entry 2) 
Using general procedure B, s-BuLi (2.64 mL of a 1.3 M solution in hexanes, 3.43 mmol, 
1.6 eq.), (+)-sparteine surrogate 6 (112 mg, 0.64 mmol, 0.3 eq.), di-i-Pr bispidine 7 (585 
mg, 2.78 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (366 mg, 375 µL, 2.14 mmol, 1.0 eq.) 
in Et2O (8 mL) and then benzaldehyde (455 mg, 435 µL, 4.28 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1S,2S)-182 (370 mg, 65%, 94:6 er by CSP-HPLC) as a colourless 
oil, [α]D +0.04 (c 1.0 in CHCl3) and (1R,2S)-182 (166 mg, 29%, 94:6 er by CSP-HPLC) 
as a colourless oil, [α]D –106.3 (c 1.0 in CHCl3). 
Lab Book Reference GB4/324 
 
 (Table 3.2, Entry 3) 
Using general procedure B, s-BuLi (0.96 mL of a 1.3 M solution in hexanes, 1.25 mmol, 
1.6 eq.), cyclohexane diamine (R,R)-8 (58 mg, 0.23 mmol, 0.3 eq.), di-i-Pr bispidine 7 
(214 mg, 1.02 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (134 mg, 137 µL, 0.78 mmol, 1.0 
eq.) in Et2O (8 mL) and then benzaldehyde (167 mg, 160 µL, 1.57 mmol, 2.0 eq.) gave 
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the crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave (1R,2R)-182 (131 mg, 63%, 84:16 er by CSP-HPLC) as a 
colourless oil, [α]D +2.2 (c 1.0 in CHCl3) and (1S,2R)-182 (57 mg, 27%, 85:15 er by 
CSP-HPLC) as a colourless oil, [α]D –79.5 (c 1.0 in CHCl3). 
Lab Book Reference GB4/334 
 
 (Table 3.3, Entry 1) 
Using general procedure B, s-BuLi (1.66 mL of a 1.3 M solution in hexanes, 2.16 mmol, 
1.6 eq.), (–)-sparteine 3 (95 mg, 0.41 mmol, 0.3 eq.), alkene bispidine 156 (391 mg, 1.76 
mmol, 1.3 eq.) and -Boc pyrrolidine 38 (234 mg, 240 µL, 1.35 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (287 mg, 275 µL, 2.70 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (220 mg, 61%, 92:8 er by CSP-HPLC) as a 
colourless oil, [α]D –2.7 (c 1.0 in CHCl3) and (1S,2R)-182 (107 mg, 30%, 88:12 er by 
CSP-HPLC) as a colourless oil, [α]D +81.8 (c 1.0 CHCl3). 
Lab Book Reference GB4/349 
 
 (Table 3.3, Entry 2) 
Using general procedure B, s-BuLi (1.15 mL of a 1.3 M solution in hexanes, 1.50 mmol, 
1.6 eq.), (–)-sparteine 3 (66 mg, 0.28 mmol, 0.3 eq.), methyl bispidine 157 (274 mg, 1.22 
mmol, 1.3 eq.) and -Boc pyrrolidine 38 (161 mg, 165 µL, 0.94 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (198 mg, 190 µL, 1.88 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (149 mg, 60%, 79:21 er by CSP-HPLC) as a 
colourless oil, [α]D –1.9 (c 1.0 in CHCl3) and (1S,2R)-182 (81 mg, 32%, 78:22 er by 
CSP-HPLC) as a colourless oil, [α]D +72.4 (c 1.0 in CHCl3). 
Lab Book Reference GB5/388 
 
 (Table 3.3, Entry 3) 
Using general procedure B, s-BuLi (1.27 mL of a 1.3 M solution in hexanes, 1.63 mmol, 
2.9 eq.), (–)-sparteine 3 (40 mg, 0.17 mmol, 0.3 eq.), bispidol 158 (167 mg, 0.74 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (98 mg, 100 µL, 0.57 mmol, 1.0 eq.) in Et2O (8 mL) 
and then benzaldehyde (199 mg, 190 µL, 1.88 mmol, 2.0 eq.) gave the crude product. 
Purification by flash column chromatography on silica with 98:2 CH2Cl2-acetone as 
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eluent gave (1R,2R)-182 (82 mg, 54%, 83:17 er by CSP-HPLC) as a colourless oil, [α]D –
1.34 (c 0.55 in CHCl3) and (1S,2R)-182 (47 mg, 31%, 77:23 er by CSP-HPLC) as a 
colourless oil, [α]D +89.6 (c 1.0 in CHCl3). 
Lab Book Reference GB4/348 
 
 (Table 3.3, Entry 4) 
Using general procedure B, s-BuLi (1.22 mL of a 1.3 M solution in hexanes, 1.59 mmol, 
1.6 eq.), (–)-sparteine 3 (70 mg, 0.30 mmol, 0.3 eq.), di-n-Pr bispidine 159 (271 mg, 1.29 
mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 0.99 mmol, 1.0 eq.) in Et2O 
(8 mL) and then benzaldehyde (209 mg, 200 µL, 1.99 mmol, 2.0 eq.) gave the crude 
product. Purification by flash column chromatography on silica with 98:2 CH2Cl2-
acetone as eluent gave (1R,2R)-182 (160 mg, 61%, 55:45 er by CSP-HPLC) as a 
colourless oil, [α]D –0.2 (c 1.0 in CHCl3) and (1S,2R)-182 (90 mg, 34%, 55:45 er by 
CPS-HPLC) as a colourless oil, [α]D +2.4 (c 1.0 in CHCl3). 
Lab Book Reference GB4/343 
 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol), 
-Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and -i-Pr (+)-sparteine surrogate 160 
(289 mg, 1.3 mmol) in Et2O (7 mL) for 3 h and then benzaldehyde (212 mg, 203 µL, 2.0 
mmol) gave the crude product which contained a 75:25 mixture of (1S,2S)-182 and 
(1R,2S)-182 by 1H NMR spectroscopy. Purification by flash column chromatography on 
silica with 98:2 CH2Cl2-acetone as eluent gave (1S,2S)-182 (140 mg, 50%, 90:10 er by  
CSP-HPLC) as a colourless oil, [α]D +2.5 (c 1.0 in CHCl3) and (1R,2S)-182 (70 mg, 25%, 
89:11 er by CSP-HPLC) as a colourless oil, [α]D –69.8 (c 1.0 in CHCl3). 
Lab Book Reference GB9/777 
 
2-(Hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (1R*,2R*)-
182 and (1S*,2R*)-182 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol), 
-Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and di-i-Pr bispidine 7 (273 mg, 1.3 
mmol) in Et2O (7 mL) for 3 h and then benzaldehyde (212 mg, 203 µL, 2.0 mmol) gave 
the crude product which contained a 75:25 mixture of (1S*,2S*)-182 and (1R*,2S*)-182 
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by 1H NMR spectroscopy. Purification by flash column chromatography on silica with 
98:2 CH2Cl2-acetone as eluent gave (1R*,2R*)-182 (170 mg, 61%) as a colourless oil and 
(1S*,2R*)-182 (86 mg, 31%) as a colourless oil. 
Lab Book Reference GB9/779 
 
2-Trimethylsilylpyrrolidine-1-carboxylic acid (R)-39 
 
N
Boc
SiMe3
(R)-39
 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol), 
-Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and -i-Pr (+)-sparteine surrogate 160 
(289 mg, 1.3 mmol) in Et2O (7 mL) for 3 h and then Me3SiCl (217 mg, 254 µL, 2.0 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 95:5 petrol-Et2O as eluent gave pyrrolidine (R)-39 (198 mg, 81%, 91:9 er by CSP-
GC) as a colourless oil, RF (95:5 petrol-Et2O) 0.4; [α]D –65.1 (c 1.0 in CHCl3) (lit.
52 [α]D 
+69.4 (c 2.22 in CHCl3) for (S)-39 of 97:3 er); 
1H NMR (400 MHz, CDCl3) δ 3.47 (br s, 
1H, NCH), 3.22 (br s, 1H, NCH2), 3.17-3.00 (m, 1H, NCH2), 1.96 (br s, 1H, CH), 1.85-
1.63 (m, 3H, CH), 1.43 (s, 9H, CMe3), 0.02 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 154.5 (C=O), 79.2 (CMe3), 78.3 (CMe3), 47.6 (NCH), 47.5 (NCH), 
46.9 (NCH2), 32.8 (CH2), 28.4 (CMe3), 27.9 (CMe3), 17.3 (CH2), 1.8 (SiMe3), 1.2 
(SiMe3); CSP-GC: β-cyclodextrin PM (100 °C) (S)-39 13.09 min, (R)-39 13.27 min. 
Spectroscopic data consistent with those reported in the literature.52 
Lab Book Reference GB9/778 
 
2-Trimethylsilylpyrrolidine-1-carboxylic acid rac-39 
 
Using general procedure A, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol), 
-Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and di-i-Pr bispidine 7 (273 mg, 1.3 
mmol) in Et2O (7 mL) for 3 h and then Me3SiCl (217 mg, 254 µL, 2.0 mmol) gave the 
crude product. Purification by flash column chromatography on silica with 95:5 petrol-
Et2O as eluent gave pyrrolidine rac-39 (213 mg, 86%) as a colourless oil.  
Lab Book Reference GB9/780 
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(S)-2-(2-Trifluoromethylphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (S)-183 
 
N
Boc
CF3
(S)-183
 
 
Using general procedure C, -Boc pyrrolidine 38 (493 mg, 505 µL, 2.88 mmol, 1.0 eq.), 
s-BuLi (2.21 mL of a 1.3 M solution in hexanes, 2.88 mmol, 1.0 eq.), (+)-sparteine 
surrogate 6 (139 mg, 0.72 mmol, 0.25 eq.) and di-i-Pr bispidine 7 (606 mg, 2.88 mmol, 
1.0 eq.) in Et2O (7.0 mL) and then ZnCl2 (1.73 mL of a 1.0 M solution in Et2O, 1.73 
mmol, 0.6 eq.), Pd(OAc)2 (31 mg, 0.14 mmol, 5 mol%), t-Bu3PHBF4 (32 mg, 0.18 mmol, 
6.25 mol%) and o-bromobenzotrifluoride (434 mg, 263 µL, 2.02 mmol, 0.7 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 99:1 CH2Cl2-
acetone as eluent gave aryl pyrrolidine (S)-183 (481 mg, 75%, 91:9 er by CSP-HPLC) as 
a white solid, mp 82-83 °C; [α]D –42.2 (c 1.4 in CHCl3); RF (99:1 CH2Cl2-acetone) 0.8; 
IR (CHCl3) 3013, 2980, 1685 (C=O), 1313, 1216, 1162, 1126, 759 cm
-1; 1H NMR (400 
MHz, CDCl3) (80:20 mixture of rotamers) δ 7.68-7.58 (m, 1H, Ar), 7.57-7.43 (m, 1H, 
Ar), 7.38-7.26 (m, 2H, Ar), 5.38-5.30 (m, 0.2H, NCH), 5.19-5.11 (m, 0.8H, NCH), 3.80-
3.64 (m, 2H, NCH), 2.48-2.39 (m, 1H, CH), 2.05-1.84 (m, 2H, CH), 1.83-1.72 (m, 1H, 
CH), 1.47 (s, 1.8H, CMe3), 1.12 (s, 7.2H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.3 (C=O), 154.1 (C=O), 
144.7 (ipso-Ar), 132.1 (Ar), 131.9 (Ar), 127.6 (q, J = 3.0 Hz, Ar), 126.6 (Ar) 126.5 (q, J 
= 24.0 Hz, CF3), 126.4 (Ar), 126.0 (Ar), 125.4 (q, J = 6.0 Hz, Ar), 123.0 (ipso-Ar), 79.4 
(CMe3), 77.2 (CMe3), 57.6 (NCH), 47.4 (NCH2), 35.9 (CH2), 28.4 (CMe3), 27.9 (CMe3), 
23.0 (CH2); MS (ESI) m/z 338 [(M + Na)
+, 100]; HRMS (ESI) m/z calcd for 
C16H20NO2F3 (M + Na)
+ 338.1338, found 338.1334 (+1.2 ppm error); CSP-HPLC: 
Chiralpak AD (99:1 hexane-i-PrOH, 0.7 mLmin–1) (R)-183 9.29 min, (S)-183 11.31 min.  
Lab book Reference GB2/155:2 
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(R)-2-(2-Trifluoromethylphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (R)-
183 
(Table 3.4, Entry 2) 
N
Boc
F3C
(R)-183
 
 
Using general procedure C, -Boc pyrrolidine 38 (280 mg, 1.64 mmol, 1.0 eq.), s-BuLi 
(1.26 mL of a 1.3 M solution in hexanes, 1.64 mmol, 1.0 eq.), (–)-sparteine 3 (96 mg, 
0.41 mmol, 0.25 eq.) and di-i-Pr bispidine 7 (345 mg, 1.64 mmol, 1.0 eq.) in Et2O (7 mL) 
and then ZnCl2 (0.98 mL of a 1.0 M solution in Et2O, 0.98 mmol, 0.6 eq.), Pd(OAc)2 (18 
mg, 0.08 mmol, 5 mol%), t-Bu3PHBF4 (18 mg, 0.10 mmol, 6.25 mol%) and o-
bromobenzotrifluoride (159 µL, 1.15 mmol, 0.7 eq.) gave the crude product. Purification 
by flash column chromatography on silica with 99:1 CH2Cl2-acetone as eluent gave aryl 
pyrrolidine (R)-183 (278 mg, 76%, 80:20 er by CSP-HPLC) as a white solid, [α]D +40.7 
(c 1.3 in CHCl3). 
Lab Book Reference GB3/246:2 
 
 
(Table 3.5, Entry 2) 
Using general procedure C, -Boc pyrrolidine 38 (216 mg, 1.27 mmol, 1.0 eq.), s-BuLi 
(1.56 mL of a 1.3 M solution in hexanes, 2.03 mmol, 1.6 eq.), (–)-sparteine 3 (89 mg, 
0.38 mmol, 0.3 eq.) and di-i-Pr bispidine 7 (347 mg, 1.65 mmol, 1.3 eq.) in Et2O (7 mL) 
and then ZnCl2 (0.76 mL of a 1.0 M solution in Et2O, 0.76 mmol, 0.6 eq.), Pd(OAc)2 (14 
mg, 0.06 mmol, 5 mol%), t-Bu3PHBF4 (14 mg, 0.08 mmol, 0.625 mol%) and o-
bromobenzotrifluoride (123 µL, 0.89 mmol, 0.7 eq.) gave the crude product. Purification 
by flash column chromatography on silica with 99:1 CH2Cl2-acetone as eluent gave aryl 
pyrrolidine (R)-183 (249 mg, 88%, 80:20 er by CSP-HPLC) as a white solid, [α]D +37.5 
(c 1.0 in CHCl3). 
Lab Book Reference GB4/336:2 
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(R)-2-(2-Methoxycarbonylphenyl) pyrrolidine-1-carboxylic acid tert-butyl ester (R)-
184 
(Table 3.5, Entry 3) 
 
N
Boc
CO2Me
(R)-184
 
 
Using general procedure C, -Boc pyrrolidine 38 (214 mg, 1.25 mmol, 1.0 eq.), s-BuLi 
(1.54 mL of a 1.3 M solution in hexanes, 2.00 mmol, 1.6 eq.), (–)-sparteine 3 (88 mg, 
0.37 mmol, 0.3 eq.) and di-i-Pr bispidine 7 (342 mg, 1.62 mmol, 1.3 eq.) in Et2O (7 mL) 
and then ZnCl2 (750 µL of a 1.0 M solution in Et2O, 0.75 mmol, 0.6 eq.), Pd(OAc)2 (14 
mg, 0.06 mmol, 5 mol%), t-Bu3PHBF4 (14 mg, 0.08 mmol, 6.25 mol%) and methyl 2-
bromobenzoate (123 µL, 0.87 mmol, 0.7 eq.) gave the crude product. Purification by 
flash column chromatography on silica with 4:1 petrol-Et2O as eluent gave aryl 
pyrrolidine (R)-184 (189 mg, 71%, 89:11 er by CSP-HPLC) as a colourless oil, [α]D 
+16.4 (c 1.0 in CHCl3); RF (4:1 petrol-EtOAc) 0.3; IR (film) 2975, 2876, 1721 (C=O, 
CO2Me), 1697 (C=O, Boc), 1479, 1450, 1434, 1394, 1365, 1256, 1164, 1116, 1076, 755 
cm–1; 1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 7.94 (d, J = 7.5 Hz, 
0.3H, Ar), 7.87 (d, J = 7.5 Hz, 0.7H, Ar), 7.45 (td, J = 7.5, 1.0 Hz, 1H, Ar), 7.33-7.17 (m, 
2H, Ar), 5.68 (br d, J = 7.5 Hz, 0.3H, NCH), 5.49 (dd, J = 8.0, 4.5 Hz, 0.7H, NCH), 3.88 
(s, 2.1H, OMe), 3.85 (s, 0.9H, OMe), 3.68-3.58 (m, 1.4H, NCH2), 3.56-3.45 (m, 0.6H, 
NCH2), 2.59-2.33 (m, 1H, CH2), 1.93-1.69 (m, 3H, CH2), 1.43 (s, 2.7H, CMe3), 1.10 (s, 
6.3H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 167.6 (C=O, CO2Me), 154.3 
(C=O, Boc), 147.3 (ipso-C6H4CO2Me), 132.0 (Ar), 130.2 (Ar), 127.9 (ipso-C6H4CH), 
126.1 (Ar), 125.8 (Ar), 79.0 (CMe3), 58.7 (OMe), 51.9 (NCH), 47.6 (NCH2), 47.3 
(NCH2), 35.5 (CH2), 34.6 (CH2), 28.5 (CMe3), 28.0 (CMe3), 23.1 (CH2); HRMS (ESI) 
m/z calcd for C17H23NO4 (M + Na)
+ 328.1519, found 328.1521 (+1.1 ppm error); CSP-
HPLC: Chiralcel OD (95:5 hexane-i-PrOH, 1.0 mLmin–1) (R)-184 5.47 min, (S)-184 6.58 
min. 
Lab Book Reference GB4/338:2 
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(Table 3.4, Entry 3) 
Using general procedure C, -Boc pyrrolidine 38 (344 mg, 2.01 mmol, 1.0 eq.), s-BuLi 
(1.55 mL of a 1.3 M solution in hexanes, 2.01 mmol, 1.0 eq.), (–)-sparteine 3 (118 mg, 
0.50 mmol, 0.25 eq.) and di-i-Pr bispidine 7 (423 mg, 2.01 mmol, 1.0 eq.) in Et2O (7 mL) 
and then ZnCl2 (1.21 mL of a 1.0 M solution in Et2O, 1.21 mmol, 0.6 eq.), Pd(OAc)2 (22 
mg, 0.1 mmol, 5 mol%), t-Bu3PHBF4 (22 mg, 0.126 mmol, 6.25 mol%) and methyl 2-
bromobenzoate (198 µL, 1.41 mmol, 0.7 eq.) gave the crude product. Purification by 
flash column chromatography on silica with 4:1 petrol-Et2O as eluent gave aryl 
pyrrolidine (R)-184 (309 mg, 50%, 81:19 er by CSP-HPLC) as a colourless oil, [α]D 
+14.9 (c 1.4 in CHCl3). 
Lab Book Reference GB3/253:2 
 
(R)-2-(2-Methoxyphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (R)-181 
(Table 3.5, Entry 1) 
 
N
Boc
MeO
(R)-181
 
 
 
Using general procedure C, -Boc pyrrolidine 38 (243 mg, 1.42 mmol, 1.0 eq.), s-BuLi 
(1.75 mL of a 1.3 M solution in hexanes, 2.27 mmol, 1.6 eq.), (–)-sparteine 3 (100 mg, 
0.43 mmol, 0.3 eq.) and di-i-Pr bispidine 7 (388 mg, 1.85 mmol, 1.3 eq.) in Et2O (7 mL) 
and then ZnCl2 (852 µL of a 1.0 M solution in Et2O, 0.85 mmol, 0.6 eq.), Pd(OAc)2 (16 
mg, 0.07 mmol, 5 mol%), t-Bu3PHBF4 (16 mg, 0.09 mmol, 6.25 mol%) and o-
bromoanisole (124 µL, 0.99 mmol, 0.7 eq.) gave the crude product. Purification by flash 
column chromatography on silica with CH2Cl2 as eluent gave aryl pyrrolidine (R)-181 
(253 mg, 92%, 89:11 er by CSP-HPLC) as a colourless oil, [α]D +59.8 (c 1.0 in acetone) 
(lit.,89 [α]D +109.0 (c 1.7 in acetone) for (R)-181 of 96:4 er). RF (98:2 CH2Cl2-acetone) 
0.2; 1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 7.26-7.13 (m, 1H, Ar), 
7.06 (d, J = 7.5 Hz, 0.7H, Ar), 7.01 (d, J = 7.5 Hz, 0.3H, Ar), 6.89 (t J = 7.5 Hz, 1H, Ar), 
6.85 (br d, J = 8.0 Hz, 1H, Ar), 5.25 (br d, J = 7.5 Hz, 0.3H, NCH), 5.18-5.01 (m, 0.7H, 
NCH), 3.83 (s, 3H, OMe), 3.69-3.40 (m, 2H, NCH2), 2.38-2.12 (m, 1H, CH2), 1.94-1.71 
(m, 3H, CH2), 1.47 (s, 2.7H, CMe3), 1.19 (s, 6.3H, CMe3); 
13C NMR (100.6 MHz, 
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CDCl3) (rotamers) δ 156.1 (C=O), 154.6 (C=O), 132.9 (ipso-Ar), 127.5 (ipso-Ar), 127.3 
(Ar), 125.9 (Ar), 120.1 (Ar), 110.3 (Ar), 110.1 (Ar), 79.0 (CMe3), 78.8 (CMe3), 56.1 
(OMe), 55.3 (NCH), 55.2 (NCH), 47.2 (NCH2), 46.8 (NCH2), 33.9 (CH2), 32.8 (CH2), 
28.5 (CMe3), 28.1 (CMe3), 23.1 (CH2). CSP-HPLC: Chiralpak AD (99:1 hexane-i-PrOH, 
0.5 mLmin-1) (R)-181 22.8 min, (S)-181 19.6 min. Spectroscopic data consistent with 
those reported in the literature.89 
Lab Book Reference GB4/337:2 
 
(Table 3.4, Entry 1) 
Using general procedure C, -Boc pyrrolidine 38 (348 mg, 2.03 mmol, 1.0 eq.), s-BuLi 
(1.56 mL of a 1.3 M solution in hexanes, 2.03 mmol, 1.0 eq.), (–)-sparteine 3 (119 mg, 
0.51 mmol, 0.25 eq.) and di-i-Pr bispidine 7 (427 mg, 2.03 mmol, 1.0 eq.) in Et2O (7 mL) 
and then ZnCl2 (1.22 mL of a 1.0 M solution in Et2O, 1.22 mmol, 0.6 eq.), Pd(OAc)2 (22 
mg, 0.1 mmol, 5 mol%), t-Bu3PHBF4 (23 mg, 0.127 mmol, 6.25 mol%) and o-
bromoanisole (177 µL, 1.42 mmol, 0.7 eq.) gave the crude product. Purification by flash 
column chromatography on silica with CH2Cl2 as eluent gave aryl pyrrolidine (R)-181 
(196 mg, 50%, 80:20 er by CSP-HPLC) as a colourless oil, [α]D +23.6 (c 1.0 in acetone). 
Lab Book Reference GB3/247:2 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine XX by s-BuLi/-i-Pr-(+)-
sparteine surrogate 160 
(Scheme 3.19) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
underAr. After cooling to –78 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 4 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 4 min (to verify the stability of readout on ReactIR). Then, a solution of -i-Pr (+)-
sparteine surrogate 160 (289 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The 
solution was stirred at –78 °C for 40 min. 
 For -Boc pyrrolidine 38, a peak at 1702 cm-1 was observed which was assigned to 
νC=O. Upon addition of s-BuLi, this peak decreased and a new peak at 1679 cm
–1 was 
observed which was assigned to νC=O in prelithiation complex 123. Upon addition of -i-
Pr (+)-sparteine surrogate 160, the peak at 1679 cm–1 decreased substantially, and the 
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peak at 1702 cm–1 increased. Over the course of 40 min, a new peak at 1646 cm–1 then 
emerged, assigned to νC=O in lithiated intermediate 185. 
Lab Book Reference GB8/727 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/-i-Pr-(+)-
sparteine surrogate 160
 
(Scheme 3.20) 
 -i-Pr (+)-sparteine surrogate 160 (289 mg, 1.3 mmol), s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) and Et2O (12 mL) were added to a flask equipped with a 
stirrer bar and ReactIR probe at rt under Ar. After cooling to –78 °C, the solution was 
stirred for 5 min and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) in Et2O (2 mL) 
was added dropwise. The solution was stirred at –78 °C for 1 h. 
 For -Boc pyrrolidine 38, a peak at 1702 cm–1 was observed which was assigned to 
νC=O. Upon addition of -Boc pyrrolidine 38, a large peak at 1702 cm
–1 and a smaller 
peak at 1680 cm–1 which was assigned to νC=O in prelithiation complex 186 were 
observed. Over the course of 1 h, there was a slow increase in a peak at 1645 cm–1 which 
was assigned to νC=O in lithiated intermediate 185, with a corresponding decrease in the 
peak at 1702 cm–1. 
Lab Book Reference GB8/726 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine XX by s-BuLi/di--i-Pr 
bispidine 7 
 (Scheme 3.22) 
 Et2O (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in Et2O (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 10 min (to verify the stability of readout on ReactIR). Then, a solution of di-i-Pr 
bispidine 7 (273 mg, 1.3 mmol) in Et2O (2 mL) was added dropwise. The solution was 
stirred at –78 °C for 40 min. 
 For -Boc pyrrolidine 38, a peak at 1702 cm-1 was observed which was assigned to 
νC=O. Upon addition of s-BuLi, this peak decreased and a new peak at 1679 cm
–1 was 
observed which was assigned to νC=O in prelithiation complex 123. Upon addition of di-i-
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Pr bispidine 7, the peak at 1679 cm–1 decreased substantially, and the peak at 1702 cm–1 
increased. Over the course of 40 min, a new peak at 1645 cm–1 then emerged, assigned to 
νC=O in lithiated intermediate 187. 
Lab Book Reference GB8/729 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/di--i-Pr 
bispidine 7 
(Scheme 3.23) 
 Di-i-Pr bispidine 7 (273 mg, 1.3 mmol), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 
1.3 mmol) and Et2O (12 mL) were added to a flask equipped with a stirrer bar and 
ReactIR probe at rt under Ar. After cooling to –78 °C, the solution was stirred for 5 min 
and a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) in Et2O (2 mL) was 
added dropwise. The solution was stirred at –78 °C for  40 min. 
 For -Boc pyrrolidine 38, a peak at 1701 cm–1 was observed which was assigned to 
νC=O. Upon addition of -Boc pyrrolidine 38, a large peak at 1701 cm
–1 and a smaller 
peak at 1682 cm–1 which was assigned to νC=O in prelithiation complex 188 were 
observed. Over the course of 40 min, there was a slow increase in a peak at 1648 cm–1 
which was assigned to νC=O in lithiated intermediate 187, with a corresponding decrease 
in the peak at 1701 cm–1. 
Lab Book Reference GB8/728 
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7.5 Experimental for Chapter 4 
(R)-2-(2-Methoxycarbonylphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (R)-
184 
N
Boc
CO2Me
(R)-184
 
 
Using general procedure D, s-BuLi (7.7 mL of a 1.3 M solution in hexanes, 10.0 mmol), 
-Boc pyrrolidine 38 (1.71 g, 1.75 mL, 10.0 mmol) and (–)-sparteine (2.34 g, 2.30 mL, 
10.0 mmol) in Et2O (35 mL) and then ZnCl2 (6.0 mL of a 1.0 M solution in Et2O, 6.0 
mmol), Pd(OAc)2 (112 mg, 0.5 mmol, 5 mol%), t-Bu3PHBF4 (112 mg, 0.625 mmol, 6.25 
mol%) and methyl 2-bromobenzoate (1.83 g, 1.19 mL, 8.5 mmol) at rt gave the crude 
product. Purifiaction by flash column chromatography on silica with 4:1 petrol-Et2O as 
eluent gave aryl pyrrolidine (R)-184 (1.37 g, 53%, 95:5 er by CSP-HPLC) as a colourless 
oil, [α]D +18.7 (c 1.0 in CHCl3). 
Lab Book Reference GB4/321 
 
(R)-1,2,3,9b-Tetrahydropyrrolo[2,1-a]isoindol-5-one (R)-200 
 
N
O
(R)-200
 
 
TFA (187 mg, 122 µL, 1.64 mmol) was added dropwise to a stirred solution of aryl 
pyrrolidine (R)-184 (100 mg, 0.33 mmol, 95:5 er) in CH2Cl2 (5 mL) at rt under Ar. The 
resulting solution was stirred at rt for 3.5 h. The solvent was evaporated under reduced 
pressure and excess TFA was removed by azeotroping with toluene (3 × 10 mL). The 
residue was dissolved in MeOH (10 mL) and then K2CO3 (227 mg, 1.64 mmol) was 
added. The resulting solution was stirred at rt under air for 16 h. The solvent was 
evaporated under reduced pressure. H2O (10 mL) and CH2Cl2 (10 mL) were added. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were dried (MgSO4) and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 1:1 
petrol-EtOAc as eluent gave isoindolone (R)-200 (39 mg, 68%) as a white solid, mp 72-
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74 °C; RF (1:1 petrol-EtOAc) 0.4; [α]D +11.3 (c 1.0 in CHCl3); IR (CHCl3) 3006, 2980, 
2895, 1684 (C=O), 1617, 1469, 1389, 1334 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, 
J = 7.5 Hz, 1H, Ar), 7.52 (td, J = 7.5, 1.0 Hz, 1H, Ar), 7.48-7.41 (m, 2H, Ar), 4.68 (dd, J 
= 10.5, 5.5 Hz, 1H, NCH), 3.78-3.66 (m, 1H, NCH2), 3.43 (ddd, J = 11.5, 8.5, 3.5 Hz, 
1H, NCH2), 2.44-2.26 (m, 3H, CH), 1.33-1.18 (m, 1H, CH); 
13C NMR (100.6 MHz, 
CDCl3) δ 171.6 (C=O), 146.4 (ipso-Ar), 133.6 (ipso-Ar), 131.5 (Ar), 128.3 (Ar), 123.9 
(Ar), 122.6 (Ar), 64.6 (NCH), 41.9 (NCH2), 29.7 (CH2), 29.2 (CH2); MS (ESI) m/z 196 
[(M + Na)+, 58], 174 [(M + H)+, 100]; HRMS (ESI) m/z calcd for C11H11NO (M + H)
+ 
174.0913, found 173.0919 (–3.4 ppm error). 
Lab Book Reference GB3/214 
 
(R)-2-(2-Carbonylphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester (R)-201 
 
N
Boc
OH
(R)-201
O
 
 
NaOH (23 mL of a 0.2 M solution in H2O, 4.52 mmol) was added dropwise to a stirred 
solution of aryl pyrrolidine (R)-184 (690 mg, 2.26 mmol, 95:5 er) in MeOH (23 mL) at rt 
under air. The resulting solution was stirred at rt for 16 h. The MeOH was evaporated 
under reduced pressure. Then, 5 M HCl(aq) was added dropwise until pH 3 and the 
aqueous solution was extracted with CH2Cl2 (5 × 10 mL). The combined organic layers 
were dried (Na2SO4) and evaporated under reduced pressure to give acid (R)-201 (500 
mg, 76%) as a white solid, mp 61-62 °C; [α]D +24.8 (c 0.9 in CHCl3); IR (CHCl3) 3010 
(OH), 2979, 1687 (C=O), 1405, 1367, 1263, 1216, 1164, 757 cm–1; 1H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 8.15-7.81 (m, 1H, Ar), 7.51 (br s, 1H, Ar), 7.38-
7.26 (m, 2H, Ar), 5.63 (br s, 1H, NCH), 3.67 (br s, 2H, NCH2), 2.52 (br s, 1H, CH), 1.98-
1.78 (m, 3H, CH), 1.45 (br s, 4.5 H, CMe3), 1.16 (br s, 4.5 H, CMe3); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 171.0 (C=O, CO2H), 154.6 (C=O, Boc), 148.3 (ipso-Ar), 
143.7 (ipso-Ar), 132.9 (Ar), 132.2 (Ar), 131.1 (Ar), 126.8 (Ar), 126.5 (Ar), 125.7 (Ar), 
80.4 (CMe3), 79.4 (CMe3), 58.7 (NCH), 58.6 (NCH), 47.9 (NCH2), 47.4 (NCH2), 35.5 
(CH2), 35.2 (CH2), 28.5 (CMe3), 28.1 (CMe3), 23.7 (CH2), 23.2 (CH2); MS (ESI) m/z 314 
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[(M + Na)+, 64], 292 [(M + H)+, 13], 236 (100), 192 (59), 174 (37); HRMS (ESI) m/z 
calcd for C16H21NO4 (M + Na)
+ 314.1363, found 314.1362 (+0.4 ppm error). 
Lab Book Reference GB3/250 
 
[2-((R)-1-Methylpyrrolidin-2-yl)phenyl]methanol (R)-199 
 
N
Me
OH
(R)-199
 
 
A solution of aryl pyrrolidine (R)-184 (1.17 g, 3.83 mmol, 95:5 er) in THF (25 mL) was 
added dropwise to a stirred suspension of LiAlH4 (1.45 g, 38.31 mmol) in THF (35 mL) 
at 0 °C under Ar. The resulting solution was stirred at rt for 1 h then stirred and heated at 
reflux for 16 h. The solution was allowed to cool to rt and then 1 M NaOH(aq) (5 mL) was 
added dropwise. The solids were removed by filtration through Celite® and washed with 
9:1 CH2Cl2-MeOH. The filtrate was evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 9:1 CH2Cl2-MeOH 
as eluent gave amino alcohol (R)-199 (529 mg, 72%) as a yellow oil, RF (9:1 CH2Cl2-
MeOH) 0.4; [α]D +31.1 (c 1.0 in CHCl3); IR (film) 3365 (OH), 2946, 2873, 2784, 1451, 
1203, 1184, 1024, 759 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.33-7.21 (m, 4H, Ar), 5.04 
(d, J = 12.5 Hz, 1H, OCH2), 4.38 (d, J = 12.5 Hz, 1H, OCH2), 3.35-3.27 (m, 2H, NCH + 
NCH2), 2.41-2.31 (m, 1H, NCH2), 2.23 (s, 3H, Me), 2.31-2.04 (m, 3H, CH), 2.03-1.92 
(m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 140.4 (ipso-Ar), 140.0 (ipso-Ar), 130.9 
(Ar), 130.8 (Ar), 128.0 (Ar), 127.6 (Ar), 73.3 (NCH), 64.7 (OCH2), 56.8 (NCH2), 40.4 
(Me), 31.5 (CH2), 23.7 (CH2); MS (ESI) m/z 192 [(M + H)
+, 100], 174 (4); HRMS (ESI) 
m/z calcd for C12H17NO (M + H)
+ 192.1383, found 192.1389 (–3.2 ppm error). 
Lab Book Reference GB4/332 
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(R)-2-Pyridin-3-ylpyrrolidine-1-carboxylic acid tert-butyl ester (R)-84
89 
 
N
Boc N
(R)-84
 
 
s-BuLi (13.48 mL of a 1.3 M solution in hexanes, 17.52 mmol) was added dropwise to a 
stirred solution of -Boc pyrrolidine 38 (3.0 g, 3.07 mL, 17.52 mmol) and (–)-sparteine 3 
(4.11 g, 4.02 mL, 17/52 mmol) in Et2O (60 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 1 h. Then, ZnCl2 (10.51 mL of a 1.0 M solution in 
Et2O, 10.51 mmol) was added and the resulting solution was stirred at –78 °C for 30 min. 
The solution was allowed to warm to rt and stirred for 30 min. Then, 3-bromopyridine 
(2.36 g, 1.44 mL, 14.91 mmol) in TBME (45 mL) was added. A mixture of t-Bu3PHBF4 
(197 mg, 1.0 mmol, 6.25 mol%) and Pd(OAc)2 (198 mg, 0.88 mmol, 5 mol%) was added 
in one portion. The reaction flask was transferred to a pre-heated oil bath and the solution 
was stirred and heated at reflux for 16 h. After cooling to rt, 35% NH4OH(aq) (3.3 mL) 
was added and the resulting mixture was stirred at rt for 1 h. The solids were removed by 
filtration through a pad of Celite®, and washed with Et2O (175 mL). The filtrate was 
washed with H2O (175 mL) and brine (175 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column chromatography 
on silica with 6:4 petrol-EtOAc as eluent gave pyridyl pyrrolidine (R)-84 (1.45 g, 40%, 
96:4 er by chiral shift NMR spectroscopy of a derivative) as a colourless oil, RF (6:4 
petrol-EtOAc) 0.2; [α]D +78.1 (c 1.0 in CH2Cl2) (lit.,
89 [α]D +83.6 (c 1.55 in CH2Cl2) for 
(R)-84 of 96:4 er); 1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 8.45-8.43 
(m, 2H, Ar), 7.50-7.43 (m, 1H, Ar), 7.25-7.16 (m, 1H, Ar), 4.93 (br s, 0.4H, NCH), 4.75 
(br s, 0.6H, NCH), 3.64-3.46 (m, 2H, NCH), 2.40-2.25 (m, 1H, CH), 1.95-1.77 (m, 3H, 
CH), 1.42 (s, 3.6H, CMe3), 1.17 (s, 5.4H, CMe3). Spectroscopic data consistent with 
those reported in the literature.89 
Lab Book Reference GB3/200 
 
 
 
 
 
 210 
(S)-2-Pyridin-3-ylpyrrolidine-1-carboxylic acid tert-butyl ester (S)-84 
 
 
N
Boc N
(S)-84
 
 
s-BuLi (1.71 mL of a 1.3 M solution in hexanes, 2.22 mmol, 1.0 eq.) was added dropwise 
to a stirred solution of (+)-sparteine surrogate 6 (97 mg, 0.56 mmol, 0.25 eq.) and di-i-Pr 
bispidine 7 (467 mg, 2.22 mmol, 1.0 eq.) in Et2O (6 mL) at –78 °C under Ar. After 
stirring at –78 °C for 15 min, a solution of -Boc pyrrolidine 38 (380 mg, 389 µL, 2.22 
mmol, 1.0 eq.) in Et2O (1 mL) was added dropwise. The resulting pale yellow solution 
was stirred at –78 °C for 4 h. Then, ZnCl2 (1.33 mL of a 1.0 M solution in Et2O, 1.33 
mmol, 0.6 eq.) was added and the resulting solution was stirred at –78 °C for 30  min. 
The solution was allowed to warm to rt and stirred for 30 min. Then, 3-bromopyridine 
(246 mg, 153 µL, 1.56 mmol, 0.7 eq.) in TBME (5 mL) was added. A mixture of t-
Bu3PHBF4 (25 mg, 0.13 mmol, 6.25 mol%) and Pd(OAc)2 (25 mg, 0.11 mmol, 5 mol%) 
was added in one portion. The reaction flask was transferred to a pre-heated oil bath and 
the solution was stirred and heated at reflux for 16 h. After cooling to rt, 35% NH4OH(aq) 
(0.3 mL) was added and the resulting mixture was stirred at rt for 1 h. The solids were 
removed by filtration through a pad of Celite® and washed with Et2O (2 × 10 mL). The 
filtrate was washed with H2O (20 mL) and brine (20 mL) dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 6:4 petrol-EtOAc as eluent gave pyridyl pyrrolidine (S)-84 
(179 mg, 46%, 92:8 er by chiral shift NMR spectroscopy of a derivative) as a colourless 
oil, [α]D +80.0 (c 1.0 in CH2Cl2) (lit.,
89 [α]D –83.6 (c 1.55 in CH2Cl2) for (R)-84 of 94:6 
er).  
Lab Book Reference GB4/286:3 
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(R)-7ornicotine (R)-210 
 
N
H
N
(R)-210
 
 
Using general procedure F, pyridyl pyrrolidine (R)-84 (750 mg, 3.02 mmol) and TFA 
(6.89 g, 4.49 mL, 60.4 mmol) in CH2Cl2 (40 mL) for 16 h gave nornicotine (R)-210 (339 
mg, 76%) as a colourless oil, [α]D +34.2 (c 1.2 in MeOH) (lit.,
232 [α]D –35.2 (c 1.0 in 
MeOH) for (S)-210 of 92:8 er); 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 2.0 Hz, 1H, 
Ar), 8.42 (dd, J = 5.0, 2.0 Hz, 1H, Ar), 7.66 (dt, J = 8.0, 2.0 Hz, 1H, Ar), 7.19 (dd, J = 
8.0, 5.0 Hz, 1H, Ar), 4.10 (t, J = 7.5 Hz, 1H, NCH), 3.20-3.11 (m, 1H, NCH2), 3.08-2.96 
(m, 1H, NCH2), 2.28 (br s, 1H, NH), 2.23-2.14 (m, 1H, CH), 1.96-1.77 (m, 2H, CH), 
1.68-1.56 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 148.2 (Ar), 147.8 (Ar), 139.9 
(ipso-Ar), 133.6 (Ar), 122.9 (Ar), 59.6 (NCH), 46.6 (NCH2), 34.0 (CH2), 25.1 (CH2). 
Spectroscopic data consistent with those reported in the literature.232 
Lab Book Reference GB3/210 
 
(R)-7icotine (R)-97 
 
N
Me N
(R)-97
 
 
Using general procedure G, nornicotine (R)-210 (169 mg, 1.14 mmol), paraformaldehyde 
(171 mg, 5.70 mmol) and formic acid (262 mg, 215 µL, 5.70 mmol) in H2O (15 mL) gave 
(R)-nicotine (R)-97 (169 mg, 91%, 96:4 er by chiral shift NMR spectroscopy in the 
presence of 2,2,2-trifluoro-1-(9-anthryl)-ethanol) as a colourless oil, [α]D +129.6 (c 0.85 
in EtOH) (lit.,232 [α]D –145.0 (c 1.0 in EtOH) for (S)-nicotine of 99.5:0.5 er);
 1H NMR 
(400 MHz, CDCl3) δ 8.52 (s, 1H, Ar), 8.47 (dd, J = 5.0, 1.5 Hz, 1H, Ar), 7.70-7.65 (m, 
1H, Ar), 7.24 (dd, J = 8.0, 5.0 Hz, Ar), 3.22 (t, J = 7.5 Hz, 1H, NCH), 3.06 (t, J = 8.5 Hz, 
1H, NCH), 2.34-2.25 (m, 1H, NCH), 2.24-2.07 (m, 4H, NMe + CH), 2.01-1.88 (m, 1H, 
CH), 1.86-1.65 (m, 2H, CH); 13C NMR (100.6 MHz, CDCl3) δ 149.4 (Ar), 148.5 (Ar), 
138.6 (ipso-Ar), 134.7 (Ar), 123.4 (Ar), 68.7 (NCH), 56.9 (NCH2), 40.2 (NMe), 35.1 
(CH2), 22.5 (CH2). Spectroscopic data consistent with those reported in the literature.
232 
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Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.079 M solution of nicotine was prepared by dissolving nicotine (R)-97 (9 mg, 0.055 
mmol) in CDCl3 (0.7 mL). Then, (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (50 mg, 0.22 
mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 1.93 (NMe, major), 
1.90 (NMe, minor). Integration of the major and minor NMe signals in the 1H NMR 
spectra indicated that nicotine (R)-97 was present in 96:4 er. 
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.078 M solution of nicotine was prepared by dissolving nicotine (R)-97 (8.9 mg, 0.055 
mmol) in CDCl3 (0.7 mL). Then, (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (49 mg, 0.22 
mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 1.93 (NMe, minor), 
1.90 (NMe, major). Integration of the major and minor NMe signals in the 1H NMR 
spectra indicated that nicotine (R)-97 was present in 95:5 er. 
Lab Book Reference GB3/211 (synthesis) and GB3/215 (chiral shift) 
 
(S)-7icotine (S)-97 
 
N
Me N
(S)-97
 
 
Using general procedure F, pyridyl pyrrolidine (S)-84 (110 mg, 0.44 mmol) and TFA 
(1.01 g, 658 µL, 8.86 mmol) in CH2Cl2 (6 mL) for 16 h gave (S)-nornicotine (S)-210. 
Then, using general procedure G, the crude product, paraformaldehyde (80 mg, 2.66 
mmol) and formic acid (123 mg, 80 µL, 2.66 mmol) in H2O (7 mL) gave (S)-nicotine (S)-
97 (68 mg, 96%, 92:8 er by chiral shift NMR spectroscopy in the presence of 2,2,2-
trifluoro-1-(9-anthryl)-ethanol) as a colourless oil, [α]D –81.0 (c 1.0 in EtOH) (lit.,
232 [α]D 
–145.0 (c 1.0 in EtOH) for (S)-nicotine of 99.5:0.5 er). Spectroscopic data consistent with 
those reported in the literature.232 
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Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.052 M solution of nicotine was prepared by dissolving nicotine (S)-97 (5 mg, 0.031 
mmol) in CDCl3 (0.6 mL). Then, (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (34 mg, 0.12 
mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 1.93 (NMe, major), 
1.90 (NMe, minor). Integration of the major and minor NMe signals in the 1H NMR 
spectra indicated that nicotine (S)-97 was present in 92:8 er. 
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.026 M solution of nicotine was prepared by dissolving nicotine (S)-97 (3 mg, 0.018 
mmol) in CDCl3 (0.7 mL). Then, (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (20 mg, 0.072 
mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 1.93 (NMe, minor), 
1.90 (NMe, major). Integration of the major and minor NMe signals in the 1H NMR 
spectra indicated that nicotine (S)-97 was present in 92:8 er. 
Lab Book Reference GB4/287 + GB4/288:1 (synthesis) and GB4/288:2 (chiral shift) 
 
3-Bromo-5-trimethylsilylethynylpyridine 218
161 
 
N
Br
SiMe3
218
 
 
Trimethylsilylacetylene (622 µL, 4.40 mmol) was added dropwise to a stirred solution of 
3,5-dibromopyridine (947 mg, 4.00 mmol), CuI (76 mg, 0.40 mmol) and Pd(PPh3)2Cl2 
(281 mg, 0.40 mmol) in Et3N (1.4 mL) at rt under Ar. The resulting solution was stirred 
at rt for 16 h. Then, H2O (6 mL) was added and the resulting solution was extacted with 
Et2O (3 × 6 mL). The combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 4:1 petrol-CH2Cl2 as eluent gave bromopyridine 218 (666 
mg, 72%) as a brown oil, 1H NMR (400 MHz, CDCl3) δ 8.62 (br s, 2H, Ar), 7.90 (s, 1H, 
Ar), 0.27 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, CDCl3) δ 151.0 (Ar), 150.3 (Ar), 141.5 
(Ar), 122.0 (ipso-Ar), 120.2 (ipso-Ar), 100.3 (C≡C), 99.7 (C≡C), –0.7 (SiMe3). 
Spectroscopic data consistent with those reported in the literature.161 
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Lab Book Reference GB4/354:2 
 
(S)-2-(5-Trimethylsilylethynylpyridin-3-yl)pyrrolidine-1-carboxylic acid tert-butyl 
ester (S)-220 
 
N
Boc N
SiMe3
(S)-220
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol) was added dropwise to a 
stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) and (+)-sparteine 
surrogate 6 (213 mg, 1.3 mmol) in Et2O (7 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 1 h. Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 
0.6 mmol) was added and the resulting solution was stirred at –78 °C for 30 min. The 
solution was allowed to warm to rt and stirred for 30 min. Then, bromopyridine 218 (178 
mg, 0.7 mmol) in TBME (5 mL) was added. A mixture of t-Bu3PHBF4 (11 mg, 0.06 
mmol, 6.25 mol%) and Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%) was added in one portion. 
The reaction flask was transfered to a pre-heated oil bath and the solution was stirred and 
heated at reflux for 16 h. After cooling to rt, 35% NH4OH(aq) (0.3 mL) was added and the 
resulting mixture was stirred at rt for 1 h. The solids were removed by filtration through a 
pad of Celite®, and washed with Et2O (20 mL). The filtrate was washed with H2O (20 
mL) and brine (20 mL), dried (Na2SO4) and evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 93:7 
CH2Cl2-MeOH as eluent gave pyridyl pyrrolidine (S)-220 (75 mg, 44%, 92:8 er by chiral 
shift NMR spectroscopy of a derivative, (S)-98) as a yellow oil, RF (93:7 CH2Cl2-MeOH) 
0.4; [α]D –57.3 (c 1.0 in CHCl3); IR (film) 2973, 2880, 2159, 1697 (C=O), 1448, 1392, 
1366, 1250, 1164, 1115, 846, 757 cm-1; 1H NMR (400 MHz, CDCl3) (70:30 mixture of 
rotamers) δ 8.56 (br s, 1H, Ar), 8.40 (br s, 1H, Ar), 7.54 (s, 1H, Ar), 4.91 (br s, 0.3H, 
NCH), 4.75 (br s, 0.7H, NCH), 3.62 (br s, 2H, NCH), 2.34 (br s, 1H, CH), 1.98-1.69 (m, 
3H, CH), 1.45 (br s, 2.7H, CMe3), 1.21 (br s, 6.3H, CMe3), 0.25 (s, 9H, SiMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 154.1 (C=O), 150.1 (Ar), 146.6 (Ar), 139.4 (ipso-Ar) 
137.0 (ipso-Ar), 135.7 (Ar), 101.3 (C≡C), 98.1 (C≡C), 79.7 (CMe3), 58.7 (NCH), 58.5 
(NCH), 47.0 (NCH2), 35.6 (CH2), 34.3 (CH2), 28.3 (CMe3), 28.0 (CMe3), 23.2 (CH2), –
 215 
0.3 (SiMe3); MS (ESI) m/z 345 [(M + H)
+, 100]; HRMS (ESI) m/z calcd for 
C19H28N2O2Si (M + H)
+ 345.1993, found 345.1995 (–0.7 ppm error). 
Lab Book Reference GB6/500:2 
 
(S)-3-Ethynyl-5-pyrrolidin-2-ylpyridine (S)-221 
 
N
H
N
(S)-221
 
 
TFA (466 mg, 304 µL, 4.09 mmol) was added dropwise to a stirred solution of pyridyl 
pyrrolidine (S)-220 (50 mg, 0.2 mmol) in CH2Cl2 (4 mL) at rt under Ar. The resulting 
solution was stirred at rt for 2 h. Then, the solvent and excess TFA were evaporated 
under reduced pressure. H2O (5 mL) was added to the residue and 5 M NaOH(aq) was 
added dropwise until pH 14. CsF (310 mg, 2.04 mmol) was added and the resulting 
solution was stirred at rt under air for 1 h. Then, 5 M HCl(aq) was added until pH 1 and the 
resulting solution was extracted with CH2Cl2 (3 × 6 mL). The aqueous layer was adjusted 
to pH 14 by addition of 5 M NaOH(aq) and extracted with Et2O (8 × 15 mL). The 
combined organic extracts were dried (Na2SO4) and evaporated under reduced pressure to 
give pyridyl pyrrolidine (S)-221 (26 mg, 76%) as a yellow oil, [α]D –100.8 (c 0.45 in 
CHCl3); IR (CHCl3) 3292 (NH), 2964, 2871, 1444, 1416, 892, 711 cm
-1; 1H NMR (400 
MHz, CDCl3) δ 8.67 (d, J = 2.0 Hz, 1H, Ar), 8.54 (d, J = 2.0 Hz, 1H, Ar), 7.82 (t, J = 2.0 
Hz, Ar), 4.16 (t, J = 7.5 Hz, 1H, NCH), 3.19 (s, 1H, C≡CH), 3.22-3.14 (m, 1H, NCH), 
3.09-3.02 (m, 1H, NCH), 2.27-2.17 (m, 1H, CH), 2.12 (br s, 1H, NH), 2.00-1.80 (m, 2H, 
CH), 1.70-1.60 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 151.0 (Ar), 148.1 (Ar), 
140.1 (ipso-Ar), 137.2 (Ar), 118.8 (ipso-Ar), 80.6 (≡CH), 80.2 (≡C), 59.4 (NCH), 46.9 
(NCH2), 34.4 (CH2), 25.5 (CH2); MS (ESI) m/z 173 [(M + H)
+, 100], 156 (13); HRMS 
(ESI) m/z calcd for C11H12N2 (M + H)
+ 173.1073, found 173.1077 (–1.9 ppm error). 
Lab Book Reference GB6/509:1 
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(S)-(+)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine, SIB1508Y (S)-98 
 
N
N
(S)-98
Me  
 
Using general procedure G, (S)-pyridyl pyrrolidine (S)-221 (26 mg, 0.15 mmol), 
paraformaldehyde (22 mg, 0.75 mmol) and formic acid (34 mg, 22 µL, 0.75 mmol) in 
H2O (3 mL) gave SIB1508Y (S)-98 (19 mg, 68%, 92:8 er by chiral shift NMR 
spectroscopy in the presence of 1-(9-anthryl)-2,2,2-trifluroethanol) as a colourless oil, 
[α]D –78.7 (c 0.7 in EtOH) (lit.,
159 [α]D –162.0 (c 0.8 in EtOH) for SIB1508Y derived 
from natural (S)-nicotine); 1H NMR (400 MHz, CDCl3) δ 8.69 (d, J = 2.0 Hz, 1H, Ar), 
8.49 (d, J = 2.0 Hz, 1H, Ar), 7.81 (t, J = 2.0 Hz, 1H, Ar), 3.24 (ddd, J = 9.5, 7.5, 2.0 Hz, 
1H, NCH), 3.20 (s, 1H, C≡CH), 3.10 (t, J = 8.0 Hz, 1H, NCH), 2.32 (q, J = 9.5 Hz, 1H, 
NCH), 2.27-2.18 (m, 1H, CH), 2.17 (s, 3H, NMe), 2.04-1.90 (m, 1H, CH), 1.89-1.76 (m, 
1H, CH), 1.75-1.63 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) δ 151.5 (Ar), 149.0 
(Ar), 138.5 (ipso-Ar), 138.0 (Ar), 119.1 (ipso-Ar), 80.5 (≡C), 80.3 (≡CH), 68.4 (NCH), 
56.9 (NCH2), 40.4 (NMe), 35.2 (CH2), 22.7 (CH2). Spectroscopic data consistent with 
those reported in the literature.159 
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.036 M solution of SIB1508Y was prepared by dissolving SIB1508Y (S)-98 (4 mg, 
0.021 mmol) in CDCl3 (0.6 mL). Then, (S)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (24 mg, 
0.087 mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 2.04 (NMe, 
major), 1.99 (NMe, minor). Integration of the major and minor NMe signals in the 1H 
NMR spectra indicated that SIB1508Y (S)-98 was present in 92:8 er. 
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.031 M solution of SIB1508Y was prepared by dissolving SIB1508Y (S)-98 (4 mg, 
0.021 mmol) in CDCl3 (0.7 mL). Then, (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (24 mg, 
0.087 mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 2.04 (NMe, 
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minor), 1.99 (NMe, major). Integration of the major and minor NMe signals in the 1H 
NMR spectra indicated that SIB1508Y (S)-98 was present in 92:8 er. 
Lab Book Reference GB6/512:1 (synthesis) and GB6/512:2 (chiral shift) 
 
Dodecahydro-4a,8a,12a-triazatriphenylene 229
163 
 
N N
N
229
 
 
Piperidine (5.0 g, 5.9 mL, 58.7 mmol) was added dropwise to a stirred solution of -
chlorosuccinimide (8.34 g, 62.5 mmol) in Et2O (60 mL) at rt under Ar. The resulting 
mixture was stirred at rt for 2 h and the solids were removed by filtration. The filtrate 
washed with water (2 × 35 mL), dried (Na2SO4) and evaporated under reduced pressure 
to give an oily residue. A solution of NaOMe in MeOH [freshly prepared from Na (1.53 
g, 66.7 mmol) and MeOH (35 mL)] was added to the oily residue at rt under Ar. The 
resulting solution was stirred and heated at reflux for 45 min. After cooling to rt, H2O 
was added until all the solids had dissolved. The layers were separated and the aqueous 
layer was extracted with Et2O (3 × 125 mL). The combined organic layers were 
evaporated under reduced pressure until a sticky residue remained. Et2O (100 mL) was 
added to the residue and the solution was dried (MgSO4) and evaporated under reduced 
pressure to give tricyclic product 229 (2.72 g, 56%) as a colourless oil, 1H NMR (400 
MHz, CDCl3) δ 3.08 (dt, J = 11.0, 5.0 Hz, 3H, NCH), 2.76 (br d, J = 5.5 Hz, 3H, NCH), 
2.04-1.91 (m, 3H, NCH), 1.76-1.58 (m, 9H, CH2), 1.57-1.46 (m, 6H, CH2), 1.31-1.18 (m, 
3H, CH2); 
13C NMR (100.6 MHz, CDCl3) δ 81.8 (NCHN), 46.0 (NCH2), 28.7 (CH2), 
25.3 (CH2), 21.8 (CH2). Spectroscopic data consistent with those reported in the 
literature.163 
Lab Book Reference GB3/234 
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1-(3,4-Dihydro-2H-pyridin-1-yl)ethanone 228 
 
N
Ac
228
 
 
A solution of dodecahydro-4a,8a,12a-triazatriphenylene 229 (2.72 g, 10.91 mmol) in 
acetic anhydride (48 mL) was stirred and heated at 50 °C under Ar for 16 h. After cooling 
to rt, EtOAc (55 mL) was added and the solution was washed with 1 M NaOH(aq) (3 × 30 
mL) and H2O (2 × 30 mL) and evaporated under reduced pressure. Saturated Na2CO3(aq) 
(40 mL) was added to the residue and the resulting aqueous solution was extracted with 
EtOAc (10 × 60 mL). The combined organic extracts were dried (MgSO4) and evaporated 
under reduced pressure to give enamide 228 (2.66 g, 65%) as a brown oil, 1H NMR (400 
MHz, CDCl3) (70:30 mixture of rotamers) δ 7.07 (dt, J = 8.5, 2.0 Hz, 0.3H, NCH=), 6.47 
(dt, J = 8.5, 2.0 Hz, 0.7H, NCH=), 4.96 (dt, J = 8.5, 4.0 Hz, 0.3H, NCH=CH), 4.86 (dt, J 
= 8.5, 4.0 Hz, 0.7H, NCH=CH), 3.58 (t, J = 6.0 Hz, 1.4H, NCH2), 3.48 (t, J = 6.0 Hz, 
0.6H, NCH2), 2.05 (s, 2.1H, Me), 2.04 (s, 0.9H, Me), 2.01-1.94 (m, 2H, CH2), 1.81-1.67 
(m, 2H, CH2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ  174.0 (C=O), 168.5 (C=O), 
125.8 (NCH=), 123.8 (NCH=), 108.7 (NCH=CH), 108.4 (NCH=CH), 44.0 (NCH2), 39.8 
(NCH2), 21.6 (CH2), 21.3 (Me), 21.2 (CH2), 21.0 (CH2), 20.9 (Me), 20.8 (CH2). 
Spectroscopic data consistent with those reported in the literature.233 
Lab Book Reference GB3/236 
 
1-(4-Bromo-3,4-dihydro-2H-pyridin-1-yl)ethanone 227 
 
N
Br
Ac
227
 
 
Br2 (356 mg, 115 µL, 2.23 mmol) was added dropwise to a stirred solution of enamide 
228 (250 mg, 2.00 mmol) in CH2Cl2 (8 mL) at –78 °C under Ar until an orange colour 
persisted. Then, i-Pr2NEt (283 mg, 381 µL, 2.19 mmol) was added and the resulting 
solution was allowed to warm to rt and stirred for 45 min. Saturated Na2S2O3(aq) (8 mL) 
was added and the two layers were separated. The aqueous layer was extracted with 
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CH2Cl2 (3 × 18 mL) and the combined organic layers were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. Purification  by flash 
column chromatography on silica with 7:3 petrol-EtOAc as eluent gave vinyl bromide 
227 (534 mg, 91%) as a colourless oil, RF (7:3 petrol-EtOAc) 0.3; IR (film) 2931, 1640 
(C=O), 1392, 1349, 1296, 1257, 986, 730 cm–1; 1H NMR (400 MHz, CDCl3) (70:30 
mixture of rotamers) δ 7.55 (t, J = 1.5 Hz, 0.3H, CH=), 6.91 (t, J = 1.5 Hz, 0.7H, CH=), 
3.69-3.63 (m, 1.4H, NCH2), 3.58-3.53 (m, 0.6H, NCH2), 2.51-2.42 (m, 2H, CH), 2.15 (s, 
2.1H, Me), 2.13 (s, 0.9H, Me), 2.03-1.06 (m, 2H, CH); 13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 168.4 (C=O), 167.8 (C=O), 126.7 (CH=), 124.9 (CH=), 108.2 (CBr), 42.8 
(NCH2), 38.5 (NCH2), 31.2 (CH2), 31.0 (CH2), 21.6 (Me), 21.3 (Me); MS (ESI) m/z 204 
[(M + H)+, 11], 148 (33), 126 (100); HRMS (ESI) m/z calcd for C7H10NO
79Br (M + H)+ 
204.0019, found 204.0019 (–0.4 ppm error). 
Lab Book Reference GB9/830 
 
(R)-2-(1-Acetyl-1,4,5,6-tetrahydropyridin-3-yl)pyrrolidine-1-carboxylic acid tert-
butyl ester (R)-226 
(Table 4.1, Entry 5) 
 
N
N
O
Boc
(R)-226
 
 
Using general procedure E, -Boc pyrrolidine 38 (395 mg, 405 µL, 2.31 mmol), s-BuLi 
(2.30 mL of a 1.3 M solution in hexanes, 3.00 mmol) and (–)-sparteine 3 (703 mg, 690 
µL, 3.00 mmol) in TBME (8 mL) and then ZnCl2 (1.39 mL of a 1.0 M solution in Et2O, 
1.39 mmol), Pd2dba3 (52 mg, 0.06 mmol, 2.5 mol%), t-Bu3PHBF4 (26 mg, 0.14 mmol, 
6.25 mol%) and vinyl bromide 227 (330 mg, 1.62 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 8:2 EtOAc-petrol as eluent 
gave -Boc maackiamine (R)-226 (266 mg, 56%, 95:5 er by CSP-HPLC) as a colourless 
oil, RF (8:2 EtOAc-petrol) 0.3; [α]D +40.9 (c 1.0 in CHCl3); IR(film) 2972, 2930, 1692 
(C=O), 1649 (C=O), 1394, 1366, 1331, 1258, 1165, 1113, 754 cm-1; 1H NMR (400 MHz, 
CDCl3) (70:30 mixture of rotamers) δ 7.13-7.02 (m, 0.3H, AcNCH), 6.39 (s, 0.7H, 
AcNCH), 4.32-4.05 (m, 1H, NCH), 3.69-3.44 (m, 4H, NCH), 2.12 (s, 3H, Me), 1.99-1.93 
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(m, 4H, CH2), 1.90-1.68 (m, 4H, CH2), 1.41 (br s, 9H, CMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 168.8 (C=O), 167.3 (C=O), 154.3 (br, NCH=C), 121.0 (NCH=C), 
79.0 (CMe3), 61.0 (NCH), 46.8 (NCH2), 44.1 (NCH2), 40.1 (NCH2), 31.7 (CH2), 30.7 
(CH2), 28.3 (CMe3), 23.4 (CH2), 21.9 (NCOMe), 21.7 (CH2), 21.3 (NCOMe), 21.1 (CH2); 
MS (ESI) m/z 317 [(M + Na)+, 100], 295 [(M + H)+, 60], 239 (18); HRMS (ESI) m/z 
calcd for C16H26N2O3 (M + Na)
+ 328.1519, found 328.1521 (–0.1 ppm error); CSP-
HPLC: Chiralpak AD (90:10 hexane-i-PrOH, 1.0 mLmin-1) (R)-226 7.60 min, (S)-226 
9.80 min.  
Lab Book Reference GB4/307 
 
(Table 4.1, Entry 1) 
Using general procedure E, -Boc pyrrolidine 38 (219 mg, 225 µL, 1.28 mmol), s-BuLi 
(1.01 mL of a 1.3 M solution in hexanes, 1.28 mmol) and (–)-sparteine 3 (300 mg, 295 
µL, 1.28 mmol) in Et2O (8 mL) and then ZnCl2 (0.77 mL of a 1.0 M solution in Et2O, 
0.77 mmol), Pd(OAc)2 (14 mg, 0.06 mmol, 5 mol%), t-Bu3PHBF4 (14 mg, 0.08 mmol, 
6.25 mol%) and vinyl bromide 227 (222 mg, 1.09 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 8:2 EtOAc-petrol as eluent 
gave -Boc maackiamine (R)-226 (108 mg, 29%, 94:6 er by CSP-HPLC) as a colourless 
oil.  
Lab Book Reference GB3/242 
 
(Table 4.1, Entry 2) 
Using general procedure E, -Boc pyrrolidine 38 (190 mg, 195 µL, 1.11 mmol), s-BuLi 
(1.11 mL of a 1.3 M solution in hexanes, 1.44 mmol) and (–)-sparteine 3 (337 mg, 330 
µL, 1.44 mmol) in TBME (8 mL) and then ZnCl2 (0.64 mL of a 1.0 M solution in Et2O, 
0.64 mmol), Pd(OAc)2 (12 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (12 mg, 0.07 mmol, 
6.26 mol%) and vinyl bromide 227 (158 mg, 0.74 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 8:2 EtOAc-petrol as eluent 
gave -Boc maackiamine (R)-226 (80 mg, 37%, 80:20 er by CSP-HPLC) as a colourless 
oil.  
Lab Book Reference GB4/292 
 
(Table 4.1, Entry 3) 
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s-BuLi (1.11 mL of a 1.3 M solution in hexanes, 1.44 mmol) was added dropwise to a 
stirred solution of -Boc pyrrolidine 38 (190 mg, 195 µL, 1.11 mmol) and (–)-sparteine 3 
(337 mg, 330 µL, 1.44 mmol) in TBME (8 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 1 h. Then, ZnCl2 (0.64 mL of a 1.0 M solution in Et2O, 
0.64 mmol) was added and the resulting solution was stirred at –78 °C for 30 min. The 
solution was allowed to warm to rt and stirred at rt for 30 min. Then, vinyl bromide 227 
(158 mg, 0.74 mmol) in TBME (1 mL) was added. A mixture of Pd(OAc)2 (12 mg, 0.05 
mmol, 5 mol%) and t-Bu3PHBF4 (12 mg, 0.07 mmol, 6.25 mol%) was added in one 
portion. The reaction flask was transferred to a pre-heated oil bath and the resulting 
mixture was stirred and heated at reflux for 16 h. After cooling to rt, 35% NH4OH(aq) (0.3 
mL) was added and the resulting mixture was stirred at rt for 1 h. The solids were 
removed by filtration through a pad of Celite®, and washed with Et2O (20 mL). The 
filtrate was washed with 10% NH4Cl(aq) (2 × 25 mL), dried (MgSO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 8:2 EtOAc-petrol as eluent gave -Boc maackiamine (R)-
226 (94 mg, 43%, 93:7 er by CSP-HPLC) as a colourless oil.  
Lab book Reference GB4/293 
 
(Table 4.1, Entry 4) 
Using general procedure E, -Boc pyrrolidine 38 (508 mg, 520 µL, 2.97 mmol), s-BuLi 
(2.98 mL of a 1.3 M solution in hexanes, 3.87 mmol) and (–)-sparteine 3 (907 mg, 890 
µL, 3.87 mmol) in TBME (8 mL) and then ZnCl2 (1.78 mL of a 1.0 M solution in Et2O, 
1.78 mmol), Pd2dba3 (68 mg, 0.07 mmol, 2.5 mol%), t-Bu3PHBF4 (33 mg, 0.17 mmol, 
6.25 mol%) and vinyl bromide 227 (425 mg, 2.08 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 8:2 EtOAc-petrol as eluent 
gave -Boc maackiamine (R)-226 (248 mg, 40%, 92:8 er by CSP-HPLC) as a colourless 
oil. 
Lab book Reference GB4/304 
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1-(5-Pyrrolidin-2-yl-3,4-dihydro-2H-pyridin-1-yl)ethanone, rac-Maackiamine rac-99  
 
N
H
N
Ac
rac-99
 
 
Using general procedure F, (R)--Boc maackiamine (R)-226 (77 mg, 0.26 mmol, 95:5 er) 
and TFA (149 mg, 97 µL, 1.31 mmol) in CH2Cl2 (5 mL) for 4 h gave rac-maackiamine 
rac-99 (448 mg, 96%,  50:50 er by chiral shift NMR spectroscopy in the presence of 1-
(9-anthryl)-2,2,2-trifluroethanol) as a brown oil, RF (7:7:2 EtOAc-hexane-Et2NH) 0.3; 
1H 
NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 7.21 (s, 0.3H, AcNCH=), 6.62 (s, 
0.7H, AcNCH=), 3.71-3.45 (m, 3H, NCH), 3.09-3.02 (m, 1H, NCH), 2.97-2.87 (m, 1H, 
NCH), 2.17-2.01 (m, 3H, CH + NH), 2.16 (s, 2.1H, Me), 2.15 (s, 0.9H, Me), 1.94-1.71 
(m, 5H, CH), 1.63-1.47 (m, 1H, CH); 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 168.6 
(C=O), 168.2 (C=O), 122.1 (NCH=C), 121.7 (NCH=C), 121.5 (NCH=C), 119.9 
(NCH=C), 62.4 (NCH), 62.3 (NCH), 46.4 (NCH2), 46.3 (NCH2), 44.2 (NCH2), 40.1 
(NCH2), 30.1 (CH2), 29.5 (CH2), 25.0 (CH2), 24.9 (CH2), 22.1 (CH2), 21.8 (CH2), 21.7 
(Me), 21.5 (CH2), 21.2 (Me), 21.0 (CH2). Spectroscopic data consistent with those 
reported in the literature.138  
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (R)- or (S)-2,2,2-trifluoro-1-(9-anthryl)-
ethanol: a 0.043 M solution of rac-maackiamine was prepared by dissolving 
maackiamine rac-XX (5 mg, 0.026 mmol) in CDCl3 (0.6 mL). Then, (S)-2,2,2-trifluoro-
1-(9-anthryl) ethanol (28 mg, 0.10 mmol) was added. Diagnostic signals: 1H NMR (400 
MHz, CDCl3) δ 6.23 (AcNCH=), 6.12 (AcNCH=). In a similar fashion, a 0.043 M 
solution of rac-maackiamine was prepared by dissolving maackiamine rac-99 (5 mg, 
0.026 mmol) in CDCl3 (0.6 mL). Then, (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (28 mg, 
0.10 mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 6.22 
(AcNCH=), 6.12 (AcNCH=). Integration of the major and minor AcNCH signals of each 
rotamer in each of the 1H NMR spectra indicated that the sample of maackiamine 99 was 
racemic. 
Lab Book Reference: GB3/239:1 (synthesis), GB4/294 (chiral shift) 
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BF3.OEt2 (85 mg, 74 µL, 0.6 mmol) was added dropwise to a stirred solution of (R)--
Boc maackiamine (R)-226 (60 mg, 0.2 mmol, 80:20 er) in CH2Cl2 (2 mL) at rt under Ar. 
The resulting solution was stirred at rt for 1.3 h and 0.5 M NaOH(aq) (2.4 mL) was added. 
The layers were separated and the aqueous was extracted with CH2Cl2 (5 × 5 mL). The 
combined organic layers were dried (Na2SO4) and evaporated under reduced pressure to 
give rac-maackiamine rac-99 (23 mg, 53%, 50:50 er by chiral shift NMR spectroscopy in 
the presence of 2,2,2-trifluoro-1-(9-anthryl)-ethanol) as a brown oil. 
Lab Book Reference GB4/294 
 
1-((R)-5-Pyrrolidin-2-yl-3,4-dihydro-2H-pyridin-1-yl)ethanone, Maackiamine (R)-99 
 
N
H
N
Ac
(R)-99
 
 
t-BuMe2SiOTf (197 mg, 170 µL, 0.8 mmol) was added dropwise to a stirred solution of 
-Boc maackiamine (R)-226 (200 mg, 0.68 mmol, 95:5 er) and pyridine (79 mg, 80 µL, 
1.0 mmol) in CH2Cl2 (10 mL) at rt under Ar. The resulting solution was stirred at rt for 
16 h and then the solvent was evaporated under reduced pressure. The residue was dried 
thoroughly under high vacuum. The residue was dissolved in saturated NH4Cl(aq) (10 mL) 
and the aqueous solution was extracted with Et2O (5 × 30 mL). The combined organic 
extracts were dried (Na2SO4) and evaporated under reduced pressure. THF (7.5 mL) was 
added to the residue and the resulting solution was added dropwise to a stirred suspension 
of CsF (152 mg, 1.0 mmol) in THF (7.5 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 16 h and the solvent was evaporated under reduced pressure. 1 M 
NaOH(aq) (15 mL) was added to the residue and the resulting aqueous solution was 
extracted with Et2O (5 × 40 mL). The combined organic extracts were dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product. Purification by 
preparative TLC on silica with 7:7:2 EtOAc-hexane-Et2NH as eluent gave (R)-
maackiamine (R)-99 (71 mg, 54%, 95:5 er by chiral shift NMR spectroscopy in the 
presence of (R)-1-(9-anthryl)-2,2,2-trifluroethanol)) as a colourless oil, RF (7:7:2 EtOAc-
hexane-Et2NH) 0.3; [α]D +12.8 (c 1.0 in EtOH) (lit.,
138 [α]D +110 (c 0.01 in EtOH) for 
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natural maackiamine). Spectroscopic data consistent with those reported in the 
literature.138  
 
Enantiomer ratio was determined by high resolution 1H NMR spectroscopy (400 MHz, 
CDCl3) in the presence of 4.0 equivalents of (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol: a 
0.043 M solution of maackiamine was prepared by dissolving maackiamine (5 mg, 0.026 
mmol) in CDCl3 (0.6 mL). Then, (R)-2,2,2-trifluoro-1-(9-anthryl)-ethanol (28 mg, 0.10 
mmol) was added. Diagnostic signals: 1H NMR (400 MHz, CDCl3) δ 6.28 (AcNCH=, 
major), 6.19 (AcNCH=, minor). Integration of the major and minor AcNCH singals of 
each rotamer in the 1H NMR spectra indicated that maackiamine (R)-99 was present in 
95:5 er. 
Lab Book Reference: GB4/316 
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7.6 Experimental for Chapter 5 
2,5-Dihydropyrrole-1-carboxylic acid tert-butyl ester 261  
 
261
N
Boc  
 
Di-t-butyl dicarbonate (3.42 g, 15.67 mmol) was added portionwise to a stirred 
solution of 3-pyrroline (1.0 g, 1.1 mL, 14.47 mmol) in CH2Cl2 (30 mL) at 0 °C under 
Ar. The resulting colourless solution was allowed to warm to rt and stirred for 16 h. 
Then, the solvent was evaporated under reduced pressure to give the crude product. 
Purification by Kügelrohr short path distillation gave -Boc-3-pyrroline 261 (2.45 g, 
100%) as a colourless oil, bp 65-75 °C/1.5 mmHg; 1H NMR (400 MHz, CDCl3) δ 
5.81-5.69 (m, 2H, HC=CH), 4.18-4.03 (m, 4H, NCH2), 1.46 (s, 9H, CMe3). 
Spectroscopic data consistent with those reported in the literature.234  
Lab Book Reference GB6/560 
 
[1,4]-Diazepane-1-carboxylic acid tert-butyl ester   
 
NH
N
Boc  
 
Di-t-butyl dicarbonate (16.4 g, 78.15 mmol) was added portionwise to a stirred 
solution of homopiperazine (15.0 g, 149.88 mmol) in CH2Cl2 (300 mL) at 0 °C. The 
resulting colourless solution was stirred at rt for 16 h. Then, the solvent was 
evaporated under reduced pressure and H2O (300 mL) and CH2Cl2 (300 mL) were 
added. The two layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 300 mL). The combined organic layers were dried (Na2SO4) and 
evaporated under reduced pressure to give -Boc homopiperazine (8.12 g, 52%) as a 
colourless oil, 1H NMR (400 MHz, CDCl3) δ 3.48-3.28 (m, 4H, NCH2), 2.91-2.70 (m, 
4H, NCH2), 1.82-1.63 (m, 2H, CH2), 1.53 (br s, 1H, NH), 1.39 (s, 9H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 155.5 (C=O), 155.3 (C=O), 79.0 (CMe3), 
78.9 (CMe3), 50.0 (NCH2), 49.6 (NCH2), 49.5 (NCH2), 49.4 (NCH2), 48.3 (NCH2), 
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48.0 (NCH2), 45.9 (NCH2), 45.2 (NCH2), 30.5 (CH2), 30.4 (CH2), 28.3 (CMe3). 
Spectroscopic data consistent with those reported in the literature.235 
Lab Book Reference GB7/651 
 
4-Benzyl-[1,4]diazepane-1-carboxylic acid tert-butyl ester 272  
 
N
N
Boc
Bn
272
 
 
-Boc homopiperazine (1.0 g, 4.99 mmol) and K2CO3 (1.38 g, 9.98 mmol) were 
added portionwise to a stirred solution of benzyl chloride (6.32 g, 5.74 mL, 4.99  
mmol) in EtOH (15 mL) at rt. The resulting white suspension was stirred and heated 
at reflux for 16 h. After cooling to rt, the solvent was evaporated under reduced 
pressue and the residue was partitioned between H2O (10 mL) and CH2Cl2 (10 mL). 
The two layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 
10 mL). The combined organic layers were dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave -Boc-ʹ-benzyl 
homopiperazine 272 (1.05 g, 72%) as a colourless oil, RF (9:1 petrol-Et2O) 0.1; bp 
212-214 °C/3.0 mmHg; IR (film) 2975, 2935, 2814, 1692 (C=O), 1478, 1455, 1413, 
1365, 1247, 1174, 1121, 732 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.28 (m, 4H, 
Ph), 7.28-7.17 (m, 1H, p-Ph), 3.62 (s, 2H, PhCH2), 3.55-3.40 (m, 4H, NCH2), 2.71-
2.56 (m, 4H, NCH2), 1.91-1.73 (m, 2H, CH2), 1.50-1.46 (m, 9H, CMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 155.6 (C=O), 155.5 (C=O), 139.2 (ipso-Ph), 128.7 
(Ph), 128.6 (Ph), 128.1 (Ph), 126.9 (Ph), 126.8 (Ph), 79.1 (CMe3), 79.1 (CMe3), 62.2 
(PhCH2), 56.1 (NCH2), 55.7 (NCH2), 54.8 (NCH2), 54.6 (NCH2), 46.7 (NCH2), 46.2 
(NCH2), 46.0 (NCH2), 45.2 (NCH2), 28.4 (CMe3), 28.3 (CMe3), 27.9 (CH2), 27.8 
(CH2); MS (ESI) m/z 291 [(M + H)
+, 100], 235 (22); HRMS (ESI) m/z calcd for 
C17H27N2O2 (M + H)
+ 291.2067, found 291.2075 (–2.9 ppm error). 
Lab Book reference GB6/518 
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2-(Hydroxyphenylmethyl)pyrrolidine-1-carboxylic acid tert-butyl ester syn-182 
and anti-182 
 
N
Boc
PhH
OH
N
Boc
PhH
OH
syn-182 ant i-182  
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) and (–)-sparteine (305 mg, 299 µL, 1.3 mmol, 1.3 eq.) in THF (7 mL) at –78 
°C under Ar. The resulting solution was stirred at –78 °C for 3 h. Then, benzaldehyde 
(212 mg, 203 µL, 2.0 mmol, 2.0 eq.) was added and the resulting solution was stirred 
at –78 °C for 10 min and allowed to warm to rt. Saturated NH4Cl(aq) (10 mL) was 
added and the two layers separated. The aqueous layer was extracted with Et2O (3 × 
10 mL) and the combined organic layers were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-
182 (171 mg, 62%, 50:50 er by CSP-HPLC) as a colourless oil and pyrrolidine anti-
182 (96 mg, 35%, 50:50 er by CSP-HPLC) as a colourless oil. The total yield of syn-
182 and anti-182 is 97%. 
Lab Book Reference GB8/676 
 
Table 5.1, Entry 1: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in Et2O (7 
mL) at –78 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (16 mg, 6%) as a colourless oil 
and pyrrolidine anti-182 (6 mg, 2%) as a colourless oil. The total yield of syn-182 and 
anti-182 is 8%.  
Lab Book Reference: GB5/413 
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Table 5.1, Entry 2: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –78 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (151 mg, 57%) as a colourless oil, 
and pyrrolidine anti-182 (85 mg, 32%) as a colourless oil. The total yield of syn-182 
and anti-182 is 89%. 
Lab Book Reference GB5/381 
 
Table 5.1, Entry 3: 
Using general procedure XX, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 
mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in 2-
methyl THF (7 mL) at –78 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 
2.0 eq.) gave the crude product. Purification by flash column chromatography on 
silica with 98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (145 mg, 55%) as 
a colourless oil, and pyrrolidine anti-182 (98 mg, 37%) as a colourless oil. The total 
yield of syn-182 and anti-182 is 92%. 
Lab Book Reference GB5/417 
 
Table 5.1, Entry 4: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in Et2O (7 
mL) at –40 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (48 mg, 18%) as a colourless oil, 
and pyrrolidine anti-182 (22 mg, 8%) as a colourless oil. The total yield of syn-182 
and anti-182 is 26%. 
Lab Book Reference GB5/415 
 
Table 5.1, Entry 5: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –40 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave the 
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crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (118 mg, 43%) as a colourless oil, 
and pyrrolidine anti-182 (58 mg, 21%) as a colourless oil. The total yield of syn-182 
and anti-182 is 64%. 
Lab Book Reference GB5/447 
 
Table 5.1, Entry 6: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in 2-methyl 
THF (7 mL) at –40 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) 
gave the crude product. Purification by flash column chromatography on silica with 
98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (150 mg, 57%) as a 
colourless oil, and pyrrolidine anti-182 (98 mg, 37%) as a colourless oil. The total 
yield of syn-182 and anti-182 is 94%. 
Lab Book Reference GB5/418 
. 
 
Table 5.1, Entry 7: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in Et2O (7 
mL) at –30 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/433 
 
Table 5.1, Entry 8: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –30 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave the 
crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (66 mg, 25%) as a colourless oil, 
and pyrrolidine anti-182 (33 mg, 12%) as a colourless oil. The total yield of syn-182 
and anti-182 is 37%. 
Lab Book Reference GB5/432 
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Table 5.1, Entry 9: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in 2-methyl 
THF (7 mL) at –30 °C for 1 h and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) 
gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/437 
 
Table 5.1, Entry 10: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –30 °C for 10 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) 
gave the crude product. Purification by flash column chromatography on silica with 
98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (162 mg, 58%) as a 
colourless oil, and pyrrolidine anti-182 (86 mg, 31%) as a colourless oil. The total 
yield of syn-182 and anti-182 is 89%. 
Lab Book Reference GB5/441 
 
Table 5.1, Entry 11: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –30 °C for 5 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
the crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (155 mg, 56%) as a colourless oil, 
and pyrrolidine anti-182 (77 mg, 28%) as a colourless oil. The total yield of syn-182 
and anti-182 is 84%. 
Lab Book Reference GB5/440 
 
Table 5.1, Entry 12: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in 2-methyl 
THF (7 mL) at –30 °C for 5 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 
eq.) gave the crude product. Purification by flash column chromatography on silica 
with 98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (126 mg, 49%) as a 
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colourless oil, and pyrrolidine anti-182 (67 mg, 24%) as a colourless oil. The total 
yield of syn-182 and anti-182 is 73%. 
Lab Book Reference GB8/691 
 
Table 5.1, Entry 13: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –20 °C for 30 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) 
gave the crude product. Purification by flash column chromatography on silica with 
98:2 CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (18 mg, 7%) as a colourless 
oil, and pyrrolidine anti-182 (7 mg, 3%) as a colourless oil. The total yield of syn-182 
and anti-182 is 10%. 
Lab Book Reference GB5/375 
 
Table 5.1, Entry 14: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –20 °C for 5 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
the crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (122 mg, 44%) as a colourless oil, 
and pyrrolidine anti-182 (61 mg, 22%) as a colourless oil. The total yield of syn-182 
and anti-182 is 66%. 
Lab Book Reference GB5/452 
 
Table 5.1, Entry 15: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –20 °C for 2 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
the crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (104 mg, 37%) as a colourless oil, 
and pyrrolidine anti-182 (56 mg, 20%) as a colourless oil. The total yield of syn-182 
and anti-182 is 57%. 
Lab Book Reference GB5/450 
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Table 5.1, Entry 16: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –10 °C for 5 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
the crude product. Purification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave pyrrolidine syn-182 (54 mg, 19%) as a colourless oil, 
and pyrrolidine anti-182 (28 mg, 10%) as a colourless oil. The total yield of syn-182 
and anti-182 is 29%. 
Lab Book Reference GB5/453 
 
Table 5.1, Entry 17: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at –10 °C for 1 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/451 
 
Table 5.1, Entry 18: 
Using general procedure H, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at 0 °C for 30 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/368 
 
Methyl-1-phenylbutan-1-ol 249  
 
OH
249
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.0 eq.) was added 
dropwise to Et2O (7 mL) at –78 °C under Ar and the resulting solution was stirred at –
78 °C for 1 h. Then, benzaldehyde (138 mg, 132 µL, 1.3 mmol, 1.0 eq.) was added 
and the resulting solution was stirred at –78 °C for 30 min. The solution was allowed 
 233 
to warm to rt and saturated NH4Cl(aq) (10 mL) was added. The two layers were 
separated and the aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 9:1 petrol-
EtOAc as eluent gave a 50:50 mixture of diastereomeric alcohols 249 (140 mg, 66%) 
as a colourless oil, RF (9:1 petrol-EtOAc) 0.2; 
1H NMR (400 MHz, CDCl3) δ 7.36-
7.16 (m, 5H, Ph), 4.46 (d, J = 6.0 Hz, 0.5H, CHO), 4.37 (d, J = 6.0 Hz, 0.5H, CHO), 
2.07 (br s, 1H, OH), 1.82-1.59 (m, 1.5H), 1.45-1.27 (m, 1H), 1.26-0.96 (m, 1H), 0.94-
0.79 (m, 4H), 0.77-0.58 (m, 1.5H); 13C NMR (100.6 MHz, CDCl3) δ 143.8 (ipso-Ph), 
143.5 (ipso-Ph), 128.1 (Ph), 127.3 (Ph), 127.1 (Ph), 126.6 (Ph), 126.3 (Ph), 78.7 
(CHO), 78.0 (CHO), 41.8 (CH), 41.5 (CH), 25.8 (CH2), 24.8 (CH2), 15.0 (Me), 13.9 
(Me), 11.6 (Me), 11.3 (Me). Spectroscopic data consistent with those reported in the 
literature.236 
Lab Book Reference GB5/424 
 
4-Methyl-1-phenylhexan-1-ol 250 
 
OH
250
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.0 eq.) was added 
dropwise to THF (7 mL) at 0 °C under Ar and the resulting solution was stirred at 0 
°C for 30 min. Then, benzaldehyde (138 mg, 132 µL, 1.3 mmol, 1.0 eq.) was added 
and the resulting solution was stirred at 0 °C for 30 min. The solution was allowed to 
warm to rt and saturated NH4Cl(aq) (10 mL) was added. The two layers were separated 
and the aqueous layer was extracted with Et2O (3 × 10 mL). The combined organic 
layers were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-
EtOAc as eluent gave a 50:50 mixture of diastereomeric alcohols 250 (72 mg, 29%, 
58% based on s-BuLi) as a yellow oil, RF (9:1 petrol-EtOAc) 0.5; IR (film) 3379 
(OH), 2959, 2932, 2873, 1454, 908, 734, 700 cm–1; 1H NMR (400 MHz, CDCl3) δ 
7.29-7.25 (m, 4H, Ph), 7.17-7.23 (m, 1H, Ph), 4.59-4.52 (m, 1H, CHO), 1.88 (br s, 
1H, OH), 1.79-1.54 (m, 2H), 1.52-1.32 (m, 0.5H), 1.32-1.16 (m, 3H), 1.11-0.93 (m, 
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1.5H), 0.81-0.73 (m, 6H); 13C NMR (100.6 MHz, CDCl3) δ 144.9 (ipso-Ph), 144.8 
(ipso-Ph), 128.4 (Ph), 127.4 (Ph), 127.4 (Ph), 125.9 (Ph), 125.8 (Ph), 75.1 (CHO), 
75.0 (CHO), 36.6 (CH2), 36.5 (CH2), 34.3 (CH), 34.3 (CH), 32.5 (CH2), 32.5 (CH2), 
29.3 (CH2), 29.3 (CH2), 19.1 (Me), 19.0 (Me), 11.3 (Me), 11.3 (Me); MS (ESI) m/z 
192 [M+, 17], 174 [(M – H2O)
+, 31], 117 (21), 107 (100), 79 (24); HRMS (ESI) m/z 
calcd for C13H20O M
+ 192.1514, found 192.1512 (–1.0 ppm error). 
Lab Book Reference GB5/427 
 
Attempted Lithiation-trapping of -Boc pyrrolidine 38 with n-BuLi and LDA 
 
Table 5.2, Entry 1: 
Using general procedure I, n-BuLi (520 µL of a 2.5 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at 0 °C for 60 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/410 
 
Table 5.2, Entry 2: 
Using general procedure I, n-BuLi (520 µL of a 2.5 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 eq.) in THF (7 
mL) at rt for 60 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 2.0 eq.) gave 
none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB5/411 
 
Table 5.2, Entry 3: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –78 °C for 60 min and benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the 
crude product. 
Lab Book Reference GB6/494 
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Table 5.2, Entry 4: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –40 °C for 30 min and benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the 
crude product. 
Lab Book Reference GB6/495 
 
Table 5.2, Entry 5: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –20 °C for 30 min and benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the 
crude product. 
Lab Book Reference GB6/498 
 
Table 5.2, Entry 6: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at 0 °C for 60 min and benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the 
crude product. 
Lab Book Reference GB6/492 
 
Table 5.2, Entry 7: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at 0 °C for 180 min and benzaldehyde (212 mg, 203 µL, 2.0 
mmol, 2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the 
crude product. 
Lab Book Reference GB6/493 
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Table 5.2, Entry 8: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at rt for 30 min and benzaldehyde (212 mg, 203 µL, 2.0 mmol, 
2.0 eq.) gave none of syn-182 and anti-182 by 1H NMR spectroscopy of the crude 
product. 
Lab Book Reference GB6/497 
 
Table 5.2, Entry 9: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at 0 °C for 30 min and benzyl bromide (342 mg, 238 µL, 2.0 
mmol, 2.0 eq.) gave no trapped product by 1H NMR spectroscopy of the crude 
product. 
Lab Book Reference GB6/502 
 
Table 5.2, Entry 10: 
Using general procedure I, LDA (650 µL of a 2.0 M solution in THF/n-heptane/ethyl 
benzene, 1.3 mmol, 1.3 eq.) and -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at rt for 30 min and benzyl bromide (342 mg, 238 µL, 2.0 
mmol, 2.0 eq.) gave no trapped product by 1H NMR spectroscopy of the crude 
product. 
Lab Book Reference GB6/501 
 
-Boc-2-methylpyrrolidine 251     
 
N Me
Boc
251
 
 
Using general procedure K, -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 
eq.), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and Me2SO4 
(252 mg, 189 µL, 2.0 mmol, 2.0 eq.) in THF (7 mL) gave the crude product. 
Purification by flash column chromatography on silica with 24:1 petrol-EtOAc as 
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eluent gave methyl pyrrolidine 251 (129 mg, 70%) as a colourless oil, RF (24:1 petrol-
EtOAc) 0.4; 1H NMR (400 MHz, CDCl3) δ 3.82 (br s, 1H, NCH), 3.32 (br s, 2H, 
NCH2), 2.02-1.89 (m, 1H, CH2), 1.89-1.80 (m, 1H, CH2), 1.80-1.68 (m, 1H, CH2), 
1.61-1.47 (m, 1H, CH2), 1.43 (s, 9H, CMe3), 1.12 (d, J = 5.5 Hz, 3H, Me); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 154.5 (C=O), 79.8 (CMe3), 78.7 (CMe3), 54.2 
(NCH), 53.9 (NCH), 52.8 (Me), 46.1 (NCH2), 33.1 (CH2), 32.4 (CH2), 28.4 (CMe3), 
23.4 (CH2), 22.9 (CH2). Spectroscopic data consistent with those reported in the 
literature.119 
Lab Book Reference GB6/476 
 
2-Allylpyrrolidine-1-carboxylic acid tert-butyl ester 252  
 
N
Boc
252
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –30 °C under Ar. The resulting solution was stirred at –30 
°C for 5 min. Then, a solution of LiCl (42 mg, 1.0 mmol) and CuCN (45 mg, 0.5 
mmol) in THF (1 mL) was added dropwise and the resulting solution was stirred at –
30 °C for 30 min. Allyl bromide (218 mg, 156 µL, 1.8 mmol) was added dropwise 
and the resulting solution was stirred at rt for 16 h. Then, 35% NH4OH(aq) (0.5 mL), 
saturated NH4Cl(aq) (4 mL) and Et2O (5 mL) were added and the resulting biphasic 
mixture was stirred at rt for 10 min. The solids were removed by filtration through 
Celite® and washed with Et2O (2 × 5 mL). The two layers of the filtrate were 
separated and the aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 9:1 petrol-
EtOAc as eluent gave allyl pyrrolidine 252 (137 mg, 65%) as a colourless oil, RF (9:1 
petrol-EtOAc) 0.4; 1H NMR δ 5.82-5.64 (m, 1H, CH=CH2), 5.13-4.93 (m, 2H, 
CH=CH2), 3.79 (br s, 1H, NCH), 3.52-3.18 (m, 2H, NCH2), 2.69-2.34 (m, 1H, 
CH2CH=CH2), 2.20-2.03 (m, 1H, CH2CH=CH2), 1.97-1.65 (m, 4H, CH2), 1.46 (s, 9H, 
CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.4 (C=O), 135.1 (CH=CH2), 
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116.9 (CH=CH2), 79.0 (CMe3), 78.8 (CMe3), 56.7 (NCH), 46.6 (NCH2), 46.2 (NCH2), 
38.9 (CH2), 38.1 (CH2), 29.9 (CH2), 29.1 (CH2), 28.4 (CMe3), 28.3 (CMe3), 23.5 
(CH2), 22.8 (CH2). Spectroscopic data consistent with those reported in the 
literature.237 
Lab Book Reference GB6/463 
 
-Boc Proline 253       
 
N
Boc
OH
O
253
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –30 °C under Ar. The resulting solution was stirred at –30 
°C for 5 min. The solution was then stirred at –30 °C under a CO2 atmosphere for 10 
min and then allowed to warm to rt. Saturated NH4Cl(aq) (10 mL) was added and the 
two layers were separated. The aqueous layer was extracted with Et2O (3 × 10 mL) 
and the combined organic layers were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1 CH2Cl2-MeOH as eluent gave -Boc proline 253 (106 mg, 49%) as a 
colourless oil, RF (9:1 CH2Cl2-MeOH) 0.3; 
1H NMR (400 MHz, CDCl3) (50:50 
mixture of rotamers) δ 4.33 (br s, 0.5H, NCH), 4.24 (br s, 0.5H, NCH), 3.62-3.14 (m, 
2H, NCH2), 2.38-2.17 (m, 1H, CH2), 2.13-1.68 (m, 3H, CH2), 1.47 (s, 4.5 H, CMe3), 
1.42 (s, 4.5 H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 155.9 (C=O, Boc), 
153.9 (C=O, CO2H), 80.9 (CMe3), 80.1 (CMe3), 59.4 (NCH), 46.9 (NCH2), 46.3 
(NCH2), 30.8 (CH2), 28.9 (CH2), 28.4 (CMe3), 28.2 (CMe3), 24.3 (CH2), 23.6 (CH2). 
Spectroscopic data consistent with those reported in the literature.52 
Lab Book Reference GB6/466 
 
 
 
Methyl (±)--(tert-butoxycarbonyl)pyrrolidine-2-carboxylate 254 and 
pyrrolidine-1,2,2-tricarboxylic acid 1-tert-butyl ester 2,2-dimethyl ester 257  
 239 
 
N
Boc O
OMe
N
Boc
CO2Me
CO2Me
254 257
 
 
Using general procedure K, -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 
eq.), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and methyl 
chloroformate (188 mg, 154 µL, 2.0 mmol, 2.0 eq.) in THF (7 mL) gave the crude 
product. Purification by flash column chromatography on silica with 9:1 petrol-
EtOAc as eluent gave methyl ester 254 (116 mg, 51%) as a colourless oil, RF (9:1 
petrol-EtOAc) 0.2; 1H NMR (400 MHz) (60:40 mixture of rotamers) δ 4.31 (dd, J = 
8.5, 3.5 Hz, 0.4H, NCH), 4.21 (dd, J = 8.0, 4.0 Hz, 0.6H, NCH), 3.72 (s, 1.2H, OMe), 
3.71 (s, 2.8H, OMe), 3.60-3.30 (m, 2H, NCH2), 2.30-2.10 (m, 1H, CH2), 2.02-1.74 
(m, 3H, CH2), 1.45 (s, 3.6H, CMe3), 1.40 (s, 5.4H, CMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 173.7 (C=O, CO2Me), 173.5 (C=O, CO2Me), 153.8 (C=O, Boc), 
153.5 (C=O, Boc), 79.8 (CMe3), 79.8 (CMe3), 59.0 (NCH), 58.6 (NCH), 52.1 (OMe), 
51.9 (OMe), 46.5 (NCH2), 46.2 (NCH2), 30.8 (CH2), 29.9 (CH2), 28.3 (CMe3), 28.2 
(CMe3), 24.3 (CH2), 23.6 (CH2) and disubstituted pyrrolidine 257 (51 mg, 18%) as a 
colourless oil, RF (9:1 petrol-EtOAc) 0.4; IR (film) 2977, 1752 (C=O, CO2Me), 1703 
(C=O, Boc), 1391, 1369, 1262, 1162, 1117 cm–1; 1H NMR (400 MHz, CDCl3) (65:35 
mixture of rotamers) δ 3.77 (s, 6H, OMe), 3.58 (t, J = 7.0 Hz, 1.3H, NCH2), 3.51 (t, J 
= 7.0 Hz, 0.7H, NCH2), 2.52-2.42 (m, 2H, CH2), 1.90-1.81 (m, 2H, CH2), 1.45 (s, 
3.15H, CMe3), 1.38 (s, 5.85H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 
169.9 (C=O, CO2Me), 169.7 (C=O, CO2Me), 153.8 (C=O, Boc), 153.3 (C=O, Boc), 
80.6 (CMe3), 80.2 (CMe3), 71.9 (NCCH2), 71.8 (NCCH2), 52.9 (OMe), 52.7 (OMe), 
47.3 (NCH2), 46.2 (NCH2), 38.2 (CH2), 36.7 (CH2), 28.2 (CMe3), 28.0 (CMe3), 23.7 
(CH2), 22.9 (CH2); MS (ESI) m/z 310 [(M + Na)
+, 26], 288 [(M + H)+, 8], 232 (29), 
188 (100); HRMS (ESI) m/z calcd for C13H21NO6 (M + Na)
+ 310.1261, found 
310.1263 (–0.5 ppm error). Spectroscopic data of 254 consistent with those reported 
in the literature.238 
Lab Book Reference GB6/468 
 
2-Trimethylsilyl pyrrolidine-1-carboxylic acid tert-butyl ester 39  
 
 240 
N
Boc
SiMe3 39
 
 
Using general procedure K, -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 
eq.), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and 
trimethylsilyl chloride (218 mg, 256 µL, 2.0 mmol, 2.0 eq.) in THF (7 mL) gave the 
crude product. Purification by flash column chromatography on silica with 95:5 
petrol-Et2O as eluent gave silyl pyrrolidine 39 (172 mg, 71%) as a colourless oil. 
Lab Book Reference GB5/460 
 
-Boc Pyrrolidine-2-carboxaldehyde 255       
 
N
Boc O
H
255
 
 
Using general procedure K, -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 1.0 
eq.), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and DMF 
(146 mg, 155 µL, 2.0 mmol, 2.0 eq.) in THF (7 mL) gave the crude product. 
Purification by flash column chromatography on silica with 1:1 petrol-Et2O as eluent 
gave aldehyde 255 (134 mg, 67%) as a colourless oil, RF (1:1 petrol-Et2O) 0.3; 
1H 
NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 9.52 (d, J = 1.5 Hz, 0.4H, 
CHO), 9.42 (d, J = 3.0 Hz, 0.6H, CHO), 4.16 (br t, J = 6.0 Hz, 0.4H, NCH), 4.02 
(ddd, J = 10.5, 6.0, 3.0 Hz, 0.6H, NCH), 3.69-3.14 (m, 2H, NCH2), 2.26-1.74 (m, 4H, 
CH2), 1.44 (s, 3.6H, CMe3), 1.39 (s, 5.4 H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 200.6 (C=O, CHO), 200.4 (C=O, CHO), 162.7 (C=O, Boc), 81.5 (CMe3), 
80.7 (CMe3), 65.0 (NCH), 64.8 (NCH), 46.8 (NCH2), 45.9 (NCH2), 33.4 (CH2), 32.7 
(CH2), 28.4 (CMe3), 28.3 (CMe3), 27.9 (CH2), 23.9 (CH2). Spectroscopic data 
consistent with those reported in the literature.119 
Lab Book Reference GB6/464 
 
 
2-Benzoylpyrrolidine-1-carboxylic acid tert-butyl ester 256   
 
 241 
N
Boc O
Ph
256
 
 
Following general procedure K, -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL), s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 
eq.) and a solution of ,-dimethylbenzamide (298 mg, 2.0 mmol, 2.0 eq.) in THF (1 
mL) gave the crude product. Purification by flash column chromatography on silica 
with 4:1 petrol-EtOAc as eluent gave benzoyl pyrrolidine 256 (211 mg, 77%) as a 
colourless oil, RF (4:1 petrol-EtOAc) 0.4; IR (CHCl3) 2979, 1696 (C=O), 1404, 1367, 
1164, 757 cm–1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 8.05-7.91 
(m, 2H, o-Ph), 7.60-7.51 (m, 1H, p-Ph), 7.50-7.41 (m, 2H, m-Ph), 5.32 (dd, J = 10.0, 
3.5 Hz, 0.4H, NCH), 5.18 (dd, J = 10.0, 3.0 Hz, 0.6H, NCH), 3.77-3.58 (m, 1H, 
NCH2), 3.56-3.43 (m, 1H, NCH2), 2.23-2.18 (m, 1H, CH2), 2.00-1.82 (m, 3H, CH2), 
1.4 (s, 5.4H, CMe3), 1.24 (s, 3.6H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) 
δ 198.9 (PhC=O), 198.3 (PhC=O), 154.4 (C=O, Boc), 153.8 (C=O, Boc), 135.1 (ipso-
Ph), 134.9 (ipso-Ph), 128.6 (Ph), 128.5 (Ph), 128.4 (Ph), 128.3 (Ph), 128.1 (Ph), 79.7 
(CMe3), 79.6 (CMe3), 61.3 (NCH), 61.0 (NCH), 46.7 (NCH2), 46.5 (NCH2), 30.8 
(CH2), 29.7 (CH2), 28.4 (CMe3), 28.1 (CMe3), 24.1 (CH2), 23.5 (CH2); MS (ESI) m/z 
298 [(M + Na)+, 12], 276 [(M + H)+, 8], 220 (23), 176 [(M + H – Boc)+, 100], 158 
(13); HRMS (ESI) m/z calcd for C16H21NO3 (M + H)
+ 276.1594, found 276. 1604 (–
3.6 ppm error). 
Lab Book Reference GB5/459:2 
 
Pyrrolidine-1,2,2-tricarboxylic acid 1-tert-butyl ester 2,2-dimethyl ester 257 
 
N
Boc
CO2Me
CO2Me
257
 
 
s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol, 2.6 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol, 
1.0 eq.) in THF (7 mL) at –78 °C under Ar. The resulting solution was stirred at –78 
°C for 1 h. Then, methyl chloroformate (283 mg, 231 µL, 3.0 mmol, 3.0 eq.) was 
added. The resulting solution was stirred at –78 °C for 1 h and then allowed to warm 
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to rt. Saturated NH4Cl(aq) (10 mL) was added and the two layers were separated. The 
aqueous layer was extracted with Et2O (3 × 10 mL) and the combined organic layers 
were dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 9:1 petrol-EtOAc as 
eluent gave disubstituted pyrrolidine 257 (219 mg, 76%) as a colourless oil. 
Lab Book Referecnce GB4/360 
 
2-(2-Trifluoromethylphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester 183 
 
N
Boc
CF3
183
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 1.0 mmol) in 
THF at –30 °C under Ar. The resulting solution was stirred at –30 °C for 5 min. Then, 
ZnCl2 (0.6 mL of a 1.0M solution in Et2O, 0.6 mmol) was added and the resulting 
solution was stirred at –30 °C for 30 min. The solution was allowed to warm to rt and 
stirred at rt for 30 min. Then, 2-bromobenzotrifluoride (160 mg, 97 µL, 0.7 mmol) 
was added. A mixture of Pd(OAc)2 (11 mg, 0.05 mmol) and t-Bu3PHBF4 (11 mg, 
0.0625 mmol) was added in one portion. The resulting solution was stirred at rt for 16 
h. 35% NH4OH(aq) (0.2 mL) was added and the solution stirred at rt for 1 h. The solids 
were removed by filtration through a pad of Celite® and washed with Et2O (20 mL). 
The filtrate was washed with 1 M HCl(aq) (20 mL) and H2O (20 mL), dried (MgSO4) 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 99:1 CH2Cl2-acetone as eluent gave aryl 
pyrrolidine 183 (161 mg, 73%) as a colourless oil. 
Lab Book Reference GB7/602 
 
 
 
 
-Boc-2-Phenyl pyrrolidine 77   
 
 243 
N
Boc
77
 
 
Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%) and bromobenzene (110 mg, 74 µL, 0.7 mmol) gave 
the crude product. Purification by flash column chromatography on silica with CH2Cl2 
as eluent gave phenyl pyrrolidine 77 (137 mg, 79%) as a white solid, RF (CH2Cl2) 0.4; 
1H NMR (400 MHz, CDCl3) (75:25 mixture of rotamers) δ 7.35-7.25 (m, 2H, Ph), 
7.25-7.08 (m, 3H, Ph), 4.97 (br s, 0.25H, NCH), 4.76 (br s, 0.75H, NCH), 3.87-3.34 
(m, 2H, NCH2), 2.32 (br s, 1H, CH2), 2.04-1.74 (m, 3H, CH2), 1.46 (br s, 2.25H, 
CMe3), 1.18 (br s, 6.75H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.6 
(C=O), 145.1 (ipso-Ph), 128.1 (Ph), 126.4 (Ph), 125.5 (Ph), 125.1 (Ph), 80.1 (CMe3), 
79.1 (CMe3), 61.3 (NCH), 47.2 (NCH2), 47.1 (NCH2), 36.0 (CH2), 35.9 (CH2), 28.4 
(CMe3), 28.1 (CMe3), 23.4 (CH2), 23.2 (CH2). Spectroscopic data consistent with 
those reported in the literature.83 
Lab Book Reference GB7/609 
 
-Boc-2-(2-Methoxyphenyl)pyrrolidine 181 
 
N
Boc
OMe
181
 
 
Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%) and 2-bromoanisole (131 mg, 86 µL, 0.7 mmol) gave 
the crude product. Pruification by flash column chromatography on silica with 98:2 
CH2Cl2-acetone as eluent gave aryl pyrrolidine 181 (155 mg, 80%) as a brown solid. 
Lab Book Reference GB6/711 
 
 
 
2-(2-Methoxycarbonylphenyl) pyrrolidine-1-carboxylic acid tert-butyl ester 184 
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N
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Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%) and methyl 2-bromobenzoate (150 mg, 98 µL, 0.7 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 4:1 petrol-EtOAc as eluent gave aryl pyrrolidine 184 (147 mg, 69%) as a yellow 
oil. 
Lab Book Reference GB7/610 
 
2-(2,5-Dimethoxyphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester 258 
 
N
Boc
OMe
OMe
258
 
 
Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.625 mmol, 6.25 mol%) and 1-bromo-2,5-dimethoxybenzene (152 mg, 105 µL, 
0.7 mmol) gave the crude product. Purification by flash column chromatography on 
silica with 6:1 petrol-EtOAc as eluent gave aryl pyrrolidine 258 (160 mg, 74%) as a 
colourless oil, RF (6:1 petrol-EtOAc) 0.4; IR (CHCl3) 3006, 2978, 1681 (C=O), 1495, 
1403, 1168 cm–1; 1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 6.82-
6.50 (m, 3H, Ar), 5.20 (br d, J = 7.5 Hz, 0.4H, NCH), 5.05 (dd, J = 8.0, 4.0 Hz, 0.6H, 
NCH), 3.78 (s, 3H, OMe), 3.74 (s, 3H, OMe), 3.69-3.31 (m, 2H, NCH2), 2.39-2.10 
(m, 1H, CH2), 1.94-1.67 (m, 3H, CH2), 1.46 (s, 3.6H, CMe3), 1.21 (s, 5.4H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.5 (C=O), 154.2 (C=O), 153.5 (ipso-
C6H3OMe), 153.3 (ipso-C6H3OMe), 151.2 (ipso-C6H3OMe), 150.4 (ipso-C6H3OMe), 
134.3 (ipso-Ar), 133.3 (ipso-Ar), 112.5 (Ar), 112.2 (Ar), 111.4 (Ar), 111.3 (Ar), 111.2 
(Ar), 110.8 (Ar), 79.1 (CMe3), 78.9 (CMe3), 56.4, 56.2, 56.0, 55.7, 55.6, 55.5, 47.2 
(NCH2), 46.8 (NCH2), 33.9 (CH2), 32.8 (CH2), 28.5 (CMe3), 28.1 (CMe3), 23.2 (CH2), 
23.0 (CH2); MS (ESI) m/z 330 [(M + Na)
+, 100], 308 [(M + H)+, 43], 252 (59), 208 
(8); HRMS (ESI) m/z calcd for C17H25NO4 (M + Na)
+ 330.1676, found 330.1680 (–
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1.2 ppm error); m/z calcd for C17H25NO4 (M + H)
+ 308.1859, found 308.1859 (–0.7 
ppm error). 
Lab Book Reference GB7/615 
 
-Boc-2-(4-Fluorophenyl)pyrrolidine 259   
 
N
Boc F
259
 
 
Using general procedure L, Pd(OAc) (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%), and 1-bromo-4-fluorobenzene (122 mg, 77 µL, 0.7 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 8:2 petrol-EtOAc as eluent gave aryl pyrrolidine 259 (158 mg, 85%) as a 
colourless oil, RF (8:2 petrol-EtOAc) 0.4; 
1H NMR (400 MHz, CDCl3) (75:25 mixture 
of rotamers) δ 7.13 (br dd, J = 8.0, 6.0 Hz, 2H, Ar), 6.98 (t, J = 8.0 Hz, 2H, Ar), 4.92 
(br s, 0.25H, NCH), 4.74 (br s, 0.75H, NCH), 3.80-3.40 (m, 2H, NCH2), 2.48-2.17 (m, 
1H, CH2), 2.00-1.69 (m, 3H, CH2), 1.46 (s, 2.25H, CMe3), 1.20 (s, 6.75H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 161.6 (d, J = 244.0 Hz, ipso-C6H4F), 154.5 
(C=O), 126.8 (d, J = 24.0 Hz, Ar), 126.5 (ipso-C6H4), 114.9 (d, J = 20.0 Hz, Ar), 79.3 
(CMe3), 60.7 (NCH), 53.4 (NCH2), 47.0 (NCH2), 36.1 (CH2), 34.9 (CH2), 28.4 
(CMe3), 28.1 (CMe3), 23.1 (CH2). Spectroscopic data consistent with those reported in 
the literature.83 
Lab Book Reference GB7/613 
 
-Boc-2-(4-carboxymethylphenyl)pyrrolidine 260   
 
N
Boc CO2Me
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Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%) and methyl 4-bromobenzoate (150 mg, 0.7 mmol) 
gave the crude product. Purification by flash column chromatography on silica with 
3:1 petrol-Et2O as eluent gave aryl pyrrolidine 260 (121 mg, 57%) as a colourless oil, 
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RF (3:1 petrol-Et2O) 0.2; 
1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 
7.97 (d, J = 8.5 Hz, 2H, o-C6H4CO2Me), 7.23 (d, J = 8.5 Hz, 2H, m-C6H4CO2Me), 
4.96 (br s, 0.3H, NCH), 4.79 (br s, 0.7H, NCH), 3.90 (s, 3H, OMe), 3.71-3.51 (m, 2H, 
NCH2), 2.46-2.21 (m, 1H, CH2), 1.99-1.79 (m, 3H, CH2), 1.45 (s, 2.7H, CMe3), 1.16 
(s, 6.3H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 166.9 (C=O, CO2Me), 
154.4 (C=O, Boc), 150.6 (ipso-C6H4CO2Me), 129.7 (Ar), 129.6 (Ar), 128.4 (ipso-Ar), 
125.4 (Ar), 79.4 (CMe3), 61.1 (OMe), 52.0 (NCH), 47.1 (NCH2), 35.9 (CH2), 34.7 
(CH2), 28.4 (CMe3), 28.1 (CMe3), 23.5 (CH2), 23.2 (CH2). Spectroscopic data 
consistent with those reported in the literature.83 
Lab Book Reference GB7/614 
 
-Boc-2-(4-Aminophenyl)pyrrolidine 81     
 
N
Boc NH2
81
 
 
Using general procedure L, Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%), t-Bu3PHBF4 (11 
mg, 0.0625 mmol, 6.25 mol%) and 4-bromoaniline (120 mg, 0.7 mmol) gave the 
crude product. Purification by flash column chromatography on silica with 1:1 petrol-
EtOAc as eluent gave aryl pyrrolidine 81 (117 mg, 64%) as an orange oil, RF (1:1 
petrol-EtOAc) 0.6; 1H NMR (400 MHz, CDCl3) (75:25 mixture of rotamers) δ 6.94 
(d, J = 7.0 Hz, 2H, m-C6H4NH2), 6.61 (d, J = 7.0 Hz, 2H, o-C6H4NH4), 4.85 (br s, 
0.25H, NCH), 4.67 (br s, 0.75H, NCH), 3.84-3.32 (m, 4H, NH2 + NCH2), 2.39-2.10 
(m, 1H, CH2), 2.02-1.66 (m, 3H, CH2), 1.44 (s, 2.25H, CMe3), 1.21 (s, 6.75H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.6 (C=O), 144.7 (ipso-C6H4NH2), 
135.3 (ipso-Ar), 135.1 (ipso-Ar), 126.5 (Ar), 114.9 (Ar), 79.0 (CMe3), 60.7 (NCH), 
47.1 (NCH2), 46.9 (NCH2), 35.9 (CH2), 28.2 (CMe3), 23.1 (CH2). Spectroscopic data 
consistent with those reported in the literature.83 
Lab Book Reference GB7/616 
 
 
Attempted Diamine-Free Lithiation-Trapping of -Boc Piperidine 44 
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Table 5.3, Entry 1: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –78 °C for 180 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/505 
 
Table 5.3, Entry 2: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –78 °C for 360 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/552 
 
Table 5.3, Entry 3: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –40 °C for 180 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/559 
 
Table 5.3, Entry 4: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –40 °C for 60 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/558 
 
Table 5.3, Entry 5: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –40 °C for 60 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/506 
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Table 5.3, Entry 6: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –40 °C for 60 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/504 
 
Table 5.3, Entry 7: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –30 °C for 5 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/503 
 
Table 5.3, Entry 8: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc piperidine 44 (185 mg, 192 µL, 1.0 mmol, 1.0 eq.) in THF (7 mL) 
at –30 °C for 5 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/554 
 
Attempted Diamine-Free Lithiation-Trapping of -Boc Homopiperidine 56 
 
Table 5.4, Entry 1: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–78 °C for 360 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/634 
 
Table 5.4, Entry 2: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
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–78 °C for 360 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/633 
 
Table 5.4, Entry 3: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–40 °C for 180 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/645 
 
Table 5.4, Entry 4: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–40 °C for 180 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/644 
 
Table 5.4, Entry 5: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–40 °C for 60 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) 
gave no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/643 
 
Table 5.4, Entry 6: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–40 °C for 60 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/642 
 
Table 5.4, Entry 7: 
 250 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–40 °C for 30 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB6/508 
 
Table 5.4, Entry 8: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–30 °C for 5 min and methyl chloroformate (189 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave 
no trapped product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/631 
 
Table 5.4, Entry 9: 
Using general procedure J, s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 
1.3 eq.) and -Boc homopiperidine 56 (199 mg, 1.0 mmol, 1.0 eq.) in THF (7 mL) at 
–30 °C for 5 min and DMF (146 mg, 155 µL, 2.0 mmol, 2.0 eq.) gave no trapped 
product by 1H NMR spectroscopy of the crude product. 
Lab Book Reference GB7/632 
 
2-Formyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 264  
 
N
Boc
H
O
264
 
 
Using general procedure K, -Boc pyrroline 261 (169 mg, 1.0 mmol), s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and DMF (146 mg, 155 µL, 2.0 
mmol) in THF (7 mL) gave the crude product. Purification by flash column 
chromatography on silica with 1:1 petrol-EtOAc as eluent gave aldehyde 264 (39 mg, 
20%) as a colourless oil, RF (1:1 petrol-EtOAc) 0.6; IR (CHCl3) 3009, 2980, 2933, 
2872, 1735 (C=O, CHO), 1692 (C=O, Boc), 1400, 1369, 1256, 1173, 1128 cm–1; 1H 
NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 9.43 (d, J = 3.0 Hz, 0.3H, 
CHO), 9.34 (d, J = 3.0 Hz, 0.7H, CHO), 6.11-6.05 (m, 0.7H, CH=CH), 6.03-5.98 (m, 
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0.3H, CH=CH), 5.67-5.60 (m, 0.3H, CH=CH), 5.59-5.53 (m, 0.7H, CH=CH), 4.94-
4.86 (m, 0.3H, NCH), 4.83-4.74 (m, 0.7H, NCH), 4.32-4.27 (m, 1.4H, NCH2), 4.25-
4.20 (m, 0.6H, NCH2), 1.49 (s, 2.7H, CMe3), 1.44 (s, 6.3H, CMe3); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 198.4 (C=O, CHO), 198.0 (C=O, CHO), 154.4 (C=O, 
Boc), 153.5 (C=O, Boc), 130.7 (CH=CH), 130.2 (CH=CH), 122.9 (CH=CH), 122.6 
(CH=CH), 81.0 (CMe3), 80.6 (CMe3), 72.7 (NCH), 72.5 (NCH), 53.8 (NCH2), 53.7 
(NCH2), 28.3 (CMe3), 28.2 (CMe3); MS (ESI) m/z 220 [(M + Na)
+, 100], 158 (25), 
142 (16), 112 (12), 98 (17); HRMS (ESI) m/z calcd for C10H15NO3 (M + Na)
+ 
220.0944, found 220.0944 (+0.3 ppm error). 
Lab Book Reference GB7/565 
 
1,4-Dioxa-8-azaspiro[4.5]decane-7,8-dicarboxylic acid 8-tert butyl ester 7-methyl 
ester 265  
N
O O
Boc
CO2Me
265
 
 
Using general procedure K, acetal piperidine 49 (243 mg, 1.0 mmol), s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.)  and methyl chloroformate (189 
mg, 155 µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by flash 
column chromatography on silica with 9:1 petrol-EtOAc as eluent gave acetal 
piperidine 265 (84 mg, 24%) as a colourless oil, RF (9:1 petrol-EtOAc) 0.1; IR 
(CHCl3) 3010, 2979, 1745 (C=O, CO2Me), 1691 (C=O, Boc), 1260, 1141, 1114 cm
–1; 
1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 4.96 (br s, 0.5H, NCH), 
4.77 (br s, 0.5H, NCH), 4.25-4.04 (m, 1H, NCH2), 4.01-3.83 (m, 5H, NCH2 + 
OCH2CH2O), 3.72 (s, 3H, OMe), 3.41-3.12 (m, 1H, CH2), 2.43-2.27 (m, 1H, CH2), 
1.86-1.70 (m, 1H, CH2), 1.69-1.54 (m, 1H, CH2), 1.47 (s, 9H, CMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 171.9 (C=O, CO2Me), 171.6 (C=O, CO2Me), 155.5 
(C=O, Boc), 155.1 (C=O, Boc), 106.2 (OCO), 80.3 (CMe3), 64.5 (OCH2), 64.1 
(OCH2), 54.1 (OMe), 53.1 (OMe), 51.9 (NCH), 51.8 (NCH), 39.9 (NCH2), 39.2 
(NCH2), 34.6 (CH2), 34.5 (CH2), 34.1 (CH2), 33.8 (CH2), 28.3 (CMe3), 28.2 (CMe3); 
MS (ESI) m/z 324 [(M + Na)+, 53], 302 [(M + H)+, 55], 278 (25), 260 (21), 246 (84), 
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228 (13), 202 (100); HRMS (ESI) m/z calcd for C14H23NO6 (M + Na)
+ 324.1418, 
found 324.1427 (–2.8 ppm error). 
Lab Book Reference GB7/579 
 
7-Trimethylsilanyl-1,4-dioxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl 
ester 50 
N
O O
Boc
SiMe3
50
 
 
Using general procedure K, acetal piperidine 49 (243 mg, 1.0 mmol), s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and Me3SiCl (217 mg, 254 µL, 2.0 
mmol) in THF (7 mL) gave the crude product. Purification by flash column 
chromatography on silica with 6:1 petrol-EtOAc as eluent gave acetal piperidine 50 
(46 mg, 14%) as a colourless oil, RF (6:1 petrol-EtOAc) 0.3; IR (CHCl3) 3009, 2957, 
1675 (C=O), 1419, 1247, 1170, 1102 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 
4H, OCH2), 3.71 (br s, 1H, NCH), 3.28 (br s, 1H, NCH2), 2.95 (br s, 1H, NCH2), 
1.83-1.55 (m, 4H, CH), 1.44 (s, 9H, CMe3), 0.08 (s, 9H, SiMe3); 
13C NMR (100.6 
MHz, CDCl3) δ 154.9 (C=O), 107.5 (OCO), 79.2 (CMe3), 64.4 (OCH2), 64.2 (OCH2), 
44.4 (CH2), 35.4 (CH2), 28.4 (CMe3), –0.9 (SiMe3); MS (ESI) m/z 338 [(M + Na)
+, 
70], 316 [(M + H)+, 100], 260 (86), 244 (85), 216 (46); HRMS (ESI) m/z calcd for 
C15H29NO4Si (M + Na)
+ 316.1939, found 316.1947 (–2.6 ppm error). 
Lab Book Reference GB7/581 
 
4-Benzyl-2-formylpiperazine-1-carboxylic acid tert-butyl ester 266  
 
N
N
Bn
Boc
H
O
266
 
 
Using general procedure K, piperazine 59 (276 mg, 1.0 mmol), s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and DMF (146 mg, 155 µL, 2.0 mmol) 
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gave the crude product. Purification by flash column chromatography on silic with 3:1 
petrol-EtOAc as eluent gave aldehyde 266 (217 mg, 71%) as a colourless oil, RF (3:1 
petrol-EtOAc) 0.9; IR (CHCl3) 2978, 2818, 1736 (C=O, CHO), 1691 (C=O, Boc), 
1392, 1967, 1298, 1170, 910 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 9.52 (s, 0.5H, CHO), 9.49 (s, 0.5H, CHO), 7.35-7.22 (m, 5H, Ph), 4.58 (br 
s, 0.5H, NCH), 4.39 (br s, 0.5H, NCH), 3.90 (d, J = 12.5 Hz, 0.5H, NCH2), 3.78 (d, J 
= 12.5 Hz, 0.5H, NCH2), 3.57 (br d, J = 13.5 Hz, 1H, NCH2Ph), 3.44 (br d, J = 13.5 
Hz, 1H, NCH2Ph), 3.30 (d, J = 12.0 Hz, 1H, NCH2), 3.16 (t, J = 12.0 Hz, 0.5H, 
NCH2), 3.06 (t, J = 12.0 Hz, 0.5H, NCH2), 2.77 (d, J = 10.0 Hz, 0.5H, NCH2), 2.71 
(d, J = 10.0 Hz, 0.5H, NCH2), 2.35-2.22 (m, 1H, NCH2), 2.12 (t, J = 12.0 Hz, 0.5H, 
NCH2), 2.11 (t, J = 12.0 Hz, 0.5H, NCH2), 1.48 (s, 4.5H, CMe3), 1.43 (s, 4.5, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 199.8 (C=O, CHO), 199.5 (C= O, CHO), 
155.7 (C=O, Boc), 155.2 (C=O, Boc), 137.4 (ipso-Ph), 128.6 (Ph), 128.3 (Ph), 127.2 
(Ph), 80.4 (CMe3), 62.5 (NCH2Ph), 61.5 (NCH), 60.4 (NCH), 52.1 (NCH2), 51.1 
(NCH2), 50.8 (NCH2), 42.0 (NCH2), 40.9 (NCH2), 28.3 (CMe3), 28.1 (CMe3); MS 
(ESI) m/z 337 (100), 323 (25), 305 [(M + H)+, 12], 249 (15); HRMS (ESI) m/z calcd 
for C17H24N2O3 (M + H)
+ 305.1860, found 305.1861(–0.6 ppm error). 
Lab Book Reference GB6/530 
 
4-Benzylpiperazine-1,2-dicarbxylic acid-1-tert-butl ester-2-methyl ester 267  
 
N
N
Bn
Boc
OMe
O
267
 
 
Using general procedure K, piperazine 59 (276 mg, 1.0 mmol), s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and methyl chloroformate (189 mg, 155 
µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by flash column 
chromatography on silica with 7:1 petrol-Et2O as eluent gave piperazine 267 (276 mg, 
83%) as a colourless oil, RF (7:1 petrol-Et2O) 0.3; 
1H NMR (400 MHz, CDCl3) (50:50 
mixture of rotamers) δ 7.39-7.18 (m, 5H, Ph), 4.72 (br s, 0.5H, NCH), 4.55 (br s, 
0.5H, NCH), 3.87 (br d, J = 14.5 Hz, 0.5H, NCH2), 3.77 (br d, J = 15.0 Hz, 0.5H, 
NCH2), 3.74 (s, 1.5H, OMe), 3.71 (s, 1.5H, OMe), 3.59 (d, J = 14.0 Hz, 0.5H, 
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NCH2Ph), 3.56 (d, J = 14.0 Hz, 0.5H, NCH2Ph), 3.48 (d, J = 14.0 Hz, 0.5H, 
NCH2Ph), 3.42 (d, J = 14.0 Hz, 0.5H, NCH2Ph), 3.37-3.10 (m, 2H, NCH2), 2.80 (br d, 
J = 11.0 Hz, 0.5H, NCH2), 2.75 (br d, J = 11.0 Hz, 0.5H, NCH2), 2.19 (td, J = 11.5, 
4.0 Hz, 1H, NCH2), 2.10 (br t, J = 12.0 Hz, 1H, NCH2), 1.48 (s, 4.5H, CMe3), 1.43 (s, 
4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 171.2 (C=O, CO2Me), 
170.9 (C=O, CO2Me), 155.7 (C=O, Boc), 155.2 (C=O, Boc), 137.6 (ipso-Ph), 128.6 
(Ph), 128.0 (Ph), 127.1 (Ph), 80.1 (CMe3), 62.2 (NCH2Ph), 55.4 (OMe), 54.3 (OMe), 
53.4 (NCH2), 52.4 (NCH2), 52.2 (NCH2), 51.8 (NCH), 41.9 (NCH2), 40.9 (NCH2), 
28.2 (CMe3), 28.1 (CMe3). Spectroscopic data consistent with those reported in the 
literature.109 
Lab Book Reference GB7/588 
 
4-Benzyl-2-trimethylsilanylpiperazine-1-carboxylic acid tert-butyl ester 268  
 
N
N
Bn
Boc
SiMe3
268
 
 
Using general procedure K, piperazine 59 (276 mg, 1.0 mmol), s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and Me3SiCl (217 mg, 260 µL, 2.0 
mmol) in THF (7 mL) gave the crude product. Purification by flash column 
chromatography on silica with 95:5 petrol-Et2O as eluent gave silyl piperazine 268 
(273 mg, 78%) as a colourless oil, RF (95:5 petrol-Et2O) 0.2; IR (CHCl3) 2956, 2804, 
1679 (C=O), 1454, 1416, 1365, 1294, 1248, 1171, 1110, 840 cm–1; 1H NMR (400 
MHz, CDCl3) δ 7.32-7.25 (m, 4H, Ph), 7.24 -7.17 (m, 1H, p-Ph), 4.18 -3.67 (m, 1H, 
NCH), 3.66 -3.45 (m, 1H, NCH2), 3.41-3.34 (m, 2H, NCH2Ph), 3.04-2.16 (m, 4H, 
NCH2), 1.90 (t, J = 11.5 Hz, 0.5H, NCH2), 1.88 (t, J = 11.5 Hz, 0.5H, NCH2), 1.42 (s, 
9H, CMe3), 0.05 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, CDCl3) δ 154.6 (C=O), 138.3 
(ipso-Ph), 129.2 (Ph), 128.1 (Ph), 127.1 (Ph), 79.2 (CMe3), 63.4 (CH2Ph), 54.2 
(NCH2), 53.1 (NCH2), 41.5 (NCH2), 28.4 (CMe3), 27.9 (NCH), –0.9 (SiMe3); MS 
(ESI) m/z 349 [(M + H)+, 100], 293 (8); HRMS (ESI) m/z calcd for C19H32N2O2Si (M 
+ H)+ 349.2306, found 349.2313 (–1.9 ppm error). 
Lab Book Reference GB7/587 
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7-Benzyl-1,1-diphenylhexahydro-oxazolo[3,4-α]pyrazin-3-one 269  
 
N
N
O
O
Bn
Ph
Ph 269
 
 
Using general procedure K, piperazine 59 (276 mg, 1.0 mmol) in THF (7 mL), s-BuLi 
(1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and a solution of 
benzophenone (364 mg, 2.0 mmol) in THF (1 mL) gave the crude product. 
Purification by flash column chromatography on silica with 85:15 petrol-EtOAc as 
eluent gave pyrazinone 269 (302 mg, 79%) as a colourless oil, RF (85:15 petrol-
EtOAc) 0.2; IR (CHCl3) 3066, 3031, 2815, 1757 (C=O), 1450, 1412, 1248, 996, 909, 
733, 699 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.63-7.52 (m, 2H, Ph), 7.46-7.21 (m, 
13H, Ph), 4.60 (dd, J = 11.5, 3.5 Hz, 1H, NCH), 3.85 (dd, J = 13.0, 3.0 Hz, 1H, 
NCH2), 3.55 (d, J = 13.0 Hz, 1H, NCH2Ph), 3.35 (d, J = 13.0 Hz, 1H, NCH2Ph), 3.14 
(td, J = 13.0, 4.0 Hz, 1H, NCH2), 2.73 (br d, J = 11.5 Hz, 1H, NCH2), 2.61 (br d, J = 
11.5 Hz, 1H, NCH2), 1.98 (td, J = 11.5, 4.0 Hz, 1H, NCH2), 1.63 (t, J = 11.5 Hz, 1H, 
NCH2); 
13C NMR (100.6 MHz, CDCl3) δ 155.8 (C=O), 142.2 (ipso-Ph), 138.5 (ipso-
Ph), 137.1 (ipso-Ph), 128.7 (Ph), 128.3 (Ph), 128.2 (Ph), 128.1 (Ph), 128.0 (Ph), 127.7 
(Ph), 127.1 (Ph), 125.7 (Ph), 125.6 (Ph), 85.0 (CPh2), 62.7 (NCH2Ph), 61.0 (NCH), 
55.6 (NCH2), 50.6 (NCH2), 41.5 (NCH2); MS (ESI) m/z 385 [(M + H)
+, 100]; HRMS 
(ESI) m/z calcd for C25H24N2O2 (M + H)
+ 385.1911, found 385.1919 (–2.2 ppm error). 
Lab Book Reference GB7/589 
 
 
 
 
 
 
 
 
 256 
4-Benzyl-2-phenylpiperazine-1-carboxylic acid tert-butyl ester 270   
 
N
N
Bn
Boc
Ph
270
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of piperazine 59 (276 mg, 1.0 mmol) in THF (7 mL) at 
–30 °C under Ar. The resulting solution was stirred at –30 °C for 5 min. Then, ZnCl2 
(0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) was added and the resulting solution 
was stirred at –30 °C for 30 min. The solution was allowed to warm to rt and stirred at 
rt for 30 min. Then, a solution of bromobenzene (110 mg, 74 µL, 0.7 mmol) in t-butyl 
methyl ether (5 mL) was added. A mixture of Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%) 
and t-Bu3PHBF4 (11 mg, 0.0625 mmol, 6.25 mol%) in one portion. The reaction flask 
was transferred to a pre-heated oil bath and the resulting solution was stirred and 
heated at reflux for 16 h. After cooling to rt, 35% NH4OH(aq) (0.2 mL) was added and 
the solution stirred at rt for 1 h. The solids were removed by filtration through Celite® 
and washed with Et2O (20 mL). The filtrate was washed with saturated brine (20 mL) 
and H2O (20 mL), dried (Na2SO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 95:5 
petrol-EtOAc as eluent gave phenyl piperazine 270 (136 mg, 55%) as a colourless oil, 
RF (95:5 petrol-EtOAc) 0.3; IR (CHCl3) 3009, 2979, 2808, 1682 (C=O), 1453, 1421, 
1367, 1168, 1123, 909, 733 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 7.52-7.45 (m, 1H, Ph), 7.42-7.16 (m, 9H, Ph), 5.21 (br s, 0.5H, NCH), 
3.96 (br s, 0.5H, NCH), 3.89 (br d, J = 13.0 Hz, 1H, NCH2), 3.77 (d, J = 13.0 Hz, 
0.5H, NCH2), 3.54 (d, J = 13.0 Hz, 0.5H, NCH2), 3.42 (d, J = 13.0 Hz, 0.5H, NCH2), 
3.28-3.19 (m, 1H, NCH2), 3.06-2.54 (m, 3H, NCH2), 2.38 (dd, J = 12.0, 4.5 Hz, 0.5H, 
NCH2), 2.14 (td, J = 12.0, 3.0 Hz, 0.5H, NCH2), 2.05 (td, J = 12.0, 3.0 Hz, 0.5H, 
NCH2), 1.45 (s, 4.5H, CMe3), 1.43 (s, 4.5H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 154.9 (C=O), 154.4 (C=O), 141.0 (ipso-Ph), 140.4 (ipso-Ph), 138.6 
(ipso-Ph), 137.8 (ipso-Ph), 129.1 (Ph), 128.7 (Ph), 128.6 (Ph), 128.2 (Ph), 128.1 (Ph), 
128.0 (Ph), 127.9 (Ph), 127.7 (Ph), 127.6 (Ph), 127.1 (Ph), 126.8 (Ph), 126.7 (Ph), 
79.8 (CMe3), 79.7 (CMe3), 67.1 (NCH), 63.1 (NCH2), 58.9 (NCH2), 54.9 (NCH2), 
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53.3 (NCH2), 51.5 (NCH2), 39.8 (NCH2), 28.4 (CMe3), 28.4 (CMe3); MS (ESI) m/z 
353 [(M + H)+, 100], 297 (6); HRMS (ESI) m/z calcd for C22H28N2O2 (M + H)
+ 
353.2224, found 353.2224 (–0.1 ppm error). 
Lab Book Reference GB7/649 
 
2-[2-(Benzylmethoxycarbonylamino)ethyl]-tert-butoxycarbonylamino acrylic 
acid methyl ester 271 
 
N
N
CO2Me
Bn
Boc
CO2Me
CH2 271
 
 
s-BuLi (2.57 mL of a 1.3 M solution in hexanes, 3.34 mmol) was added dropwise to a 
stirred solution of piperazine 59 (355 mg, 1.28 mmol) in THF (7 mL) at –78 °C under 
Ar. The resulting solution was stirred at –78 °C for 3 h. Then, methyl chloroformate 
(366 mg, 300 µL, 3.85 mmol) was added dropwise. The resulting solution was stirred 
at –78 °C for 1 h. Then, the resulting solution was allowed to warm to rt and saturated 
NH4Cl(aq) (10 mL) was added. The two layers were separated and the aqueous layer 
was extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 95:5 petrol-EtOAc as 
eluent gave alkene 271 (177 mg, 45%) as a colourless oil, RF (95:5 petrol-EtOAc) 0.1; 
IR (CHCl3) 2978, 1703 (C=O, CO2Me + Boc), 1476, 1439, 1393, 1367, 1246, 1163 
cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.36-7.17 (m, 5H, 
Ph), 5.88 (br s, 0.5H, CH2=), 5.84 (br s, 0.5H, CH2=), 5.53 (br s, 0.5H, CH2=), 5.31 
(br s, 0.5H, CH2=), 4.51 (s, 2H, CH2Ph), 3.78-3.66 (m, 8H, 2 × OMe + NCH2), 3.65-
3.48 (m, 1H, NCH2), 3.47-3.35 (m, 1H, NCH2), 1.40 (s, 9H, CMe3); 
13C NMR (100.6 
MHz, CDCl6) (rotamers) δ 165.2 (C=O), 157.0 (C=O), 156.8 (C=O), 153.6 (C=O), 
140.4 (C=CH2), 140.0 (C=CH2), 137.6 (ipso-Ph), 128.5 (Ph), 127.9 (Ph), 127.2 (Ph), 
127.1 (Ph), 117.2 (CH2=), 116.7 (CH2=), 81.2 (CMe3), 81.1 (CMe3), 52.7 (OMe), 52.2 
(OMe), 51.0 (CH2Ph), 50.7 (CH2Ph), 47.9 (NCH2), 47.2 (NCH2), 45.3 (NCH2), 44.3 
(NCH2), 28.1 (CMe3), 28.0 (CMe3); MS (ESI) m/z 393 [(M + H)
+, 53], 337 (17), 293 
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(100); HRMS (ESI) m/z calcd for C20H28N2O6 (M + H)
+ 393.2020, found 393.2022 (–
0.6 ppm error). 
Lab Book Reference GB5/400 
 
4-Benzyl-2-formyl[1,4]diazepane-1-carboxylic acid tert-butyl ester 273 
 
N
N
Bn
Boc
H
O
273
 
 
Using general procedure K, homopiperazine 272 (290 mg, 1.0 mmol), s-BuLi (1.0 mL 
of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and DMF (146 mg, 155 µL, 2.0 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 3:1 petrol-EtOAc as eluent gave aldehyde 273 (131 mg, 41%) as a colourless oil, 
RF (3:1 petrol-EtOAc) 0.4; IR (CHCl3) 2972, 2929, 2817, 1730 (C=O, CHO), 1691 
(C=O, Boc), 1453, 1392, 1365, 1300, 1252, 1155, 737 cm–1; 1H NMR (400 MHz, 
CDCl3) (60:40 mixture of rotamers) δ 9.51 (s, 0.4H, CHO), 9.46 (s, 0.6H, CHO), 
7.36-7.22 (m, 5H, Ph), 4.53 (dd, J = 8.0, 3.5 Hz, 0.4H, NCH), 4.20 (dd, J = 8.0, 3.5 
Hz, 0.6H, NCH), 4.12 (dd, J = 14.5, 8.0 Hz, 0.4H, NCH2), 3.90 (ddd, J = 14.5, 8.0, 
2.5 Hz, 0.6H, NCH2), 3.68-3.54 (m, 2.4H, NCH2), 3.44 (ddd, J = 15.0, 9.0, 2.5 Hz, 
0.6H, NCH2), 3.19-3.07 (m, 1H, NCH2), 2.98 (dd, J = 14.5, 4.0 Hz, 0.4H, NCH2), 
2.91 (dd, J = 14.5, 3.0 Hz, 0.6H, NCH2), 2.79-2.63 (m, 1H, NCH2), 2.59-2.50 (m, 
0.4H, NCH2), 2.45 (ddd, J = 12.0, 8.5, 3.0 Hz, 0.6H, NCH2), 1.86-1.64 (m, 2H, CH2), 
1.49 (s, 3.6H, CMe3), 1.41 (s, 5.4H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 201.5 (CHO), 200.9 (CHO), 155.8 (C=O, Boc), 154.9 (C=O, Boc), 138.6 
(ipso-Ph), 138.3 (ipso-Ph), 128.8 (Ph), 128.7 (Ph), 128.3 (Ph), 128.3 (Ph), 127.3 (Ph), 
127.2 (Ph), 80.8 (CMe3), 80.4 (CMe3), 65.5 (NCH), 64.8 (NCH), 62.5 (NCH2), 61.7 
(NCH2), 56.4 (NCH2), 55.9 (NCH2), 53.6 (NCH2), 53.5 (NCH2), 44.7 (NCH2), 43.9 
(NCH2), 29.3 (CH2), 28.9 (CH2), 28.4 (CMe3), 28.2 (CMe3); MS (ESI) m/z 351 [(M + 
MeOH + H)+, 12], 337 [(M + H2O + H)
+, 100], 319 [(M + H)+, 72], 263 (62); HRMS 
(ESI) m/z calcd for C18H26N2O3 (M + H)
+ 319.2016, found 319.2006 (+3.4 ppm 
error). 
Lab Book Reference GB6/531 
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3-(2-Hydroxyethyl)-4-methylene-5,5-diphenyloxazolidin-2-one 275 
 
OH
N
O
O
CH2
Ph
Ph
275
 
 
s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol) was added dropwise to a 
stirred solution of -Boc-4-morpholine 274 (187 mg, 1.0 mmol) in THF (7 mL) at –
30 °C under Ar. The resulting solution was stirred at –30 °C for 5 min. Then, a 
solution of benzophenone (546 mg, 3.0 mmol) in THF (1 mL) was added. The 
resulting solution was stirred at –30 °C for 10 min. Then, the resulting mixture was 
allowed to warm to rt and 1 M NaOH(aq) (10 mL) was added. The two layers were 
separated and the aqueous layer was extracted with Et2O (3 × 10 mL). The combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 1:1 petrol-
EtOAc as eluent gave oxazolidinone 275 (190 mg, 64%) as a colourless oil, RF (1:1 
petrol-EtOAc) 0.4; IR (film) 3456 (OH), 3062, 2938, 1766 (C=O), 1681, 1655, 1448, 
1401, 1336, 1231, 1023 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.50-7.28 (m, 10H, Ph), 
4.65 (d, J = 3.0 Hz, 1H, CH2=), 4.21 (d, J = 3.0 Hz, 1H, CH2=), 3.83 (t, J = 5.5 Hz, 
2H, CH2O), 3.69 (t, J = 5.5 Hz, 2H, CH2N); 
13C NMR (100.6 MHz, CDCl3) δ 155.8 
(C=O), 147.1 (C=CH2), 140.3 (ipso-Ph), 128.6 (Ph), 128.3 (Ph), 127.0 (Ph), 89.2 
(CPh2), 86.7 (CH2=), 58.9 (CH2O), 44.1 (CH2N); MS (ESI) m/z 318 [(M + Na)
+, 67], 
296 [(M + H)+, 100], 252 (42); HRMS (ESI) m/z calcd for C18H17NO3 (M + Na)
+ 
318.1101, found 318.1094 (+2.2 ppm error). 
Lab Book Reference GB7/564 
 
Attempted s-BuLi/(–)-sparteine-mediated lithiation-trapping of -Boc 
morpholine 274 
 
Me3SiO
H
N
Boc HO
H
N
Boc
279 280  
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s-BuLi (2.0 mL of a 1.3 M solution in hexanes, 2.6 mmol) was added dropwise to a 
stirred solution of -Boc-4-morpholine 274 (187 mg, 1.0 mmol) and (–)-sparteine 3 
(609 mg, 597 µL, 2.6 mmol) in Et2O (7 mL) at –78 °C under Ar. The resulting 
solution was stirred at –78 °C for 60 min. Then, Me3SiCl (326 mg, 381 µL, 3.0 mmol) 
was added and the resulting solution was stirred at –78 °C for 10 min. Then, the 
mixture was allowed to warm to rt and saturated NH4.Cl(aq) (10 mL) was added. The 
two layers were separated and the aqueous layer was extracted with Et2O (3 ×10 mL). 
The combined organic layers were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on 
silica with 9:1 and then 2:1 petrol-Et2O and then 100% EtOAc gave O-trimethylsilyl-
-Boc ethanolamine 279 (177 mg, 76%) as a colourless oil, RF (2:1 petrol-Et2O) 0.9; 
1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 4.03-3.94 (m, 1H, OCH2), 
3.94-3.85 (m, 1H, OCH2), 3.57-3.49 (m, 1H, NCH2), 3.40-3.28 (m, 1H, NCH2), 1.44 
(br s, 9H, CMe3), 0.09 (br s, 9H, SiMe3) and -Boc ethanolamine 280 (12 mg, 7%) as 
a colourless oil, RF (EtOAc) 0.5; 
1H NMR (400 MHz, CDCl3) (50:50 mixture of 
rotamers) δ 4.99 (br s, 1H, OH), 3.71 (t, J = 5.0 Hz, 2H, OCH2), 3.30 (t, J = 5.0 Hz, 
1H, NCH2), 3.29 (t, J = 5.0 Hz, 1H, NCH2), 2.42 (br s, 1H, NH), 1.45 (s, 9H, CMe3). 
Spectroscopic data of 279239 and 280231 consistent with those reported in the 
literature. 
 
3-Isopropyl-5-trimethylsilylimidazolidine-1-carboxylic acid tert-butyl ester 281 
 
N
N
Boc
SiMe3
i-Pr
281
 
 
Using general procedure M, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and Me3SiCl (217 
mg, 253 µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by flash 
column chromatography on silica with 5:1 petrol-EtOAc as eluent gave silyl 
imidazolidine 281 (210 mg, 73%) as a colourless oil, RF (5:1 petrol-EtOAc) 0.3; 
1H 
NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 4.36 (d, J = 6.0 Hz, 0.4H, 
NCH2N), 4.28 (d, J = 6.0 Hz, 0.6H, NCH2N), 3.63 (d, J = 6.0 Hz, 0.4H, NCH2N), 
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3.56 (d, J = 6.0 Hz, 0.6H, NCH2N), 3.31-3.18 (m, 1H, NCHCH2), 3.15-2.95 (m, 1H, 
NCHCH2), 2.55 (br t, J = 7.5 Hz, 0.4H, NCHSi), 2.39 (br t, J = 7.5 Hz, 0.6H, 
NCHSi), 2.33 (septet, J = 6.5 Hz, 1H, NCHMe2), 1.44 (s, 3.6H, CMe3), 1.42 (s, 5.4H, 
CMe3), 1.07 (d, J = 6.5 Hz, 6H, CHMe2), 0.05 (s, 9H, SiMe3); 
13C NMR (100.6 MHz, 
CDCl3) (rotamers) δ 153.4 (C=O), 79.7 (CMe3), 78.9 (CMe3), 67.6 (NCH2N), 53.4 
(NCHCH2), 53.0 (NCHMe2), 28.4 (NCHSi), 28.2 (NCHSi), 21.6 (CMe3), 21.5 
(CMe3), –2.4 (SiMe3), –3.6 (SiMe3). Spectroscopic data consistent with those reported 
in the literature.75 
Lab Book Reference GB7/573 
 
Using general procedure K, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and Me3SiCl (271 
mg, 253 µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by flash 
column chromatography on silica with 5:1 petrol-EtOAc as eluent gave silyl 
imidazolidine 281 (181 mg, 63%) as a colourless oil. 
Lab Book Reference GB7/562 
 
5-Allyl-3-Isopropylimidazoidine-1-carboxylic acid tert-butyl ester 282   
 
N
N
Boc
i-Pr
282
 
 
Using general procedure M, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and allyl bromide 
(242 mg, 173 µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by 
flash column chromatography on silica with 1:1 petrol-EtOAc as eluent gave 
imidazolidine 282 as a colourless oil, RF (1:1 petrol-EtOAc) 0.7; 
1H NMR (400 MHz, 
CDCl3) (55:45 mixture of rotamers) δ 5.94-5.42 (m, 1H, CH=CH2), 5.24-4.78 (m, 2H, 
CH=CH2), 4.22 (d, J = 6.0 Hz, 0.55H, NCH2H), 4.03 (d, J = 6.0 Hz, 0.45H, NCH2N), 
3.93-3.68 (m, 2H, NCH2H + NCHCH2), 2.94 (t, J = 8.0 Hz, 0.55H, NCHCH2), 2.87 (t, 
J = 8.0 Hz, 0.45H, NCHCH2), 2.74-2.42 (m, 2H, NCHCH2 + CH2=CHCH2), 2.34 
(septet, 1H, J = 6.5 Hz, NCHMe2), 2.30-2.61 (m, 1H, CH2=CHCH2), 1.43 (s, 9H, 
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CMe3), 1.05 (d, J = 6.5 Hz, 3.3H, NCHMe2), 1.04 (d, J = 6.5 Hz, 2.7H, NCHMe2); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 153.4 (C=O), 153.3 (C=O), 134.6 
(CH=CH2), 134.4 (CH=CH2), 117.3 (CH=CH2), 79.6 (CMe3), 67.2 (NCH2N), 55.9 
(NCH2), 55.7 (NCHCH2), 55.0 (NCH2), 53.1 (NCHMe2), 38.0 (CH2=CHCH2), 37.3 
(CH2=CHCH2), 28.3 (CMe3), 21.4 (NCHMe2). Spectroscopic data consistent with 
those reported in the literature.75 
Lab Book Reference GB7/618 
 
3-Isopropyl-5-phenylcarbamoylimidazolidine-1-carboxylic acid tert-butyl ester 
283  
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Using general procedure M, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and 
phenylisocycanate (238 mg, 217 µL, 2.0 mmol) in THF (7 mL) gave the crude 
product. Purification by flash column chromatography on silica with 1:1 petrol-
EtOAc as eluent gave imidazolidine 283 (245 mg, 74%) as a white solid, RF (1:1 
petrol-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers), δ 9.25 
(br s, 0.5H, NH), 8.27 (br s, 0.5H, NH), 7.51 (d, J = 8.0 Hz, 2H, Ph), 7.31 (br s, 2H, 
Ph), 7.09 (br s, 1H, Ph), 4.64-4.23 (m, 1.5H, NCH + NCH2N), 4.23-4.08 (m, 0.5H, 
NCH2N), 4.08-3.93 (m, 1H, NCH2N), 3.65-3.39 (m, 0.5H, NCH2), 3.32-3.09 (m, 1H, 
NCH2), 3.09-2.73 (m, 1H, NCH2), 2.50 (septet, J = 6.5 Hz, 1H, NCHMe2), 1.45 (br s, 
9H, CMe3), 1.12 (d, J = 6.5 Hz, 6H, NCHMe2); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 169.6 (C=O, amide), 153.4 (C=O, Boc), 137.5 (ipso-Ph), 128.8 (Ph), 
124.0 (Ph), 119.6 (Ph), 81.4 (CMe3), 67.2 (NCH2N), 67.1 (NCH2N), 61.2 (NCH2), 
55.1 (NCH), 52.5 (NCHMe2), 28.2 (CMe3), 21.3 (NCHMe2). Spectroscopic data 
consistent with those reported in the literature.75 
Lab book Reference GB7/603 
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3-Isopropyl-5-methylimidazolidine-1-carboxylic acid tert-butyl ester 284 
 
N
N
Boc
Me
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Using general procedure M, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and iodomethane 
(284 mg, 125 µL, 2.0 mmol) in THF (7 mL) gave the crude product. Purification by 
flash column chromatography on silica with 5:1 petrol-EtOAc as eluent gave 
imidazolidine 284 (151 mg, 66%) as a colourless oil, RF (5:1 petrol-EtOAc) 0.1; 
1H 
NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) δ 4.23 (d, J = 6.0 Hz, 0.55H, 
NCH2N), 4.04 (d, J = 6.0Hz, 0.45H, NCH2N), 3.97-3.66 (m, 2H, NCHMe + NCH2N), 
3.05 (t, J = 8.0 Hz, 0.55H, NCHCH2), 2.97 (t, J = 8.0 Hz, 0.45H, NCHCH2), 2.41-
2.21 (NCHCH2 + NCHMe2), 1.41 (s, 9H, CMe3), 1.24 (d, J = 6.0 Hz, 1.35H, Me), 
1.19 (d, J = 6.0Hz, 1.65H, Me), 1.05 (d, J = 6.0 Hz, 3.3H, NCHMe2), 1.04 (d, J = 6.0 
Hz, 2.7H, NCHMe2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 153.8 (C=O), 79.4 
(CMe3), 67.1 (NCH2N), 59.0 (NCHCH2), 58.1 (NCHCH2), 53.2 (NCHMe), 52.2 
(NCHMe2), 28.4 (CMe3), 21.4 (NCHMe2), 21.3 (NCHMe2), 19.7 (Me), 19.2 (Me). 
Spectroscopic data consistent with those reported in the literature.75 
Lab Book Reference GB7/604 
 
1-Isopropyl-5-tributylstannylimidazolidine-1-carboxylic acid tert-butyl ester 285
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Using general procedure M, -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol), s-
BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) and tributylstannyl 
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chloride (651 mg, 542 µL, 2.0 mmol) in THF (7 mL) gave the crude product. 
Purification by flash column chromatography on silica with 95:5 petrol-EtOAc as 
eluent gave imidazolidine 285 (287 mg, 57%) as a colourless oil, RF (95:5 petrol-
EtOAc) 0.5; 1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 4.22 (d, J = 
6.0 Hz, 0.7H, NCH2N), 4.12 (d, J = 6.0 Hz, 0.3H, NCH2N), 3.86 (d, J = 6.0 Hz, 0.3H, 
NCH2N), 3.60 (d, J = 6.0 Hz, 0.7H, NCH2N), 3.67-3.55 (m, 0.3H, NCHSn), 3.43 (dd, 
J = 10.0, 6.5 Hz, 0.7H, NCHSn), 3.18 (dd, J = 9.5, 6.5 Hz, 0.7H, NCHCH2), 3.03 (dd, 
J = 9.0, 7.0 Hz, 0.3H, NCHCH2), 2.79 (dd, J = 9.0, 6.0 Hz, 0.3H, NCHCH2), 2.52 (t, J 
= 9.5 Hz, 0.7H, NCHCH2), 2.39 (septet, J = 6.0 Hz, 1H, NCHMe2), 1.62-1.38 (m, 6H, 
SnCH2), 1.42 (s, 9H, CMe3), 1.37-1.22 (m, 6H, SnCH2CH2), 1.11 (d, J = 6.0 Hz, 
1.8H, NCHMe2), 1.09 (d, J = 4.0 Hz, 4.2H, NCHMe2), 1.00-0.75 (m, 15H, 
SnCH2CH2CH2 + SnCH2CH2CH2Me); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 
152.9 (C=O), 152.8 (C=O), 79.7 (CMe3), 78.9 (CMe3), 66.8 (NCH2N), 66.7 
(NCH2N), 55.7 (NCHCH2), 55.2 (NCHCH2), 53.3 (NCHMe2), 53.0 (NCHMe2), 45.9 
(NCHSn), 45.0 (NCHSn), 29.0 (SnCH2), 28.4 (CMe3), 27.9 (CMe3), 27.7 (SnCH2), 
27.4 (SnCH2CH2), 26.7 (SnCH2CH2), 21.6 (NCHMe2), 20.4 (NCHMe2), 13.6 
(CH2Me), 13.5 (CH2Me), 9.9 (CH2Me), 9.4 (CH2Me). Spectroscopic data consistent 
with those reported in the literature.75 
Lab Book Reference GB7/620 
 
3-Isopropyl-5-phenylimidazolidine-1-carboxylic acid tert-butyl ester 286 
 
N
N
i-Pr
Boc
Ph
286
 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc-i-Pr imidazolidine 64 (214 mg, 1.0 mmol) in 
THF (7 mL) at –30 °C under Ar. The resulting solution was stirred at –30 °C for 10 
min. Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) was added and the 
resulting solution was stirred at –30 °C for 30 min. The solution was allowed to warm 
to rt and stirred at rt for 30 min. Then, bromobenzene (110 mg, 74 µL, 0.7 mmol) in 
TBME (5 mL) was added. A mixture of Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%) and t-
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Bu3PHBF4 (11 mg, 0.0625 mmol, 6.25 mol%) was added in one portion. The reaction 
flask was transferred to a pre-heated oil bath and the solution was stirred and heated at 
reflux for 16 h. After cooling to rt, 35% NH4OH(aq) (0.2 mL) was added and the 
resulting mixture was stirred at rt for 1 h. The solids were removed by filtration 
through a pad of Celite® and washed with Et2O (20 mL). The filtrate was washed with 
saturated brine (20 mL) and H2O (20 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-EtOAc as eluent gave phenyl imidazolidine 
286 (87 mg, 43%) as a colourless oil, RF (9:1 petrol-EtOAc) 0.2; IR (CHCl3) 3015, 
2978, 1690 (C=O), 1410, 1217, 1165, 908, 777, 738 cm–1; 1H NMR (400 MHz, 
CDCl3) (75:25 mixture of rotamers) δ 7.39-7.21 (m, 5H, Ph), 4.89 (br t, J = 7.0 Hz, 
0.25 H, NCHPh), 4.77 (t, J = 8.0 Hz, 0.75H, NCHPh), 4.53 (d, J = 6.0 Hz, 0.75H, 
NCH2N), 4.32 (d, J = 5.0 Hz, 0.25H, NCH2N), 4.17-4.06 (m, 1H, NCH2N), 3.39 (t, J 
= 8.0 Hz, 0.75H, NCHCH2), 3.29 (t, J = 7.0 Hz, 0.25H, NCHCH2), 2.68-2.57 (m, 1H, 
NCHCH2), 2.46 (septet, J = 6.5 Hz, 1H, NCHMe2), 1.44 (s, 2.25H, CMe3), 1.17 (s, 
6.75H, CMe3), 1.12 (d, J = 6.5 Hz, 1.5H, NCHMe2), 1.11 (d, J = 6.5 Hz, 4.5H, 
NCHMe2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 153.6 (C=O), 142.8 (ipso-Ph), 
128.4 (Ph), 128.1 (Ph), 127.0 (Ph), 126.4 (Ph), 126.1 (Ph), 79.6 (CMe3), 68.2 
(NCH2N), 68.0 (NCH2N), 60.9 (NCHPh), 60.6 (NCHCH3), 53.1 (NCHMe2), 28.4 
(CMe3), 28.0 (CMe3), 21.6 (NCHMe2), 21.5 (NCHMe2); MS (ESI) m/z 291 [(M + H)
+, 
100], 235 (45); HRMS (ESI) m/z calcd for C17H26N2O2 (M + H)
+ 291.2067, found 
291.2073 (–1.0 ppm error). 
Lab Book Reference GB7/654 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexanes, 1.3 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 1.0 mmol) 
in THF (7 mL) at –30 °C under Ar. The resulting solution was stirred at –30 °C for 10 
min. Then, ZnCl2 (0.6 mL of a 1.0 M solution in Et2O, 0.6 mmol) as added and the 
resulting solution was stirred at –30 °C for 30 min. The solution was allowed to warm 
to rt and stirred at rt for 30 min. Then, bromobenzene (110 mg, 74 µL, 0.7 mmol) in 
TBME (5 mL) was added. A mixture of Pd(OAc)2 (11 mg, 0.05 mmol, 5 mol%) and t-
Bu3PHBF4 (11 mg, 0.0625 mmol, 6.25 mol%) was added in one portion. The 
resulting solution was stirred at rt for 16 h. 35% NH4OH(aq) (0.2 mL) was added and 
the reaction solution was stirred at rt for 1 h. The solids were removed by filtration 
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through a pad of Celite® and washed with Et2O (20 mL). The filtrate was washed with 
saturated brine (20 mL) and H2O (20 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-EtOAc as eluent gave phenyl imidazolidine 
286 (43 mg, 21%) as a colourless oil. 
Lab Book Reference GB7/653 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/THF (–30 
°C) 
(Scheme 5.24) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –30 °C for 5 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added. The solution was stirred at –30 °C for 20 min. 
 For -Boc pyrrolidine 38, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. Upon addition of s-BuLi, a new peak at 1646 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 287. After a lithiation time of 3 min, complete 
lithiation of -Boc pyrrolidine 38 to lithiated intermediate 287 was observed. No peak 
corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/667 
 
ReactIR monitoring of the lithiation of -Boc pyrrolidine 38 by s-BuLi/THF (–78 
°C) 
(Scheme 5.25) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc pyrrolidine 38 (171 mg, 175 µL, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 15 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added. The solution was stirred at –78 °C 45 min. 
 For -Boc pyrrolidine 38, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. Upon addition of s-BuLi, a new peak at 1660 cm
–1 was observed which was 
assigned to νC=O in the lithiated intermediate 287. After a lithiation time of 45 min, 
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lithiation was still incomplete. No peak corresponding to a prelithiation complex was 
observed. 
Lab Book Reference GB8/725 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/THF (–30 °C) 
(Scheme 5.26) 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of -Boc-ʹ-benzyl piperazine 59 (276 mg, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –30 °C for 10 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –30 °C 
for 10 min. 
 For -Boc-ʹ-benzyl piperazine 59, a peak at 1698 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1646 cm
–1 which was 
assigned to νC=O of the lithiated intermediate 288. After a lithiation time of 3 min, 
complete lithiation of -Boc-ʹ-benzyl piperazine 59 to lithiated intermediate 288 was 
observed. No peak corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/750 
 
ReactIR monitoring of the lithiation of piperazine 59 by s-BuLi/THF (–78 °C) 
(Scheme 5.27) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzyl piperazine 59 (276 mg, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 5 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C. 
for 45 min. 
 For -Boc-ʹ-benzyl piperazine 59, a peak at 1696 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak appeared at 1646 cm
–1 which was 
assigned to νC=O of the lithiated intermediate 288. After a lithiation time of 45 min, 
complete lithiation of -Boc-ʹ-benzyl piperazine 59 to lithiated intermediate 288 was 
observed. No peak corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/751 
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Attampted ReactIR monitoring of the lithiation of -Boc piperidine 44 by s-
BuLi/TMEDA in THF 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc piperidine 44 (185 mg, 192 µL, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 10 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C 
for 10 min (to verify the stability of readout on ReactIR). Then, TMEDA (151 mg, 196 
µL, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 45 min. 
 For -Boc piperidine 44, a peak at 1695 cm–1 was observed which was assigned to 
νC=O. No other peaks were observed after the addition of s-BuLi or TMEDA. 
Lab Book Reference GB8/669 
 
Attampted ReactIR monitoring of the lithiation of -Boc piperidine 44 by s-
BuLi/THF 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to rt, –30 °C, a solution of -Boc piperidine 44 (185 mg, 192 µL, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred for 10 min (to 
verify stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution in 
hexanes, 1.0 mmol) was added dropwise. The solution was stirred at –30 °C for 25 min. 
 For -Boc piperidine 44, a peak at 1694 cm–1 was observed which was assigned to 
νC=O. No other peaks were observed after the addition of s-BuLi. 
Lab Book Reference GB8/670 
 
Attampted ReactIR monitoring of the lithiation of -Boc piperidine 44 by s-
BuLi/(+)-sparteine surrogate 6 in THF 
 THF (10 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc piperidine 44 (185 mg, 192 µL, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 30 
min (to verify stability of readout on ReactIR). Then, a solution of (+)-sparteine surrogate 
6 (227 mg, 1.3 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –
78 °C for 20 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of 
a 1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 20 min. 
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 For -Boc piperidine 44, a peak at 1695 cm–1 was observed which was assigned to 
νC=O. No other peaks were observed after the addition of s-BuLi and (+)-sparteine 
surrogate. 
Lab Book Reference GB8/671 
 
ReactIR monitoring of the lithiation of -Boc-ʹ-iso-propylimidazolidine 64 by s-
BuLi/THF (–78 °C) 
(Scheme 5.29) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 10 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.0 mmol) was added dropwise. The solution was stirred at –78 °C 
for 25 min. 
 For -Boc-ʹ-i-Pr imidazolidine 64, a peak at 1705 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak at 1663 cm
–1 appeared which was 
assigned to νC=O of lithiated intermediate 290. After a lithiation time of 3 min, partial 
lithiation (~60%) of -Boc-ʹ-i-Pr imidazolidine 64 to lithiated intermediate 290 was 
observed. After a further 20 min incubation, no further lithiation was observed. No peak 
corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/672 
 
ReactIR monitoring of the lithiation of -Boc-’-iso-propylimidazolidine 64 by s-
BuLi/THF (–30 °C) 
(Scheme 5.30) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of -Boc-ʹ-i-Pr imidazolidine 64 (214 mg, 
1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –30 °C for 8 
min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M 
solution in hexanes, 1.0 mmol) was added dropwise. The solution was stirred at –30 °C 
for 10 min. 
 For -Boc-ʹ-i-Pr imidazolidine 64, a peak at 1705 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak at 1662 cm
–1 appeared which was 
assigned to νC=O of lithiated intermediate 290. After a lithiation time of 3 min, partial 
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lithiation of -Boc-ʹ-i-Pr imidazolidine 64 to lithiated intermediate 290 was observed. 
After a further 7 min incubation, slower complete lithiation of -Boc-ʹ-i-Pr 
imidazolidine 64 was observed. No peak corresponding to a prelithiation complex was 
observed. 
Lab Book Reference GB8/673 
 
ReactIR monitoring of the lithiation of -Boc-’-benzylhomopiperazine 272 by s-
BuLi/THF (–78 °C) 
(Scheme 5.31) 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of -Boc-ʹ-benzyl homopiperazine 272 
(290 mg, 1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 
°C for 10 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
78 °C for 1 h. 
 For -Boc-ʹ-benzyl hompiperazine 272, a peak at 1694 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak at 1645 cm
–1 appeared which was 
assigned to νC=O of lithiated intermediate 291. After a lithiation time of 1 h, partial 
lithiation (~40%) of -Boc-ʹ-benzyl homopiperazine 272 to lithiated intermediate 291 
was observed. No peak corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/674 
 
ReactIR monitoring of the lithiation of -Boc-’-benzylhomopiperazine 272 by s-
BuLi/THF (–30 °C) 
(Scheme 5.32) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of -Boc-ʹ-benzyl homopiperazine 272 
(290 mg, 1.0 mmol) in THF (2 mL) was added dropwise. The solution was stirred at –30 
°C for 10 min (to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 
1.3 M solution in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –
30 °C for 1 h. 
 For -Boc-ʹ-benzyl hompiperazine 272, a peak at 1695 cm–1 was observed which was 
assigned to νC=O. After addition of s-BuLi, a new peak at 1646 cm
–1 appeared which was 
assigned to νC=O of lithiated intermediate 291. After a lithiation time of 20 min, partial 
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lithiation (~60%) of -Boc-ʹ-benzyl homopiperazine 272 to lithiated intermediate 291 
was observed. After a further 40 min incubation, no further lithiation was observed. No 
peak corresponding to a prelithiation complex was observed. 
Lab Book Reference GB8/675 
 
ReactIR monitoring of the lithiation of O-alkyl carbamate 100 by s-BuLi/THF 
(Scheme 5.32) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –78 °C, a solution of O-alkyl carbamate 100 (263 mg, 1.0 
mmol) in THF (2 mL) was added dropwise. The solution was stirred at –78 °C for 10 min 
(to verify the stability of readout on ReactIR). Then, s-BuLi (1.0 mL of a 1.3 M solution 
in hexanes, 1.3 mmol) was added dropwise. The solution was stirred at –78 °C for 1 h. 
 For O-alkyl carbamate 100, a peak at 1694 cm–1 was observed which was assigned to 
νC=O. After addition of s-BuLi, a new broad peak at 1630 cm
–1 appeared which was 
assigned to νC=O of lithiated intermediate 292. After a lithiation time of 1 h, lithiation was 
still incomplete (~40% completion). No peak corresponding to a prelithiation complex 
was observed. 
Lab Book Reference GB8/684 
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7.7 Experimental for Chapter 6 
rac-2-Phenyl pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester rac-
343 
(Table 6.2, entry 1) 
N
Boc
Ph
OMe
O
rac-343
 
 
Using general procedure N, s-BuLi (615 µL of a 1.3 M solution in hexanes, 0.80 mmol) 
and phenyl pyrrolidine rac-77 (153 mg, 0.62 mmol) in THF (4 mL) at –78 °C for 30 min 
and methyl chloroformate (117 mg, 95 µL, 1.24 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine rac-343 (33 mg, 17%) as a colourless oil, RF (3:1 petrol-Et2O) 0.2; IR 
(film) 2977, 1747 (C=O, CO2Me), 1697 (C=O, Boc), 1391, 1250, 1162 cm
–1; 1H NMR 
(400 MHz, CDCl3) (75:25 mixture of rotamers) δ 7.40-7.30 (m, 4H, Ph), 7.30-7.21 (m, 
1H, Ph), 3.76 (s, 2.25H, OMe), 3.73 (s, 0.75H, OMe), 3.75-3.55 (m, 2H, NCH2), 2.67-
2.52 (m, 1H, CH2), 2.32-2.22 (m, 1H, CH2), 1.95-1.84 (m, 1H, CH2), 1.72-1.60 (m, 1H, 
CH2), 1.49 (s, 2.25H, CMe3), 1.21 (s, 6.75H, CMe3); 
13C NMR (100.6 MHz, CDCl3) 
(rotamers) δ 173.7 (C=O, CO2Me), 162.0 (C=O, CO2Me), 154.5 (C=O, Boc), 154.2 
(C=O, Boc), 140.6 (ipso-Ph), 138.0 (ipso-Ph), 128.6 (Ph), 127.8 (Ph), 127.6 (Ph), 127.4 
(Ph), 127.3 (Ph), 127.1 (Ph), 80.2 (CMe3), 78.8 (CMe3), 71.5 (NC), 71.4 (NC), 52.2 
(OMe), 47.5 (NCH2), 44.5 (NCH2), 43.2 (CH2), 41.5 (CH2), 35.8 (CH2), 33.1 (CH2), 28.0 
(CMe3), 27.7 (CMe3); MS (ESI) m/z 328 [(M + Na)
+, 100], 250 (55), 206 (27); HRMS 
(ESI) m/z calcd for C17H21NO4 (M + Na)
+ 328.1519, found 328.1526 (–2.1 ppm error). 
Lab Book Reference GB8/699 
 
 (Table 6.2, entry 2) 
Using general procedure N, n-BuLi (250 µL of a 2.05 M solution in hexanes, 0.50 mmol) 
and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) in THF (4 mL) at –78 °C for 60 min 
and methyl chloroformate (76 mg, 62 µL, 0.80 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine rac-343 (41 mg, 33%) as a colourless oil and recovered phenyl 
pyrrolidine rac-77 (66 mg, 66% recovery) as a colourless oil. 
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Lab Book Reference GB8/704 
 
 (Table 6.2, entry 3) 
Using general procedure N, n-BuLi (250 µL of a 2.05 M solution in hexanes, 0.50 mmol) 
and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) in THF (4 mL) at –78 °C for 180 
min and methyl chloroformate (76 mg, 62 µL, 0.80 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine rac-343 (48 mg, 39%) as a colourless oil and recovered phenyl 
pyrrolidine rac-77 (52 mg, 52% recovery) as a colourless oil. 
Lab Book Reference GB8/705 
 
 (Table 6.2, entry 4) 
Using general procedure O, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol), 
TMEDA (58 mg, 75 µL, 0.5 mmol) and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) 
in THF (4 mL) at –78 °C for 60 min and methyl chloroformate (76 mg, 62 µL, 0.80 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 3:1 petrol-Et2O as eluent gave pyrrolidine rac-343 (38 mg, 31%) as a colourless oil 
and recovered phenyl pyrrolidine rac-77 (65 mg, 65% recovery) as a colourless oil. 
Lab Book Reference GB8/708 
 
 (Table 6.2, entry 5) 
Using general procedure O, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol), 
TMEDA (58 mg, 75 µL, 0.5 mmol) and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) 
in THF (4 mL) at –78 °C for 180 min and methyl chloroformate (76 mg, 62 µL, 0.80 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 3:1 petrol-Et2O as eluent gave pyrrolidine rac-343 (40 mg, 33%) as a colourless oil 
and recovered phenyl pyrrolidine rac-77 (49 mg, 49% recovery) as a colourless oil. 
Lab Book Reference GB8/709 
 
 (Table 6.2, entry 6) 
Using general procedure O, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol), 
TMEDA (58 mg, 75 µL, 0.5 mmol) and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) 
in Et2O (4 mL) at –78 °C for 60 min and methyl chloroformate (76 mg, 62 µL, 0.80 
mmol) gave the crude product. Purification by flash column chromatography on silica 
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with 3:1 petrol-Et2O as eluent gave pyrrolidine rac-343 (35 mg, 29%) as a colourless oil 
and recovered phenyl pyrrolidine rac-77 (70 mg, 70% recovery) as a colourless oil. 
Lab Book Reference GB8/714 
 
 (Table 6.2, entry 7) 
Using general procedure O, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol), 
TMEDA (58 mg, 75 µL, 0.5 mmol) and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) 
in Et2O (4 mL) at –78 °C for 180 min and methyl chloroformate (76 mg, 62 µL, 0.80 
mmol) gave the crude product. Purification by flash column chromatography on silica 
with 3:1 petrol-Et2O as eluent gave pyrrolidine rac-343 (39 mg, 32%) as a colourless oil 
and recovered phenyl pyrrolidine rac-77 (52 mg, 52% recovery) as a colourless oil. 
Lab Book Reference GB8/715 
 
 (Table 6.3, entry 3) 
Using general procedure N, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol) 
and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) in THF (4 mL) at 0 °C for 10 min 
and methyl chloroformate (76 mg, 62 µL, 0.80 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine rac-343 (88 mg, 72%) as a colourless oil. 
Lab Book Reference GB8/713 
 
 (Table 6.3, entry 4) 
Using general procedure N, n-BuLi (200 µL of a 2.5 M solution in hexanes, 0.50 mmol) 
and phenyl pyrrolidine rac-77 (100 mg, 0.40 mmol) in THF (4 mL) at 0 °C for 5 min and 
methyl chloroformate (76 mg, 62 µL, 0.80 mmol) gave the crude product. Purification by 
flash column chromatography on silica with 3:1 petrol-Et2O as eluent gave pyrrolidine 
rac-343 (94 mg, 77%) as a colourless oil. 
Lab Book Reference GB8/712 
 
 (Table 6.3, entry 5) 
Using general procedure N, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine rac-77 (50 mg, 0.20 mmol) in THF (4 mL) at rt for 5 min and 
methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. Purification by 
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flash column chromatography on silica with 3:1 petrol-Et2O as eluent gave pyrrolidine 
rac-343 (25 mg, 41%) as a colourless oil. 
Lab Book Reference GB9/785 
 
rac-2-Methyl-2-phenylpyrrolidine-1-carboxylic acid tert-butyl ester rac-334 
 
N
Boc
Ph
Me
rac-334
 
 
Using general procedure P, n-BuLi (232 µL of a 2.5 M solution in hexanes, 0.58 mmol) 
and phenyl pyrrolidine rac-77 (110 mg, 0.44 mmol) in THF (4 mL) and dimethyl sulfate 
(112 mg, 84 µL, 0.89 mmol) gave the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine rac-334 (158 
mg, 98%) as a colourless oil, RF (9:1 petrol-Et2O) 0.2; IR (CHCl3) 3017, 2975, 1674 
(C=O), 1400, 1216, 759 cm–1; 1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 
7.32-7.18 (m, 5H, Ph), 3.74-3.66 (m, 2H, NCH2), 2.11-1.98 (m, 2H, CH2), 1.90-1.81 (m, 
2H, CH2), 1.74 (s, 0.9H, Me), 1.58 (s, 2.1H, Me), 1.45 (s, 2.7H, CMe3), 1.11 (s, 6.3H, 
Me); 13C NMR (100.6 MHz, CDCl3) (rotamers) δ 154.7 (C=O), 148.8 (ipso-Ph), 128.1 
(Ph), 126.2 (Ph), 125.3 (Ph), 79.1 (CMe3), 64.8 (NC), 48.6 (NCH2), 48.4 (NCH2), 45.6 
(CH2), 28.3 (CMe3), 27.8 (CMe3), 25.1 (CH2), 21.8 (CH2); MS (ESI) m/z 284 [(M + Na)
+, 
100], 206 (65); HRMS (ESI) m/z calcd for C16H23NO2 (M + Na)
+ 284.1621, found 
284.1617 (+1.5 ppm error). 
Lab Book Reference GB8/722 
 
rac-2-Phenyl-2-phenylcarbamoylpyrrolidine-1-carboxylic acid tert-butyl ester rac-
347 
 
N
Boc
Ph
N
H
O
rac-347
Ph
 
 
Using general procedure P, n-BuLi (232 µL of a 2.5 M solution in hexanes, 0.58 mmol) 
and phenyl pyrrolidine rac-77 (110 mg, 0.44 mmol) in THF (4 mL) and phenyl 
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isocyanate (106 mg, 97 µL, 0.89 mmol) gave the crude product. Purification by flash 
column chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine rac-347 
(158 mg, 98%) as a colourless oil, RF (9:1 petrol-Et2O) 0.2; IR (CHCl3) 2976, 1718 
(C=O, amide), 1688 (C=O, Boc), 1600, 1555, 1446, 1390, 1368, 1154, 756 cm–1; 1H 
NMR (400 MHz, CDCl3) δ 7.63-7.55 (m, 2H, Ph), 7.34-7.29 (m, 6H, Ph), 7.24-7.28 (m, 
2H, Ph), 3.86-3.57 (m, 2H, NCH2), 3.34-3.15 (br s, 1H, NH), 2.05-1.67 (m, 4H, CH2), 
1.51 (s, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 170.8 (C=O, amide), 
156.5 (C=O, Boc), 153.1 (ipso-Ph), 152.2 (ipso-Ph), 141.5 (ipso-Ph), 139.2 (ipso-Ph), 
129.0 (Ph), 128.9 (Ph), 128.8 (Ph), 128.5 (Ph), 127.4 (Ph), 125.0 (Ph), 123.9 (Ph), 123.8 
(Ph), 123.0 (Ph), 119.9 (Ph), 119.7 (Ph), 118.6 (Ph), 81.1 (CMe3), 75.0 (NC), 49.9 
(NCH2), 41.4 (CH2), 28.0 (CMe3), 27.5 (CMe3), 23.3 (CH2); MS (ESI) m/z 389 [(M + 
Na)+, 100], 367 [(M + H)+, 39], 311 (46), 267 (32); HRMS (ESI) m/z C22H26N2O3 (M + 
Na)+ 389.1836, found 389.1827 (+2.2 ppm error). 
Lab Book Reference GB8/721 
 
rac-1,1,7a-Triphenyltetrahydropyrrolo[1,2-c]oxazol-3-one rac-348 
 
N
O
O
Ph
Ph
Ph
rac-348
 
 
Using general procedure P, n-BuLi (124 µL of a 2.5 M solution in hexanes, 0.31 mmol) 
and phenyl pyrrolidine rac-77 (60 mg, 0.24 mmol) in THF (4 mL) and benzophenone (88 
mg, 0.48 mmol) in THF (1 mL) gave the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave oxazolidone rac-348 (87 
mg, 84%) as a white solid, mp 134-135 °C; RF (9:1 petrol-Et2O) 0.1; IR (CHCl3) 3018, 
1747 (C=O), 1449, 1350, 1216, 1016, 759, 704, 668 cm–1; 1H NMR (400 MHz, CDCl3) δ 
7.81-7.73 (m, 2H, Ph), 7.48-7.38 (m, 2H, Ph), 7.38-7.30 (m, 1H, Ph), 7.30-7.22 (m, 2H, 
Ph), 7.20-7.11 (m, 3H, Ph), 7.04-6.92 (m, 5H, Ph), 3.88 (ddd, J = 12.0, 9.0, 7.0 Hz, 1H, 
NCH2), 2.90 (ddd, J = 12.0, 10.0, 3.5 Hz, 1H, NCH2), 2.63 (dd, J = 12.0, 7.0 Hz, 1H, 
CH2), 2.00-1.89 (m, 1H, CH2), 1.69-1.58 (m, 1H, CH2), 1.56-1.40 (m, 1H, CH2); 
13C 
NMR (100.6 MHz, CDCl3) δ 161.3 (C=O), 140.9 (ipso-Ph), 140.8 (ipso-Ph), 136.9 (ipso-
Ph), 128.7 (Ph), 128.4 (Ph), 128.3 (Ph), 128.0 (Ph), 127.8 (Ph), 127.6 (Ph), 127.4 (Ph), 
126.7 (Ph), 126.5 (Ph), 126.3 (Ph), 89.2 (OCPh2), 80.3 (NC), 44.2 (NCH2), 34.3 (CH2), 
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23.1 (CH2); MS (ESI) m/z 378 [(M + Na)
+, 84], 356 [(M + H)+, 100]; HRMS (ESI) m/z 
calcd for C24H21NO2 (M + H)
+ 356.1645, found 356.1640 (+1.3 ppm error). 
Lab Book Reference GB8/741 
 
rac-2-Allyl-2-phenylpyrrolidine-1-carboxylic acid tert-butyl ester rac-349 
 
N
Boc
Ph
rac-349
 
 
Using general procedure P, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine rac-77 (50 mg, 0.20 mmol) in THF (4 mL) and allyl bromide (48 
mg, 35 µL, 0.40 mmol) gave the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine rac-349 (54 mg, 
95%) as a colourless oil, RF (9:1 petrol-Et2O) 0.2; IR (CHCl3) 3018, 2979, 1675 (C=O), 
1395, 1367, 1216, 1159 cm–1; 1H NMR (400 MHz, CDCl3) (70:30 mixture of rotamers) δ 
7.33-7.27 (m, 2H, Ph), 7.24-7.16 (m, 3H, Ph), 5.93-5.73 (m, 0.7H, CH=), 5.26-5.12 (m, 
1.3H, CH= + CH2=), 3.91-3.77 (m, 0.7H, CH2=), 3.75-3.64 (m, 0.3H, CH2=), 3.55-3.31 
(m, 1H, NCH2), 3.20-3.08 (m, 0.3H, NCH2), 2.88-2.70 (m, 0.7H, NCH2), 2.66-2.56 (m, 
0.3H, CH2), 2.39-2.20 (m, 0.7H, CH2), 1.98-1.82 (m, 0.6H, CH2), 1.81-1.67 (m, 1.4H, 
CH2), 1.60-1.54 (m, 1H, CH2), 1.46 (s, 2.7H, CMe3), 1.19 (s, 6.3H, CMe3); 
13C NMR 
(100.6 MHz, CDCl3) (rotamers) δ 154.7 (C=O), 148.5 (ipso-Ph), 148.4 (ipso-Ph), 134.4 
(CH=), 128.4 (Ph), 128.1 (Ph), 126.4 (Ph), 126.3 (Ph), 125.2 (Ph), 125.1 (Ph), 118.8 
(CH2=), 79.4 (CMe3), 78.8 (CMe3), 68.1 (NC), 61.2 (NC), 49.1 (NCH2), 49.0 (NCH2), 
42.2 (CH2), 41.3 (CH2), 41.2 (CH2), 28.3 (CMe3), 27.9 (CMe3), 20.8 (CH2); MS (ESI) m/z 
310 [(M + Na)+, 79], 288 [(M + H)+, 10], 232 (100); HRMS (ESI) m/z calcd for 
C18H25NO2 (M + H)
+ 288.1958, found 288.1955 (+0.9 ppm error). 
Lab Book Reference GB9/788 
 
rac-2-Phenyl-2-tributylstannanylpyrrolidine-1-carboxylic acid tert-butyl ester rac-
350 
 
N
Boc
Ph
SnBu3
r ac-350
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Using general procedure P, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine rac-77 (50 mg, 0.20 mmol) in THF (4 mL) and tributylstannyl 
chloride (130 mg, 108 µL, 0.40 mmol) gave the crude product. Purification by flash 
column chromatography on silica with 99:1 petrol-Et2O as eluent gave pyrrolidine rac-
350 (90 mg, 84%) as a colourless oil, RF (99:1 petrol-Et2O) 0.2; IR (CHCl3) 2956, 2924, 
2871, 1678 (C=O), 1402, 1158, 1132 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.24 (dd, J = 
8.5, 7.5 Hz, 2H, m-Ph), 7.04 (br t, J = 7.5 Hz, 1H, p-Ph), 6.98 (dd, J = 8.5, 1.0 Hz, 2H, o-
Ph), 3.50 (ddd, J = 11.0, 9.0, 1.5 Hz, 1H, NCH2), 3.33 (td, J = 11.0, 7.0 Hz, 1H, NCH2), 
2.41 (dd, J = 12.5, 5.0 Hz, 1H, CH2), 2.15 (td, J = 12.0, 6.0 Hz, 1H, CH2), 1.83-1.68 (m, 
1H, CH2), 1.58-1.48 (m, 1H, CH2), 1.51 (s, 9H, CMe3), 1.46-1.34 (m, 6H, CH2), 1.31-
1.18 (m, 6H, CH2), 0.93-0.73 (m, 15H, CH2 + Me); 
13C NMR (100.6 MHz, CDCl3) δ 
155.6 (C=O), 148.1 (ipso-Ph), 128.3 (Ph), 124.3 (Ph), 123.9 (Ph), 78.9 (CMe3), 62.8 
(NC), 46.3 (NCH2), 38.4 (CH2), 28.9 (CH2), 28.3 (CMe3), 27.3 (CH2), 23.5 (CH2), 13.4 
(Me), 11.7 (CH2); MS (ESI) m/z 560 [(M + Na)
+, 13], 480 (100), 424 (12); HRMS (ESI) 
m/z calcd for C27H47NO2Sn (M + Na)
+ 560.2526, found 560.2526 (0.0 ppm error). 
Lab Book Reference GB9/789 
 
rac-2-Phenyl-2-trimethylsilanylpyrrolidine-1-carboxylic acid tert-butyl ester rac-351 
 
N
Boc
Ph
SiMe3
rac-351
 
 
Using general procedure P, n-BuLi (232 µL of a 2.5 M solution in hexanes, 0.58 mmol) 
and phenyl pyrrolidine rac-77 (110 mg, 0.44 mmol) in THF (4 mL) and Me3SiCl (97 mg, 
113 µL, 0.89 mmol) gave the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine rac-351 (158 
mg, 65%) as a colourless oil, RF (9:1 petrol-Et2O) 0.9; IR (film) 2972, 1695 (C=O), 1396, 
1246, 1165, 1126, 843 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.27 (t, J = 7.0 Hz, 2H, m-
Ph), 7.16-7.08 (m, 3H, Ph), 3.52 (t, J = 9.5 Hz, 1H, NCH2), 3.32 (ddd, J = 11.0, 9.5, 7.0 
Hz, 1H, NCH2), 2.21 (t, J = 12.0 Hz, 1H, CH2), 2.02 (ddd, J = 13.0, 12.0, 6.0 Hz, 1H, 
CH2), 1.76-1.67 (m, 1H, CH2), 1.57-1.46 (m, 1H, CH2), 1.50 (s, 9H, CMe3), 0.03 (s, 9H, 
SiMe3); 
13C NMR (100.6 MHz, CDCl3) δ 155.4 (C=O), 145.3 (ipso-Ph), 128.3 (Ph), 
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125.3 (Ph), 125.0 (Ph), 78.7 (CMe3), 60.9 (NC), 47.6 (NCH2), 37.9 (CH2), 28.3 (CMe3), 
22.7 (CH2), –1.5 (SiMe3); MS (ESI) m/z 342 [(M + Na)
+, 36], 320 [(M + H)+, 19], 264 
(39), 248 (100); HRMS (ESI) m/z calcd for C18H29NO2Si (M + H)
+ 320.2040, found 
320.2035 (+1.6 ppm error). 
Lab book Reference GB8/723 
 
rac-2-Phenylpyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester rac-
343 
N
Boc
Ph
OMe
O
rac-343
 
 
Using general procedure Q, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine (R)-77 (50 mg, 0.20 mmol, 97:3 er) in THF (4 mL) at 0 °C for 5 
min and methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine rac-343 (50 mg, 82%, 50:50 er by CSP-HPLC) as a colourless oil, CSP-
HPLC: Chiralcel OD (99.5:0.5 hexane-i-PrOH, 1 mL min–1) (R)-343 21.8 min, (S)-343 
24.8 min. 
Lab Book Reference GB9/809 
 
(R)- or (S)-2-Phenylpyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl 
ester (R)- or (S)-343 
N
Boc
Ph
OMe
O
(R)- or (S)-343
 
 
(Table 6.4, entry 1) 
Using general procedure Q, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine (R)-77 (50 mg, 0.20 mmol, 97:3 er) in THF (4 mL) at –78 °C for 
60 min and methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine (R)- or (S)-343 (19 mg, 31%, 97:3 er by CSP-HPLC) as a colourless oil, 
[α]D +13.1 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel OD (99.5:0.5 hexane-i-PrOH, 1 mL 
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min–1) major enantiomer 21.8 min, minor enantiomer 24.8 min and recovered (R)-77 (31 
mg, 62% recovery) as a colourless oil. 
Lab Book Reference GB9/810 
 
 (Table 6.4, entry 2) 
Using general procedure Q, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine (R)-77 (50 mg, 0.20 mmol, 97:3 er) in THF (4 mL) at –50 °C for 
10 min and methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine (R)- or (S)-343 (45 mg, 74%, 90:10 er by CSP-HPLC) as a colourless 
oil, [α]D +34.1 (c 0.73 in CHCl3); CSP-HPLC: Chiralpcel OD (99.5:0.5 hexane-i-PrOH, 1 
mL min–1) major enanitomer 343 21.8 min, minor enantiomer 343 24.8 min. 
Lab Book Reference GB9/813 
 
 (Table 6.4, entry 3) 
Using general procedure Q, n-BuLi (64 µL of a 2.5 M solution in hexanes, 0.16 mmol) 
and phenyl pyrrolidine (R)-77 (30 mg, 0.12 mmol, 97:3 er) in THF (4 mL) at –50 °C for 5 
min and methyl chloroformate (23 mg, 19 µL, 0.24 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine (R)- or (S)-343 (28 mg, 78%, 94:6 er by CSP-HPLC) as a colourless oil, 
[α]D +46.7 (c 0.525 in CHCl3); CSP-HPLC: Chiralcel OD (99.5:0.5 hexane-i-PrOH, 1 mL 
min–1) major enantiomer 343 21.8 min, minor enantiomer 343 24.8 min. 
Lab Book Reference GB9/820 
 
 (Table 6.4, entry 4) 
Using general procedure Q, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine (R)-77 (50 mg, 0.20 mmol, 97:3 er) in THF (4 mL) at –40 °C for 5 
min and methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine (R)- or (S)-343 (42 mg, 69%, 85:15 er by CSP-HPLC) as a colourless 
oil, [α]D +39.1 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel OD (99.5:0.5 hexane-i-PrOH, 1 
mL min–1) major enantiomer 343 21.8 min, minor enantiomer 343 24.8 min. 
Lab Book Reference GB9/812 
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 (Table 6.4, entry 5) 
Using general procedure Q, n-BuLi (104 µL of a 2.5 M solution in hexanes, 0.26 mmol) 
and phenyl pyrrolidine (R)-77 (50 mg, 0.20 mmol, 97:3 er) in THF (4 mL) at –30 °C for 5 
min and methyl chloroformate (38 mg, 31 µL, 0.40 mmol) gave the crude product. 
Purification by flash column chromatography on silica with 3:1 petrol-Et2O as eluent 
gave pyrrolidine (R)- or (S)-343 (48 mg, 79%, 65:35 er by CSP-HPLC) as a colourless 
oil, [α]D +17.5 (c 1.0 in CHCl3); CSP-HPLC: Chiralcel OD (99.5:0.5 hexane-i-PrOH, 1 
mL min–1) major enantiomer 343 21.8 min, minor enantiomer 343 24.8 min. 
Lab Book Reference GB9/811 
 
(R)- or (S)-2-Methyl-2-phenylpyrrolidine-1-carboxylic acid tert-butyl ester (R)- or 
(S)-334 
 
N
Boc
Ph
Me
(R)- or (S)-334
 
 
Using general procedure R, n-BuLi (96 µL of a 2.5 M solution in hexanes, 0.24 mmol) 
and phenyl pyrrolidine (R)-77 (46 mg, 0.18 mmol, 97:3 er) in THF (4 mL) and dimethyl 
sulfate (47 mg, 35 µL, 0.37 mmol) gave the crude product. Purification by flash column 
chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine (R)- or (S)-334 
(41 mg, 87%, 93:7 er by CSP-HPLC) as a colourless oil, [α]D +6.4 (c 0.25 in CHCl3); 
CSP-HPLC: Chiralcel OD (99:1 hexane-i-PrOH, 1 mL min–1) minor enantiomer 334 6.53 
min, major enantiomer 334 7.43 min. 
Lab Book Reference GB9:822 
 
(R)- or (S)-2-Phenyl-2-phenylcarbamoylpyrrolidine-1-carboxylic acid tert-butyl 
ester (R)- or (S)-347 
 
N
Boc
Ph
N
H
O
(R)- or (S)-347
Ph
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Using general procedure R, n-BuLi (96 µL of a 2.5 M solution in hexanes, 0.24 mmol) 
and phenyl pyrrolidine (R)-77 (46 mg, 0.18 mmol, 97:3 er) in THF (4 mL) and phenyl 
isocyanate (41 mg, 37 µL, 0.37 mmol) gave the crude product. Purification by flash 
column chromatography on silica with 9:1 petrol-Et2O as eluent gave pyrrolidine (R)- or 
(S)-347 (55 mg, 83%, 95:5 er by CSP-HPLC) as a colourless oil, [α]D +21.3 (c 1.125 in 
CHCl3); CSP-HPLC: Chiralpak AD (99:1 hexane-i-PrOH, 1 mL min
–1) minor enantiomer 
347 6.38 min, major enantiomer 347 9.95 min. 
Lab Book Reference GB9/823 
 
rac-2-Allyl-2-phenylpyrrolidine-1-carboxylic acid tert-butyl ester rac-349 
 
N
Boc
Ph
rac-349
 
 
Using general procedure R, n-BuLi (96 µL of a 2.5 M solution in hexanes, 0.24 mmol) 
and phenyl pyrrolidine (R)-77 (46 mg, 0.18 mmol, 97:3 er) in THF (4 mL) and allyl 
bromide (45mg, 32 µL, 0.37 mmol) gave the crude product. Purification by flash column 
chromatography in silia with 9:1 petrol-Et2O as eluent gave pyrrolidine rac-349 (41 mg, 
84%, 50:50 er by CSP-HPLC) as a colourless oil, CSP-HPLC: Chiralcel OD (99:1 
hexane-i-PrOH, 1 mL min–1) 5.39 min, 5.99 min. 
Lab Book Reference GB9/821 
 
ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (–78 °C) 
(Scheme 6.21) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
underAr. After cooling to –78 °C, a solution of 2-phenyl pyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 2 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred –78 °C for 12 min. 
 For 2-phenyl pyrrolidine 77, a peak at 1696 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1644 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 2 min, partial 
 283 
lithiation (~40%) of 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was 
observed. After a further 10 min incubation at –78 °C, no further lithiation was observed. 
Lab Book Reference GB9/794   
 
ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (0 °C) 
(Scheme 6.22) 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to 0 °C, a solution of 2-phenyl pyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 2 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at 0 °C for 5 min.  
 For 2-phenyl pyrrolidine 77, a peak at 1701 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1643 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 2 min, complete 
lithiation of 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was observed. 
Lab Book Reference GB9/793 
 
ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (–30 °C) 
(Figure 6.2) 
77
ν C=O 1698 cm
-1
346
ν C=O 1642 cm
-1
+77
+n-BuLi
 
 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –30 °C, a solution of 2-phenyl pyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 2 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –30 °C for 5 min. 
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 For 2-phenyl pyrrolidine 77, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1642 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 2 min, complete 
lithiation of 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was observed.  
Lab Book Reference GB9/795   
 
ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (–40 °C) 
(Figure 6.2) 
 
77
ν C=O 1698 cm
-1
346
ν C=O 1643 cm
-1
+77
+n-BuLi
 
 
THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –40 °C, a solution of 2-phenylpyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 3 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –40 °C for 7 min. 
 For 2-phenyl pyrrolidine 77, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1643 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 3 min, complete 
lithiation of 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was observed.  
Lab Book Reference GB9/797   
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ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (–50 °C) 
(Figure 6.2) 
 
77
ν C=O 1698 cm
-1 346
ν C=O 1643 cm
-1
+77
+n-BuLi
 
 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –50 °C, a solution of 2-phenyl pyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 3 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –50 °C for 15 min. 
 For 2-phenyl pyrrolidine 77, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1643 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 2 min, partial 
lithiation (~50%) of the 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was 
observed. After a further 13 min incubation at –50 °C, complete lithiation of 2-phenyl 
pyrrolidine77 to give lithiated intermediate 346 was observed. 
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ReactIR monitoring of the lithiation of phenyl pyrrolidine 77 (–60 °C) 
(Figure 6.2) 
 
77
ν C=O 1698 cm
-1 346
ν C=O 1643 cm
-1
+77
+n-BuLi
 
 
 THF (12 mL) was added to a flask equipped with a stirrer bar and ReactIR probe at rt 
under Ar. After cooling to –60 °C, a solution of 2-phenyl pyrrolidine 77 (247 mg, 1.0 
mmol) in THF (2 mL) was added. The solution was stirred for 2 min (to verify the 
stability of readout on ReactIR). Then, n-BuLi (520 µL of a 2.5 M solution in hexanes, 
1.3 mmol) was added dropwise. The solution was stirred at –60 °C for 30 min. 
 For 2-phenyl pyrrolidine 77, a peak at 1698 cm–1 was observed which was assigned to 
νC=O. After addition of n-BuLi, a new peak at 1643 cm
–1 was observed which was 
assigned to νC=O in lithiated intermediate 346. After a lithiation time of 2 min, partial 
lithiation (~50%) of the 2-phenyl pyrrolidine 77 to give lithiated intermediate 346 was 
observed. After a further 27 min incubation at –60 °C, additional slow lithiation of 2-
phenyl pyrrolidine 77 to lithiated intermediate 346 was observed. 
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